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Abstract  
This thesis explores the potential for using symptoms as a tool to bring forward the 
diagnosis of ovarian cancer.  Current evidence supports the existence of prediagnostic 
symptoms, however symptom lead time has yet to be adequately quantified.  „Targeted 
screening‟ is one possible approach to expediting diagnosis.  This would involve 
offering a blood test (e.g. CA125 or a future biomarker) to postmenopausal women 
presenting to primary care with symptoms possibly related to ovarian cancer.  Key 
barriers include the non-specific nature of ovarian cancer symptoms and potential 
impact on GP workload.  The main aims of this PhD research project were: 
 To quantify the lead time of symptoms in ovarian cancer.   
 To estimate the GP workload associated with offering a blood test to 
postmenopausal women with ovarian cancer symptoms. 
Following a background to ovarian cancer symptoms research; a brief overview of the 
epidemiology of ovarian cancer, a case-control study to quantify symptom lead time, 
and a cross-sectional pilot study to estimate GP workload and symptom specificity in 
women aged 45-74 in the general population is presented.  This is complemented by a 
systematic review focussed on the evidence for symptom lead time in ovarian cancer 
since 1980, with an update on ovarian cancer symptoms and a discussion of some of 
the methodological issues.  The main findings showed that the diagnostic process 
could be initiated at least 3 months prior to the current date of diagnosis, in 45% to 
74% of cases.  However, pilot data suggest that 13%-35% of women in the general 
population aged ≥45 would be offered „targeted screening‟ in 1 year.  Delays in ovarian 
cancer diagnosis of concern were identified but require further examination.  Timing of 
symptoms is also an important consideration. 
The concluding chapter summarises the main findings of this thesis and discusses 
possibilities for future research. 
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PART I: BACKGROUND 
Part I will contextualise the setting for this thesis project by providing a summary of: 
 Ovarian cancer symptoms 
 Epidemiology of ovarian cancer 
 Current screening possibilities 
 Treatment 
 Why this research was needed 
Also included is a systematic review of the recent literature on ovarian cancer 
symptoms with a focus on the timing of ovarian cancer symptoms and methodological 
issues. 
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1 CHAPTER 1: Ovarian Cancer Overview 
1.1 Introduction 
Ovarian cancer is the leading cause of mortality for women with gynaecological 
malignancies in the United Kingdom (UK) and many other Western countries.1  The 
majority of women are diagnosed at advanced stages when prognosis is poor and 5-
year survival rate is as low as 15%.2  Early stage disease is associated with a more 
favourable 5-year survival rate of 70%, but only 20% of women present at this stage.2  
Recently, there have been improvements in 5-year survival, and a substantial increase 
in 10-year survival is expected in the near future.3  Stage at diagnosis is one of the 
strongest predictors of survival4 hence, there is great incentive to diagnose women 
„early‟ while disease is localised, however this has proven to be challenging.  Although 
ovarian cancer is an ideal candidate for screening, there is currently no proven 
screening mechanism, even for high-risk groups.5  Given that an acceptable screening 
program has yet to be identified, „early‟ diagnosis relies heavily on timely presentation 
to health care and physician ability to make the diagnosis.  The situation is 
compounded by the absence of an identifiable premalignant lesion or specific 
biomarker, and a tenuous symptom profile.   
Historically, ovarian cancer has been perceived as a „silent‟ or „whispering‟ disease that 
rarely produces symptoms until disease has spread beyond the ovaries.  Yet, 
symptoms are the most frequently cited reason for the medical consultation leading to 
diagnosis in ovarian cancer.6, 7  However, this is not surprising given that there is no 
screening programme.  A plethora of studies have served to disprove the „silent 
disease‟ myth, and there is great interest in using symptoms as a diagnostic tool for 
detecting ovarian cancer.  Hence, research efforts in symptoms have intensified.  One 
of the key papers to trigger this surge in research was a survey by Goff et al. which 
helped to identify and establish the existence of prediagnostic symptoms in ovarian 
cancer.8  Importantly, the study also linked delays in diagnosis and women ignoring 
symptoms to late stage disease.  Although this study helped to raise awareness of 
prediagnostic symptoms in ovarian cancer; it relied solely on subjective data from 
women, with no objective data to support the findings.  Nevertheless, the main findings 
have been confirmed by several subsequent medical record studies.9-16 
Overall, symptoms appear to be relatively common in the immediate period leading up 
to diagnosis, but it remains unclear what role, if any, they could have in promoting 
diagnosis at earlier stages of disease.  Unfortunately, most of the symptoms are subtle 
17 
and non-specific, and none are exclusively associated with ovarian cancer.  In general, 
symptoms tend to be abdominal or gastrointestinal rather than gynaecological,8, 12, 15, 17-
19 and most are relatively common complaints in postmenopausal women.  
Furthermore, the fact that the symptoms are likely to be common in the general 
population raises the critical issue of low specificity.  The specificity of any „screening‟ 
test for ovarian cancer is crucial given that false positives can lead to serious 
psychological and physiological morbidity.  As such, while patient support groups moot 
that symptoms hold the key to early diagnosis, most of the medical community have 
remained largely reticent; unconvinced until there is stronger evidence.  This 
disagreement has sparked a „help versus harm‟ debate (discussed in further detail later 
in this Chapter).    
Regrettably, only sparse information exists regarding the actual timing of symptoms 
prior to ovarian cancer diagnosis.  Much of the current data represents symptoms at 
diagnosis, and the data relating to timing have been presented in a convoluted manner.  
Presumably, symptoms fluctuate with time in terms of type, severity and frequency.  
Therefore, it is sensible to examine what symptoms are present at different periods 
before diagnosis, and in what proportion of women.  This would give a clearer picture 
of symptom development and any potential opportunities for earlier diagnosis.  So far, 
only three studies have used this approach.10, 20, 21 
There is growing pressure to act upon symptoms in ovarian cancer.  In January 2007 
„Joanna‟s Law‟ was passed in the United States (US), which committed $16.5 million of 
federal funding to educate women and their healthcare providers on ovarian cancer 
signs and symptoms (http://www.johannaslaw.org).  This was followed by an ovarian 
cancer consensus symptoms statement (June 2007) which stated that any women with 
pelvic/abdominal pain, bloating, difficulty eating/feeling full quickly or urinary 
frequency/urgency almost daily for more than a few weeks, should visit a physician for 
pelvic examination (http://www.wcn.org/materials/gcam.html).  The UK followed suit 
in October 2008, with a consensus statement published as a collaborative effort 
between the University College London (UCL) Institute for Women‟s Health, the Eve 
Appeal and Ovacome 
(http://www.ovacome.org.uk/Resources/OvarianCancerUKConsensusStatement
).  Although the UK consensus statement was more conservative than its US 
equivalent, it still encourages women to seek healthcare for symptoms which are both 
highly subjective and vague.  Thus, there is ongoing promotion of using symptoms as a 
tool for earlier ovarian cancer diagnosis, however the evidence to support any benefit is 
non-existent.  Many researchers and clinicians believe that such efforts are premature 
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especially given that prevalence of the same symptoms in the general population is 
unknown. 
1.1.1 Symptoms Research 
Symptoms are ubiquitous and represent the primary reason for most outpatient clinic 
visits.22  Presenting symptoms are those that cause a person to seek healthcare, 
however they may not always be the first symptom(s) to appear.  For research 
purposes, the subjective nature of symptoms is a major complicating factor.  The 
presence of an objective manifestation such as cough makes symptom assessment 
much more straightforward, but is a rarity.  Furthermore, the background prevalence of 
common symptoms is substantial in outpatient clinic populations, therefore many 
coincidental associations may be incorrectly interpreted as causal.23, 24  Symptoms are 
often self-limiting, and there is likely to be a large proportion of women with vague 
symptoms in the non-consulting general population.25   
Other issues in symptom research include the variable periodicity of symptoms (e.g. 
vomiting may occur 5 times in 1 day but constipation could be all day for one week), 
and interference from medication and other exogenous compounds (due to side effects 
and/or efficacy).24, 26  Perhaps an even greater hurdle is the significant impact of 
elicitation method on symptom reporting.  The number and type of symptoms detected 
can vary dramatically depending on whether they are elicited by checklist or 
spontaneous reporting.27, 28   
All of these factors need to be taken into consideration when designing studies 
investigating ovarian cancer symptoms.  Yet, many of these issues have not been 
acknowledged in the ovarian cancer symptoms literature. 
1.1.2  ‘Help Versus Harm’ Issue 
The rationale for increasing symptom awareness is based on the assumption that 
earlier detection of symptoms will lead to earlier stage disease, and therefore better 
survival.  An online survey carried out in the US found that only 15% of women aged 
≥40 knew about ovarian cancer symptoms (http://www.mnovarian.org/article-
090705.htm).  In the UK, a nationwide survey performed by Dr Foster Intelligence 
found that 66% of women were unable to name a single symptom associated with 
ovarian cancer (http://www.ovarian.org.uk/news/awareness_study.asp).  While 
these findings certainly identify a gap in knowledge, they do not validate any 
symptoms-based testing.  Prompt diagnosis after symptom recognition is likely to have 
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a psychological benefit, but there is currently no evidence for any favourable effects on 
survival or overall mortality.  Furthermore, encouraging women to go to their general 
practitioner (GP) for vague symptoms could impact on GP workload by increasing the 
number of presentations from the „worried well‟.  In addition, there are other possible 
deleterious effects such as unnecessary anxiety and potentially, invasive surgery.  
There are minimal data to support the effectiveness of increased cancer symptom 
awareness except for well defined symptoms such as breast lumps and breast cancer.  
Equally, there is little evidence to suggest increased awareness affects GP workload or 
patient anxiety.29 
Raising awareness of ovarian cancer symptoms in GPs is complicated by the fact that 
the average GP will see just one case of ovarian cancer every five years.30  However, 
many still hope that encouraging GPs to at least consider an ovarian malignancy may 
hasten diagnosis.  
1.2 Rationale for Research Project 
Research focussed on prediagnostic symptoms in ovarian cancer has gained 
momentum over recent years, however, scarce data exist on the UK population.  It is 
clear that symptoms in ovarian cancer exist, but the current knowledge-base relies 
heavily on symptoms at diagnosis.  The next logical step is to identify whether these 
symptoms are detectable early enough to expedite diagnosis (via earlier referral), and 
in turn prevent or at least postpone death from ovarian cancer.  Essentially, this relates 
to the quantification of symptom lead time and the proportion of women with ovarian 
cancer that may have this lead time.  A crucial element of this is the proportion of 
women in the general population who also have the symptoms.   
Clearly, it would be inappropriate to offer invasive and costly procedures to every 
woman that presents to primary care with vague symptoms.  However, it may be 
feasible to identify a cluster of symptoms that would increase the index of suspicion for 
ovarian cancer sufficiently to justify „screening‟ in a subpopulation.  In this scenario, 
women in whom there is a moderate to high suspicion of disease would still be 
managed via the current routes (i.e. urgent ultrasound or rapid referral).   
„Screening‟ is most conventionally applied to an asymptomatic population.  It may be 
defined as “the systematic application of a test or enquiry, to identify individuals at 
sufficient risk of a specific disorder to benefit from further investigation or direct 
preventative action, among persons who have not sought medical attention on account 
of symptoms of that disorder”.31  The term „targeted screening‟ will be employed in this 
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thesis, even though testing based on symptoms is not strictly compatible with the 
aforementioned definition of screening.  However, this nonclamenture may be justified 
by the fact that testing would only be offered to women in whom there is only a very low 
suspicion of ovarian cancer, and the vast majority of women tested are expected to be 
disease-free. 
„Targeted screening‟ is most likely to be offered to postmenopausal women only (or 
based on an age restriction).  Such a restriction would significantly improve the positive 
predictive value of symptoms by taking advantage of the age-specific incidence of 
ovarian cancer (>85% of women with ovarian cancer are aged 45 and over32, 33) and 
the fact that most women with disease are postmenopausal.  In addition, because 
prognosis tends to be poorer in these women, there is a higher chance of impacting on 
survival and mortality. 
Ovarian cancer symptom data are extremely complex and most studies have not 
addressed this in their design.  Previous studies have been inconsistent in terms of 
study population, methodology and symptom definitions.  There is a clear need to 
better establish symptom incidence (cases and controls) and any associated diagnostic 
delays in a UK population.   
This thesis will explore the potential for „targeted ovarian cancer screening‟ by: 
1) Establishing the distribution of symptom duration prior to ovarian cancer diagnosis 
2) Estimating the proportion of apparently healthy women that would be offered 
„targeted screening‟ over the course of 1 year 
3) Taking into account some of the practical issues of „targeted screening‟, such as 
impact on GP workload. 
1.3 Studies Included in this Thesis 
This thesis was based on a Cancer Research UK project grant awarded to Professor 
Peter Sasieni to investigate the scope for „targeted‟ ovarian cancer screening.  A series 
of studies were performed under the umbrella of this project grant, of which this thesis 
will include three:  
1) A systematic review of the timing of prediagnostic ovarian cancer symptoms. 
2) A case-control study to investigate symptoms and events preceding ovarian cancer 
diagnosis. 
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3) A pilot primary care study to estimate the GP workload associated with offering 
„targeted‟ ovarian cancer screening. 
All of the participants of the symptoms case-control study were identified within the 
framework of a larger case-control study called UK Ovarian Cancer Population Study 
(UKOPS), funded by the Oak Foundation via the Eve Appeal (lead investigators Dr 
Usha Menon, Dr Simon Gayther, Professor Ian Jacobs).  Data in the symptoms study 
were collected as an addition to the data already planned for collection in the main 
UKOPS study, with the exception of the questionnaire and the basic case details 
(histology, date of diagnosis etc.). 
1.4 Epidemiology of Ovarian Cancer 
Ovarian cancer is a disease of predominantly older postmenopausal women.  In 
general, the natural history of ovarian cancer is poorly understood.  There are 3 major 
categories of ovarian cancer including epithelial, germ cell and stromal cell.  Epithelial 
ovarian cancer (EOC) is by far the most common comprising 90% of all ovarian 
malignancies.34  As such, research efforts are largely directed at this subtype.  EOC is 
thought to arise from the surface epithelium covering the ovary and may differentiate 
into serous, endometrioid, clear cell, mucinous and poorly differentiated subtypes.   
Increased parity, combined oral contraceptive use, tubal ligation and hysterectomy are 
all established as being protective for ovarian cancer.  In contrast, increasing age, and 
mutations in BRCA1 and BRCA2 are the strongest risk factors for disease. 
1.4.1 Incidence 
Incidence in the UK has been rising, a total of 6806 ovarian cancer cases were 
diagnosed in 2005.32, 35, 36  Ovarian cancer incidence increases with increasing age, 
almost 84% of affected women are aged 50 or older (5745 of 6806).  Sharp increases 
in incidence coincide around the typical age of menopause (incidence in 
postmenopausal women is about 40 per 100,000 per year).37  In the future, incidence 
may start to decrease as a more women who have used oral contraceptives (which are 
protective for disease) will become postmenopausal,38 however this could be countered 
by increases in the number of women who are living longer. 
1.4.2 Survival 
The UK age-standardised five-year survival rates have doubled between 1971 and 
2001, hence long-term survival is also expected to increase.39  Stage at diagnosis 
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remains the strongest predictor of survival, and women with early disease have five-
year survival rates in excess of 70%.37   
1.4.3 Mortality 
Ovarian cancer is the fifth leading cause of death for women with 4407 dying from 
disease per year.35, 40  This is equivalent to 6% of all female cancer deaths. 
1.4.4 Risk Factors 
Age 
Increasing age is a major risk factor, and the highest incidence rates are for women 
aged 65 and above.32  The highest incidence rates are observed for women aged 65 
and over.32, 35, 36  Only a minority of cases are aged under 50, and these tend to be non-
epithelial subtypes with favourable prognoses.41 
Geography 
The highest rates of ovarian cancer are observed in Northern Europe and the United 
States, while the lowest are in Asia and Africa.37  Population migrant studies have 
shown that risk increases in women who migrate from countries of lower to higher risk, 
providing evidence for a role of environmental factors.42 
Reproductive Factors 
A long menstrual life has been postulated to be a risk factor for ovarian cancer.  
Overall, late menopause and age at menarche have not been shown to have any effect 
on the risk of disease.  Only weak associations between increasing age at natural 
menopause and risk of disease have been identified.42 
Parity 
The protective effect of parity is well established in ovarian cancer.  One study showed 
a risk reduction of 40% for the first birth, with further risk reduction for each subsequent 
birth.43  Conversely, nulliparity predisposes women to an increased risk of ovarian 
cancer.  The effect of incomplete pregnancies is less clear, although these may be 
mildly protective.42   
Oral Contraceptive Use  
The association between combined oral contraceptive pill use and reduced ovarian 
cancer risk is another well demonstrated protective factor.37  Risk reduction increases 
with duration of use and the trend continues for up to 20 years after termination of 
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use.44  The mechanism is thought to be via cessation of ovulation and/or reduction in 
gonadotrophin levels. 
Breast feeding 
Overall, breastfeeding is thought to be protective.  This may be specific to histological 
subtype.37 
Infertility & Infertility Drugs 
Since nulliparity can increase the risk of ovarian cancer, it is difficult to study the effect 
of infertility alone.  Women who are nulliparous are not necessarily subfertile.  Studies 
examining the effects of infertility and fertility treatment have produced conflicting 
results.  The situation is complicated by the difficulties with defining infertility type and 
controlling for the various fertility treatments.  A pooled analysis of eight case-control 
studies showed that risk of ovarian cancer was increased in nulligravid women who 
had at least 5 years of unsuccessful attempts at pregnancy.45 
So far, no clear relationship between fertility drugs and risk of ovarian cancer has been 
identified.37, 42 
Hormone Replacement Therapy (HRT) 
Oestrogen replacement therapy (ERT) alone has been shown to be associated with 
greater risk increases than oestrogen-progestin therapy.46  Ever-users versus never-
users of ERT have an increased risk between 19-24%.46   
Genetic 
Only 5-10% of ovarian cancer cases are attributable to familial links, the remainder are 
sporadic.37  While hereditary predisposition accounts for a very small percentage of 
cases, it is the strongest risk factor for disease.  A meta-analysis showed that relative 
risk with an affected first-degree relative is 3.1 (95% CI 2.6, 3.7) and increases 
proportionately with each additional first or second degree relative affected.47  The 
majority of relevant mutations are BRCA1- and BRCA2-mediated.  Lifetime risk for 
BRCA1 carriers is 16-44% and 27% for BRCA2 carriers.42  Hereditary non-polyposis 
colorectal cancer syndrome (HNPCC) also increases the risk of developing disease.  
However, this is to a lesser extent with only 10% lifetime risk for HNPCC carriers.48  
Other 
Evidence from most studies suggest a protective effect of tubal ligation and 
hysterectomy.  Risk reductions between 10% and 80% have been observed for tubal 
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ligation and a modest protective effect for hysterectomy.37  Notably, protection 
diminishes within 20 years after surgery implying that the observed effect may be due 
to inspection of ovaries at the time of surgery. 
An increased incidence of endometriosis has been found in women with endometrioid 
and clear cell ovarian cancers.42  Many of these were found to be in continuum with the 
carcinomas suggesting that endometriosis may play a precursory role in the 
oncogenesis of these histological subtypes. 
The relationship between diet and ovarian cancer is unclear.37, 42  High consumption of 
olive oil and green vegetables is thought to decrease risk while a high intake of animal 
fats and meat have been associated with increased risk.   
A link between body mass index (BMI) and ovarian cancer has been purported, 
particularly in association with the upper percentiles of body mass index.37  However, 
the precise details of this relationship is yet to be established. 
Talcum powder use on the perineum is a contentious risk factor for ovarian cancer.  A 
meta-analysis of 16 studies demonstrated a relative risk of 1.33 (95%CI 1.16 to 1.45) 
however no dose-response relationship could be identified.49  More recently, further 
studies have found weak associations between talc use and ovarian cancer.50 
Polycystic ovary syndrome (PCOS) is thought to increase the risk of disease, however, 
there is insufficient evidence in this area.37  
1.5 Early Detection & Screening in Ovarian Cancer 
In ovarian cancer, a single screening test would require particularly high specificity 
since a positive test usually mandates an invasive surgical procedure.  An arbitrary 
goal of at least 10% Positive Predictive Value (PPV) is generally accepted, which 
would mean there would be ten unnecessary operations performed for every case 
found.51  However, it is becoming increasingly unlikely that a single test will be 
employed in ovarian cancer screening.   
The main strategies for screening involve both biochemical and morphological markers.  
The most thoroughly investigated of these include antigen serum marker CA125 and 
transvaginal ultrasound.  Neither of these techniques alone has sufficient specificity 
and sensitivity to utilise for screening.  
Screening is unlikely to be beneficial if most screen-detected cancers are borderline or 
tumours that would have in any case been confined to the ovaries at presentation.  A 
25 
reduction in mortality is more likely to be associated with screen-detection of early-
stage serous or undifferentiated carcinomas since they are usually advanced at 
presentation.  There are currently two large randomised controlled studies investigating 
the efficacy of screening in the general population using CA125 testing and 
transvaginal ultrasound.  In the UK, there is the United Kingdom Collaborative Trial of 
Ovarian Cancer Screening (UKCTOCS) and in the US there is the Prostate, Lung, 
Colorectal and Ovarian cancer screening trial (PLCO).  Both are due to report mortality 
data around 2015, but until then the possible mortality benefit from screening remains 
unknown.     
1.5.1 Transvaginal Sonography (TVS) 
Transvaginal sonography (TVS) is used to assess ovarian volume and visualise 
ovarian morphology.  It has relatively high sensitivity but insufficient specificity in 
asymptomatic women.52  In addition, the high costs are restrictive, and specialist skills 
are required for accurate scan interpretation.  As a first-line test TVS has demonstrated 
higher sensitivity for early stage disease.53 
1.5.2 Tumour Markers 
Cancer antigen 125 (CA125) is a high molecular weight glycoprotein, and it is the most 
extensively investigated tumour marker for ovarian malignancies.  Serum levels are 
elevated in 50%-60% of stage I cancers (not screen-detected)54 and in more than 90% 
of women with more advanced stages.55  Elevation may be observed as long as 10 to 
60 months before diagnosis.54  However, CA125 expression is minimal or absent in 
20% of ovarian cancers, particularly in mucinous subtypes.55  Furthermore, CA125 is 
non-specific and may be raised during menstruation and in various other conditions 
including fibroids, diverticulitis and endometriosis.56  A useful distinguishing feature of 
malignant versus benign suprathreshold CA125 values is rising levels from serial 
testing.  Combination of CA125 with other markers to improve sensitivity has been 
evaluated, however, to date this has only been achieved at the expense of specificity.54, 
57  Recent advancements include the use of an algorithm that accounts for the rate of 
change of CA125 which increases sensitivity.58  The risk of ovarian cancer (ROC) 
algorithm accounts for a woman‟s age-specific incidence of ovarian cancer and serial 
CA125 profile to give a more accurate estimate of risk.58 
There are a host of other biomarkers being evaluated but to date, none have met the 
stringent sensitivity and specificity requirements for screening in ovarian cancer.   
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1.5.3 Multimodal Screening (MMS) 
So far, the best screening results have been achieved with multimodal screening 
(MMS) using both CA125 and transvaginal ultrasound in a postmenopausal 
population.59, 60  This approach was evaluated in 22,000 postmenopausal women, 
specificity was 99.9%, sensitivity was 78.6% and PPV was 26.8% at 1-year follow-up.59  
A randomised controlled trial using the same population found a significant difference 
in the median survival rate for screened versus control women (72.9 months vs. 41.8 
months, p=0.011).61    
As mentioned previously, there are two ongoing studies designed to assess the 
efficacy of multimodal screening (PLCO and UKCTOCS).  Prevalence screening 
results have been published for both studies.62, 63  In the PLCO study, 28,816 women 
had at least one of CA125 and TVS.62  1706 (5.9%) women had at least one abnormal 
test, resulting in 570 surgical investigations.  A total of 29 neoplasms were identified 
(26 ovarian, 2 fallopian and 1 primary peritoneal), of which 19 were epithelial invasive 
cancers.  Of the 29 neoplasms, 9 women were positive on both tests (31%).  PPV of 
either test for invasive epithelial cancer was just 1.1%, but 23.5% if both tests were 
positive.   
In UKCTOCS, 50,075 women received multimodal screening, of whom 4555 had 
repeat testing, leading to 97 surgical evaluations.63  A total of 42 ovarian or tubal 
cancers were detected.  Of these 34 were primary invasive epithelial ovarian and tubal 
cancers, and a further 4 were detected as interval cancers.  Corresponding sensitivity 
for primary invasive epithelial ovarian and tubal malignancies was 89.5% and 
specificity was 99.8%.  PPV was relatively high at 43.3%. For TVS alone, sensitivity, 
specificity and PPV were 84.9%, 98.2% and 5.3%, respectively.  The results for MMS 
are encouraging but no conclusions may be drawn until mortality data are processed in 
2015. 
1.5.4 Proteomics 
Proteomics aims to identify protein patterns (signatures) or peptides in serum that may 
be specific to the disease in question.  Advances in bioinformatics have contributed 
immensely to proteomics and a huge amount of research is ongoing.  Although 
proteomics represents a promising area of research, extensive validation is required for 
any putative markers discovered.  Reproducibility of some encouraging results has 
already proven to be problematic.64, 65  Consequently, it may be some time before any 
proteomic biomarker for ovarian cancer reaches clinical practice. 
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1.6 Challenges to Early Detection 
1.6.1 Dual Pathways of Oncogenesis 
Potentially, there is an additional challenge in the detection of early stage ovarian 
cancer.  Our understanding of the natural history of ovarian cancer is poor, and to date, 
no premalignant lesion has been identified (although this is a contentious issue).  It is 
possible that disease progression in epithelial ovarian cancer is heterogeneous with 
some early stage tumours becoming large without regional or distal spread while some 
advanced stage malignancies may develop rapidly with little opportunity for „early 
detection‟.66  Thus, some tumours that are commonly detected at early stages could be 
biologically distinct from their late stage counterparts with slower growth rates and a 
lower propensity to metastasize.66  Observations that support this include a tendency 
for early stage carcinomas to have larger tumour size, better differentiation, non-serous 
histology, and to be more common in younger women.9, 12  Specifically, only 3% of 
women with late stage disease were found to have a grade I tumour versus 54% of 
women with early stage disease.12  Seventy-eight percent of early stage disease 
patients presented with a tumour >10 cm in diameter compared with only 32% of late 
stage patients.  Attanucci et al. also found that tumour size was significantly larger in 
early stage disease (13.5  6.8 cm versus 9.0  6.3 cm, p=0.004), although the sample 
size was small (early n=33, advanced n=81).  Additionally, several studies have 
reported longer symptom duration in borderline versus invasive tumours,6, 67, 68 and 
early versus late stage disease.69  One would expect the opposite if there was temporal 
relationship between symptom duration and stage of disease. 
There are morphologic and molecular genetic data to support this theory.  Each 
histological subtype in epithelial ovarian cancer (EOC) appears to undergo distinct 
changes and develop via different pathways.70  Certainly, the most common subtypes 
of EOC are serous and undifferentiated and these are much more likely to be stage III-
IV at diagnosis.71  On the other hand, borderline, mucinous, endometrioid cancers are 
more likely to be confined to the ovaries at presentation are usually clinically detected 
at early stages and have a more favourable prognosis.71   
Based on this evidence, it has been proposed that a significant proportion of high grade 
serous cancers arise de novo from the ovary surface epithelium or its inclusion cysts 
enabling rapid spread when only microscopic in size.72  Conversely, low grade serous 
and mucinous tumours probably arise from within, or contiguous to, their benign or 
borderline counterparts and follow the classical stepwise adenoma-borderline-
carcinoma sequence.  Clear cell and endometrioid cancers appear to originate from 
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endometriosis73 (see Figure 1-1).  This theory of divergent pathways for oncogenesis 
challenges the presumption that temporally „early‟ diagnosis will invariably translate into 
detection of disease while still confined to the ovaries.   
Nonetheless, it is unlikely that all advanced stage cancers develop at such a rate that 
attempts to bring forward diagnosis are futile or impossible, and early detection via 
symptoms remains a critical area of investigation.  It remains entirely plausible that 
some women are detected at advanced stages as a result of prolonged intervals 
between symptom onset and diagnosis.  
Figure 1-1 Dual Pathways of Epithelial Ovarian Cancer Oncogenesis (adapted 
from Scully et al. 2000)74 
 
1.6.2 Misdiagnoses 
Due to the non-specific nature of the symptoms, ovarian cancer may be initially 
misdiagnosed as other diseases or conditions such as irritable bowel syndrome (IBS), 
diverticulitis, cholecystitis, and urinary tract infection (UTI) or cystitis.8, 11, 16, 17, 75-78  A 
study performed in the UK found that 60% of women were initially sent to non-
gynaecological hospital departments.11  In the same study, half of the 16 women with a 
delayed referral of three months or longer were initially misdiagnosed with IBS.  Survey 
results from 1725 self-selected women with ovarian cancer found that 30% believed 
that misdiagnosis was a barrier to receiving a prompt diagnosis.8  Importantly, the 
same study found that initial misdiagnosis was associated with later stage disease.   
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Although misdiagnosis is regarded as physician failure, it should also be recognised 
that the average GP will see only one case every five years in the UK.30  Hence, the 
rationale for initially suspecting other more common diseases is substantiated.   
In the literature, IBS and diverticulitis have often been perceived as being associated 
with misdiagnosis of ovarian cancer.10, 11, 16, 77  Hence, the proportion of women that had 
each disease (documented in the medical records) was examined for both of the 
studies in this thesis.  Misuse of terms pertaining to diverticular conditions is common 
in both lay persons and medical professionals.79  Diverticulum (diverticula plural) is a 
pouch or sac that bulges out from the colon that is thought to be caused by increasing 
intraluminal pressure required to eliminate faeces, particularly in low fibre diets.  The 
condition of having diverticula is referred to as diverticulosis, which can be completely 
asymptomatic.80  Diverticular disease is simply diverticulosis with symptoms which can 
include abdominal cramping, bloating, diarrhoea and constipation.81  Diverticulitis is 
when diverticula become inflamed and in complicated cases these may become 
infected and perforate.  For the purposes of this thesis, all of the terms for diverticular 
conditions were included as diverticulitis since we expected them to be used 
interchangeably in the medical records. 
1.7 Current UK Referral Guidelines for Ovarian Cancer 
Under current UK policy, anyone with suspected cancer should be seen by the 
appropriate specialist within two weeks of urgent GP referral.82  An indication that this 
policy is being adhered to is that 70% of British women with ovarian cancer were seen 
in hospital within 2 weeks of GP referral (including urgent and non-urgent referral).11  
Although these results seem encouraging, the enduring perception amongst patients is 
that delays in ovarian cancer diagnosis are commonplace.  A more recent UK study 
had less supportive findings, only 24% of women diagnosed with ovarian cancer had 
an urgent referral.83   
According to the NICE (National Institute for Clinical Excellence) guidelines, abdominal 
palpation should be carried out in women presenting with „any unexplained abdominal 
or urinary symptoms‟.84  Pelvic examination is recommended if there is „significant 
concern‟ and if „appropriate and acceptable to the patient‟.  The guidelines also 
stipulate that: 
 Women with a palpable abdominal or pelvic mass should be sent for urgent 
ultrasound (if the mass is not obviously uterine fibroids or of gastrointestinal or 
urological origin) and urgent referral if the scan is suggestive of malignancy. 
 Women with postmenopausal bleeding (if not on HRT) should be referred urgently.   
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The degree to which these guidelines are having a positive impact on the speed of 
ovarian cancer detection is unclear.  One possible barrier is GP uncertainty with regard 
to urgent ultrasound and the decision to use rapid referral.85 
1.8 Ovarian Cancer Treatment 
Women with suspected ovarian cancer have a risk of malignancy index (RMI) 
calculated based on ultrasound results, menopausal status and CA125 levels.  Those 
who have a RMI >200 are considered to be at high risk of disease and receive care 
under a gynaecologist oncologist.  The standard treatment for all stages of ovarian 
cancer includes cytoreductive („debulking‟) surgery, chemotherapy and/or radiotherapy.  
The specific combination of these treatments is dependent on prognostic factors such 
as stage, tumour grade and clear cell histology.  FIGO (International Federation of 
Gynaecology and Obstetrics) staging is performed by surgery and this largely 
determines the need for further treatment (see Table 1-1). 
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Table 1-1 FIGO Staging86 
Stage I Tumour confined to the ovaries 
IA 
Tumour limited to one ovary; no tumour on external surface; capsule intact.  
No malignant cells in ascites or peritoneal washings 
IB As above, but tumour limited to both ovaries 
IC 
Tumour limited to one or both ovaries with any of the following: tumour on 
external surface; ruptured capsule; malignant cells in ascites or peritoneal 
washings 
Stage II Tumour involving one or both ovaries with pelvic extension  
IIA 
Extension and/or implants in uterus and/or fallopian tubes. No malignant cells 
in ascites or peritoneal washings 
IIB 
Extension to other pelvic organs. No malignant cells in ascites or peritoneal 
washings 
IIC 
Tumour staged either IIA or IIB with malignant cells in ascites or peritoneal 
washings 
Stage III 
Tumour involving one or both ovaries with microscopically confirmed 
peritoneal metastases outside the pelvis and/or regional lymph node 
metastases. Liver capsule metastasis equals Stage III. 
IIIA Microscopic peritoneal metastases beyond the pelvis 
IIIB 
Macroscopic peritoneal metastasis beyond the pelvis, none exceeding 2cm in 
diameter 
IIIC 
Peritoneal metastases beyond the pelvis greater than 2cm in diameter and/or 
regional lymph node metastasis 
Stage IV Distant metastasis 
1.8.1 Treatment for Early Stage Disease 
Primary surgery is first-line treatment for early stage disease.  This typically involves 
total hysterectomy, bilateral salpingo-oophorectomy (removal of both ovaries and the 
fallopian tubes), omentectomy and removing as much of the cancerous tissue as 
possible (debulking or cytoreduction).  Tumour grade refers to the degree of 
differentiation of the tumour cells, that is, the extent to which the cells resemble the 
tissue of origin.  Grade 1 (well-differentiated) tumours have cells that closely resemble 
normal ovarian tissue, grade 2 (moderately differentiated) tumours have some cells 
that resemble the tissue of origin but display signs of frank malignancy, and grade 3 
(poorly differentiated) tumours have cells that appear abnormal.  In general, the better 
differentiated a tumour is, the less aggressive it behaves.  Hence, patients with well-
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differentiated stage IA and IB tumours are usually managed without adjuvant 
chemotherapy.  Clear cell carcinomas are the exception to this rule since they are 
much more likely to recur (in comparison to other histological types), tend to have a 
poor response to chemotherapy and generally have a less favourable prognosis.87  As 
such, usually all women with clear cell histology receive chemotherapy regardless of 
stage.  Accurate surgical staging is critical for early stage disease since it determines 
whether or not the patient will require chemotherapy.  If a woman is under-staged she 
may not receive potentially life-saving chemotherapy. 
1.8.2 Treatment for Advanced Stage Disease 
For ovarian malignancies of stage IC and higher, primary cytoreductive surgery is 
performed to minimise tumour burden before chemotherapy.  In advanced stage 
disease, optimal debulking (i.e. leaving <1 cm of residual disease) is critical since it 
translates into a survival benefit.88  Chemotherapy is usually administered after 
cytoreductive surgery however there is ongoing research to find out if treatment given 
in the reverse order (i.e. neoadjuvant chemotherapy) would be advantageous (EORTC 
55971 and MRC-CHORUS study).  Women with very advanced disease may also 
receive first-line chemotherapy as their disease may not be safely operable.  Adjuvant 
chemotherapy for ovarian carcinoma typically involves six cycles of a platinum 
compound such as cisplatin or carboplatin with or without paclitaxel (Taxol®).   
Nowadays, radiotherapy is rarely used, but it may be given to women with advanced 
disease to help control symptoms or to women with stage IC or II cancers who have no 
signs of malignancy in the abdomen and minimal deposits in the pelvis.   
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2 CHAPTER 2: Systematic Review of the Timing of 
Prediagnostic Ovarian Cancer Symptoms 
2.1 Introduction 
Over the past few decades, numerous studies on ovarian cancer symptoms have been 
carried out.  Most of these set out to prove that women with ovarian cancer experience 
symptoms before diagnosis.  Overall, the study designs and methods used for 
symptom studies have been inconsistent, but despite this heterogeneity, certain 
themes have emerged with regard to what types of symptoms are common prior to 
diagnosis.  Specifically, the vast majority of women have at least one symptom, 
regardless of the data collection method (direct from women or medical records), 
including women with early stage disease.6-10, 12-17, 19, 67, 68, 75, 78, 89-92  In 2005, a 
systematic review on ovarian cancer symptoms was published by the Primary Care 
group in Oxford.93  This review provided a much needed summary of the evidence for 
symptoms associated with ovarian cancer diagnosis, however the timing of 
prediagnostic symptoms was not evaluated.  Symptoms have been reported to be 
present for months or even years, prior to diagnosis, but the evidence to support these 
claims is extremely variable and needs clarification.   
Although many studies have purported to examine prediagnostic symptoms, in reality, 
most have presented data that include a mixture of symptoms before and at diagnosis.  
This is partly due to the fact that „symptoms before diagnosis‟ is likely to have been 
interpreted in various ways (e.g. symptoms at presentation, before referral, before 
biopsy results, or before final diagnosis).  As such, there is a high probability that many 
of the symptoms reported, started just weeks or days before diagnosis, when most 
women would already be in the secondary or tertiary care system.  The underlying goal 
of research on prediagnostic symptoms in ovarian cancer is to find out whether 
diagnosis can be bought forward by acting on symptoms.  Therefore, the crucial period 
to quantify is the interval between symptom onset and referral, when there is potential 
to intervene by expediting referral, and thereby, diagnosis.  In addition, symptom data 
are complex to collect and analyse.  Many of the issues relating to these complexities 
have not been taken into account in the literature.   
Using symptoms to distinguish between benign and malignant tumours or early and 
late stage disease has obvious appeal.  Unfortunately, so far researchers have failed to 
demonstrate clear separation in symptom profile according to histology, tumour type or 
stage of disease.  Borderline, benign and malignant masses appear to generate a 
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similar spectrum of symptoms.12, 68, 75  Certainly, some symptoms appear more 
prominently within particular groups, however, there are no features which would 
accurately discriminate between groups.   
This review will provide an updated overview of the studies performed to date, and it 
will suggest that symptoms are indeed present prior to diagnosis, however, the timing 
of these is still unclear.  The available evidence for the duration of symptoms before 
diagnosis will be summarised, and the most common prediagnostic symptoms will be 
highlighted.  Potential symptom discriminatory factors for stage, tumour type and 
presence or absence of ovarian cancer will be discussed in light of their relevance to 
this project.  Emphasis will be on data from the population of women who are most 
likely to benefit from a symptoms-based diagnostic tool, i.e. women aged ≥45, with 
invasive epithelial ovarian cancer.  Finally, some of the key methodological issues will 
be discussed.  
2.2 Aims 
2.2.1 Primary Aim 
 To evaluate and summarise the existing evidence on the timing of symptoms before 
diagnosis of ovarian cancer. 
2.2.2 Secondary Aims 
 To provide an updated overview of symptoms prior to ovarian cancer diagnosis, 
with a focus on the most common symptoms. 
 To summarise key methodological issues in ovarian cancer symptom studies. 
 To summarise the existing evidence on symptoms associated with tumour status 
(benign, borderline, invasive) and stage of disease (early, late). 
2.3 Methods 
2.3.1 Search Strategy 
A detailed electronic search using OVID MedLine® (1980 to September 2007) and 
CINAHL was carried out (see Table 2-1).  It was difficult to obtain a specific search 
strategy, since the term „symptom‟ commonly appears in journal articles of all types.  
The original search included the MeSH (medical subject heading) term SIGNS & 
SYMPTOMS however, this resulted in over 1000 additional papers so this was 
excluded in the final search.     
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Table 2-1 Search Strategy 
1 
2 
3 
 
4 
5 
6 
7 
Ovar$3 
OVARIAN-NEOPLASMS#.DE. 
(cancer$3 OR malignan$4 OR tumour$3 OR tumor$3 OR neoplasm$3 OR carcinoma$3 
OR adenocarcinom$3).TI, AB. 
Symptom$7 
1 NEAR 3 
3 OR 5 
4 WITH 5 
A total of 251 articles were retrieved using the search strategy (166 from Medline and 
85 from CINAHL).  Certain restrictions were imposed on the methods due to limited 
resources.  Only papers written in English were considered.  The SIGLE (System for 
Information on Grey Literature in Europe) database was not searched.  However, the 
PhD thesis of Clare Bankhead94 constituted one source of grey literature.  Several 
abstracts relating to ovarian cancer symptoms from conference proceedings were 
assessed, but none were identified as relevant.  No journals were hand-searched, 
however the bibliographies of retrieved papers in the final set were scoured for 
additional papers, as were several review articles.68, 92, 93  This resulted in 5 additional 
papers11, 95-98 that were not detected in the electronic database search.  EMBASE was 
not searched since it is a more pharmaceutically-inclined database.  The final update 
was performed in December 2008 which identified 7 additional papers.21, 99-104  This 
resulted in a total of 264 articles to be assessed for inclusion. 
2.3.2 Selection 
The following criteria were used to select eligible studies for the review: 
 Study design – Original research articles with quantitative symptom data.  Case 
studies were excluded, as were papers focussed on a single symptom.  
 Publication year between 1980 to present - Only recently published studies were of 
interest for several reasons; (1) a systematic review in this area was performed in 
2005 and many of the same papers were included; (2) symptom duration/delays 
may have changed (3) the symptom spectrum in primary care may have changed; 
and (4) interest in symptoms as a tool for early diagnosis is a relatively new 
concept. 
 Participants – women newly diagnosed with primary ovarian cancer (not recurrent 
disease).  Studies focussed on women aged below 45 were excluded since 
younger women tend to have earlier stage disease with more favourable prognosis, 
non-serous histology, different symptoms and comprise less than 15% of women 
with ovarian cancer.32, 33  Likewise, articles which focussed on non-epithelial 
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subtypes were excluded since these are rare and symptoms often different from 
those produced by epithelial ovarian cancer.   
 Outcomes – Duration of symptoms before diagnosis of ovarian cancer (including 
data on delays in diagnosis), proportion of women reporting symptoms before 
diagnosis (individual and grouped symptoms), the most common symptoms 
reported by women prior to ovarian cancer diagnosis. 
 Other – Exclude if not in English. 
Two reviewers (Anita Lim; AL and Alejandra Castanon; AC) independently evaluated 
the eligibility of the studies and selected the relevant papers using information from the 
title and abstract.  Any disagreements were discussed, which resulted in 43 papers to 
be assessed in greater detail.  Fourteen studies15, 18, 76, 77, 95, 99, 103, 105-111 were further 
excluded from this short-list during secondary review using the entire paper.  Questions 
over study validity or any other aspect of the data were discussed on an ad-hoc basis 
with a third reviewer (Peter Sasieni, PS).  Reasons for all exclusions are listed in Table 
2-2. 
Table 2-2 Reasons for Excluding Studies 
First Review (based on title and abstract) 
Case study (n=14) 
Not original research (review, news article, letters etc.) (n=67) 
Focus on recurrent disease (n=3) 
Not about ovarian cancer (n=45) 
Focus on Non-EOC disease (n=5) 
Not about pre-diagnostic symptoms (n=84) 
Study population younger than 45 (n=3) 
Second Review (based on entire article) 
Focus on a single symptom (n=2) 
Symptoms data split by histological subtype (n=2) 
Same data already reviewed in another source by the same author (n=1) 
No data on symptoms from women with ovarian cancer (n=1) 
Not a study (n=1) 
Aim to assess or develop symptom index not evaluate prediagnostic symptoms (n=2) 
Qualitative study (no quantitative data) (n=2) 
Not clear where data were from (n=1) 
Symptom data inadequate (n=1) 
Insufficient case details (n=1) 
2.3.3 Data Extraction & Validity 
A total of 29 studies were eligible for final review.6-14, 16, 17, 19-21, 67-69, 75, 78, 89, 90, 94, 96-98, 100, 
101, 104, 112  Data extraction was performed unblinded by only one reviewer (AL) due to 
limited resources.   
The studies were grouped according to data collection method 
(questionnaire/interview, medical record review, or coded insurance billing records) and 
design. 
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2.4 Results 
2.4.1 Timing of Prediagnostic Symptoms 
Establishing the time between symptom onset and diagnosis (or referral) is a critical 
step in any paradigm for promoting earlier diagnosis via symptoms.  From this, it is 
possible to ascertain the potential lead time of symptoms.  In the literature, the interval 
between symptom onset and diagnosis has been labelled as either symptom duration, 
or (total) delay.  The term „delay‟ implies that there has been unnecessary 
postponement of an event, whereas „duration‟ merely suggests that the time the event 
spans over has been quantified.  Although these terms are distinct, they are derived 
using the same dates (symptom onset date, date of diagnosis) and therefore, refer to 
the same interval.   
Twenty-three6-8, 10-14, 16-21, 67-69, 75, 78, 89, 94, 104, 112 of the studies identified in the original 
search contained information relating to the timing of symptoms.  However, the 
measurement of symptom duration or delay was rarely a primary objective.  Hence, the 
data are scant, variable and have been presented in ways which have made it difficult 
to perform any formal quantitative pooling or meta-analysis.  Two of the studies will not 
be discussed since the data on duration were not useful (i.e. combined with data on 
benign tumours,104 or split by histological type18).   
Typically, duration data have been presented as mean or median time from symptom 
onset to diagnosis, or as the proportion of women with any symptom at predefined 
periods before diagnosis (e.g. <1 month, <3 months, >6months).  The distribution of 
duration data is often skewed, thus, presenting a mean may be inappropriate.  Often, it 
is not clear if calculations relating to duration and delay were restricted to symptomatic 
women, or if asymptomatic women were also included.  Inclusion of asymptomatic 
women would unduly skew the data towards shorter duration or delay, since they would 
be designated a duration or delay of zero.   
Another consideration is the possibility of contamination by symptoms that are 
coincidental rather than due to ovarian cancer.  This is a particular problem in ovarian 
cancer due to the non-specific nature of the symptoms (e.g. abdominal pain, fatigue).  
Indeed, some of the data available on symptom duration and delay suggest 
suspiciously long periods of time.6, 13, 112  Although it is impossible to know for certain 
which symptoms are truly attributable to ovarian cancer and which are not, it is 
important to acknowledge, and try to control for, this issue.  Moreover, this has not 
been discussed in the ovarian cancer symptom literature.   
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Finally, duration and delays will differ depending on whether data are self-reported by 
women or extracted from medical records.  In self-reported data, the accuracy of 
symptom onset dates is dependent on the women‟s ability to recall and is naturally 
subject to recall bias (if collected retrospectively).  Further inaccuracies may stem from 
the women‟s perception of what constitutes a „symptom‟.  For medical record data, 
recording error and recording bias can be a problem, also the visit date may be used 
rather than the true symptom onset date.  Data obtained using these two methods can 
be vastly different and should be considered separately.  The issues relating to this are 
discussed in more detail later.   
As a corollary of the issues and inconsistencies described above, the tables relating to 
duration or delay may appear to be incomplete; however, the data provided are as 
comprehensive as possible.  Table 2-3 and Table 2-4 provide a summary of the 
available data relating to time from symptom onset to ovarian cancer diagnosis (data 
presented in weeks were converted to months to allow comparability across studies).  
In the tables, duration for borderline and invasive disease were separated (whenever 
possible), since borderline symptom duration appeared to be longer.6, 13, 67, 68  Also, 
both the total number of women and the number (or proportion) of symptomatic women 
were presented because symptom duration was often calculated for symptomatic 
women only.  Finally, median duration was used to complete the proportion of women 
with >3 or >6 months duration, whenever possible (e.g. from a median of 4 months it 
can be deduced that more than 50% of women had a duration of >3 months). 
Overall, the data were fairly heterogeneous, particularly with regard to the range of 
symptom duration.  The largest range reported for any symptom was 0 to 8 years 
(medical record data).13  Symptomatic ovarian cancer that is undiagnosed for 8 years is 
probably extremely rare and potentially, this range may have been exaggerated by the 
inclusion of symptoms that were present due to other diseases.  The majority of studies 
have found that the mean or median symptom duration is less than 6 months.6, 13, 67, 78, 
89, 112  However, a median of 12 months has been reported by a US and a UK study.7, 94  
In general, the mean and median symptom duration for medical record studies were 
shorter than those derived from survey studies.  Most medical record studies have 
shown that 50%-70% of women are diagnosed within 3 months of symptom onset.  
Questionnaire and interview study results are much more mixed.  Collectively, the data 
on symptom duration are extremely heterogeneous and no strong conclusions can be 
drawn.  It is unclear whether this heterogeneity stems from differences in methodology 
or differences in study population or country-specific differences. 
39 
Table 2-5 shows symptom duration for individual symptoms.  No obvious patterns 
could be observed with regard to symptom duration and symptom type, or data 
collection method.  Duration was very similar within each study, values were typically 
between 2 to 4 months.   
Three studies have examined the timing of prediagnostic symptoms by dividing the 
months before diagnosis into periods and measuring symptom reporting in each period 
for cases versus controls.10, 20, 21  According to these studies, symptoms of ovarian 
cancer were detectable within 12 months of diagnosis.  Smith and colleagues found 
significantly higher case symptom frequencies on health insurance claims 10-12 
months before diagnosis for abdominal swelling and pelvic pain.20  Medical records 
from a prepaid health care system showed that abdominal pain was recorded 
significantly more in late stage cases (stage IC-IV) than controls (20% vs. 6%, 
respectively) 6-12 months prior to diagnosis.10  In the same study, very few symptoms 
were documented in excess for early stage disease (IA-IB), although as with late stage 
disease, abdominal pain was the most common symptom 6 months prior to diagnosis.  
Wynn et al. found that case-control symptoms diverged 2-3 months (60-90 days) 
before diagnosis on health insurance claims.21  Unfortunately, symptom reporting is 
likely to be underestimated by these studies as only indirect methods of data collection 
were used.   
Symptom duration was a main study outcome in a study based in Israel.112  The 
authors examined the effect of symptom duration on prognostic factors.  No 
relationship between stage, grade, residual tumour and symptom duration was found.  
Unfortunately, the quality of the data was questionable; only 371 of 1005 (37%) cases 
had symptoms recorded in medical notes, and just 187 (50%) of these had symptom 
duration data.  Therefore, it is unclear how reliable the data were. 
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Table 2-3 Symptom Duration for Any Symptom (i.e. Symptom Onset to Diagnosis) – Questionnaire or Interview Studies 
Study 
Data 
Source 
Total No. Symptomatic No. 
Symptom Duration for Any Symptom (months) 
Mean Median Range >3m* >6m* 
Goff et al. 
8
 2000 
(USA) 
Q 
1725 (T) 
385 (E), 1209 (L) 
95% (T) 
89% (E),97% (L)  
4 (E) 
5 (L) 
- - 70% (T) 35% (T) 
Vine et al.
6
 2001 
(USA)
a
 
I 
616 (IOC) 
151 (BL) 
556 (IOC) 
127 (BL) 
- 
4 (IOC) 
6 (BL) 
1-99 (IOC) 
1-99 (BL) 
>50% (IOC) 
>50% (BL) 
<50% (IOC) 
50% (BL) 
Koldjeski et al.
78
 
2003 (USA) 
Q, I 19 19 3
b
 - 0-12
b
 - - 
Chan et al.
89
 2003 
(HK) 
Q 
80 (T) 
43 (E), 37 (L) 
72 (T) 
1
b
 (T) 
1
b
 (E), 
 
0.4
b
 (L) 
- - - - 
Vine et al.
7
 2003 
(USA) 
Q, I 
200 (IOC) 
67 (BL) 
95% (T) - 12 (T) - >50% >50% 
Webb et al.
68
 2004 
(Australia)
 a
 
I 
218 (E) 
447 (L) 
185 (E) 
389 (L) 
- - - 
29% (E) 
27% (L) 
- 
Bankhead C.
94
 2005 
(UK) 
Q, I 44 44 - 12 2-48 >50% >50% 
*Proportion of women diagnosed more than 3 or 6 months after (first) symptom onset 
a
 Values calculated based on number of symptomatic women with invasive disease 
b
 Values converted from weeks to months by multiplying by 7, dividing by 30.4375 and rounding to the nearest month (rounded to 1 decimal place if less than 1 
month) 
Q=Questionnaire, I=Interview, IOC=Invasive Ovarian Cancer, BL=Borderline, T=Total, E=Early Stage, L=Late Stage 
Note: Italicised values are deduced from the median 
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Table 2-4 Symptom Duration for Any Symptom (i.e. Symptom Onset to Diagnosis) – Medical Record Studies 
Study 
Data 
Source 
Total No. Symptomatic No. 
Symptom Duration for Any Symptom (months) 
Mean Median Range >3m* >6m* 
Eltabbakh et 
al.
67
1999 (USA)
a
 
MR 
50 (IOC) 
22 (BL) 
41 (IOC) 
15 (BL) 
3 (IOC) 
8 (BL) 
- 
0-14 (IOC) 
1-24 (BL) 
- 24% (IOC+BL) 
Yawn et al.
16
 2004 
(USA) 
MR 107 91 - - 0-18 - 13%
a
 
Thulesius et al.
14
 
2004 (Sweden)
b
 
MR 99 74 - 2 - - - 
Lataifeh et al.
12
 2005 
(Australia)
c
 
MR 
200 (T) 
100 (E), 100 (L) 
190 (T) 
90 (E), 100 (L) 
- - - 
30% (T) 
30% (E), 31% (L) 
- 
Paulsen et al.
13
 2005 
(Norway)
d
 
MR 486 349 - 2 0-105 - - 
Menzcer et al.
112
 
2008 (Israel) 
MR 1005 187 - 2 1-60 - - 
*Proportion of women diagnosed more than 3 or 6 months after (first) symptom onset 
a
 Proportion of all women (i.e. symptomatic and asymptomatic).   
b
 Values converted from weeks to months by multiplying by 7, dividing by 30.4375 and rounding to the nearest month 
c
 Unclear if proportions are calculated based on all women or symptomatic women only 
d
 Symptom onset to date of first hospitalisation 
MR=Medical Records, IOC=Invasive Ovarian Cancer, BL=Borderline, T=Total, E=Early Stage, L=Late Stage 
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Table 2-5 Symptom Duration for Individual Symptoms 
Study 
Data 
Source 
n 
Mean or Median Symptom Duration (months) 
Abdominal 
Pain 
Abdominal 
Distension 
Bloating Fatigue 
Bowel 
Irregular 
Urinary 
Vine et al.
6
 2001 
(USA)
 a
  
I 616 2
f
 - - - 3 3 
Olson et al.
69
 2001 
(USA)
b
  
Q, I 
168 (T) 
37 (E) 
118 (L) 
6
d
 (T) 
8
d
 (E) 
6
d
 (L) 
- 
5
e
 (T) 
6
e
 (E) 
5
e
 (L) 
6 (T) 
7 (E) 
5 (L) 
6/5
c
 (T) 
5/8
c
 (E) 
6/4
c
 (L) 
6 (T) 
7 (E) 
5 (L) 
Vine et al.
7
 2003 
(USA)
 a, g
  
Q, I 200 2-4 2-4 - 5-7 5-7 5-7 
Goff et al.
75
 2004 
(USA)
a
 
Q 44 4 3 - 3 3/3
c
 4 
Paulsen et al
13
. 
2005 (Norway)
 a, h
  
MR 486 2 2 - 3
i
 3 2 
a
 Median 
b
 Mean 
c
 Constipation/Diarrhoea 
d
 Unusual abdominal or lower back pain 
e
 Unusual bloating, fullness and pressure in the abdomen or pelvis
 
f
 Pelvic discomfort 
g
 Values were only given as a range in the paper 
h
 First symptom experienced to first hospitalisation 
i
 Persistent fatigue or weight loss 
Q=Questionnaire, I=Interview, MR=Medical Records, T=Total, E=Early Stage, L=Late Stage 
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Diagnostic Delays 
As aforementioned, delays are inherently linked with symptom duration and lead time 
since they are both derived from the same information; and it is only the way in which 
the data are interpreted that differs.  Although total delay is the same as symptom 
duration, it is pertinent to discuss the possible causes of delay and to closer examine 
the different components of delay (i.e. patient versus provider delay).  The term „delay‟ 
carries negative connotations which imply that there is an avoidable prolongation of 
events.  Indeed, the investigation of diagnostic delays seeks to identify the length of 
time that diagnosis can be feasibly brought forward by the eradication of unnecessary 
delays.  However, there are certain processes between symptom onset and diagnosis 
that are valid and/or mandatory steps in the diagnostic pathway.  These may include 
the perfectly reasonable (patient) decision to wait several days or weeks before 
consulting for vague symptoms, and the equally sensible GP approach of „watching 
and waiting‟ after initial presentation for vague symptoms (unless symptoms are 
specific e.g. abdominal distension).  Also, the processing of CA125 tests, performance 
of ultrasound, and time taken to obtain a specialist appointment and surgery date, all 
require a minimum passing of time.  Hence, the labelling of the interval between 
symptom onset and diagnosis as „delay‟ is inaccurate and misleading.  All of these 
factors should be considered when interpreting delay data.  Moreover, it would be 
prudent to devise and standardise a better term to describe the interval in question.  
For the purposes of this thesis, the term „delay‟ will be employed to keep consistency 
with the literature. 
Diagnostic delays can be divided into patient delay (ignoring or misinterpreting 
symptoms, putting off GP visits) and provider delay (misdiagnosis, referral waiting 
times, omission of appropriate tests).  Crucially, delays and women ignoring symptoms 
have been associated with late stage disease.8  The calculation of delays is subject to 
the same limitations as the derivation of symptom duration data.  As such, existing 
delay data are as sporadic as duration data. 
Patient Delay 
Patient delay is usually defined as time from symptom onset (i.e. date that the woman 
becomes aware of the symptom) to first clinic visit for symptoms.  Only limited data on 
patient delay are available.  Several studies have found that most women (~80%) 
presented to clinic within 3 months of symptom onset (see Table 2-6).11, 12, 17, 19, 75  
Mean and median patient delay was 1 month or less for most studies according to both 
survey and medical record data.  The largest study reported a longer delay however, 
only a range was presented for the median (2-3 months) which is unusual, and 
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explanatory data were not provided.8  Two papers have reported a very short 
median/mean time from symptom onset to presentation.11, 89  The first, was a UK GP 
record study which found that 78% of women presented to the GP within four weeks of 
symptom onset.11  Interestingly, this study found that 18-month survival was not 
affected by delays however the authors did not adjust for stage in the analysis.113  The 
second, was a Hong Kong-based study which found that according to self-reported 
data, most women sought medical help within two weeks from symptom onset.89   
Overall, the literature suggests that most women with ovarian cancer present to a 
doctor within 1 month of symptom onset (see Table 2-6).  However, approximately a 
third of women have a delay of 3 months or more, which may be an area for 
improvement.  The distribution of delay in this 30% of women requires further 
elucidation. 
Provider Delay 
Provider delay is usually defined as time from first presentation to a doctor for a 
symptom to date of diagnosis.  This period covers both health system delays (waiting 
times for test results, imaging, referral appointments) and time taken for physicians 
(primary care and specialists) to make the diagnosis.  Identifying which was the first 
critical consultation for ovarian cancer symptoms is not straightforward and can vary 
depending on the definitions and methods used to derive this date.  In addition, 
deciding which symptoms were present and due to ovarian cancer can be highly 
subjective.  Provider delays may be underestimated in the literature by studies that use 
medical records as the sole data source, since many symptoms reported by patients go 
unrecorded.  On the other hand, one might reason that provider delay is more accurate 
than patient delay since all the required dates are recorded in the medical notes and do 
not depend on retrospectively recalled data from women.  Date of diagnosis was not 
clearly defined in most studies.  If date of diagnosis was self-reported from women, it is 
likely to differ from those taken from medical notes since this could be interpreted as 
the date they were first told they might have cancer as opposed to date of surgery or 
positive biopsy.  
Table 2-6 shows that approximately 60%-70% of women are diagnosed within 3 
months of presentation.  As with patient delay, mean and median provider delay 
appears to be 1 month or less for most studies, regardless of data collection method.  
Once mandatory diagnostic procedures are accounted for, these already short provider 
delays would become even more trivial.  However, again it is important to note that 
there are still around 30%-40% of women with symptoms that are diagnosed more than 
3 months after first presentation to a doctor. 
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The diverse methodology and forms of data presentation make it difficult to assess 
whether provider and patient delays are comparable across studies.  However, within 
studies it seems that patient and provider delay delays are similar (see Table 2-6, note 
that delays in weeks were converted to months).14, 75, 89   
Collectively, the data imply that most women with ovarian cancer have a relatively short 
patient or provider delay.  However, roughly a third of women have a patient or provider 
delay of >3 months.  In addition, there is a tendency for delays in early versus late 
stage, and borderline versus invasive disease, to be longer (Table 2-6). 
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Table 2-6 Patient and Provider Delay 
Study 
Data 
Source 
n 
Patient Delay (months) Provider Delay (months) 
Mean Median >3m* Mean Median >3m* 
Smith et al.
17
 1985 (USA) Q, I 82 - 1 23% - - - 
Flam et al.
19
 1988 (Sweden) I 172 (E) 
190 (L) 
-  14% (E) 
23% (L) 
- - 12% (E) 
20% (L) 
Goff et al.
8
 2000 (USA) Q 1725 - 2-3 - - - 45% 
Vine et al.
6
 2001 (USA) I 616 - - - - 1 25% 
Vine et al.
7
 2003 (USA) Q, I 65 (E) 
135 (L) 
- 4 (E) 
2 (L) 
- - 3 (E) - 
Chan et al.
89
 2003 (HK)
 a
 Q 80 (T) 
43 (E), 37 (L) 
0.4 (T) 
0.3 (E), 0.4 (L) 
- - 0.2 (T) 
0.2 (E), 0.1 (L) 
- - 
Webb et al.
68
 2004 
(Australia)
 a
 
Q, I 665 (IOC) 
146 (BL) 
- 0.9 (IOC+BL) - - 0.5 (IOC+BL) - 
Goff et al.
75
 2004 (USA) Q 44 - - 40% - - - 
Kirwan et al.
11
 2002
b 
(UK) MR 102 - - 22% - - 27% 
Thulesius et al.
14
 2004 
(Sweden)
a
 
MR 99 - 1 - - 1 - 
Paulsen et al.
13
 2005 
(Norway) 
MR 486 - - 55% - - 39% 
*Proportion of women diagnosed more than 3 months patient or provider delay
 
a
 Values converted from weeks to months by multiplying by 7, dividing by 30.4375 and rounding to the nearest month (rounded to 1 decimal place if less than 1 
month) 
b
 Time from first presentation to referral 
Q=Questionnaire, I=Interview, MR=Medical Records, IOC=Invasive Ovarian Cancer, BL=Borderline, T=Total, E=Early Stage, L=Late Stage 
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2.4.2 Updated Overview of Ovarian Cancer Symptoms 
In the current review, a total of 29 papers were evaluated.  Eleven studies were based 
on medical record data,9-14, 16, 67, 96, 97, 100 14 used self-reported data,6-8, 17, 19, 68, 69, 75, 78, 89, 
90, 94, 104 and 3 utilised coded insurance billing records.21, 92, 101  Two further papers 
derived data from a mixture of medical records and interview.98, 112  Not all of the 
studies that were evaluated in the previous systematic review were included in the 
current review (and vice-versa), as the aims were not the same.   
A meta-analysis from the previous systematic review showed that the majority of 
women with ovarian cancer have symptoms before (or at) diagnosis (93% and 77% 
according to self-reported and medical record data, respectively).93  Women who are 
reported as „asymptomatic‟ are presumably either diagnosed incidentally while 
undergoing examinations or procedures for other morbidities, or detected via some sort 
of screening procedure.  Women who present acutely as emergency cases may also 
have been classified as „asymptomatic‟, however this is not quite correct since they 
must have had symptoms to prompt the emergency visit.  Unfortunately, most authors 
have not provided details of the classification, thus the true proportion of asymptomatic 
women is not clear.   
Table 2-7 to Table 2-10 summarise the studies performed to date in terms of the 
participants, selection of cases and controls, data collection method, symptom 
elicitation method, period over which symptoms were asked about, and the three most 
common (sensitive) symptoms reported by ovarian cancer cases.  All of the studies 
used retrospective data (i.e. the data collected pertained to events that had occurred in 
the past).  Some of the studies included borderline and benign tumours in their 
definition of „cases‟, however for simplicity, some of the data in the tables were limited 
to invasive disease.  
Abdominal/pelvic pain or discomfort, abdominal distension/swelling and bloating are 
the most commonly reported symptoms regardless of the data collection methods (see 
Table 2-7 to Table 2-10).7, 20, 69, 75, 101  Other symptoms of note include fatigue, 
indigestion, change in bowel habit, constipation, urinary symptoms, loss of appetite, 
nausea, palpable mass, weight loss, and irregular vaginal bleeding.6-8, 15-19, 67-69, 75, 89, 91  
In general, the comparability across studies is limited by grouping of symptoms 
(discussed further in methodological issues section).  Several studies9, 19, 20, 68, 112 have 
presented gastrointestinal (GI) symptoms as a group, which makes it impossible to 
assess sensitivity of individual GI symptoms.  Also, the classification of GI symptoms 
may have differed between studies, and it is not clear in some studies what was 
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included under this heading.  Nevertheless, it is clear that abdominal and 
gastrointestinal symptoms predominate in ovarian cancer.  Gynaecological symptoms 
are among the least frequently reported symptoms in most studies.8, 12, 15, 17-19  
Presumably, this is due to the fact that most women develop disease after menopause 
when the ovaries lack physiological function.  Other symptoms that have been 
associated with ovarian cancer include back pain,8, 10, 11, 19, 75, 90, 98, 104 leg swelling,75, 90, 98 
pain with intercourse,7, 8, 104 difficulty breathing,7, 13, 14, 17, 19, 90, 104 and diarrhoea.17, 69, 75  
However, these are reported less frequently (less than <50% of women).  
As expected, symptom prevalence is much lower in medical record and coded 
insurance bill studies in comparison to questionnaire/interview studies.  However, the 
overall symptom spectrum remained similar for all of the data sources.  Similarly, no 
patterns were observed for studies that examined the 12 months before diagnosis 
versus studies that evaluated no specific period.   
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Table 2-7 Questionnaire & Interview Studies 
STUDY 
STUDY 
DESIGN 
PARTICIPANTS PERIOD COLLECTED MOST COMMON CASE SYMPTOMS 
Smith & Anderson
17
 
1985 (USA)
a
 
RCS, Q, I, SR 82 OC cases (36 local, 46 
distant) from population-
based cancer registry 
Age 20-54 
 
Symptoms that prompted 
healthcare-seeking.   
Mean time from diagnosis: 10 
weeks, range 1-3 months. 
Abdominal swelling (70%) 
Fatigue (56%) 
Abdominal pain (48%) 
Flam et al.
19
 1988 
(Sweden)
b
 
RCS, I, unclear 
if CL or SR  
362 OC cases (172 stage IA-
IIA,190 stage IIB-IV) referred 
to a specific gynaecology 
department.  
Age not given 
 
Women questioned prior to 
admission about symptoms 
before treatment. 
Abdominal swelling (27%/24%) 
GI symptoms (15%/24%) 
Abdominal pain (17%/11%) 
Igoe et al.
90
 1997 
(USA)
c
 
RCS, Q, CL, SR 50 invasive & BL OC 
identified via the internet.   
Age 35-75 
Women asked about symptoms 
preceding diagnosis.   
Median time from diagnosis: 20 
months 
 
Fatigue (82%) 
Abdominal swelling (78%) 
Indigestion (72%) 
Goff et al.
8
 2000 
(USA & Canada) 
RCS, CL  1725 OC cases (385 stage I-
II, 1209 stage III-IV, 131 
unknown) identified from 
mailed survey 
Age 18-84  
Symptoms before diagnosis. 
Median time from diagnosis: 24 
months 
Increased abdominal size (61%) 
Abdominal bloating (57%) 
Fatigue (47%) 
a
 Percentages shown are for proportion of symptomatic women 
b
 Percentages shown are split by early stage/late stage 
c
 Percentages shown are for invasive and borderline 
RCS=Retrospective Case Series, CC=Case-control, Q=Questionnaire, I=Interview, CL=Checklist, SR=Spontaneous reporting, OC=Ovarian Cancer, BL=Borderline 
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STUDY 
STUDY 
DESIGN 
PARTICIPANTS PERIOD COLLECTED MOST COMMON CASE SYMPTOMS 
Olson et al.
69
 
2001 (USA) 
CC, Q, I, 
CL, SR 
138 OC cases (37 stage I-II, 118 
stage III-IV) identified at two 
hospitals, 251 population controls.   
Age ≥18 
 
Symptoms present in the 6-12 months 
before diagnosis.  Mean time from 
diagnosis: 4.7 months 
Unusual bloating, fullness & pressure in 
abdomen/pelvis (71%) 
Unusual abdominal or lower back pain 
(52%) 
Unusual lack of energy (43%) 
 
Vine et al
6
. 
2001 (USA)
a
 
RCS, Q, 
I, CL, SR 
767 OC cases (616 invasive, 151 
BL) from existing CC study. 
Age 20-69 
 
 
Symptoms before diagnosis.  
Diagnosed within last 6 months.   
Pelvic discomfort (71%) 
Bowel irregularity (47%) 
Urinary frequency/urgency (37%) 
 
Vine et al
7
. 
2003 (USA)
b
 
CC, I, CL, 
SR 
267 EOC cases (65 stage I-II, 135 
stage III-IV, 67 BL), 317 controls 
from existing population-based CC 
study. 
Age 20-74 
 
Time from diagnosis median: 4.6 
months.  Symptoms present for at 
least 2 weeks during year before 
diagnosis. 
Pelvic/abdominal discomfort/pain (64%) 
Bloating or feeling of fullness (62%) 
Distended/hard abdomen (59%)  
Chan et al
89
. 
2003 (HK) 
RCS, I, 
SR 
80 EOC cases (43 stage I-II, 37 
stage III-IV) from a single 
gynaecology department. 
Age 18-70 
 
Interviewed before treatment.  
Symptoms before diagnosis. 
Abdominal pain/discomfort (26%) 
Abdominal distension (25%) 
Menstrual symptoms (15%) 
a 
Percentages shown are for invasive cases only 
b 
Cases could also report symptoms on the checklist of any duration 
RCS=Retrospective Case Series, CC=Case-Control, I=Interview; CL=Checklist; SR=Spontaneously Reported, EOC=Epithelial Ovarian Cancer, OC=Ovarian 
Cancer, BL=Borderline  
 5
1
 
STUDY 
STUDY 
DESIGN 
PARTICIPANTS PERIOD COLLECTED MOST COMMON CASE SYMPTOMS 
Koldjeski et al.
78
 
2003 (USA) 
RCS, I, Q, 
CL, SR 
19 OC cases referred from regional 
cancer clinics (6 stage I-II, 13 stage III-
IV). 
Age 28-73 
 
Time from diagnosis: 2-3 weeks. 
Prediagnostic symptoms. 
Bloating (84%) 
Vague abdominal pain (68%) 
Indigestion (63%) 
Webb et al.
68
 
2004 
(Australia)
a
 
CC, Q, I, 
SR 
811 EOC cases (218 stage I-II, 447 
stage III-IV, 146 BL) from an existing CC 
study.  
Age 18-79 
 
 
Symptoms that first prompted 
doctor visit.  Maximum of 4 
different symptoms could be 
reported.   
 
Abdominal pain/pressure (44%)  
Abdominal swelling/tightening (39%) 
GI (15%)  
Goff et al. 
75
 
2004 (USA)
b
 
CC, CL 128 ovarian tumours (44 invasive EOC 
cases [11 stage I-II, 33 stage III-IV], 74 
benign, 10 BL), approached 
preoperatively at 2 cancer centres. 1011 
controls visiting 2 primary care clinics. 
Age 15-90 
Cases completed survey before 
definitive diagnosis.  Symptoms 
in 12 months before diagnosis. 
Increased abdominal size (64%)  
Bloating (70%)  
Fatigue (61%)  
a 
Percentages shown are for proportion of symptomatic women 
b
 Percentages shown are for invasive cases only 
RCS=Retrospective Case Series, CC=Case-Control, I=Interview, CL=Checklist, SR=Spontaneously Reported, EOC=Epithelial Ovarian Cancer, BL=Borderline,   
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STUDY 
STUDY 
DESIGN 
PARTICIPANTS PERIOD COLLECTED MOST COMMON CASE SYMPTOMS 
Olsen et al.
104
 
2007 
(Australia)
a, b
 
RCS, I, SR, 
CL 
244 invasive OC cases (89 stage I-II, 155 
stage III-IV) 62 BL, 151 benign, identified 
via gynaecology cancer centre.  
Age 18-79 
 
Time from diagnosis: median 12 
months.  Symptoms before 
diagnosis and at presentation. 
Abdominal pain/pressure (56%/58%) 
Abdominal swelling (43%/60%) 
Gas/nausea/indigestion (34%/44%) 
Bankhead C.
94
 
2005 (UK)
c
 
O, I, SR  44 cases (40 OC, 2 PP, 2 other 
gynaecological cancers), 80 non-cancer 
cases (59 benign, 21 normal findings), all 
referred to hospital for suspected ovarian 
malignancy. 
Mean age 59 (cases), 48 (non-cancer 
cases) 
Interviewed before definitive 
diagnosis or soon after 
diagnosis. Symptoms prior to 
interview 
Abdominal distension (±Bloating) (86%) 
Malaise (73%) 
Abdominal pain (59%) 
 
a 
Percentages shown are for proportion of symptomatic women 
b
 Percentages shown are split by early stage/late stage 
c
 Percentages shown are for the 44 cases only 
RCS=Retrospective Case Series, CC=Case-Control, O=Observational, I=Interview, CL=Checklist, SR=Spontaneously Reported, OC=Ovarian Cancer, 
BL=Borderline, PP=Primary Peritoneal  
 5
3
 
Table 2-8 Medical Record Studies 
STUDY 
STUDY 
DESIGN 
PARTICIPANTS PERIOD COLLECTED MOST COMMON CASE SYMPTOMS 
Kennedy & 
Gordon
97
 1981 
(UK) 
 
RCS, HR 97 OC cases from a 
single hospital.  
Age 11-83 
Presenting symptoms Abdominal pain (34%) 
Abdominal distension (21%) 
Abdominal mass (10%) 
Piura et al.
96
 1998 
(Israel)
a
 
RCS, HR 52 OPSC Stage III-IV, 15 
PPSC from a single 
hospital 
Mean age OPSC 56 
Mean age PPSC 62 
 
Presenting signs and symptoms Abdominal mass (79%) 
Ascites (39%) 
Pleural effusion (12%) 
Eltabbakh et al.
67
 
1999 (USA)
a
 
RCS, HR 50 stage I-II IOC cases, 
22 BL, identified from 
cancer registry.  
Age 16-89 
 
Presenting symptoms Abdominal/pelvic pain (38%) 
Increased abdominal girth/bloatedness (28%) 
Vaginal bleeding (22%) 
Kirwin et al.
11
 2002 
(UK) 
RCS, GP 135 EOC cases (38 stage 
I-II, 78 stage III-IV, 19 
unstaged) from audit of 
Mersey area.  
Age Not given 
12 months before diagnosis Abdominal pain (48%) 
Change in bowel habit (25%) 
Abdominal swelling (19%) 
a
 Percentages are for invasive ovarian cancer cases only 
RCS=Retrospective Case Series, HR=Hospital Records, GP=GP Records, EOC=Epithelial Ovarian Cancer, IOC=Invasive Ovarian Cancer, BL=Borderline, 
OPSC=Ovarian Papillary Serous Carcinoma, PPSC=Peritoneal Papillary Serous Carcinoma 
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STUDY 
STUDY 
DESIGN 
PARTICIPANTS PERIOD COLLECTED MOST COMMON CASE SYMPTOMS 
Attanucci et 
al.
9
2004 (USA)
a,
 
b
 
CC, HR 114 IOC cases, 33 BL, 76 
benign identified via tumour 
registry board.  
Age 15-86 
Symptoms recorded at initial 
consultation before surgery. 
Pain (57%) 
GI (54%) 
Constitutional 
c
 (43%) 
Thulesius et al.
14
 
2004 (Sweden) 
RCS, 
GP, HR 
99 OC (41 stage I-II, 58 stage 
III-IV) identified via regional 
tumour registry.  
Mean age 63 
12 months before diagnosis Urinary & GI (compression) (38%)  
Abdominal pain (38%) 
Abdominal swelling (33%) 
Yawn et al.
16
 2004 
(USA)
d
 
RCS, 
GP, HR 
107 IOC (42 stage I-II, 62 
stage III-IV, 3 unstaged) 
identified via diagnostic 
database for Olmsted County 
Age 30-98 
 
Two years before diagnosis Abdominal pain (38%) 
Bloating/increased abdominal girth (13%) 
Urinary symptoms (13%) 
Lataifeh et al.
12
 
2005 (Australia) 
RCS, 
HR 
200 invasive EOC cases (100 
stage IA-IB, 100) stage IIIC) 
from a tertiary referral centre 
for gynaecological cancer. 
Age not given 
Presenting symptoms Abdominal pain (48%)  
Abdominal swelling (47%)  
Abdominal bloating (12%)  
a
 Percentages are for invasive ovarian cancer cases only  
b
 Percentages calculated by Anita Lim 
c 
Fatigue, fever, weight loss, weight gain 
d 
Primary peritoneal cancers were included
 
RCS=Retrospective Case Series, HR=Hospital Records, GP=GP Records, OC=Ovarian Cancer, IOC=Invasive Ovarian Cancer, EOC=Epithelial Ovarian Cancer, 
BL=Borderline 
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STUDY 
STUDY 
DESIGN 
PARTICIPANTS PERIOD COLLECTED MOST COMMON CASE SYMPTOMS 
Friedman et al.
10
 
2005 (USA)
a
 
RCS, 
GP, HR 
102 OC cases, (33 stage IA-
IB, 69 stage IC-IV), 102 age-
matched controls. All women 
enrolled on Kaiser 
Permanente Medical Care 
Program. 
Age 29-87 
Two years prior to diagnosis 
divided into 0-6, 6-12, 12-24 
months 
Abdominal pain (55%) 
Fatigue/weakness/lack of energy 
(39%)  
Headache (38%)  
 
Abdominal Pain (46%) 
Abdominal bloating/ 
fullness/pressure (23%) 
Nausea (20%) 
 
Abdominal pain (20%) 
Nausea (15%) 
 
Anytime (2 years) 
 
 
 
 
6 months before 
diagnosis 
 
 
 
1 year-6 months 
before diagnosis 
 
Paulsen et al.
13
 
2005 (Norway)
b
 
RCS, 
HR 
623 EOC (486 invasive, 137 
BL) identified via cancer 
registry.  
Age 25-94 
Data are from notifications to 
cancer registry and medical 
records 
Abdominal pain/discomfort (53%) 
Distended/tense abdomen (44%) 
Bowel irregularity (26%) 
Persisting fatigue or weight loss (26%) 
Deligdisch et al.
100
 
2007 (USA & 
France) 
RCS, 
HR 
76 stage I IOC cases.  
Age not given 
Symptoms at presentation Symptomatic pelvic mass (46%) 
Vaginal bleeding (28%)  
Asymptomatic pelvic mass (21%) 
a
 Stages IC-IV only 
b
 Percentages are for invasive cases only 
RCS=Retrospective Case Series, HR=Hospital Records, GP=GP Records, IOC=Invasive Ovarian Cancer, EOC=Epithelial Ovarian Cancer, OC=Ovarian Cancer, 
BL=Borderline 
 
 5
6
 
Table 2-9 Interview and Medical Record Data Studies  
STUDY 
STUDY 
DESIGN 
PARTICIPANTS PERIOD COLLECTED MOST COMMON CASE SYMPTOMS 
Beck et al.
98
 
2001 (USA)
a
 
RCS, I, HR 52 early stage (I-II) OC cases operated 
on by the lead author.  
Age 30-85. 
Time from diagnosis: median 62 
months.  Symptoms at presentation 
from medical records (n=52), and 
interview with those still alive (43/46). 
 
Pain (abdominal or pelvic) (35%) 
Increased abdominal girth (33%) 
Vaginal bleeding (15%) 
Menczer et 
al.
112
 2008 
(Israel)
b
 
I, unclear if 
CL or SR, 
HR  
1005 EOC cases identified from existing 
CC study. 
Symptoms at presentation 
 
Abdominal pain (65%) 
Abdominal swelling (35%) 
GI (27%) 
a
 Unclear if percentages relate to combination of interview and medical record data or medical record data alone 
b 
Only 37% had symptoms recorded 
RCS=Retrospective Case Series, CC=Case-Control, I=Interview; HR=Hospital Records, CL=Checklist; SR=Spontaneously Reported, OC=Ovarian Cancer, 
EOC=Epithelial Ovarian Cancer 
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Table 2-10 Coded Insurance/Billing Claim Records 
STUDY 
STUDY 
DESIGN 
PARTICIPANTS PERIOD COLLECTED MOST COMMON CASE SYMPTOMS 
Smith et al.
114
 
2005 (USA)
a
 
CC. 
Predetermined 
symptom list, 
ICD-9 codes 
1895 OC cases (287 stage IC-II, 
1453 stage III-IV, 245 unstaged), 
10941 breast cancer controls, 6024 
cancer-free controls.  All women 
enrolled in Medicare in California. 
Age 68-101 
36 months before 
diagnosis, divided into 
quarters starting at 1-3 
months prior to diagnosis  
Abdominal pain (31%)  
Abdominal swelling (17%) 
GI (8%)  
 
Abdominal pain (9%) 
Abdominal swelling (2%)  
GI (2%)  
 
1-3 Months  
 
 
 
4-6 Months  
 
Ryerson et al.
101
 
2007 (USA)
b
 
RCS, 
Predetermined 
symptom list, 
ICD-9 codes 
3250 OC cases (601 stage I-IB, 
196 stage IC-II, 2453 stage III-IV) 
from the SEER-Medicare database.   
Age 65-98 
 
Claims with symptoms 
within 12 months of 
diagnosis 
Abdominal pain and tenderness (49%) 
Abdominal or pelvic swelling (43%) 
Constipation, diarrhoea, other digestive disorders 
(18%) 
Wynn et al.
21
 
2007 (USA)
c
 
CC. 
Predetermined 
symptom list, 
ICD-9 codes 
920 OC cases, 2760 matched 
controls from a national claims and 
encounters database 
(MarketScan). 
Median age 59 
National claims and 
encounters database. 
Symptoms within 9 months 
of diagnosis 
Abdominal symptoms (36%) 
Chest/respiratory symptoms 
(17%) 
Urethra/urinary tract disorders 
(13%) 
270-31 days 
before diagnosis 
 a
 Medicare provider claims linked to California SEER database 
b
 Medicare claims linked to SEER cancer registries 
c
 Thomson Healthcare‟s Medstat MarketScan Commercial Claims & Encounters & Medicare Supplemental Databases. 
RCS=Retrospective Case Series, CC=Case-Control, OC=Ovarian Cancer, SEER=Surveillance, Epidemiology, and End Results 
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2.4.2.1 Case-Control Studies  
Five case-control studies have been published comparing women with ovarian cancer 
to women without ovarian cancer.7, 10, 20, 69, 75  Notably, the Vine and Olson studies used 
healthy volunteers which can overinflate case-control differences via a „healthy 
volunteer effect‟.7, 69  The remaining 3 studies used women seeking healthcare.10, 20, 75  
Overall, the main findings include that women with ovarian cancer have symptoms of 
shorter duration (i.e. recent onset), greater severity and higher frequency in 
comparison to cancer-free women.7, 10, 20, 69, 75  Women with ovarian cancer also 
experienced a higher number of symptoms.7, 69, 75   
As expected, larger odds ratios (OR) were observed in the studies using controls who 
were not actively seeking healthcare (see Table 2-11).7, 20, 69, 75  The highest odds ratios 
obtained for three of the case-control studies were for abdominal distension.7, 20, 75   
The proportion of controls that reported symptoms was relatively high in some of the 
studies that collected data directly from women.69, 75  In one study, 38% reported 
bloating and 30% had abdominal pain.75  Conversely, symptom reporting was much 
lower in studies using medical records or coded insurance claims.10, 20 
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Table 2-11 Frequency & Odds Ratios for Common Symptoms in Case-Control Studies 
 
Olson et al.
69
 2001 
(USA) 
Vine et al.
7
 2003 
(USA) 
Goff et al.
75
 2004 
(USA) 
Smith et al.
20
 2005
*
 
(USA)
e
 
Friedman et al.
10
 2005 
(USA) 
Cases (Ca) 168 267
b
 44 1985 102 
Controls (Co) 251 317 1011 6024 102 
Symptom 
% 
Ca/Co 
OR 
(95%CI) 
% 
Ca/Co 
OR 
(95%CI) 
% 
Ca/Co 
OR 
(95%CI) 
% 
Ca/Co 
OR 
(95%CI) 
% 
Ca/Co 
OR 
(95%CI) 
Abdominal Pain 52/15
a
 
6.2 
(4.0, 9.6) 
64/10
c
 
16.2  
(10.3, 25.3) 
50/30 
2.3 
(1.2, 4.4) 
31/4 
6.2 
(5.2, 7.4) 
55/19 
8.9 
(4.0, 20.3) 
Abdominal 
Distension 
- - 59/5
d
 
29.2 
(16.5, 51.8) 
64/19 
7.4 
(3.8, 14.2) 
17/0
f
 
39.2 
(22.5, 68.1) 
- - 
Bloating 71/9 
25.3 
(15.6, 40.9) 
62/10 
14.6 
(9.4, 22.8) 
70/38 
3.6 
(1.8, 7.0) 
- - 30/6
g
 
6.4 
(2.6, 26.3) 
a 
Unusual abdominal or lower back pain  
b 
Includes borderline and invasive cases 
c 
Pelvic/abdominal discomfort/pain 
d
 Distended or hard abdomen  
e
 1-3 months before diagnosis 
f
 Abdominal or pelvic swelling or mass 
g
 Abdominal bloating, fullness, pressure 
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Severity & Frequency 
It has been suggested that subtleties in symptom frequency and severity may have a 
critical role in facilitating earlier diagnosis via symptoms.69, 75, 94  Indeed, ovarian 
carcinomas have been shown to give rise to symptoms that are persistent and 
frequent.69, 75  Only one study has asked women about symptom severity directly.  They 
found that patients with ovarian malignancy had significantly more severe symptoms in 
comparison to women with benign masses and other clinic patients.75   
However, severity and frequency of symptoms are liable to change over time and with 
disease progression.  Also, the two parameters may not be independent, and 
perceived severity probably intensifies with increased frequency.  The definition of what 
constitutes a single episode of symptoms can vary with different symptoms, and the 
frequency of symptoms can be irrelevant for some symptoms.  For example, a single 
episode of postmenopausal bleeding can be of greater concern than four episodes of 
nausea or vomiting, and both could occur over a single day.  As such, comparability of 
frequency data for different symptoms can be limited.  Similarly, asking about the 
severity of an abdominal lump is vague and potentially irrelevant.  Thus, the collection 
and interpretation of severity and frequency data requires careful consideration.  
Ultimately, to be a useful discriminatory factor, differences in symptom severity and 
frequency would need to be apparent relatively early on in symptom onset to provide a 
sufficient window of opportunity to intervene.  Although, potentially worsening of 
severity and/or frequency could be useful. 
Number of Symptoms 
The number of symptoms experienced was significantly greater in ovarian cancer 
compared to controls in two studies performed in the US.69, 75  In the Olson study, 
cases reported a mean of 3.0 (± 1.8) symptoms while controls had a mean of 0.8 (± 
1.3) (p<0.001).69  Ninety-three per cent of cases reported at least one symptom, 
compared with only 43% of controls.  Goff‟s group showed that the median number of 
symptoms was 8 for cases versus 2 for controls.75  Vine et al. found that cases were 
more likely to report having multiple (≥3) symptoms than population-based controls 
(81% versus 18%, respectively).7   
Symptom Duration 
In a questionnaire study, Goff et al. reported median symptom durations between 3-6 
months for women with ovarian cancer compared to 11-12 months for clinic controls.75  
However, there were age differences between the two groups, women in the clinic 
61 
population included a vast age range (15-90 years) with a median of 45, whereas 
women with ovarian carcinoma had a median age of 55 (range not reported).   
2.4.2.2 Early versus Advanced Disease 
A symptom profile specific to early stage disease has obvious appeal, given the 
significantly more favourable early stage survival rates.  Unfortunately, once patients 
have been divided into early versus late stage, the numbers have often been too small 
for any meaningful comparisons.  Ideally, one would hope to be able to identify 
symptoms in women with advanced disease, which were also present when the tumour 
was still localised (i.e. early stage).  This would provide evidence that a stage shift was 
possible via „early‟ symptom detection and a „targeted screening‟ approach.  Although 
women with early stage disease have symptoms, to date, a clear temporal relationship 
between symptoms of early and late disease has not been established.   
The limited data available indicate that women with early and late stage disease share 
the same symptom spectrum.  There are however, some disparities.  Abdominal 
swelling, 7, 68, 104 fatigue,7, 68, 69 and gastrointestinal symptoms,8, 9, 19, 68, 89, 101 are cited 
more often by women with advanced stage disease.  In contrast, urinary symptoms9, 68 
and gynaecological symptoms9, 12, 68, 101 and an abdominal mass9, 68 are more frequently 
associated with early stage disease.   
Most studies have reported that women with early disease are more likely to be 
asymptomatic before diagnosis in comparison to patients with advanced disease.7, 9, 12, 
16, 19, 68, 69, 89, 104  Only one study reported to the contrary.8  Women with advanced 
disease also tend to have a higher number of symptoms.8, 12, 75, 104 
Some groups have attempted to identify symptoms specific to early stage disease by 
focussing on those that are reported first chronologically.7, 68  Overall, the first 
symptoms reported were similar in early and late stage disease, and only non-
significant trends have been identified.  Vine et al.7 found that pelvic/abdominal 
discomfort or pain was the most commonly reported first or second symptom for early 
and advanced stages.  Webb and colleagues found that abdominal pain/pressure and 
abdominal swelling/tightening were most commonly reported as the first symptoms in 
early (I-II) and late (III-IV) stage disease.68   
Two questionnaire studies have reported longer symptom duration associated with 
early stage disease (Table 2-5) however, one had very few early stage cases (n=37 
stage I-II),69 and the other defined early stage narrowly as IA-IIA.19  Longer symptom 
duration with early stage disease could be indicative of a less aggressive cancer (as is 
62 
the case in breast cancer).115  In contrast, several other studies found no difference in 
symptom duration for early versus late stage disease.8, 12, 68   
In general, there is very little data to suggest that there is a direct relationship between 
earlier presentation and diagnosis of early stage disease.  Several researchers have 
postulated that differences in tumour biology may explain this phenomenon.9, 12, 66, 112  
Potentially, women detected at advanced stages could have disease that is more 
aggressive and rapidly metastasizing such that symptoms only appear when disease 
has already progressed.  Conversely, women found with early stage malignancies may 
have disease that is less aggressive, allowing tumours to grow to a large size while 
disease is still localised.  
2.4.2.3 Benign & Borderline Tumours versus Malignant Tumours 
The focus of this project was at the primary care level, and how much earlier the 
referral to gynaecological-oncology could be made by acting on symptoms.  The 
process of discriminating between benign, borderline and malignant tumours would 
then be performed at the secondary or tertiary care level.  Hence, using symptoms for 
discriminating between these tumour types was not of interest in this thesis.  
Furthermore, the existing evidence suggested that it would not be possible (given that 
each tumour type seems to produce similar symptoms).6, 7, 9, 13, 67, 68, 75  Therefore, 
benign tumours were excluded from the case-control study (Part II).  Conversely, 
borderline tumours were included because of their inclusion in the survival and 
mortality national statistics for ovarian cancer.   
Two studies have compared the symptoms associated with benign versus malignant 
tumours.9, 75  Both showed that women with benign and malignant masses had 
comparable symptom profiles.  Also, the proportion of women that present with 
symptoms is comparable for benign and malignant ovarian neoplasms.9, 75   
Borderline and invasive tumours display no distinctive symptom qualities that would 
help separate the two groups with certainty, although some minor differences may 
exist.6, 7, 13, 67, 68  A Norwegian study reported significantly more abdominal pain, bowel 
irregularity, fatigue or weight loss and respiratory difficulties with invasive versus 
borderline disease.13  Likewise, a study in North America found that pelvic discomfort 
and bowel irregularity were significantly more common in women with invasive versus 
borderline tumours.6  Studies have also shown that women with borderline disease are 
more likely to be asymptomatic at diagnosis and tend to have longer symptom duration 
than women with invasive cancer.6, 13, 67, 68  
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2.4.3 Key Methodological Issues 
On a research level, examination of prediagnostic symptoms is hampered by the 
relatively low incidence of disease and the undifferentiated nature of the symptoms.  A 
case-control study design can overcome the problems with investigating rare diseases, 
but the accurate assessment of highly subjective symptoms requires careful 
consideration of methodology and study design.  The methodological flaws in some 
studies have limited the interpretation.  The main issues will be discussed in this 
review, including: 
 Data Collection Issues - Methods of symptom elicitation (spontaneous reporting 
versus checklist, lack of validated questionnaires) 
 Recall and Recording Errors 
 Retrospective versus Prospective Study Design 
 Selection Bias  
 Semantic Issues 
 Poor Definition of Study Populations  
Data Collection Issues 
Symptom data can be derived either directly (from women) or indirectly (from medical 
notes); both methods have their inherent drawbacks and each may detect symptoms 
that differ in quality and threshold.  Data collected from women (for research) are 
considered to be flawed by subjectivity whereas data from medical notes are regarded 
as objective but limited (for reasons discussed later).  In general, a research setting is 
likely to capture symptoms that patients do not report in clinic.  Obtaining retrospective 
symptom data directly from women has typically involved either the application of 
various checklists within a questionnaire (most of which are unvalidated), or the use of 
open-ended questions (spontaneous symptom reporting).  These may be in the format 
of an interview or a self-administered questionnaire.  Spontaneous reporting of 
symptoms is known to elicit lower response rates than specific questioning.27, 28  Also, 
the threshold for spontaneous symptom reporting may be altered by variables such as 
patient personality and skills of the interviewer or physician.24  In contrast, data that are 
obtained directly from the subject may over inflate symptom prevalence due to the 
tendency for subjects to answer positively to symptoms asked about on a checklist.24  
However, this method can also detect symptoms that physicians fail to recognise or 
record. 
Studies with data extracted from medical records have been classified as retrospective 
however the symptom data collected are really contemporaneous in that they have 
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been recorded at the time of reporting by the women.  For self-administered 
questionnaires, the women‟s comprehension of the terms (or jargon) used to describe 
the symptoms is crucial.  Similarly, the words used by women to describe vague 
symptoms are subject to interpretation and may be paraphrased by the interviewer or 
GP when recorded.  For instance, the phrase “I‟m really blown up” could be recorded 
as abdominal bloating, abdominal swelling or gas.  Such scenarios introduce some 
degree of variation, but this can be reduced by applying strict predetermined symptom 
definitions.  Another important factor is that medical records tend to be diagnosis-
driven;24 often a diagnosis will be recorded rather than symptoms.  In case-control 
studies this is less important, since the effect will be uniform for both groups, however 
symptom sensitivity (i.e. the full spectrum of symptoms experienced) will be 
underrepresented.   
Symptom reporting is also affected by whether or not women associate their symptoms 
with cancer.17, 107  If women perceive their symptoms to be due to other causes, 
symptoms may go unreported.  
A second but different issue is with data that are recorded for non-research purposes 
(e.g. medical records).  Symptom recording in this setting is prone to incompleteness 
and recording errors.   
Recall and Recording Errors 
Recall bias is a particular problem in the ovarian cancer population as the diagnosis is 
traumatic and patient anxiety and mood at the time of recall can affect perception of 
symptoms.116  If symptom data are collected after surgery or chemotherapy, one might 
expect additional recall bias.  Furthermore, symptoms may abate or change post-
treatment, and chemotherapy could induce new symptoms or worsen pre-existing 
symptoms.  Recruiting women who are about to undergo surgery for pelvic masses of 
(as yet) unknown aetiology may circumvent relative recall bias (i.e. recall bias between 
women with malignant versus benign tumours).  However, this approach does not 
address the problem of absolute recall bias (i.e. comparisons with women from the 
general „healthy‟ population), since all women with suspected malignancy will have 
some degree of anxiety over their pending diagnosis and major surgical procedure.  In 
addition, some women may be warned preoperatively that a cancer diagnosis is almost 
certain if there are strong clinical indications of malignancy.  For these reasons, it is 
unlikely that study design will completely overcome the issue of recall bias when 
retrospective data are collected directly from women.  A very large prospective study is 
required to achieve this. 
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Retrospective data collection is also subject to general inaccuracy from errors in recall.  
Various factors such as age, gender and severity may contribute to differences in the 
ability to recall events.  However, a more important determining factor in accuracy of 
recall is time-elapsed since the event.  The longer this period is, the greater the 
memory decay and recall error.117  The Memorial Sloan-Kettering group asked women 
about symptoms that were present in the 6-12 months before diagnosis.69  Although 
this is a useful interval to examine in terms of possible lead time from prediagnostic 
symptoms, it seems unlikely that women would be able to accurately recall such a 
specific time period. 
Data extraction from medical notes eliminates recall bias and error but relies on 
clinicians to record symptoms completely and accurately.  Recording error can occur in 
the form of recording inaccuracies (e.g. mislabelling of symptoms reported) or complete 
omission of symptoms, particularly for symptoms that are deemed insignificant.  
Indeed, prediagnostic symptoms are much more common when (retrospectively) self-
reported than when ascertained from medical notes.16, 118  This is exemplified by the 
meta-analysis results of Bankhead‟s systematic review.93  The proportion of patients 
who were asymptomatic was 23% when data were extracted from medical record 
studies but only 7% when studies collected data directly from patients.  While recall 
bias almost certainly plays a role in this, it is also likely that not all symptoms 
mentioned by women are recorded during medical consultation.  Equally, women may 
fail to mention all of their symptoms and focus only on the most bothersome.94   
A new consideration is the unknown impact of the move from paper to electronic 
patient records (EPR) on data quality.  In general, the quality of disease documentation 
is probably enhanced but the recording of symptoms may be reduced.119-122  The use of 
clinical codes could potentially discourage GPs from documenting all symptoms 
mentioned since accurate recording requires intimate knowledge of the coding system.  
There have been reports of large inter-practice variation in coding including multiple 
ways in which the same clinical concept may be represented.123  In addition, clinicians 
who struggle to navigate around computer systems may record less symptom details, 
particularly if under time constraints in a busy practice.  Most EPR systems also allow 
free text entry for consultation data, and this is the most likely place for symptom data 
to be recorded.  Unfortunately, free text is much more difficult to search and extract 
data from for research purposes in comparison to codes.  In the future, electronic 
patient records may prove to be of great utility, such as in the rapid identification and 
flagging of symptom complexes (or clusters) associated with ovarian malignancy, or 
simply to encourage consideration of ovarian cancer as a differential diagnosis. 
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Lastly, there may be disparities between symptoms that are extracted from hospital 
notes versus GP medical records given the difference in focus between primary, 
secondary and tertiary care.  For example, hospital records may only contain 
symptoms present at admission or those deemed relevant to the disease being 
investigated.  Recording error probably also varies between countries with diversities in 
medical record keeping practices.124  
Retrospective versus Prospective Study Design 
A prospective study would be ideal, but difficult given the relatively low incidence of 
ovarian cancer.  The key issues pertaining to retrospective versus prospective design 
in ovarian cancer symptom studies relate to the whether or not women are required to 
report past events.  Recall bias not only affects symptom data that have been reported 
by women after they have been diagnosed, but also impacts on data once women 
become aware that they may have a serious morbidity (i.e. before definitive diagnosis).  
Recall error refers to the inaccuracy that stems from asking for data after events have 
occurred.  Thus, recall error will affect any retrospectively reported symptom data.  A 
survey study carried out by Goff et al. purported to be prospective because data were 
collected data pre-surgery.75  A truly prospective study of ovarian cancer symptoms 
would involve recording symptoms as they occur in a cohort of „healthy‟ women and 
following the women for a number of years or until ovarian malignancy is diagnosed.   
Selection Bias 
There are two main types of bias that affect ovarian cancer studies - survivor bias and 
self-selection bias.  Ovarian cancer has both high morbidity and mortality, hence 
recruitment of an unbiased patient population to research studies can be challenging.  
Five-year survival rates for ovarian cancer are poor, hence studies using women who 
are more than 5 years post-diagnosis can create a survivor bias (over 40% of ovarian 
cancer patients will die within one year of diagnosis in England39).   
Self-selection bias can be an issue, especially with studies that recruit via ovarian 
cancer support groups or their websites.8, 90  Certain women may be overrepresented in 
these studies (e.g. proactive women, women who are internet-savvy), while others may 
choose not to participate.  Non-participation may occur to a greater extent amongst 
women with advanced stage cancers who have a poor prognosis or women who are 
generally in poor health at the time of approach for recruitment.  Potentially, physicians 
or family members may not even allow researchers to approach women for 
recruitment.  Also, cultural attitudes may have an effect on the decision to participate in 
research studies.125   
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The ideal control group for a case-control study depends on what the aims of the study 
are.  If a study aims to identify symptom differences that would aid in making a 
differential diagnosis, then women presenting to primary care with symptoms would 
comprise a suitable control group.  However, a considerable number of symptoms do 
not prompt clinic visits for various reasons (e.g. self-treatment, non-debilitating, 
spontaneous resolution, alternative medicine).24, 126  Therefore, if the desired outcome 
is to identify symptoms that would help discriminate disease based on those 
experienced by women in the general population, women who are not consulting need 
to be included in the control group.  Selecting women who are actively seeking 
healthcare creates a bias towards women who are more likely to be symptomatic and 
are less likely to have ignored symptoms.  However, symptoms that are ignored may 
be qualitatively different from those that prompt healthcare-seeking behaviour (e.g. mild 
and transient symptoms are less likely to be reported).   
Semantic Issues 
Symptoms have been described and defined inconsistently in the ovarian cancer 
literature.  This has limited the comparability of studies and made it difficult to decipher 
what is truly being measured by the terms used.  Several different words and phrases 
haven been used to confirm the presence of abdominal bloating and abdominal 
distension.16, 67, 75  The terms „abdominal bloating‟, „abdominal swelling‟, „abdominal 
distension‟ and „increased abdominal size/girth‟ have been used interchangeably in 
different studies.  For example, Eltabbakh and colleagues have used the terms 
„bloatedness‟ and „increased abdominal girth‟ indiscriminately.67  Similarly, an American 
study used „bloating or increased abdominal girth‟ as a single symptom category in a 
review of medical records.16  In reality, symptoms such as abdominal bloating and 
swelling may not be independent.  If the abdomen is distended or swollen, a sensation 
of bloating is likely to be present in tandem.  These are the sorts of issues that a 
validated questionnaire would help with. 
Of equal relevance is how women interpret these terms in symptom checklists or when 
asked to spontaneously report symptoms.  Research performed by Dr Clare Bankhead 
(Oxford University) as part of a PhD thesis, found that women used symptom terms 
interchangeably.94  Specifically, it was noted that women were referring to two distinct 
events when using the term „bloating‟.  One was a persistent distension of the 
abdomen and the other was a transient distension or a fluctuating sensation of 
discomfort.94  Also, use of the word „symptom‟ itself may lead to underreporting of 
symptoms in ovarian cancer studies.  This is because many women (and possibly their 
doctors) do not associate the health changes experienced with ovarian cancer even 
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after the diagnosis has been made.  Constipation is another term which can be 
confusing.  Prevalence of this symptom has been shown to differ when self-reported 
(yes/no) compared to when specific symptom criteria are gathered (i.e. information on 
straining, number of defecations per week, incomplete evacuation).127 
Mislabelling and misinterpretation of symptoms is an important consideration when 
designing studies with direct questioning of women, as non-medical subjects are 
unlikely to understand the meaning of anatomical and medical terms.  This is a likely 
source of confusion for women completing questionnaires, and may be a barrier for 
symptom communication in the clinical setting.   
Inconsistent grouping of symptoms is also an issue.  For example, a study may report 
on the presence of „urinary symptoms‟ which can include any combination of 
(unspecified) urinary symptoms,16, 68, 69, 89 whereas others may report on individual 
urinary symptoms separately (such as dysuria, frequency, urgency, stress 
incontinence).12  Prevalence for individual symptoms is often presented alongside 
prevalence of grouped symptoms, thus care must be taken when interpreting these 
values.  Also, symptoms have been presented in overly broad categories such as 
„constitutional‟, „mass effect‟, „gastrointestinal‟, and „pain‟.9  Consequently, only broad 
conclusions can be drawn on symptoms.  Another issue is the unusual grouping of 
symptoms, for example dyspnoea has been grouped with back pain.19   
The issues pertaining to the use of the term „delays in diagnosis‟ are also important, but 
have already been discussed.   
Poor Definition of Study Populations 
Use of diverse groupings has also made comparisons across studies awkward.  For 
example, some studies have defined „early stage‟ disease as stage I-II while others 
have used stage IA-IB. 10, 19  Furthermore, some studies have included cases in which 
staging has not been confirmed.  Since there is great interest in identifying symptoms 
associated with early stage disease, complete FIGO staging should be available for all 
women, unless staging was not possible (e.g. inoperable tumours).  It should be noted 
that staging in women who have received neoadjuvant chemotherapy can be 
misleading since due to downstaging of metastases after tumour shrinkage.  Likewise, 
despite the heterogeneity associated with prognosis and histology, histological details 
are often omitted or incomplete in the literature.17, 19, 69, 75, 90, 110   
Tumour status is another important variable that has been inconsistently reported.  
Some studies have not provided any details of what tumour types were included.  This 
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is particularly important for tumours that may behave differently from invasive ovarian 
cancer such as borderline tumours.  Borderline tumours have such different prognosis 
and behaviour from invasive disease that they mandate consideration as a separate 
entity.128  Groups that provide national cancer statistics (such as the Office for National 
Statistics) have acknowledged the inaccuracies in survival data stemming from the 
inclusion of borderline cancers in the tumour registries.1  Also, primary peritoneal 
cancers have been included as ovarian cancer cases in some studies.16, 94  These 
malignancies can be indistinguishable at presentation and treatment is also similar, 
nevertheless primary peritoneal is still regarded as a separate disease and should 
probably be regarded as such. 
Finally, it is crucial to discriminate between consulting and non-consulting women in the 
control population.  Symptoms in the non-consulting population are often managed 
outside of the formal healthcare system, and only a minority ever reach primary care.25  
If symptom prevalence in the non-consulting population is used, case-control 
differences will be underestimated and numbers needed to investigate (NNI) will be 
overestimated. 
2.5 Discussion 
Table 2-12 Key Ovarian Cancer Symptom Attributes 
Most women with ovarian cancer have symptoms before or at diagnosis 
Abdominal pain, bloating and abdominal distension are the most common symptoms regardless 
of data collection method 
Symptom profiles of benign/borderline/invasive disease are similar 
It has already been established that ovarian cancer elicits symptoms before diagnosis 
(key attributes of ovarian cancer symptoms are listed in Table 2-12).  In this respect, 
research into ovarian cancer symptoms has turned the first corner.  To take this area of 
research on to the next level, the goal should be to quantify the potential lead time of 
symptoms.  This review has demonstrated that the timing of symptoms prior to ovarian 
cancer diagnosis requires further clarification.   
It is paramount to measure the period between symptom onset and diagnosis, since 
this interval needs to be sizeable enough to justify any further research into using 
symptoms as a diagnostic tool for ovarian cancer.  Evidence so far has been extremely 
heterogeneous (see Table 2-3 and Table 2-4).  Crucially, interpretation of symptom 
lead time needs to allow time for both the woman to make the GP appointment 
(expecting women to present on the same day as symptom onset is unreasonable), 
and mandatory diagnostic procedures to take place (CA125 testing, TVS, etc.).  It is 
also important to note that delays in diagnosis may be changing due to factors such as 
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the implementation of directives to reduce cancer waiting times and greater consumer 
and physician awareness of the symptoms linked to ovarian cancer.  Furthermore, one 
might expect delays to be shorter in countries where patients can make a specialist 
appointment without GP referral, and GPs have no „gate-keeping‟ role.  There is a need 
to establish the current length and sources of delay, and also to evaluate any potential 
impact on survival.  However, it is also important to note that a shorter interval between 
oncogenesis and diagnosis may not influence survival.   
Finally, any future studies should ensure that they address the various methodological 
issues raised in this review.  The terminology used in ovarian cancer symptom studies 
needs to be clarified.  This includes the words and phrases used to define and describe 
symptoms, and the terms used to define and refer to symptom duration and delays.  
Inconsistent and unclear definitions have hindered the interpretation of studies and the 
pooling of data.  With regard to delays in diagnosis, it would be sensible to move away 
from using this pejorative terminology and to establish a more appropriate term.  Future 
studies should ensure greater transparency in the methods used to derive symptom 
duration and delays.  Standardisation of the methodology for quantifying the interval 
between symptom onset and diagnosis is also overdue.  In this thesis, the symptoms 
checklist in the case-control study (Part II) was specifically designed to try and address 
some of the issues with terminology.  Thus, any potentially ambiguous terms were 
accompanied by descriptions in parentheses.  Additionally, use of the term „symptom‟ 
was avoided in the questionnaire in order to encourage completion and full data 
capture.   
Recently, a validated ovarian cancer symptoms questionnaire was developed in the UK 
as part of a PhD project.  Although previous authors78 have claimed to have used a 
validated ovarian cancer symptoms questionnaire, no details of the validation process 
were provided and the questionnaire does not appear to have been used in any other 
published studies.  The symptoms questionnaire developed in the UK has been fully 
validated using the EORTC (European Organisation for Research and Treatment of 
Cancer) guidelines.  As such, use of this questionnaire should help resolve some of the 
issues with poorly defined symptoms. 
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PART II: A CASE-CONTROL STUDY TO INVESTIGATE 
SYMPTOMS & EVENTS PRECEDING OVARIAN 
CANCER DIAGNOSIS 
Part II is comprised of a case-control study to examine symptom lead time and events 
prior to ovarian cancer diagnosis. 
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3 CHAPTER 3: Background & Methods 
3.1 Background 
Most ovarian cancer symptoms studies have been small retrospective studies carried 
out in the United States or Scandinavia.  Very few have been performed in a UK 
population.11, 97, 99  Given the lack of symptom lead time data and the potential for 
country-specific differences, it seemed pertinent to undertake a study that would 
establish the situation in a UK population. The various methodological issues 
(discussed in the systematic review) further justified a new study.  Ascertainment of the 
potential symptom lead time and refinement of ovarian cancer symptomology were of 
particular interest.  An excellent opportunity arose to collaborate with a large UK-based 
case-control study (UKOPS) that had already been set-up and was about to start 
recruitment.   
3.1.1 UK Ovarian Cancer Population Study (UKOPS) 
UKOPS (UK Ovarian Cancer Population Study) was a multicentre case-control study 
focused on biological markers of ovarian cancer.  Specifically, the study hoped to 
identify novel biomarkers for early diagnosis, prediction of prognosis and monitoring of 
recurrence of ovarian cancer, and to identify genes with moderate penetrance for 
ovarian cancer using Single Nucleotide Polymorphism (SNP).  The lead investigators 
were Dr Usha Menon, Dr Simon Gather, and Professor Ian Jacobs (University College 
London, Gynaecological Cancer Research Centre).  Subjects were recruited from 10 
centres across the UK including London, North Wales, Middlesbrough, Southend, 
Gateshead, Bristol, Portsmouth, Belfast, East Kent and Manchester.  The study 
planned to recruit 2000 cases (1000 newly diagnosed women and 1000 previously 
diagnosed women), 1500 women with benign/borderline neoplasms and 5000 
„apparently healthy‟ control women.  Various sub-studies were nested within UKOPS, 
each with their individual objectives.  The main UKOPS study completed recruitment in 
April 2009.   
UKOPS was launched early on in this PhD and provided an ideal opportunity to collect 
ovarian cancer symptom data from a cohort of women with theoretically reduced recall 
bias.  In addition, the UKOPS protocol was already finalised and submitted for Ethics 
approval before collaboration for the current project was agreed, which eliminated the 
usual study set-up delays.  Another convenient factor was that the co-ordinating centre 
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was in London (UCLH) where all the data could be easily accessed.  All of the subjects 
in the current chapter were collected within the framework of UKOPS.   
Recruitment to UKOPS took place in three different settings; (1) women attending with 
suspected ovarian cancer (potential final diagnoses includes invasive ovarian or 
fallopian tube cancer, invasive non-ovarian cancer, borderline ovarian cancer, benign 
neoplasms, normal ovaries) (2) women undergoing treatment or follow-up of ovarian 
cancer; and (3) unselected women from the UK Collaborative Trial of Ovarian Cancer 
Screening (UKCTOCS) population-based trial of ovarian cancer screening (see 3.1.2).  
At baseline, all study participants were required to give blood (for SNP and biomarker 
analysis) and to complete a questionnaire about putative risk factors for ovarian 
cancer.  In addition, women undergoing surgery (i.e. potential cases) were also asked 
to donate tissue. 
Cases in the UKOPS study were women aged 25 and above with histological 
confirmation of primary invasive or borderline ovarian or fallopian tube cancer (see 
below for full eligibility criteria).  The Gynaecological Cancer Research Centre (GCRC) 
is also the lead centre for UKCTOCS, which is a population-based ovarian cancer 
screening study (see section 3.1.2 for details).  UKOPS control subjects were 
postmenopausal women participating in the multimodal arm of the UKCTOCS study.  
They were approached for UKOPS study recruitment at their annual UKCTOCS 
screening visit.  The UKOPS eligibility criteria below pertain to the main study.  For the 
symptoms substudy, only women aged 45 and above who met case criteria (1) and (2) 
were included as cases. Similarly, only women who met control criterion (2) were 
included as controls.  However, women who met control criterion (1) and were later 
confirmed as borderline cancers were included as cases in the symptoms substudy (if 
aged ≥45).  More specific details are listed under 3.3.1 Symptom Substudy Population. 
UKOPS Inclusion Criteria 
Cases: 
(1) Women with an adnexal mass suspicious of ovarian cancer who were about to 
undergo surgery.  (Once final histology was confirmed, women with borderline or 
benign tumours were reclassified in line with the endpoints of each UKOPS sub-study.  
Women with normal findings were excluded).   
(2) Women with a probable diagnosis of primary invasive ovarian cancer who were not 
undergoing surgery (i.e. women with unresectable tumours or who were too unwell for 
surgery) or who were scheduled for neoadjuvant chemotherapy.   
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(3) Women with a confirmed diagnosis of primary invasive or borderline 
ovarian/fallopian tube cancer (i.e. previously diagnosed women).   
Controls: 
(1) Women with a possible benign or borderline adnexal mass who were about to 
undergo surgery.  (Women with normal findings were excluded).   
(2) Apparently healthy women recruited from the multimodal arm of UKCTOCS when 
they attended for annual screening.  (More detailed eligibility criteria are below).   
UKOPS Exclusion Criteria 
(1) Currently active non-ovarian malignancy 
(2) Age below 25 years 
(3) Unable to give informed consent 
3.1.2 UK Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) 
UKCTOCS is a population-based study designed to assess the impact of screening on 
ovarian cancer mortality in the UK.  It is the largest randomised controlled study in 
ovarian cancer screening to date, with over 200,000 women recruited from 12 regional 
centres (London, Bristol, North Wales, Portsmouth, Belfast, Middlesbrough, 
Manchester, Liverpool, Nottingham, Cardiff, Derby, Gateshead).  Notably, some of the 
UKCTOCS and UKOPS centres overlap (i.e. London, Bristol, North Wales, Portsmouth, 
Belfast, Middlesbrough, Manchester, Gateshead).  A total of 1,243,282 women were 
sent invitations of which 202,638 were randomised. 
Participants were randomised to one of three arms: 
 Multimodal Group (50,640) – annual screening with serum CA125 as the 
primary test and repeat CA125 and transvaginal ultrasound as the secondary 
test. 
 Ultrasound Group (50,639) – annual screening with transvaginal ultrasound 
as the primary test and repeat detailed ultrasound in 6-8 weeks as the 
secondary test 
 Control Group (101,359) – no screening 
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Women in the screening arms are to be screened until 31st December 2011, and the 
primary endpoint is ovarian cancer mortality on 31st December 2014.  The UKCTOCS 
recruitment phase was completed in September 2005.  Participation was by invitation 
only.  Letters of invitation were sent to women aged 50-74 randomly selected from the 
age/sex registers of the health authorities geographically-related to the 13 study centre 
catchment areas.  Women who responded could participate if they met the following 
eligibility criteria.   
UKCTOCS Inclusion criteria  
 Age 50-74 years inclusive 
 Postmenopausal:  
o >12 months amenorrhoea following a natural menopause or hysterectomy 
or; 
o >12 months of hormone replacement therapy commenced for 
menopausal symptoms  
UKCTOCS Exclusion criteria 
 Bilateral oophorectomy  
 Currently active non-ovarian malignancy (excluding skin cancer)  
 Women who have had an ovarian malignancy in the past  
 Women at high-risk of ovarian cancer due to a familial predisposition  
 Women participating in other ovarian cancer screening trials 
3.2 Aims & Objectives (Symptom Substudy) 
3.2.1 Study Aim 
To investigate the potential for diagnosis of ovarian cancer to be expedited via prompt 
symptom recognition. 
3.2.2 Primary Objectives 
 To identify the type, duration, severity and frequency of symptoms present at 
different time periods prior to diagnosis of ovarian cancer (cases) or study 
enrolment (controls). 
 To calculate the proportion of cases that would be identified using symptoms at 
different time points before diagnosis. 
 To identify the frequency of GP visits in the 2 year period prior to diagnosis of 
ovarian cancer (cases) or recruitment (controls). 
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3.2.3 Secondary Objectives 
 To assess the time interval between symptom onset and first visit to a GP.  
 To assess the time interval between first GP visit for symptoms related to ovarian 
cancer to referral, and from referral to diagnosis (cases only). 
 To relate symptom history to the type and stage of cancer. 
 To distinguish between new and chronic symptoms reported.  
 To explore the potential for developing a crude symptoms index. 
3.3 Methods 
3.3.1 Symptom Substudy Population 
3.3.1.1 Cases 
Symptom Substudy Inclusion Criteria 
 Histological or cytological confirmation of primary ovarian (ICD-10 C56) or fallopian 
tube (ICD-10 C57.0) cancer 
 Age 45 and above 
 Newly diagnosed (within 3 months of consent to main UKOPS study) 
 Telephone interview – performed a maximum of 3 months after diagnosis 
All histological subtypes were included but preference was given to women with 
invasive epithelial ovarian cancer.  This is because these women contribute heavily to 
the low survival rates, and therefore were of greatest interest.  Newly diagnosed 
women did not necessarily have definitive diagnosis at the time of study entry.  
However, cases who were recruited into UKOPS before definitive diagnosis were only 
included in the present study once histology was confirmed.  Previously diagnosed 
cases were excluded to minimise recall bias and recall error.  Inclusion was initially 
limited to women who had confirmed diagnosis no more than one month before 
recruitment.  Unfortunately, case recruitment was slower than anticipated, so data were 
also collected on women who were consented within 3 months of diagnosis.   
The age restriction was chosen to comply with the overall project aim of investigating 
the potential for „targeted‟ ovarian cancer screening, which is unlikely to be offered to 
premenopausal women.  The rationale for this is that premenopausal women tend to 
have tumours with a favourable prognosis, and more than 85% of women with ovarian 
cancer are aged 45 or older.32  Thus, the positive predictive value of any symptoms 
index would be substantially lower in a premenopausal group.  At first, cases aged over 
74 were also excluded since screening is not routinely offered to this age group due to 
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the limited potential for gain in life years.  However, part way through the study it was 
decided that inclusion of women over 74 would be worthwhile to increase study 
numbers since recruitment was poor.   
3.3.1.2 Controls 
Symptom Substudy Inclusion Criteria 
 Postmenopausal women from the multimodal arm of UKCTOCS who agreed to 
participate in UKOPS main study (approached at their annual screening visit) 
 Aged 50-74 (at UKCTOCS entry) 
 Telephone interview – performed a maximum of 3 months after consent to main 
UKOPS study. 
Since there were significantly more controls than cases recruited to UKOPS, only a 
subset of UKOPS control women were included in the current study (see Figure 3-1).  
At study outset, control women were selected sporadically according to no specific 
criteria (n=56).  After June 2007, controls were randomly selected using a frequency 
matching approach to balance for year of birth and agreement to telephone interview.  
The majority of controls were collected in this randomised manner (212/268).  
Figure 3-1 Study Schematic 
 
3.3.2 Study Design 
This was a multicentre, retrospective case-control study in the UK.  Recruitment took 
place at the following ten study centres: London, Bristol, North Wales, Portsmouth, 
Belfast, Middlesbrough, Gateshead, Manchester, Southend and East Kent.  Cases 
were collected from all ten centres, and controls were collected from all but East Kent 
and Southend. 
Symptom Substudy Cases
Previously 
Diagnosed 
(>3 mths)
Newly 
Diagnosed 
(≤3 mths)
UKOPS CASES UKOPS CONTROLS
Symptom Substudy Controls
UKCTOCS Multimodal Arm
UKOPS 
Controls
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Symptom data were obtained both directly (questionnaire and telephone interview) and 
indirectly (GP notes) from the women.  In order to gain the best possible symptom 
data, three different collection methods were used (in different proportions): 
 Paper questionnaire 
 Telephone interview 
 GP notes 
All women recruited to the main UKOPS study completed a symptoms questionnaire 
(see Appendix I) and gave permission for the research team to access their medical 
notes on the main study consent form.  The telephone interview was optional and 
consent for this was indicated on a tick box on the symptoms questionnaire.  For 
questionnaire and interview, symptoms of any duration were included as long as they 
were present (anytime) during the 12 months prior to diagnosis or consent.  For GP 
notes, any symptoms that were recorded during the 24 months prior to diagnosis or 
consent were included.   
Recruitment of women and questionnaire administration were carried out by the 
designated research nurses for UKOPS.  The data extraction and analysis for all 3 data 
sources were performed by the author of this thesis (Anita Lim), as were the telephone 
interviews and the GP note collection and review (see Figure 3-2).  Case details were 
taken from the main UKOPS study (i.e. FIGO staging, tumour grade etc.). 
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Figure 3-2 Schematic Diagram Showing Data Collected for Symptoms Substudy 
& Data Taken from the Main UKOPS Study 
 
Developing and Piloting of the Questionnaire 
The UKOPS group had already designed and submitted a questionnaire for ethical 
approval before the addition of this thesis project was agreed.  It contained a symptom 
section which was based largely on a questionnaire used in one of the Goff studies.75  
However, it did not ask for sufficient data to meet our study objectives.  Furthermore, it 
was positioned at the end of a 20 page document which was intended for women to 
complete unassisted.  Hence, a second version (amendment 1) was quickly developed 
in collaboration with core members of the UKOPS study team, to be implemented 
before recruitment started.  Version 2 was the first questionnaire used in the symptoms 
substudy.  Several factors were taken into account in this second version.  Firstly, 
based on research performed by Dr Clare Bankhead (Oxford University) as part of a 
PhD thesis, it was clear that women used particular symptom terms interchangeably 
(for example „abdominal bloating‟ and „abdominal swelling‟).94  Thus, any potentially 
ambiguous terms were accompanied by descriptions in parentheses.  Secondly, 
nausea and vomiting were combined as they were presumed to be highly correlated.   
Blood & Tissue Questionnaire
Case Details (FIGO 
stage, grade, date 
of diagnosis, etc.)
Telephone Interview GP Notes
UKOPS MAIN STUDY 
SYMPTOMS SUBSTUDY DATA
Questionnaire:  
Symptoms  Section
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The third version (amendment 3) was produced in June 2006 after there had been time 
to review the data quality of returned questionnaires which was relatively poor.  The 
evolution between version 2 and 3 of the questionnaire was based on informal piloting 
of several different versions and brief consultation with a psychologist who was 
experienced with questionnaire development (Professor Jane Wardle).  Initially, five 
non-medical female members of staff in the department completed the draft 
questionnaires and their feedback was incorporated.  Next, the amended drafts were 
piloted in face-to-face interviews with five cases and a „watch and listen‟ technique was 
applied.  This technique involved watching subjects complete the questionnaire and 
noting any issues with completion that were observed or vocalised.  A final version was 
produced based on the collective feedback.  In addition, the title was changed to 
„Health Changes‟ since there was debate over the ambiguity of the term „physical 
changes‟ which was used in version 2.   
These procedures were not ideal in terms of questionnaire development and validation, 
but timelines and limited resources did not permit formal validation.  The desired goal 
of the piloting was to improve data quality.  In brief, frequency was changed to an 
ordinal categorical scale, the wording of the questions was revised, and an extra page 
was added for additional information.  Also, a sentence was added to specify that 
severity and frequency should be rated for the symptom at the time it first started since 
these are likely to change over time.  In particular, one would expect worsening 
severity and frequency with disease progression.   
3.3.3 Questionnaire 
Baseline questionnaires were completed at the time of recruitment.  For controls, 
recruitment was during attendance for annual UKCTOCS screening.  For cases, 
recruitment was during pre-admission visits or on hospital wards before surgery or 
chemotherapy (i.e. pre-treatment).   
There were two different versions of the questionnaire used in the symptom substudy 
(version 2 and 3, see Table 3-1 and Appendix I).  Both versions asked women to 
indicate if they had experienced any symptoms from a checklist in the last 12 months. 
Version 2 contained a checklist of 17 symptoms associated with ovarian cancer (as 
identified by previous studies) with an additional box for „other changes‟.  Women were 
asked to provide the following information: 
 Severity on an ordinal categorical scale (mild, moderate, severe) 
 Frequency in number of days per month 
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 Duration in months indicated as a range of calendar months (how long the 
symptom was present prior to diagnosis/questionnaire completion) 
 If the symptom was ongoing (tick box) 
 If the symptom was reported to their GP and if so, when?   
Version 3 consisted of a checklist of 14 symptoms with a box for „other symptoms‟, with 
a second page for additional information.  Subjects were asked to provide details of the 
following: 
 Start date (month and year) 
 Severity (at time symptom started) on an ordinal categorical scale (mild, moderate, 
severe) 
 Frequency (at time symptom started) in number of days per month on an ordinal 
categorical scale (1-4, 5-15, 16-31) 
 Duration in months (how long the symptom was present prior to 
diagnosis/questionnaire completion) 
 If the symptom was ongoing (Y/N) 
 If the symptom was reported to their GP and if so, the approximate date of 
consultation (month/year).   
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Table 3-1 Comparison of Questionnaire Checklist Symptoms for Version 2 & 3 
Version 2 Version 3 
Pelvic/Abdominal Pain Pelvic/Abdominal Pain or Discomfort 
Back Pain Back Pain 
Indigestion  Indigestion 
- Loss of Appetite 
Nausea or Vomiting Nausea or Vomiting 
Weight Loss (unplanned) or appearance of 
weight loss 
Weight Loss (unplanned) or appearance of 
weight loss  
Abdominal Swelling (actual increase in size or 
girth) 
Increase in Abdominal Size 
Abdominal Bloating (feels full and tight) Abdomen Feels Bloated 
Able to Feel a Lump in Abdomen Able to Feel a Lump in Abdomen 
Urinating more often than usual or feeling an 
urgent need to go 
Urinating more often than usual or feeling an 
urgent need to go 
Constipation Constipation 
Diarrhoea Diarrhoea 
Fatigue  Fatigue 
Irregular Periods  Irregular Vaginal Bleeding* 
Bleeding after menopause - 
Bleeding with Intercourse - 
Pain during Intercourse - 
Leg swelling - 
*Due to limited space on the questionnaire irregular vaginal bleeding included other vaginal 
bleeding irregularities (e.g. post-coital bleeding, postmenopausal bleeding etc.). 
Note: See Appendix I for copies of the questionnaires. 
The questionnaire was designed to be self-administered however, early feedback 
indicated that support was needed.  Hence, research nurses were instructed to explain 
how to complete the questionnaire and to be available to answer questions.  If the 
nurse could not be present (e.g. due to time constraints); subjects completed the 
questionnaires unassisted.  In order to encourage consistency, a list of symptom 
definitions (see Appendix II) was given to the nurses for reference.  The list also 
included specific definitions for each severity rating (see Table 3-2).  These definitions 
were only intended to be used if women were unclear about how to assign a severity 
rating.   
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Table 3-2 Severity Definitions 
Mild 
Moderate 
Severe 
Symptom easily tolerable, did not interfere with usual activities 
Symptom hard to tolerate, interfered somewhat with usual activities 
Symptom was so intolerable that usual activities could not be performed 
3.3.4 Telephone Interview 
Participation in the telephone interviews was optional and only those who gave specific 
consent were contacted.  All interviews were performed by the same interviewer (Anita 
Lim).  They were conducted unblinded since it was highly probable that cases would 
discuss events surrounding their cancer diagnosis.  Also, cases were expected to be 
psychologically and physically frail (or possibly even deceased) by the time contact 
was attempted for interview, and the interviewer needed to be sensitive to this.  
Interviews for cases took place preferably before chemotherapy began and within 3 
months of surgery or positive biopsy.  No limits were placed on the number of contact 
attempts for cases if there was no answer or the women were not available for 
interview (provided the women were happy to be re-contacted at a later point).  
As mentioned previously, agreement to telephone interview was used as one of the 
stratifiers for random control selection.  Only controls who were recently recruited 
(within 3 months of consent) were contacted.  A record of women who consented to 
telephone interview but were not contactable was maintained.  A maximum of 3 contact 
attempts were made for each woman after which they were replaced with the next 
control on a ranked random number list.  All controls were interviewed within 3 months 
of consent.  If a subject was not contactable within the 3 month period no further 
attempt to interview was made on the grounds that recall would be less reliable.   
Each telephone call began in the same manner based on a predetermined script, to 
ensure consideration for the women‟s state of well-being at the time of the call and 
consistency (see Appendix III and IV).  Women were given the opportunity to withdraw 
their consent for interview or reschedule the interview for another time.  All interviews 
were performed using a standardised questionnaire (see Appendix V).  Any verbatim 
comments of interest were also recorded.  These were used to help inform the 
interview answers but were not formally analysed.  The interview consisted of the same 
symptom list as the paper questionnaire with some additional questions.  One deviation 
from the questionnaire was that „loss of appetite‟ was combined with „feeling full 
quickly‟ (i.e. „loss of appetite or feeling full quickly‟).  This symptom combination had 
appeared on one of the draft questionnaires but was later edited to „loss of appetite‟.  
Unfortunately, this was not updated on the telephone survey, and when the 
discrepancy was noticed, many interviews had already been performed, hence the 
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combination was kept to maintain consistency.  As with the questionnaire, symptoms of 
any duration were included as long as they were present (anytime) during the 12 
months prior to diagnosis or consent.  Cases were also asked about their diagnostic 
route and were reminded to exclude any symptoms that started after diagnosis.  This 
was particularly emphasized to cases who had already started chemotherapy at the 
time of interview.  Again, the severity definitions listed in Table 3-2 were only referred 
to if women were confused about the categories. 
Since the interview was intended to help gain the best possible symptom data, they 
were originally conducted with a copy of the subject‟s paper questionnaire present so 
that any ambiguous symptoms on paper could be clarified or probed.  The interviewer 
did not inform the subjects of any inconsistencies between the two questionnaire 
answers.  Referral to the subject‟s questionnaire was discontinued early on in the study 
since there seemed to be little additional information gained by probing based on 
questionnaire answers and the questionnaire was not always received at the 
coordinating centre in time.   
As with the questionnaire, aspects of the interview were amended in the early phases 
of the study.  The first few interviews included questions about medication or 
treatments used to treat symptoms however, on further consideration it was decided 
that these data would not contribute greatly to the study.  Interviews conducted 
between September 2006 and July 2007 (cases n=72, controls n=59) included four 
additional symptoms based on Dr Clare Bankhead‟s thesis findings.94  These were 
shoulder pain, dizziness, change in taste and night sweats.  Case-control differences 
were not detected on an anecdotal level for any of the additional symptoms.  The 
decision to stop asking about these symptoms was taken following discussions with the 
clinical investigators.   
After several interviews, it became apparent that some symptoms were associated with 
activity (e.g. back pain and gardening) or were seasonal (e.g. leg swelling in hot 
weather).  Also, some women were reluctant to report symptoms for which a cause 
was already attributed or that were mild and transient.  Also, if a symptom occurred for 
a few days but only 2-3 times a year, this information would not be captured by the 
frequency question making it difficult to complete data for this parameter.  In an attempt 
to deal with these issues, a note was made if the symptom was: 
 Mild and transient 
 Attributed to an illness or condition 
 Activity-dependent 
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 Intermittent, seasonal or episodic 
Subjects were also asked if the symptom worsened, improved or stayed the same over 
time.   
In order to aid recall accuracy, the use of an event history calendar (EHC) was 
originally planned for telephone interviews.  This was to consist of the subject‟s 
birthday, significant life events (e.g. anniversary, deaths, retirement, holidays, family 
celebrations) and major public holidays.  These events were to act as cues to help the 
subjects report more accurately on the timing of their symptoms by taking advantage of 
the ways in which autobiographical memories are stored and structured.129  It was to 
take place before the formal interview took place.  This event calendar was to cover the 
12 months leading up to the month of diagnosis and events were to act as timing cues.  
As there was uncertainty with regard to the benefits and feasibility of using such a tool 
in this setting, the EHC was treated as a pilot and several mock interviews with 
volunteers (not in the study) were carried out.  These „dry-runs‟ indicated that interview 
time was greatly prolonged by the EHC (to approximately 1 hour) and given the poor 
health status of the patient population it was deemed that the potential improvement in 
data quality at the cost of patient well-being was not justified.  Thus, wherever possible 
anchor points (e.g. public and personal holidays, seasons, birthdays, Christmas etc) 
were used in place of the EHC.  
3.3.5 Face-to-Face Interview 
Five newly diagnosed cases were interviewed face-to-face (as inpatients) to allow 
informal piloting during symptom questionnaire development.  Due to logistical and 
monetary issues, these were restricted to patients who were treated at UCLH.  These 
interviews were analysed together with telephone interview data and are not presented 
separately due to small numbers. 
3.3.6 GP Notes 
GP notes were requested for all subjects in the symptoms substudy for the two year 
period prior to date of diagnosis or consent for cases and controls, respectively.  
Despite this request being made for all subjects, expectations were that records for 
only a proportion of women would be received.  The information requested included 
medical history, consultation notes, test results and clinic letters.  For GP practices with 
electronic and paper records, copies of both were requested.  Subjects for whom only 
clinic letters were received were excluded from the GP note analysis.  Data were 
extracted from the notes by the same researcher, and again, this was conducted 
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unblinded for reasons of practicality.  Clinic letters included incoming and outgoing 
letters, and were only databased if any symptoms possibly related to ovarian cancer 
were recorded (see below).   
Data extracted for all subjects included: 
 Dates of any consultations in the two years prior to „cut-off date‟ (cases) or consent 
(controls).  See definition of „cut-off‟ date below 
 Any signs or symptoms (coded and free text) 
 Symptom onset dates.  If this was missing, the visit date was used instead 
 If a blood test was ordered at a visit 
 Whether any per rectal (PR), abdominal or pelvic vaginal examinations were 
performed at the visit  
 Dates of diagnosis for irritable bowel syndrome (IBS) and diverticular conditions 
since they have been associated with misdiagnosis of ovarian cancer in the 
literature.8  Diverticular conditions included diverticulosis, diverticulitis and 
diverticular disease.  Diverticulosis was included even though it is often 
asymptomatic since all diverticular conditions appeared to be recorded 
interchangeably in the GP notes. 
 If clinic letters mentioned any symptoms possibly related to ovarian cancer, the 
clinic date and type of symptom(s) were recorded.  If a symptom onset or duration 
was described, these were also recorded. 
For cases, the following additional data were extracted whenever possible: 
 Dates of CA125 tests and ultrasound scans (pelvic, transvaginal or abdominal) 
 Pre-treatment CA125 levels (result closest to treatment date if more than one)  
 First referral made by GP (date and type) 
 A „cut-off date‟ for when ovarian aetiology was first suspected. „Cut-off date‟ was 
defined as the date when suspicion of ovarian aetiology was first documented.  For 
example if any of the following text was recorded; „?ovarian‟ „?ovarian cyst‟ „?pelvic 
mass‟ „?ovary‟. 
 Route of diagnosis 
 Symptom details from multidisciplinary team (MDT) letters (if available).  These 
were often helpful in deciphering route of diagnosis. 
Consultations included face-to-face visits (surgery, home, out-of-hours) and telephone 
calls.  Accident and emergency (A&E) visits (recorded in GP notes) were included even 
though they are not GP visits, since symptoms reported at these were of interest.  
Visits for blood drawing only, or telephone calls to report test results only, were 
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excluded.  Each consultation was classified as either „problem‟ or „routine‟.  In brief, 
„problems‟ were consultations for which the main reason was a new or undiagnosed 
problem.  „Routine‟ consultations included nurse visits or regularly scheduled GP visits 
such as monitoring of hypertension, diabetes or asthma, smears and vaccinations.  
„Problem‟ visit coding overrode „routine‟ if a problem was raised or discussed at a 
routine visit.  Full details of the classification system are in Appendix VI. 
The current project aims to bring forward diagnosis by expediting the date of 
appropriate referral (i.e. gynaecological-oncology).  Therefore, frequency of visits and 
symptoms that developed after ovarian cancer was already suspected were of little 
interest.  Hence, case GP visits were only databased up until a „cut-off date‟ (as 
defined above).  
Only symptoms considered to be possibly related or attributable to ovarian cancer were 
databased in detail (see 3.3.10 and Appendix VI).  Initially, the list of possibly related 
symptoms was kept as broad as possible.  Emphasis was placed upon abdominal, 
gastrointestinal, urinary, pelvic and gynaecological symptoms.  If a diagnosis was 
recorded without specific symptom(s) (e.g. „cystitis‟), the diagnosis was databased.  
After an exhaustive list was created it was discussed with the clinical investigators to 
produce a final list of relevant symptoms (see Appendix VI).  The same symptom 
classification was applied to all 3 data sources.   
Data on clinic letters, blood tests, examinations by the GP and dates of CA125 and 
ultrasound were not analysed in the current thesis.  However, these are planned to be 
included in a future more in-depth analysis. 
3.3.7 Ethical Approval 
Ethical approval for the study was granted from the joint UCL/UCLH (University College 
London/University College Hospital London) Ethics Committee.  Subjects in the 
symptoms substudy were recruited between February 2006 and April 2008.   
3.3.8 Sample Size Considerations 
Formal power and sample size calculations were not performed since the study did not 
primarily aim to identify differences between two groups (case-control).  Rather, the 
primary aim was to determine the proportion of women with ovarian cancer with „early‟ 
symptoms.  Thus, it was appropriate to discuss sample size in terms of sensitivity for 
the proportion of symptomatic cases that could be detected x months (e.g. 3, 6, 9) in 
advance, and the width of the associated 95% confidence intervals (CI).   
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The main study (UKOPS) initially set out to obtain 1000 newly diagnosed cases.  
Based on this estimate, 600 telephone interviews were planned in 500 cases and 100 
controls.  However, recruitment was much slower than expected and targets were 
adjusted accordingly to collect questionnaires from 250 newly diagnosed cases and 
250 controls and perform telephone interviews in 150 cases and 150 controls.  GP 
notes were requested for all women but were only received for a proportion of women 
(see 3.3.6).   
For a sensitivity between 30% and 70% with the original sample size of 600 cases, the 
sensitivity could be estimated with a 95% confidence interval of ±4% (absolute 
sensitivity, see Table 3-3).  With the actual sample size of 254 cases, the 95% 
confidence interval changed to ±6%.  Hence the reduced sample size changed the 
expected width of the 95% confidence interval for the proportion of cases with the 
symptom from 0.07 to 0.12.   
Table 3-3 95% Confidence Intervals (CI) Associated with 30% & 70% Sensitivity 
for Symptoms 
30% Sensitivity 95%CI Approx. width of 95%CI 
Original Sample Size n=600 26.4% to 33.8% ±4% 
Actual Sample Size n=250* 24.4% to 36.1% ±6% 
70% Sensitivity   
Original Sample Size n=600 66.2% to 73.6% ±4% 
Actual Sample Size n=250* 63.9% to 75.6% ±6% 
*Rounded number (actual number of cases is 254) 
Finally, given that the symptom data were collected from 3 different sources, the overall 
symptom data quality was expected to be much higher than that produced by previous 
studies.  
3.3.9 Data Cleaning 
Many issues arose with regard to data quality and cleaning.  Some questionnaires had 
missing or nonsensical data (see Appendix VIII), some women gave vague interview 
answers (e.g. answers of „not really‟ for symptom presence) and GP notes contained 
free text that required interpretation (e.g. symptom recorded as „blown up‟).   
Symptom classification was also more problematic than anticipated and decisions had 
to be made for symptoms that could reasonably belong under more than one category.  
For example, epigastric pain could be coded as indigestion or abdominal pain.  As 
described in 3.3.6, all symptoms were discussed with the clinical investigators to set up 
a systematic coding frame and symptoms were grouped accordingly.   
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In order to address these issues, a set of databasing rules were drawn up (see 
Appendix VI).  The following is a summary of how the major issues were dealt with: 
 Missing or partial symptom variables (start dates, duration, end dates) were derived 
using existing data whenever possible (see Appendix VII) 
 Nonsensical data were corrected when it could be clearly justified (e.g. if a 
questionnaire was completed in September 2006 but had a symptom recorded as 
starting in June 2007, with a recorded duration of 3 months; the onset date would 
be amended to June 2006).  Otherwise, these were changed to missing. 
 If the „Y/N‟ answer was not completed on the questionnaire next to a symptom, the 
symptom was assumed not to be present (i.e. „No‟) unless other data were 
completed for that symptom (e.g. severity, frequency) in which case the symptom 
was assumed to be present (i.e. „Yes‟). 
 On the questionnaire, ongoing status was assumed to be „yes‟ if ongoing was 
missing 
 Symptoms were classified and grouped to reduce the list of over 300 symptoms 
documented (see Appendix VI).   
 Symptoms within each classification heading were assumed to be part of the same 
complex.  E.g. if a woman reported epigastric pain and belching that occurred 
separately, both would be considered to be indigestion. 
 If more than one symptom was recoded to a single symptom resulting in multiple 
symptom parameters (e.g. loose stools and frequent bowel motions were both 
coded as diarrhoea), the following rules were applied; use the 
o Earliest symptom onset date 
o Latest symptom end date 
o Maximum duration  
o Maximum severity 
o Maximum frequency 
o Earliest date of „Yes‟ to GP visit 
o Answers of „Yes‟ to ongoing overrides „No‟ to ongoing 
 Symptoms that started >2 years before diagnosis or recruitment were treated as a 
separate group (symptoms that started before this were considered to be unlikely to 
be related to ovarian cancer).  Exact onset dates and duration for these symptoms 
were not derived if missing. 
 Symptoms from all 3 sources were coded as „other unrelated‟ without specific 
details (onset date, severity etc.) if they were not on the list of „possibly related‟ 
symptoms 
 Symptoms with a reported onset date after diagnosis or consent were dropped. 
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 If >1 unrelated symptom was reported, only one was databased as „other 
unrelated‟. 
 Blank questionnaires were treated as missing data (i.e. no questionnaire). 
 All symptoms on the list of „possibly related‟ symptoms were databased regardless 
of medical history (i.e. no assumptions were made about symptom aetiology) 
The list of „possibly related‟ symptoms excludes some of the more unusual 
presentations of ovarian cancer (such as hirsutism or paraesthesia) as these 
symptoms were considered too rare to be included for the current study purposes.   
Due to limited space on the questionnaire, irregular vaginal bleeding (IVB) was broadly 
defined to include all vaginal bleeding irregularities.  However, on interview and GP 
notes postmenopausal bleeding (PMB) and post-coital bleeding were separated out 
from IVB since they were of special interest.  A change in bowel habit is much more 
likely to be salient than any pre-existing tendency to constipation or diarrhoea that is 
„normal‟ for a woman.  Therefore, in GP note data, a change in bowel habit was 
recorded if it was clear that bowel symptoms (including constipation and diarrhoea) 
were unusual for that woman or represented a change from the norm.  By contrast, 
change in bowel habit was only databased from the questionnaire and interview if 
women reported mucous in stool or change in stool consistency, shape or size.  As 
such, some of the change in bowel habit data in GP notes will be represented by 
constipation or diarrhoea in the self-reported data (i.e. questionnaire and interview) and 
vice-versa.  This issue was resolved by limiting the main results to symptoms that were 
new in the last two years before reference date.  These differences in symptom 
definitions for the various sources are summarised in Figure 3-3. 
Clinic letters were databased, but not formally analysed since their original purpose 
was to supplement the GP note data, especially for women in whom GP note data 
quality was poor.  Some GP notes contained no consultation details over the period 
although it was clear a GP referral had been made before diagnosis. 
Three women had already completed upfront chemotherapy at study entry.  This was 
discovered after their data were already collected for the current study hence, they 
were included in the main analysis.  See the Data Analysis section for details of an 
analysis which excluded these women (and other subjects). 
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Figure 3-3 Interchangeable Symptom Definitions in Questionnaire versus Other 
Data Sources 
 
*Includes mucous in stool, changes in consistency, shape or size of stool 
**Preferentially includes diarrhoea and constipation if these were indicated to be a change from 
normal bowel habit.  Also includes mucous in stool, changes in frequency, consistency, shape 
or size of stool 
3.3.10 Definition of Study Variables 
Case Details 
Case details such as date of diagnosis, FIGO staging, tumour histology and grade 
were sourced from the main UKOPS study.  Date of diagnosis (DOD) was taken as 
date of first surgery or positive biopsy.  Final staging and histology were confirmed by 
an independent pathologist.  Histology was classified according to the International 
Classification of Diseases for Oncology, morphology for neoplasms, 3rd Edition (ICD-
O-3).130  „Cut-off‟ date was the date when suspicion of ovarian aetiology was first 
documented.  For example, if any of the following text was recorded; „?ovarian‟ 
„?ovarian cyst‟ „?pelvic mass‟ „?ovary‟. 
Early and advanced stage disease comprised FIGO stage I-II and III-IV tumours, 
respectively.  This included borderline tumours and excluded unstaged tumours.   
The route of diagnosis for cases was investigated by extracting data on first referral 
made by the GP.  First referral was defined as the first referral made by the GP for any 
symptom(s) possibly related to ovarian cancer.  For women who presented as 
 
Questionnaire & Interview GP Notes 
Questionnaire Interview & GP Notes 
Irregular Vaginal Bleeding 
Postmenopausal 
bleeding 
Post-coital bleeding 
Irregular vaginal bleeding 
Constipation 
Diarrhoea 
Change in bowel habit* 
Change in bowel habit** 
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emergencies before a GP referral was made or referral appointment was undertaken, 
accident and emergency (A&E) was considered to be the first referral (patient- or GP-
initiated).  Women in whom disease was identified via screening studies or incidental 
findings were excluded from this classification system.  Incidental diagnosis was 
defined as diagnosis solely by chance investigations (opportunistic diagnosis).  This 
excluded women who presented with symptoms possibly related to ovarian cancer that 
were investigated for other diseases.  Date of first referral was taken from the GP 
medical records.  For women in whom no notes were received, date of first referral was 
taken from MDT letters, or interview and questionnaire whenever possible.  Default 
dates of the 15th of the month were used if only month and year of referral were known.   
Timing Variables 
Timing of prediagnostic symptoms was calculated relative to a reference date.  For 
cases this was the date of diagnosis, and for controls this was the date of consent.  
The two years before reference date was divided into prediagnostic periods comprising 
0-2, 3-5, 6-8 etc.  Each period was equivalent to one quarter of a year.  These were 
calculated such that „0-2‟ included symptoms that occurred anytime between 0 months 
up to, but excluding 3 months (i.e. 2.99 months) before reference date.  
Timing of symptoms in the GP notes was problematic since there was no information 
on symptom duration.  For this study, it was assumed that symptoms started from the 
earliest time recorded and continued up until diagnosis or consent. 
In general, symptom lead time is considered to be the time between symptom onset 
and diagnosis.  Symptoms at diagnosis were of little interest since they provide no 
information on the proportion of women who could benefit from any intervention based 
on symptoms.  The greatest opportunity for intervention is the interval between 
symptom onset and referral.  For clarity, two definitions of symptom lead time will be 
used in this thesis; actual lead time (time from symptom onset to referral) and 
diagnostic lead time (time from symptom onset to diagnosis) (see Figure 3-4). 
Figure 3-4 Symptom Lead Time Definitions 
 
Symptom Onset 1st GP Visit Referral Diagnosis
Actual Lead Time
Diagnostic  Lead Time
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Delays in diagnosis 
As discussed in the systematic review, the term „delay‟ is not an appropriate label for 
the interval between symptom onset to diagnosis, however, it was used in this thesis to 
maintain consistency with the literature.  Delays in diagnosis were evaluated in terms of 
total delay, patient delay and provider delay (see Figure 3-5).  Total delay was defined 
as time from first symptom onset to date of diagnosis.  Patient delay was defined as 
time from first symptom to first GP visit.  Provider delay was defined as time from first 
GP visit to date of diagnosis.   
Figure 3-5 Schematic Diagram showing Delays in Diagnosis 
 
*GP visit for a symptom related to ovarian cancer 
Symptom Variables 
As described above, all symptoms were categorised as either „possibly related‟ or 
„unrelated‟ (i.e. „other unrelated‟) to ovarian cancer, based on the literature6-8, 11-13, 15-17, 
19, 67-69, 75, 89, 91 and consultation with the clinical investigators.  All of the symptoms 
featured on the questionnaire/interview were presented individually.  Of the remaining 
„possibly related‟ symptoms, only those that were reported by cases in significantly 
greater proportions than controls (any source) were presented individually (for 
symptoms reported at anytime, excluding those that started >2 years prior).   
The symptoms were grouped (as per usual practice) under the key body systems 
affected by ovarian cancer.  These included abdominal, gastrointestinal, urinary, 
gynaecological and general.  „General‟ included systemic symptoms such as weight 
loss, fatigue, loss of appetite.  Details of each category are listed in Appendix VI under 
„Major Symptom Groups‟.  As with individual symptoms, grouped symptom frequency 
was calculated for each quarter before diagnosis.  This provided an overall impression 
of symptom development according to the different body systems of interest. 
The Goff Symptom Index108 was the first potential symptoms tool for ovarian cancer 
diagnosis to be developed and published.  It is currently being evaluated prospectively 
Symptom 
Onset
Diagnosis
Total Delay
1st GP Visit*
Patient Delay Provider Delay
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in a primary care setting.  In the present study, the Goff Index was applied to the self-
reported data for women aged 50 and above as per Table 3-4.  GP notes did not have 
the duration and frequency information required for the index.  Notably, difficulty eating 
and feeling full quickly were not specifically asked for in the present study which may 
reduce the sensitivity calculated for the index.  Symptom frequency of 16-31 days per 
month was used in place of the >12 times per month criterion.   
Table 3-4 Goff Symptom Index 
 Goff Index Thesis Data 
Symptoms 
Pelvic or Abdominal Pain Pelvic/Abdominal Pain/Discomfort 
↑Abdominal Size or Bloating ↑Abdominal Size or Bloating 
Difficulty Eating or Feeling Full Quickly Feeling Full Quickly* 
Criteria 
Any 1 of these symptoms Any 1 of these symptoms  
New in the last year New in the last year 
Occurred >12 times per month Occurred 16-31 days per month 
*Feeling full quickly was only specifically asked about on interview, however this was combined 
with loss of appetite (i.e. „loss of appetite or feeling full quickly‟) 
3.3.11 Data Analysis 
All statistical analyses were performed using STATA for windows (version 10.0, 
StataCorp LP, College Station TX).  Each data source was analysed separately, 
however combined data were used to investigate missing onset dates and in the 
calculation of total delays (in diagnosis).  A number of statistical methods have been 
used in this thesis.  In general, the analysis consisted of: 
 Descriptive statistics 
 Analysis of new symptoms in a specified period 
 Analysis of new symptoms regarded as a process in time 
Descriptive analysis included proportions (expressed as percentages) for categorical 
variables, and means and standard deviations as well as medians and interquartile 
range, and range, for numeric variables.   
The timing of symptoms was considered using several different approaches depending 
on the variable of interest (see Table 3-5).  The cumulative distributions of symptoms 
that were new over the 24 months prior to diagnosis were plotted for individual 
symptoms and symptom groups. 
Symptoms were considered as a process in time in order to investigate and quantify 
the potential lead time (diagnostic and actual).  Starting from two years prior to 
diagnosis, the hazard of a new symptom was calculated as a function of time.  These 
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were presented with the two year period before diagnosis split into quarters.  For some 
of the tables, 15-23 months were combined since case-control differences were 
negligible over this period.  The estimated continuation odds ratio was based on the 
two-by-two table of cases and controls with symptoms during the quarter, and without 
symptoms at the beginning of the quarter.  Only a small number of controls had 
symptoms in any one quarter, therefore we assumed that the proportion of new 
symptoms in controls in each quarter was the same (i.e. constant), and used 1/8th of 
the proportion with a new symptom in the 24 months.  This approach had the 
advantage of reducing the variance for the continuation odds ratios, which can be large 
with small numbers.  Analysis of the data (and in particular the data on combined 
symptoms) showed that this was a very reasonable assumption.  Confidence intervals 
were based on normal approximation to log-odds ratio using a specially derived 
formula for the standard deviation taking into account the averaging of the control data 
(see section on continuation odds ratios). 
As described below, the decision was made to concentrate on symptoms incident in 
one year during 3-14 (i.e. 3 to 14.99) months prior to diagnosis.  These binary 
„exposure‟ variables were considered in terms of the proportion of cases with 
symptoms (sensitivity), the proportion of controls with symptoms (1-specificity), and the 
odds ratios of ovarian cancer associated with symptoms.  The latter was estimated via 
logistic regression both univariately and multivariately.  Statistical significance for 
univariate variables was assessed using a Chi-Squared test (or Fisher‟s Exact test for 
small expected values). 
Table 3-5 Timing Categories for Analysis 
Symptom Variable Timing (months prior to diagnosis) 
Symptom Incidence 0 to 24 
Symptom Lead Time 0 to 24 
Sensitivity & Specificity 3 to 14.99 (i.e. 1 year) 
Delays 0 to 15 
Symptoms at Diagnosis Anytime* 
*Must have been present during 12 months prior to diagnosis 
Two separate analyses groups were formed.  The main analysis group included all 
symptoms reported (regardless of onset date).  The second analysis excluded 
symptoms that started more than two years before diagnosis or consent.  This was 
based on the assumption that symptoms starting more than two years before diagnosis 
were unlikely to be associated with ovarian cancer.   
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Symptom Lead Time 
Symptom frequencies, and crude odds ratios (OR) with 95% confidence intervals 
(95%CI) were calculated for symptoms listed on the questionnaire and some additional 
„possibly related‟ symptoms for each prediagnostic period.  Logistic regression was 
used to estimate the probability of symptoms occurring in each period.  ORs (crude) 
were also calculated for symptom groups.  The number of borderline cancers (n=34) 
was considered too small for any subgroup analysis. 
As mentioned previously, symptom lead time was classified as either diagnostic lead 
time or actual lead time.  In this study, the median time from referral to diagnosis was 
1.6 months (IQR 1.1-2.5).  To ensure that our results would be applicable to a clinical 
setting, this period was accounted for in the assessment of actual lead time and 
symptom incidence (over one year).  For actual symptom lead time, this period was 
assumed to be 2 months.  For symptom incidence over one year, this was assumed to 
be 3 months.  This additional month was added to be conservative because it is 
unlikely that one month or less of (actual) lead time would offer any significant benefit.  
As such, any symptoms that started within 3 months (2.99 months) of diagnosis were 
excluded and only symptoms present over 3 to 14.99 months were included.   
Sensitivity & Specificity for Detecting Ovarian Cancer 1 Year Before Diagnosis – 
A Novel Definition Based on Cumulative Symptom Incidence 
The sensitivity and specificity of identifying women with ovarian cancer using new 
symptoms cannot be easily estimated from retrospective data.  The terms sensitivity 
and specificity typically relate to the performance characteristics of a screening test 
which is usually cross-sectional.  For the purposes of this study, we were interested in 
calculating cumulative symptom incidence over 1 year since „targeted screening‟ is 
most likely to be offered for incident not prevalent symptoms.  If women in the general 
population were to be asked at random if they had symptoms, then the proportion of 
„controls‟ with symptoms on any given day would be 1-specificity, however this would 
refer to symptom prevalence not incidence.  The sensitivity would be the proportion of 
women with (as yet) undetected ovarian cancer who had symptoms, however this is 
currently unknown.  Hence, sensitivity in this study has been defined as the proportion 
of women with ovarian cancer who had any given symptom(s) in question.  Generally, 
this was applied to symptom incidence over 1 year.  1-Specificity has been defined as 
the proportion of controls who reported incident symptoms over 1 year.  In practice, 
one would not pick women from the general population at random, but rather, wait until 
they present to primary care with new symptoms.  One might then ask what proportion 
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of women aged 50-74 would present each year, and what proportion of the cases that 
would have been diagnosed during the next 12 months would have symptoms. 
Sensitivity and specificity (for cumulative symptom incidence) were calculated for 
symptoms present over 1 year, excluding the first 3 months before reference date (i.e. 
3-14 months).  As mentioned above, this period was felt to provide a better estimate of 
symptom sensitivity with „real‟ potential lead time.   
Early versus Late Stage Symptoms 
Differences in symptom incidence for early versus late stage disease were analysed 
using a log-rank test. 
Delays in Diagnosis 
Delays were assessed individually for each source as patient delay, provider delay and 
total delay (see section 3.3.10 for definitions).  Calculations were performed using an 
approach that aimed to exclude pre-existing symptoms that were unrelated to ovarian 
cancer.  Specifically, only „possibly related‟ symptoms that appeared for the first time in 
the 15 months before diagnosis were included in delay calculations.  Hence, first GP 
visit was the date of first GP visit for a „possibly related‟ symptom that started in the 15 
months before diagnosis.  This cut-off of 15 months prior to diagnosis was based on 
the longest interval before diagnosis that case-control differences appeared to diverge 
in the main results.   
Note that by using this approach, women who had no „possibly related‟ symptoms that 
started in the 15 months before diagnosis, were excluded from the analysis of delay 
(i.e. were considered to have no delay).  Likewise, women who had no visits to the GP 
or no GP notes available were excluded from the calculation of provider delays.  In 
addition, the first GP visit for interview and questionnaire was self-reported, hence, if 
this date was missing; patient and provider delays could not be calculated.  Screen-
detected and incidentally diagnosed women were excluded from delay calculations. 
Total delay was also derived using combined data; this was calculated using the first 
symptom onset date (earliest from all sources) to date of diagnosis.  Provider delays 
were further examined by quantifying the interval between first GP visit for a symptom 
and date of (1) first referral to any specialist and (2) first appropriate referral (i.e. 
referral to gynaecology).  This allowed closer examination of how long it took from 
initial GP visit to referral.  The most appropriate referral is rapid referral G/O however, 
for the purposes of this analysis, appropriate referral was defined as first referral to a 
gynaecology department.  If this date was not known, the date that ovarian aetiology 
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was first suspected (i.e. „cut-off‟ date) was used instead.  Only GP note data were used 
to estimate time to referral since self-reported data were considered to be too 
unreliable.  If date of referral was not known, time to referral was not derived.  
Goff Symptoms Index 
The Goff symptoms Index108 rules were applied to self-reported data for symptoms of 
any onset date and symptoms present 3-14 months before diagnosis.   
Symptoms Indices 
In an exploratory analysis, two crude symptom scores were developed.  The first was 
based on univariate analysis results, the second utilised multivariate analysis.  For the 
multivariate analysis, backwards stepwise selection regression was performed on the 
questionnaire data (for symptoms present at anytime) using p=0.05 as the significance 
level for entry into the model and p=0.1 as the criteria for removal from the model.  
Symptoms that were dropped because they predicted case status perfectly were forced 
back into the model. 
Continuation Odds Ratios 
Any potential symptoms tool would be based on new symptoms since one would not 
test repeatedly (within a given time frame) for the same symptom.  A continuation odds 
ratio131 was calculated to examine the risk associated with having a (new) symptom 
and developing disease within the next x number of months (similar to a hazard).  In 
this scenario, the timing element is crucial and women who already have the symptom 
are not of interest.  Continuation odds ratios (cOR) were calculated based on the 
women who were still „at risk‟ of developing a particular symptom at each time point.  
As such, women who had already reported the symptom at any previous time point 
(including longstanding symptoms and symptoms with missing start dates) were 
excluded from the total number of women „at risk‟.  Given that the rate of new 
symptoms in controls was assumed to be constant, an average rate was calculated for 
each symptom and used to calculate the cORs and 95%CIs, in the place of the actual 
numbers of controls in each period.  Half a control was added to each calculation to 
provide stability and allow derivation of odds ratios for symptoms that were not reported 
by any controls.  The cORs for women who never reported the symptoms (i.e. „none‟) 
were not calculated.  The following is an example of how a continuation odds ratio is 
calculated.   
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Months 
Before 
Diagnosis 
Cases Controls 
None 50 210 
0-2 100 5 
3-5 50 5 
6-8 20 5 
9-11 10 5 
12+ 20 20 
TOTAL 250 250 
Assuming we wish to calculate a continuation odds ratio (cOR) for the period 3-5 
months before diagnosis: 
 
The continuation odds is the number who develop the symptom in the interval (3-5 
months), divided by the number (of those who have not already developed the 
symptom) who do not develop the symptom in the interval.  Note that the odds are 
calculated using the number of women still „at risk‟ of developing the symptom, as the 
denominator (i.e. women who have not reported the symptom plus the number of 
women who report the symptom at the next time point of 0-2 months).  Also, for the 
calculations in the present study the equation was slightly more complicated as women 
with missing onset dates and symptoms present for >2 years were subtracted from 
total number of cases and controls, and half a control was added when calculating the 
average rate.  A specific example using actual data from the study is in Appendix IX.  
Severity & Frequency 
Analyses of symptom severity and frequency were limited to self-reported data only as 
these data were not readily available in GP notes.  This was performed for „possibly 
related‟ symptoms only and was done on an individual and group level.  Symptom 
frequency was not analysed for symptoms with unusual timing patterns or for 
symptoms in which frequency is irrelevant (in the context of „targeted screening‟ based 
on incident symptoms).  Specifically these symptoms were lump in abdomen, change 
in bowel habit, irregular vaginal bleeding, vaginal discharge, weight loss and 
postmenopausal bleeding (PMB).  Symptom severity was examined with the exception 
of irregular vaginal bleeding, PMB, vaginal discharge, change in bowel habit, and lump 
in abdomen.   
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Urinary Symptoms 
Urinary frequency and urgency are the most common urinary symptoms reported in 
previous studies of ovarian cancer (presumably due to tumour pressure effects).6-8, 12, 13, 
69, 75, 90  Hence, these were separated out in the surveys and analysis.  Urinary 
symptoms such as incontinence, retention, dysuria or haematuria were also databased 
but as a separate group named „urinary other‟.  Urge incontinence, even in the 
presence of urgency, was classified as „urinary other‟.  This was based on the rationale 
that investigations to confirm detrusor instability or overactive bladder were likely to 
have been performed if documented as „urge incontinence‟ rather than „urgency‟.  If the 
terms „UTI‟ (urinary tract infection) and „cystitis‟ were recorded without specific 
symptom details, they were also grouped under „urinary other‟ even though both are 
usually associated with frequency.  In order to check that this did not create any bias; 
an analysis with these terms grouped with „urinary frequency/urgency‟ was performed 
but produced similar results.  Both classification rules produced highly significant case-
control differences. 
Screen-Detected Women 
Women who were detected via screening studies were included in the main analysis 
but were excluded from delays in diagnosis calculations.  This included women from 
both the population-based screening study (UKCTOCS) and high-risk women from the 
UKFOCS study (UK Familial Ovarian Cancer Study).  The rationale for their inclusion in 
the main study was that almost all screen-detected women reported at least one 
possibly related symptom on at least one data source.  In addition, often their data was 
already collected before it was known that they were screen-detected. 
Exclusions 
In a subgroup analysis, cases were restricted to postmenopausal women aged 45-74, 
with primary invasive ovarian or tubal cancer who had consented before or on date of 
diagnosis.  Controls were also restricted to women aged 45-74.  Data on the following 
were dropped: 
 Screen-detected women (via UKCTOCS or UKFOCS) 
 Questionnaires that were completed after diagnosis 
 Version 2 of the questionnaire (most women completed version 3) 
 Interviews performed after chemotherapy started or >3 months after diagnosis 
(cases) or consent (controls) 
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Results from this restricted analysis did not differ greatly from those in the main 
analysis, hence were not presented. 
Missing Data 
There was a sizeable amount of missing data on the self-reported data (i.e. 
questionnaire and interview).  Most notably these included symptom onset dates, 
severity and frequency (see Table 3-6).  Missing onset dates were derived from 
duration data (as per Appendix VII) whenever possible.  Unfortunately, this was not 
possible if duration data were missing or if duration was recorded but symptoms were 
not ongoing.  Data in Table 3-6 show symptoms with missing data that could not be 
derived in the data cleaning process.  A small proportion of missing data could be 
ascribed to various symptom attributes such as symptoms that fluctuated with activity 
or meteorological seasons.  However, the majority were missing with no explanatory 
information, and did not appear to be missing at random.  If the data were missing at 
random we would have found the distribution of onset dates (for cases and controls 
separately) in the interview to be similar for those with missing and non-missing dates 
on questionnaire.  Rather, the missing onset date tended to be more than 2 years 
before reference date, particularly for controls.  This was of greatest concern for control 
questionnaire data since 34% of symptom onset dates were missing, and therefore 
would be unaccounted for in calculations involving lead time.  By contrast, missing 
onset dates were much rarer in cases (8%).   
Although one might expect there to be minimal missing data from the interview, this did 
not occur in our study as some women simply could not remember some of the 
symptom details requested.  Severity and frequency data were missing on interview in 
slightly high proportions for cases compared with controls, whereas the converse was 
true on questionnaire.  It is not clear why this occurred, although interviews in cases 
were certainly more complicated and drawn out than those in controls.   
As mentioned above, combining the data sources for analysis was felt to be beyond the 
scope of this thesis.  However, for missing data, interview answers were used to gain 
insight on possible reasons why symptom onset dates were missing on the 
questionnaire.   
Interviews were performed in 52 of the missing case symptoms and 108 of the missing 
control symptoms.  Of these, 17% (9/52) of the symptoms for cases and 11% (12/108) 
for controls, were not reported on interview.  For those that did have the symptom 
recorded on interview, 6% (3/52) still had missing onset dates for cases and 10% 
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(11/108) for controls.  Table 3-8 shows data on the informative interview answers for 
symptoms that had a missing start date on the questionnaire. 
  
 1
0
3
 
Table 3-6 Proportion of Symptoms with Missing Symptom Onset Date, Severity or Frequency for Self-reported Data 
Number Missing/Total Number (percentage) 
 Missing Data Unexplained Missing Data* 
 Cases Controls Cases Controls 
Missing Onset Date 
 Questionnaire 
 Interview 
 
115/1487 (8) 
28/973 (3) 
 
161/479 (34) 
73/461 (16) 
 
110/1482 (7) 
12/957 (1) 
 
161/470 (34) 
16/404 (4) 
Severity** 
 Questionnaire 
 Interview 
 
148/1372 (11) 
155/897 (17) 
 
110/470 (23) 
58/449 (13) 
 
133/1357 (10) 
143/885 (16) 
 
90/450 (20) 
44/435 (10) 
Frequency*** 
 Questionnaire 
 Interview 
 
155/1288 (12) 
209/858 (24) 
 
114/461 (24) 
154/445 (35) 
 
134/1267 (11) 
150/799 (19) 
 
88/435 (20) 
56/347 (16) 
*Excludes symptoms that were mild and transient, activity-dependent, episodic, seasonal, intermittent or started more than 2 years prior. 
**Excludes change in bowel habit, irregular vaginal bleeding (IVB), vaginal discharge, abdominal lump, postmenopausal bleeding (PMB) 
***Excludes change in bowel habit, IVB, vaginal discharge, abdominal lump, PMB, weight loss 
N.B. Excludes unrelated and possibly related symptoms that were considered too rare to present individually 
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Table 3-7 Proportion of Missing Onset Dates on Questionnaire for Any Symptom* 
Any Symptom* Cases Controls 
Total number of symptoms 1487 479 
Total number of symptoms with missing onset 
date on questionnaire 
115 (8%) 161 (34%) 
*Excludes unrelated symptoms and possibly related symptoms that were too rare to present 
individually (e.g. pain during intercourse) 
Table 3-8 Symptoms with Missing Onset Date on Questionnaire with Onset Date 
on Interview 
Number of Symptoms (percentage) 
Months before reference date Cases Controls 
 0-5  16 (40%) 11 (13%) 
 6-11  7 (18%) 7 (8%) 
 12-23  4 (10%) 4 (5%) 
 >24 13 (33%) 63 (74%) 
Total 40 (100%) 85 (100%) 
„0-5‟ months is 0 to 5.99 months etc. 
In Table 3-6, it can be seen that cases completed the questionnaire better than controls 
(in terms of there being less missing data).  For controls, of the symptoms for which a 
start date was recorded on interview but missing on questionnaire, 74% were reported 
as starting >2 years before consent.  These data indicate that most control symptoms 
with missing onset dates on questionnaire were either trivial or longstanding.  
Conversely, case symptoms with no onset dates on questionnaire were usually 
reported on interview to be either within 0-5 months of diagnosis (40%) or longstanding 
(33%).   
Based on these findings, the decision was made to treat symptoms with missing onset 
dates as if they were longstanding (i.e. present for >2 years) and exclude them from 
the symptom lead time calculations.  The rationale for excluding longstanding 
symptoms from the main study results is detailed in section 4.1 Results.  This was a 
relatively conservative approach given that symptoms in cases were actually more 
likely to start within the two years.  Symptoms with missing onset dates were still 
included in the results showing symptoms present at anytime (i.e. not split into 
prediagnostic periods).  Since the data were collected from multiple sources, these 
issues with missing values will be addressed more formally in a future combined 
analysis. 
Missing severity and frequency were only a minor concern since they were not a main 
outcome.  According to linear tests for trend, missing severity and frequency were more 
likely to be mild or infrequent (1-4 days per month) on both data sources.  This 
demonstrated that severity and frequency were not missing at random.  However, the 
fact that symptoms with missing severity and frequency were more likely to be mild or 
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infrequent was considered to be sufficient to justification to assume that these 
symptoms were less important. 
Combined Analysis 
Combining the three data sources for analysis would require development of a special 
algorithm to take into account the various advantages and disadvantages of each 
source.  In addition, construct validity for the questionnaire and interview and 
intraindividual variation between the sources would need to be considered.  Such an 
analysis was felt to be beyond the scope of this thesis and is planned to be completed 
as part of continued work on the study data. 
106 
4 CHAPTER 4: Case-Control Results  
4.1 Results 
A total of 263 newly diagnosed cases and 268 controls were initially included in the 
study.  Nine of the cases were later confirmed to be primary peritoneal, leaving a total 
of 254 eligible cases.  Demographic details are shown in Table 4-1.  Median age at 
study entry was 64 years for both groups and the majority of women were White.  One 
case was diagnosed 13 days before her 45th birthday (aged 44), which is below the age 
threshold, but was included since her data had already been collected and the age 
difference was marginal. 
Figure 4-1 provides details of the distribution of data sources collected.  Almost all 
subjects completed a questionnaire, and interview and GP note data were obtained for 
a similar proportion of cases and controls in each group.   
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Table 4-1 Demographics 
Number (%) 
 Cases 
n=254 
Controls 
n=268 
Age in years (at diagnosis or consent)   
 Median (IQR) 64 (56-72) 64 (57–72) 
 Mean (±SD) 64 (10) 65 (8) 
 Range 44 - 90 52 – 78 
Age Distribution    
 44-50 years 30 (12) - 
 51-55 years 26 (10) 33 (12) 
 56-60 years 39 (15) 63 (24) 
 61-65 years 41 (16) 50 (19) 
 66-70 years 46 (18) 42 (16) 
 71-75 years 33 (13) 52 (19) 
 76-80 years 23 (9) 28 (10) 
 81-85 years 13 (5) - 
 86-90 years 3 (1) - 
Ethnicity 
 White 
 Other 
 
247 (97) 
7 (3) 
 
263 (98) 
5 (2) 
Centre 
 Belfast 
 Bristol 
 East Kent 
 Gateshead 
 Manchester 
 Middlesbrough 
 North Wales 
 Portsmouth 
 Southend 
 London* 
 
30 (12) 
43 (17) 
39 (15) 
17 (7) 
2 (1) 
3 (1) 
12 (5) 
6 (2) 
38 (15) 
64 (25) 
 
39 (15) 
67 (25) 
- 
16 (6) 
6 (2) 
8 (3) 
50 (19) 
3 (1) 
- 
79 (29) 
Menopausal Status 
 Post-menopausal 
 Pre- or Peri- menopausal 
 Unknown 
Relevant Medical History (GP notes) 
 IBS 
 Diverticular conditions** 
 
215 (85) 
30 (4) 
9 (12) 
 
14/223 (6) 
23/223 (10) 
 
268 (100) 
- 
- 
 
16/227 (7) 
21/227 (9) 
*Cases were from University College London Hospital, Controls were from Barts and The 
London NHS Trust 
**Includes diverticular disease, diverticulosis, diverticulitis 
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Figure 4-1 Distribution of Data Sources Collected 
 
*Includes 5 face-to-face interviews 
 
Questionnaire
Q only (6%) 
n=14
Interview
I only (0%) 
n=0
GP Notes
GP only (2%) 
n=5
Total Questionnaire (98%)
n=249
Total Interview (57%)
n=145*
Total GP Notes (88%)
n=223
Q+I only (7%)
n=17
GP+I only (0%)
n=0
Q+GP only (35%)
n=90
All 3 Sources (50%)
n=128
Total Cases
n=254
Questionnaire
Q only (10%) 
n=27
Interview
I only (0%) 
n=0
GP Notes
GP only (0%) 
n=0
Total Questionnaire (100%)
n=268
Total Interview (47%)
n=125
Total GP Notes (85%)
n=227
Q+I only (5%)
n=14
GP+I only (0%)
n=0
Q+GP only (43%)
n=116
All 3 Sources (41%)
n=111
Total Controls
n=268
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Cases included 254 women with primary ovarian or fallopian tube cancer, 34 of which 
were borderline tumours.  Most of the tumours were epithelial (98%).  As shown in 
Table 4-2, 40% of cases were early stage (I-II) at diagnosis and 53% were advanced 
stage (III-IV).  Seven percent of cases were unstaged, and these were predominantly 
borderline cancers (12/17).  As mentioned previously, date of diagnosis was taken as 
the date of surgery or date of first positive biopsy.  Most cases were consented before 
or on the date of diagnosis (198/254, 78%).  Of the remaining cases, 18 were recruited 
more than one month after diagnosis.  Two cases were consented more than 4 months 
after diagnosis but this included (2 of the 3) women who had already completed upfront 
chemotherapy (see 3.3.9 Data Cleaning).  The median time between „cut-off‟ date (i.e. 
date ovarian aetiology was first suspected) and diagnosis was 1.3 months (IQR 0.7-
1.9).   
CA125 data were available for 92% of cases.  Serum levels were raised in 87% of early 
stage and 98% of late stage cancers (see Table 4-3).  The proportion of cases and 
controls with documented IBS or diverticular conditions was similar.  Dates of diagnosis 
for IBS or diverticular conditions were available for only a proportion of cases (IBS n=7, 
diverticular n=17) and controls (IBS n=5, diverticular n=14).  Of the cases with, only 2 
of the 7 had a diagnosis of IBS that was new in the year before cancer diagnosis.  For 
diverticular conditions this was 6 out of 17 cases. 
110 
Table 4-2 Case Details 
Number (percentage) 
FIGO Stage   
I 85 (33) Early 
II 17 (7) 102 (40) 
III 107 (42) Late 
IV 28 (11) 135 (53) 
Unstaged* 17 (7)  
Tumour Grade  
1 25 (10) 
2 47 (19) 
3 111 (44) 
Ungraded 181 (71) 
Tumour Type  
EOC** 250 (98) 
 Invasive  216 (86) 
 Borderline  34 (14) 
Non-EOC  4 (2) 
Histology ICD-O Classification  
Ovary (C56)  
Carcinoma  
 Serous 118 (46) 
 Mucinous 37 (15) 
 Endometrioid 24 (9) 
 Clear Cell 17 (7) 
 Adenocarcinoma NOS 11 (4) 
 Other Specified Carcinoma 27 (11) 
 Unspecified Carcinoma 4 (2) 
Other Specified Malignant Neoplasm*** 10 (4) 
Sex Cord-Stromal 5 (1) 
Fallopian Tube (C57.0)  
Carcinoma  
 Serous 1 (0) 
*Borderline (n=12), granulosa cell (n=2), primary invasive ovarian cancer (n=3, two of whom 
were receiving upfront chemotherapy so staging was not yet performed) 
**Includes synchronous cancers (n=3) 
***Mixed mullerian tumours (n=10) 
Abbreviation: EOC is epithelial ovarian cancer 
Table 4-3 CA125 Levels (Cases) 
 Not Available CA125 Available Total 
  Normal Elevated  
Early 5 (5%) 13 (13%) 84 (87%) 102 
Late 12 (9%) 3 (2%) 120 (98%) 135 
Unstaged 3 (18%) 3 (21%) 11 (79%) 17 
Total 20 (8%) 19 (8%) 215 (92%) 254 
Note: CA125 levels ≥30 units/ml (postmenopausal) and ≥35 units/ml (pre-menopausal) were 
considered to be raised 
Three important attributes of the symptom data were noticeable immediately: 
1) Relative to cases, controls reported more symptoms that started >2 years 
before reference date (i.e. longstanding symptoms), particularly on interview 
(see Figure 4-2). 
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2) The proportion of symptoms 12-24 months before diagnosis (or consent) 
was extremely similar amongst cases and controls (see Figure 4-2), 
3) Controls demonstrated a relatively constant rate of new symptoms over the 
two years prior to consent (see Figure 4-3),  
Implications of 1) are that symptom specificity is underestimated if longstanding 
symptoms are included.  The effects of this were greatest in the interview data.  Table 
4-4 shows the dramatic change in odds ratios when longstanding symptoms are 
omitted from interview data.  Notably, the proportion of controls with bloating at 0-2 
months before consent is >3 times larger if longstanding bloating is included (7% 
versus 23%, see Figure 4-2). 
Table 4-4 Crude Case-Control Odds Ratios (95%CI) Including versus Excluding 
Longstanding Symptoms Reported on Interview (Anytime) 
Symptom Incl. >2 Year* Excl. >2 Year** 
Abdominal Bloating 2.44 (1.49, 3.98) 5.93 (3.37, 10.43) 
Constipation 1.62 (0.97, 2.71) 3.95 (1.93, 8.09) 
Indigestion 1.04 (0.64, 1.67) 2.03 (1.18, 3.50) 
Fatigue 1.61 (0.99, 2.62) 3.43 (2.05, 5.74) 
*Including symptoms that started >2 years before reference date 
**Excluding symptoms that started >2 years before reference date 
Bolded values have 95% confidence intervals above 1.0 
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Figure 4-2 Interview Symptom Prevalence Per Prediagnostic Quarter With & 
Without Longstanding Symptoms (Vertical Bars are 95% Confidence Intervals)  
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Figure 4-3 Control Grouped Symptom Prevalence Per Prediagnostic Quarter 
Excluding Longstanding Symptoms for Each Data Source (Vertical Bars are 95% 
Confidence Intervals) 
 
Another point of interest was that the majority of salient case symptoms were new in 
the year before diagnosis according to all data sources (Figure 4-4).  In contrast, the 
same symptoms in controls typically started more than one year before the reference 
date.   
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Figure 4-4 Proportion of ‘New’ versus ‘Old’ Symptoms in Cases & Controls for 3 
Common Symptoms Per Data Source  
Note: Note: All symptoms were present during the year before reference date, including 
longstanding symptoms.  „New‟ denotes symptoms that first started during the year before 
reference date.  „Old‟ denotes symptoms that first started more than one year before the 
reference date. 
Abbreviations: Incr. is increased 
Any referral algorithm using symptoms would be based on the first presentation for any 
given symptom (or symptoms).  That is, one would not test repeatedly for the same 
symptom (within a certain timeframe).  For these reasons, symptoms that started more 
than two years prior to reference date were omitted from the main graphs and 
separated out in the main tables.  Also, symptom graphs were plotted as the 
cumulative incidence of new symptoms (i.e. new within the two years prior to reference 
date).  This approach has the advantage of showing the proportion of controls that 
would be „included‟ in each year if one were to offer testing based on symptoms.  
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Finally, given that the rate of new symptoms in controls was approximately constant, an 
average rate per month was estimated for each symptom.  These estimates were used 
(after appropriate weighting) in place of the actual proportions of controls when 
calculating odds ratios for different periods before diagnosis.  This allowed for a more 
direct comparison of the risk, and therefore lead time associated with individual 
symptoms for each prediagnostic period.   
4.1.1 Questionnaire 
Although it was requisite for all study participants to fill out a questionnaire, these were 
not received for four cases.  An additional case questionnaire was dropped due to 
unreliable data since all symptoms were recorded as starting after diagnosis despite 
several prediagnostic symptoms being present in the GP notes.  This resulted in 
questionnaire data for a total of 249 (98%) cases and 268 (100%) controls.  The 
majority of women completed the questionnaire before, or on the day of diagnosis 
(cases 77%) or consent (controls 99%).  Of the 58 cases who completed the 
questionnaire after the date of diagnosis, 3 had already received neoadjuvant 
chemotherapy and the remaining 55 were either scheduled for neoadjuvant 
chemotherapy (i.e. had positive biopsy but not treatment) or had malignant biopsy 
results before the primary site of cancer was known.  Eighty-nine percent of cases and 
90% of controls completed version 3 of the questionnaire, and the remainder 
completed version 2.  Version 2 was used between February 2006 and August 2006, in 
26 cases and 20 controls.  Version 3 was used from June 2006 to April 2008, in 223 
cases and 248 controls.   
The proportion of women who received assistance from the study nurses to complete 
the questionnaire was unknown, and it was difficult to control this aspect of data 
collection, especially given that the main drive for UKOPS was to obtain biological 
rather than epidemiological endpoints.  Study nurses were under pressure to process 
blood samples for the main study within strict time constraints. 
Among those who completed a questionnaire, 98% of cases versus 62% controls 
reported at least one symptom in the year before diagnosis or consent.  Once 
longstanding symptoms were excluded, this changed to 96% and 49% for cases and 
controls, respectively.  Of the cases that reported no symptoms on questionnaire, all 
had symptoms possibly related to ovarian cancer in their GP notes or interview.  
Symptom reporting was generally higher in cases than controls.  Overall, the most 
commonly reported symptoms at anytime (excluding longstanding) in cases were 
abdominal bloating (69%), increased abdominal size (67%), pelvic/abdominal pain or 
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discomfort (53%) and fatigue (50%).  In contrast, the most frequent control symptoms 
were back pain (16%), indigestion (16%), fatigue (15%) and abdominal bloating (13%).  
Note that these percentages refer to symptoms reported at anytime, and therefore do 
not relate directly to the cumulative frequency graphs.   
Figure 4-5 shows cumulative frequency for the most common case symptoms over the 
two years before diagnosis.  Longstanding symptoms are excluded, so each line 
represents symptoms that were new in the two years before reference date.  Strikingly, 
cases and controls start to diverge around 15 months prior to reference date for all four 
symptoms.  Constipation, loss of appetite, diarrhoea, nausea/vomiting, irregular vaginal 
bleeding and weight loss started to diverge from 9 months before reference date (data 
not shown but see Table 4-7).  Urinary frequency/urgency and indigestion appeared to 
separate later from around 6 months before reference date.   
Figure 4-5 Cumulative Symptom Frequency for the Most Common Symptoms in 
Cases on Questionnaire for Two Years Before Reference Date 
 
4.1.2 Telephone Interview 
Telephone interview response rates were high in both groups with 79% of newly 
diagnosed cases and 70% controls indicating consent on the questionnaire.  Of the 
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cases who consented, interviews were not performed in 46.  This was because women 
were either deceased (n=6), not well enough (n=6), not contactable within reasonable 
time from diagnosis (n=29), or had changed their mind (n=5).  Attrition of control 
interviews was due to failure to make contact within timelines (n=64) and women 
changing their mind (n=1).  This resulted in interviews conducted with 145 cases and 
125 controls.   
Interviews took place within 3 months of consent or diagnosis.  However, there were 
some exceptions to this (cases n=11, controls n=7).  These were mostly due to 
oversight, and all but two cases were interviewed within 5 months of diagnosis.  An 
attempt was made to contact all cases who agreed to telephone interview, unless the 
details of consent for interview were received more than 3 months after diagnosis or 
consent.  The majority of interviews were conducted during working hours which 
potentially created bias against women who were in full-time employment, however 
women were also contacted at work whenever possible.   
Case interviews lasted a median of 18 minutes (IQR 13-24), whereas control interviews 
elapsed over a shorter median period of 8 minutes (IQR 5-11).  Interviews ideally took 
place before initiation of chemotherapy however, logistically this was difficult and 32% 
(47/145) of women had already started treatment by the time of the interview (see 
Table 4-5).  Of these women, the median time from starting chemotherapy to interview 
was 0.6 months (IQR 0.2-1.1).  Median time between diagnosis or consent and 
interview was one month for both cases (IQR 0.8-1.7) and controls (IQR 0.6-2.0).  
Table 4-5 Timing of Interviews 
 
Cases 
(n=145) 
Controls 
(n=125) 
Time from DOD/ICF Months 
 Median (IQR) 
 
1.2 (0.8-1.7) 
 
0.9 (0.6-2.0) 
Before Chemotherapy Start 98/145 (68%) - 
After Chemotherapy Start 47/145 (32%) - 
All cases reported at least one relevant symptom on interview, as did 90% of controls.  
Interestingly, this included more than half of the women who had recorded no 
symptoms on questionnaire.  If longstanding symptoms were ignored, 99% of cases 
and 73% of controls reported at least one possibly related symptom.  As with the 
questionnaire, increased abdominal size (77%), pelvic/abdominal pain or discomfort 
(57%), abdominal bloating (56%) and fatigue (55%) were the most frequently 
experienced symptoms for cases over any time period (excluding longstanding).  For 
controls, these were fatigue (26%), indigestion (22%), abdominal bloating (18%), and 
increased abdominal size (16%). 
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Figure 4-6 shows cumulative incidence of the most common case symptoms reported 
on interview (excluding longstanding symptoms).  In general, case-control differences 
started closer to diagnosis than those observed for questionnaire data.  
Pelvic/abdominal pain or discomfort started to show case-control separation from 12 
months prior to diagnosis.  For abdominal bloating, increased abdominal size and 
fatigue divergence appeared later at around 9 months before diagnosis, as did loss of 
appetite (feeling full quickly).  Weight loss, indigestion, urinary frequency or urgency, 
nausea/vomiting began to separate 6 months before diagnosis.   
Figure 4-6 Cumulative Symptom Frequency for the Most Common Symptoms in 
Cases on Interview for Two Years Before Reference Date 
 
Overall, symptom reporting was higher on interview than questionnaire even after 
omission of longstanding symptoms (see Figure 4-7 and Figure 4-8).  Back pain, 
bloating, pelvic/abdominal pain or discomfort, increased abdominal size, constipation, 
fatigue, indigestion and urinary frequency or urgency were reported in substantially 
higher proportions on interview for controls.  However, most of these appeared to be 
longstanding.   
This pattern of increased symptom reporting on interview was also observed in cases 
but to a much smaller extent.  Weight loss, bloating, diarrhoea, nausea or vomiting, and 
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lump in abdomen were the only case symptoms less frequent on interview but all 
others increased.  
Figure 4-7 Questionnaire versus Interview Symptom Prevalence for Cases and 
Controls Including Longstanding Symptoms 
 
Note: „Loss of appetite‟ is „Loss of appetite or feeling full quickly‟ on interview  
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Figure 4-8 Questionnaire versus Interview Symptom Prevalence for Cases and 
Controls Excluding Longstanding Symptoms 
 
Note: „Loss of appetite‟ is „Loss of appetite or feeling full quickly‟ on interview  
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4.1.3 GP Notes 
GP notes were received for 223 (88%) cases and 227 (85%) controls.  Only 3% of 
cases had no potentially related symptoms recorded in their GP notes during the two 
years before diagnosis.  This proportion was higher in controls with 32% of women 
without any potentially related ovarian cancer symptoms documented.  Unlike self-
reported data, persistence of symptoms was difficult to establish since there was 
insufficient information on symptom duration.  Clearly, a single recording of a symptom 
12 months before diagnosis does not necessarily mean that the symptom continued 
until diagnosis.  However, for the purposes of this study, symptom persistence was 
irrelevant since women would be tested based on the first appearance of symptoms.  
An important point to note is that GP note data were only extracted up until a „cut-off 
point‟ for cases (i.e. date that ovarian or pelvic aetiology was first suspected).  
However, the date of diagnosis was still used as the reference date for calculating the 
two year prediagnostic periods.  Therefore, the data between 0-3 months before 
diagnosis do not necessarily represent symptoms at diagnosis, and overall symptom 
prevalence at diagnosis will be underestimated for cases. 
As expected, symptom reporting/recording was lower in GP notes than the self-
reported data sources.  Recording of fatigue, indigestion and diarrhoea was extremely 
similar for cases and controls, and divergence was small even 3 months prior to 
diagnosis.  Another distinguishing factor from the self-reported data was that urinary 
symptoms featured more heavily for both cases and controls.  For cases, the 
symptoms most frequently recorded (excluding longstanding) were pelvic/abdominal 
pain or discomfort (58%), urinary other symptoms (37%), increased abdominal size 
(27%) and nausea/vomiting (25%).  The most common symptoms (excluding 
longstanding) in control women were back pain (18%), indigestion (16%), fatigue (16%) 
and urinary other (16%).   
Cumulative incidence of the most common case symptoms are shown in Figure 4-9.  In 
general, symptom sensitivity was low with less than 40% of women reporting three of 
the most common symptoms.  Separation of case-control symptoms was evident 
around 6 months before diagnosis for pelvic/abdominal pain or discomfort and 
increased abdominal size (see Figure 4-9).  Constipation, change in bowel habit, 
bloating also showed signs of case-control divergence at this time point, however most 
of the remaining possibly related ovarian cancer symptoms began to separate 3 prior 
months to diagnosis, including nausea/vomiting.   
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Figure 4-9 Cumulative Symptom Frequency for the Most Common Symptoms 
Recorded in GP Notes for Cases over Two Years Before Reference Date 
 
Note: „Urinary other‟ includes symptoms such as urinary retention, incontinence, dysuria, 
haematuria, and change in urine smell or colour. 
4.1.4 Symptoms At Diagnosis 
Although it is of clinical interest to document the symptoms present at diagnosis of 
ovarian cancer, this was not a primary aim of the study.  On the questionnaire, all 
women were asked to specify whether each symptom was „ongoing‟, but this field was 
not always completed.  
Symptoms present within one month of reference date were considered to be 
representative of symptoms at diagnosis.  Since this was to examine all symptoms 
present at diagnosis (regardless of when they started), symptoms that had a missing 
onset date (if the symptom was ongoing) and symptoms that started more than two 
years before reference date were included.  GP note data are not shown since visits 
were only examined up to a „cut-off‟ date and therefore did not accurately reflect 
symptoms at diagnosis. 
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The most common symptoms at diagnosis for cases were increased abdominal size, 
abdominal bloating and pelvic/abdominal pain or discomfort for both sources.  The vast 
majority of cases (97%) reported at least one relevant symptom on the questionnaire 
as did all cases did so on interview.  This included screen-detected and incidentally-
diagnosed women.  According to both sources, most cases also had at least 3 
symptoms.  In contrast, controls reported the highest symptom frequencies for bloating, 
back pain and indigestion on questionnaire.  This pattern was repeated on interview 
with the exception of bloating, which was replaced by fatigue.  Almost half of control 
women had no symptoms on the questionnaire, but only 13% claimed the same during 
interview.  Note that on the questionnaire, the term „irregular vaginal bleeding‟ included 
postmenopausal bleeding and other bleeding irregularities such as post-coital bleeding 
and irregular menses.  Odds ratios were not calculated since case-control differences 
at diagnosis are of lesser interest than those at least 3 months prior to diagnosis. 
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Table 4-6 Symptoms At Diagnosis 
 Questionnaire Interview 
Symptoms 
Cases 
(n=249) 
Controls 
(n=268) 
Cases 
(n=145) 
Controls 
(n=125) 
Pelvic/Abdo. Pain Discomfort 57% 12% 63% 23% 
Abdominal Bloating 71% 17% 62% 39% 
↑Abdominal Size 70% 12% 79% 27% 
Back Pain 38% 31% 54% 52% 
Change in Bowel Habit 1% 0% 10% 1% 
Constipation 34% 15% 36% 26% 
Diarrhoea 20% 9% 18% 15% 
Indigestion 38% 21% 52% 52% 
Nausea or Vomiting 30% 4% 27% 9% 
Lump in Abdomen 25% 1% 19% 2% 
Urinary Freq./Urgency 43% 15% 50% 37% 
Urinary Other* 4% 0% 26% 3% 
PMB 1% 0% 8% 2% 
IVB 10% 1% 5% 0% 
Vaginal Discharge 2% 0% 6% 4% 
Fatigue 52% 16% 61% 49% 
Loss of Appetite** 34% 1% 41% 6% 
Weight Loss 31% 1% 27% 2% 
Other Possibly Related 15% 7% 42% 38% 
None 3% 43% 0% 13% 
Other Unrelated 2% 0% 0% 0% 
Number of Symptoms     
0 8 (3%) 116 (43%) 0 (0%) 16 (13%) 
1 23 (9%) 46 (17%) 3 (2%) 10 (8%) 
2 16 (6%) 39 (15%) 7 (5%) 16 (13%) 
3+ 202 (81%) 67 (25%) 135 (93%) 83 (66%) 
*‟Urinary other‟ includes dysuria, retention, haematuria, incontinence, and change in urine 
colour or smell  
**‟Loss of appetite or feeling full quickly‟ on interview 
Bolded values are the 3 most common symptoms per source 
Abbreviations: Abdo. is abdominal, Freq. is frequency, IVB is irregular vaginal bleeding, PMB is 
postmenopausal bleeding. 
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4.1.5 Timing and Predictive Potential of Prediagnostic Symptoms 
As previously inferred, any potential symptoms index would most sensibly be based on 
the first time specific symptoms appeared, or the first time a woman presented for 
those symptom(s).  Table 4-7 contains continuation odds ratios (cOR) for individual 
symptoms which account for women who have already had the symptom, and only 
uses women who are still „at risk‟ of developing a particular symptom at each time 
point.  Note that each woman may have reported more than one symptom in the table.  
Also, the rate of new symptoms in controls was assumed to be constant (refer to Data 
Analysis for further details).   
Overall, significantly elevated cORs were observed for most symptoms 6-8 months 
before diagnosis.  The longest diagnostic lead time was seen on the questionnaire at 
12-14 months before diagnosis for abdominal bloating (cOR 8.3 [95%CI 3.8, 18.2]), 
increased abdominal size (cOR 8.2, [95%CI 2.9, 22.8]), fatigue (cOR 5.7 [95%CI 2.8, 
11.8]), pelvic/abdominal pain or discomfort (cOR 4.8 [95%CI 1.9, 12.4]), diarrhoea 
(cOR 3.7 [95%CI 1.1, 12.1]) and constipation (cOR 3.6 [95%CI 1.1, 12.3]).  Urinary 
frequency/urgency was also present in significantly more cases than controls at the 
same time point in the GP notes (cOR 2.9 [95%CI 1.2, 6.8]).  No symptoms were 
reported in significantly higher numbers of cases than controls for interview data at 12-
14 months before diagnosis. 
On GP notes, cORs were also significantly elevated 9-11 months before diagnosis for 
pelvic/abdominal pain or discomfort, urinary frequency/urgency, urinary other, loss of 
appetite, and irregular vaginal bleeding.   
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Table 4-7 ‘New’ Symptom Frequency, Continuation Odds Ratios & 95% Confidence Intervals at Different Periods before Diagnosis 
Months 
Before 
Diagnosis 
Questionnaire Interview GP Notes 
Cases 
(n=249) 
Controls 
(n=268) 
cOR 95% CI 
Cases 
(n=145) 
Controls 
(n=125) 
cOR 95% CI 
Cases 
(n=223) 
Controls 
(n=227) 
cOR 95% CI 
Pelvic/Abdominal Pain or Discomfort 
         
None* 39% 87% - - 33% 74% - - 42% 85% - - 
0-2 21% 0% 73.9 (37.1, 146.9) 17% 2% 24.9 (11.2, 55.0) 22% 2% 23.9 (14.5, 39.4) 
3-5 13% 1% 30.7 (15.2, 62.2) 19% 6% 18.7 (8.8, 39.8) 16% 1% 11.4 (6.9, 19.0) 
6-8 7% 1% 13.1 (6.0, 28.3) 8% 0% 5.9 (2.5, 13.8) 2% 1% 1.3 (0.5, 3.4) 
9-11 3% 1% 5.7 (2.3, 14.2) 6% 1% 3.6 (1.4, 9.1) 6% 3% 3.3 (1.7, 6.5) 
12-14 3% 0% 4.8 (1.9, 12.4) 1% 2% 0.9 (0.2, 3.9) 2% 4% 1.2 (0.5, 3.2) 
15-23 2% 1% 0.9 (0.3, 2.8) 3% 1% 0.6 (0.2, 1.8) 8% 4% 1.4 (0.8, 2.5) 
>2 Years** 8% 6% 1.6 (0.8, 3.1) 11% 12% 0.9 (0.4, 1.9) 2% 0% 4.1 (0.5, 37.2) 
Missing*** 4% 3% 1.6 (0.6, 4.2) 1% 2% 0.9 (0.1, 6.2) 0% 0% - - 
Abdominal Bloating 
        
None* 27% 80% - - 37% 58% - - 79% 96% - - 
0-2 33% 0% 136.9 (68.8, 272.3) 25% 2% 34.3 (12.1, 96.9) 13% 0% 32.7 (14.8, 72.3) 
3-5 14% 1% 25.5 (12.6, 51.8) 15% 2% 12.7 (4.5, 36.0) 5% 1% 12.2 (5.0, 29.8) 
6-8 6% 1% 9.9 (4.5, 21.6) 8% 0% 5.7 (1.9, 16.9) 1% 1% 1.9 (0.4, 9.0) 
9-11 4% 1% 5.1 (2.1, 12.5) 5% 2% 3.0 (0.9, 9.9) 0% 0% 1.0 (0.1, 7.6) 
12-14 6% 1% 8.3 (3.8, 18.2) 1% 2% 0.8 (0.2, 4.4) 0% 0% - - 
15-23 1% 1% 0.5 (0.1, 1.9) 1% 1% 0.1 (0.0, 1.2) 2% 1% 1.3 (0.4, 4.2) 
>2 Years** 4% 7% 0.6 (0.3, 1.3) 8% 24% 0.2 (0.1, 0.5) 0% 0% - - 
Missing*** 5% 8% 0.6 (0.3, 1.3) 1% 9% 0.1 (0.0, 0.6) 0% 0% - - 
*Did not have symptom during the 12 months before reference date.  **Symptom started >2 years before reference date.  ***Symptom onset date missing.   
Note: „0-2‟=0-2.99 months etc. cOR 95%CI are calculated relative to the number of women at risk of symptom for each time point.  An average rate of „new‟ control 
symptom frequency was used for each symptom.  Half a control was added to each calculation for stability.  Bolded values have 95% confidence intervals above 1.0.   
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Months 
Before 
Diagnosis 
Questionnaire Interview GP Notes 
Cases 
(n=249) 
Controls 
(n=268) 
cOR 95% CI 
Cases 
(n=145) 
Controls 
(n=125) 
cOR 95% CI 
Cases 
(n=223) 
Controls 
(n=227) 
cOR 95% CI 
Increase in Abdominal Size 
        None* 29% 88% - - 21% 73% - - 73% 99% - - 
0-2 36% 0% 272.8 (120.5, 617.8) 36% 5% 100.4 (42.7, 235.9) 20% 0% 193.9 (53.4, 704.6) 
3-5 14% 0% 49.6 (21.5, 114.2) 20% 2% 20.8 (9.1, 47.8) 5% 0% 38.2 (9.6, 152.7) 
6-8 6% 0% 17.0 (6.8, 42.3) 12% 1% 9.7 (4.1, 23.0) 0% 0% - - 
9-11 3% 1% 8.4 (3.0, 23.6) 6% 2% 3.8 (1.4, 10.2) 1% 0% 6.6 (1.0, 42.7) 
12-14 3% 1% 8.2 (2.9, 22.8) 0% 0% - - 0% 0% 3.3 (0.3, 33.5) 
15-23 1% 0% 1.0 (0.3, 3.8) 2% 0% 0.5 (0.1, 1.7) 0% 0% 1.1 (0.1, 11.1) 
>2 Years** 4% 4% 1.1 (0.4, 2.6) 3% 12% 0.2 (0.1, 0.6) 0% 0% - - 
Missing*** 3% 6% 0.6 (0.2, 1.3) 1% 6% 0.1 (0.0, 1.0) 0% 0% - - 
             
Back Pain 
            
None* 58% 67% - - 42% 46% - - 78% 82% - - 
0-2 10% 1% 12.6 (5.9, 26.5) 10% 0% 13.8 (2.7, 71.4) 2% 2% 0.8 (0.3, 2.3) 
3-5 4% 1% 4.2 (1.7, 10.1) 2% 1% 2.5 (0.4, 16.4) 4% 1% 1.7 (0.8, 3.6) 
6-8 2% 1% 2.0 (0.7, 5.8) 4% 0% 4.8 (0.9, 26.3) 2% 3% 0.8 (0.3, 2.3) 
9-11 2% 1% 2.4 (0.9, 6.5) 4% 2% 4.5 (0.8, 24.3) 4% 2% 1.8 (0.9, 3.8) 
12-14 2% 1% 1.5 (0.5, 4.9) 1% 1% 0.7 (0.1, 8.2) 3% 1% 1.4 (0.6, 3.2) 
15-23 2% 2% 0.5 (0.2, 1.6) 0% 2% - - 7% 9% 1.1 (0.6, 1.9) 
>2 Years** 17% 17% 0.9 (0.6, 1.5) 32% 40% 0.7 (0.4, 1.1) 0% 0% - - 
Missing*** 2% 8% 0.3 (0.1, 0.7) 5% 9% 0.5 (0.2, 1.4) 0% 0% - - 
*Did not have symptom during the 12 months before reference date.  **Symptom started >2 years before reference date.  ***Symptom onset date missing.   
Note: „0-2‟=0-2.99 months etc. cOR 95%CI are calculated relative to the number of women at risk of symptom for each time point.  An average rate of „new‟ control 
symptom frequency was used for each symptom.  Half a control was added to each calculation for stability.  Bolded values have 95% confidence intervals above 1.0.   
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Months 
Before 
Diagnosis 
Questionnaire Interview GP Notes 
Cases 
(n=249) 
Controls 
(n=268) 
cOR 95% CI 
Cases 
(n=145) 
Controls 
(n=125) 
cOR 95% CI 
Cases 
(n=223) 
Controls 
(n=227) 
cOR 95% CI 
Constipation 
           
None* 65% 85% - - 61% 72% - - 75% 91% - - 
0-2 12% 0% 36.8 (16.1, 84.2) 10% 2% 25.0 (6.3, 100.1) 11% 1% 12.0 (6.5, 22.3) 
3-5 6% 1% 15.0 (6.1, 36.9) 10% 0% 23.3 (5.9, 91.8) 6% 0% 5.9 (2.9, 12.0) 
6-8 3% 0% 7.5 (2.7, 20.6) 3% 1% 6.8 (1.5, 31.8) 2% 1% 1.6 (0.5, 4.7) 
9-11 0% 1% 0.9 (0.1, 7.3) 3% 0% 5.3 (1.1, 25.9) 1% 2% 1.2 (0.4, 4.0) 
12-14 2% 1% 3.6 (1.1, 12.3) 0% 0% - - 2% 1% 2.0 (0.7, 5.3) 
15-23 2% 1% 1.2 (0.4, 4.0) 1% 0% 0.4 (0.0, 4.4) 2% 4% 0.7 (0.2, 1.7) 
>2 Years** 5% 5% 0.9 (0.4, 2.0) 11% 20% 0.5 (0.2, 0.9) 0% 0% - - 
Missing*** 5% 6% 0.8 (0.4, 1.7) 1% 5% 0.1 (0.0, 1.2) 0% 0% - - 
 
            
Diarrhoea 
           
None* 78% 90% - - 81% 82% - - 85% 90% - - 
0-2 8% 1% 20.0 (8.7, 46.3) 3% 2% 6.3 (1.6, 24.1) 5% 0% 4.2 (2.0, 8.9) 
3-5 3% 0% 7.7 (2.9, 20.7) 2% 0% 3.6 (0.8, 16.6) 2% 0% 1.5 (0.5, 4.3) 
6-8 2% 0% 5.6 (1.9, 16.2) 3% 1% 4.8 (1.2, 19.4) 1% 2% 0.7 (0.2, 3.1) 
9-11 0% 1% 0.9 (0.1, 7.3) 1% 0% 1.2 (0.1, 10.5) 1% 0% 1.1 (0.3, 3.7) 
12-14 2% 1% 3.7 (1.1, 12.1) 1% 2% 1.2 (0.1, 10.4) 2% 2% 1.5 (0.5, 4.3) 
15-23 0% 0% 0.3 (0.0, 2.4) 1% 0% 0.4 (0.0, 3.5) 4% 4% 1.1 (0.5, 2.4) 
>2 Years** 2% 2% 1.1 (0.3, 3.4) 8% 10% 0.7 (0.3, 1.7) 0% 0% - - 
Missing*** 4% 4% 1.1 (0.5, 2.5) 1% 5% 0.1 (0.0, 1.2) 0% 0% - - 
*Did not have symptom during the 12 months before reference date.  **Symptom started >2 years before reference date.  ***Symptom onset date missing.   
Note: „0-2‟=0-2.99 months etc. cOR 95%CI are calculated relative to the number of women at risk of symptom for each time point.  An average rate of „new‟ control 
symptom frequency was used for each symptom.  Half a control was added to each calculation for stability.  Bolded values have 95% confidence intervals above 1.0.   
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Months 
Before 
Diagnosis 
Questionnaire Interview GP Notes 
Cases 
(n=249) 
Controls 
(n=268) 
cOR 95% CI 
Cases 
(n=145) 
Controls 
(n=125) 
cOR 95% CI 
Cases 
(n=223) 
Controls 
(n=227) 
cOR 95% CI 
Change Bowel Habit 
          
None* - - - - 89% 99% - - 82% 94% - - 
0-2 - - - - 5% 0% 35.7 (6.0, 212.1) 8% 1% 11.6 (5.6, 23.8) 
3-5 - - - - 3% 0% 19.4 (2.9, 128.5) 4% 0% 4.7 (2.0, 11.4) 
6-8 - - - - 1% 0% 9.4 (1.1, 79.2) 1% 0% 1.7 (0.5, 6.0) 
9-11 - - - - 0% 0% 0.0 - 2% 1% 2.3 (0.7, 7.0) 
12-14 - - - - 1% 1% 4.7 (0.4, 58.9) 1% 2% 1.7 (0.5, 5.9) 
15-23 - - - - 0% 0% - - 2% 2% 0.7 (0.2, 2.3) 
>2 Years** - - - - 1% 0% - - 0% 0% - - 
Missing*** - - - - 0% 0% - - 0% 0% - - 
 
            
Indigestion 
           
None* 59% 75% - - 46% 46% - - 78% 84% - - 
0-2 12% 1% 20.3 (9.5, 43.3) 14% 2% 11.2 (3.2, 38.8) 4% 1% 2.3 (1.1, 4.9) 
3-5 6% 0% 9.4 (4.2, 21.4) 9% 2% 5.7 (1.6, 20.1) 4% 2% 2.2 (1.0, 4.8) 
6-8 2% 1% 2.2 (0.7, 7.1) 4% 0% 2.4 (0.6, 9.2) 2% 2% 1.2 (0.5, 3.1) 
9-11 2% 2% 2.7 (0.9, 8.0) 4% 2% 2.3 (0.6, 8.7) 1% 1% 0.7 (0.2, 2.4) 
12-14 3% 1% 4.3 (1.7, 10.9) 0% 3% - - 3% 3% 1.5 (0.6, 3.5) 
15-23 0% 0% 0.2 (0.0, 1.3) 1% 1% 0.1 (0.0, 1.1) 8% 7% 1.4 (0.8, 2.5) 
>2 Years** 10% 9% 1.0 (0.6, 1.9) 19% 34% 0.4 (0.2, 0.7) 0% 1% 0.5 (0.0, 5.6) 
Missing*** 6% 10% 0.5 (0.3, 1.0) 3% 10% 0.3 (0.1, 0.9) 0% 0% - - 
*Did not have symptom during the 12 months before reference date.  **Symptom started >2 years before reference date.  ***Symptom onset date missing.   
Note: „0-2‟=0-2.99 months etc. OR 95%CI are calculated relative to the number of women at risk of symptom for each time point.  An average rate of „new‟ control 
symptom frequency was used for each symptom.  Half a control was added to each calculation for stability.  Bolded values have 95% confidence intervals above 1.0.   
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Months 
Before 
Diagnosis 
Questionnaire Interview GP Notes 
Cases 
(n=249) 
Controls 
(n=268) 
cOR 95% CI 
Cases 
(n=145) 
Controls 
(n=125) 
cOR 95% CI 
Cases 
(n=223) 
Controls 
(n=227) 
cOR 95% CI 
Nausea/Vomiting 
           None* 67% 93% - - 70% 88% - - 75% 89% - - 
0-2 18% 3% 52.7 (25.8, 107.8) 16% 4% 26.6 (10.7, 66.2) 11% 2% 9.1 (5.1, 16.2) 
3-5 6% 0% 12.6 (5.5, 29.0) 8% 2% 10.5 (3.9, 28.4) 3% 1% 2.2 (1.0, 5.3) 
6-8 2% 0% 4.2 (1.4, 12.6) 1% 0% 0.9 (0.1, 7.3) 0% 1% 0.3 (0.0, 2.3) 
9-11 0% 0% 0.0 - 1% 0% 1.8 (0.4, 8.7) 2% 1% 1.6 (0.6, 4.2) 
12-14 1% 1% 1.7 (0.4, 7.7) 0% 0% - - 2% 2% 1.3 (0.4, 3.6) 
15-23 1% 0% 0.6 (0.1, 2.6) 1% 0% 0.3 (0.0, 2.4) 6% 5% 1.5 (0.8, 2.8) 
>2 Years** 2% 1% 1.7 (0.5, 6.0) 3% 3% 0.8 (0.2, 3.4) 0% 0% - - 
Missing*** 3% 1% 2.2 (0.7, 7.4) 1% 3% 0.4 (0.1, 2.3) 0% 0% - - 
 
            
Lump in Abdomen 
 
      
 
   
None* 73% 99% - - 81% 98% - - 86% 100% - - 
0-2 17% 0% 998.2 (59.8, 16661.9) 12% 2% 59.8 (15.6, 229.9) 11% 0% 474.3 (28.7, 7847.4) 
3-5 4% 0% 188.0 (10.7, 3301.1) 2% 0% 8.7 (1.6, 47.2) 2% 0% 83.9 (4.6, 1544.0) 
6-8 2% 0% 90.0 (4.8, 1688.0) 2% 0% 8.5 (1.6, 46.1) 0% 0% 16.4 (0.5, 490.9) 
9-11 0% 0% - - 1% 0% 5.6 (0.9, 36.0) 0% 0% - - 
12-14 0% 0% - - 1% 0% 2.8 (0.3, 28.1) 0% 0% - - 
15-23 0% 0% 5.9 (0.2, 178.7) 0% 0% - - 0% 0% 5.4 (0.2, 162.7) 
>2 Years** 0% 1% 0.5 (0.0, 6.1) 0% 0% - - 0% 0% - - 
Missing*** 2% 0% - - 0% 0% - - 0% 0% - - 
*Did not have symptom during the 12 months before reference date.  **Symptom started >2 years before reference date.  ***Symptom onset date missing.   
Note: „0-2‟=0-2.99 months etc. cOR 95%CI are calculated relative to the number of women at risk of symptom for each time point.  An average rate of „new‟ control 
symptom frequency was used for each symptom.  Half a control was added to each calculation for stability.  Bolded values have 95% confidence intervals above 1.0.   
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Months 
Before 
Diagnosis 
Questionnaire Interview GP Notes 
Cases 
(n=249) 
Controls 
(n=268) 
cOR 95% CI 
Cases 
(n=145) 
Controls 
(n=125) 
cOR 95% CI 
Cases 
(n=223) 
Controls 
(n=227) 
cOR 95% CI 
Urinary Frequency/Urgency 
          
None* 56% 83% - - 50% 63% - - 77% 91% - - 
0-2 21% 1% 37.9 (20.1, 71.4) 14% 2% 12.9 (5.0, 33.2) 7% 1% 7.1 (3.5, 14.2) 
3-5 9% 0% 11.8 (5.9, 23.7) 12% 3% 9.3 (3.7, 23.7) 4% 3% 3.9 (1.8, 8.8) 
6-8 4% 1% 4.4 (1.9, 10.3) 3% 0% 2.2 (0.7, 7.2) 1% 0% 0.8 (0.2, 3.7) 
9-11 2% 2% 1.9 (0.6, 5.8) 6% 6% 3.9 (1.4, 10.7) 4% 1% 4.2 (2.0, 9.2) 
12-14 1% 1% 0.9 (0.2, 4.1) 1% 0% 0.4 (0.0, 3.3) 3% 2% 2.9 (1.2, 6.8) 
15-23 0% 0% 0.2 (0.0, 1.2) 0% 0% - - 4% 2% 1.1 (0.5, 2.4) 
>2 Years** 5% 5% 1.0 (0.4, 2.1) 12% 24% 0.4 (0.2, 0.8) 0% 0% - - 
Missing*** 3% 6% 0.5 (0.2, 1.2) 1% 2% 0.6 (0.1, 3.5) 0% 0% - - 
             
Urinary Other 
           
None* - - - 
 
73% 96% - - 63% 84% - - 
0-2 - - - - 12% 2% 46.4 (14.1, 152.5) 10% 2% 7.4 (4.2, 13.2) 
3-5 - - - - 5% 0% 15.5 (4.1, 57.8) 8% 2% 5.1 (2.8, 9.4) 
6-8 - - - - 3% 0% 8.4 (1.9, 36.3) 2% 1% 1.3 (0.5, 3.4) 
9-11 - - - - 1% 0% 4.1 (0.7, 23.7) 5% 3% 2.9 (1.4, 5.8) 
12-14 - - - - 1% 0% 2.0 (0.2, 18.9) 3% 4% 1.5 (0.6, 3.6) 
15-23 - - - - 0% 0% - - 8% 3% 1.5 (0.8, 2.7) 
>2 Years** - - - - 3% 1% 4.5 (0.5, 38.7) 0% 1% 0.3 (0.0, 3.3) 
Missing*** - - - - 1% 1% 1.7 (0.2, 19.4) 0% 0% - - 
*Did not have symptom during the 12 months before reference date.  **Symptom started >2 years before reference date.  ***Symptom onset date missing.   
Note: „0-2‟=0-2.99 months etc. cOR 95%CI are calculated relative to the number of women at risk of symptom for each time point.  An average rate of „new‟ control 
symptom frequency was used for each symptom.  Half a control was added to each calculation for stability.  Bolded values have 95% confidence intervals above 1.0.   
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Months 
Before 
Diagnosis 
Questionnaire Interview GP Notes 
Cases 
(n=249) 
Controls 
(n=268) 
cOR 95% CI 
Cases 
(n=145) 
Controls 
(n=125) 
cOR 95% CI 
Cases 
(n=223) 
Controls 
(n=227) 
cOR 95% CI 
Fatigue 
            
None* 46% 81% - - 38% 50% - - 77% 84% - - 
0-2 20% 1% 35.5 (19.5, 64.7) 12% 6% 7.2 (2.8, 18.1) 8% 2% 4.4 (2.4, 8.0) 
3-5 9% 1% 11.5 (5.9, 22.2) 19% 2% 8.5 (3.6, 19.8) 4% 1% 2.3 (1.1, 4.7) 
6-8 6% 0% 7.1 (3.5, 14.4) 9% 1% 3.1 (1.3, 7.7) 1% 2% 0.7 (0.2, 2.2) 
9-11 2% 2% 2.1 (0.8, 5.7) 11% 9% 3.5 (1.5, 8.2) 2% 1% 0.9 (0.3, 2.5) 
12-14 6% 1% 5.7 (2.8, 11.8) 3% 0% 0.8 (0.2, 2.6) 1% 2% 0.4 (0.1, 1.9) 
15-23 4% 1% 1.2 (0.5, 2.6) 2% 1% 0.2 (0.1, 0.7) 7% 7% 1.1 (0.6, 2.1) 
>2 Years** 3% 4% 0.8 (0.3, 1.9) 6% 24% 0.2 (0.1, 0.4) 0% 0% - - 
Missing*** 4% 7% 0.6 (0.3, 1.3) 0% 9% - - 0% 0% - - 
             
Weight Loss 
           
None* 66% 97% - - 73% 97% - - 85% 97% - - 
0-2 16% 0% 77.1 (32.6, 182.2) 8% 1% 24.3 (8.0, 73.9) 9% 0% 26.0 (11.1, 61.2) 
3-5 8% 0% 32.7 (13.2, 80.8) 12% 1% 31.0 (10.7, 90.0) 2% 0% 5.6 (1.8, 17.6) 
6-8 4% 0% 15.6 (5.8, 41.9) 3% 1% 8.0 (2.2, 29.1) 0% 0% 1.1 (0.1, 8.9) 
9-11 1% 0% 4.1 (1.0, 16.2) 1% 1% 3.1 (0.6, 16.6) 0% 0% - - 
12-14 1% 1% 2.7 (0.5, 13.2) 1% 0% 1.5 (0.2, 13.5) 0% 0% 1.1 (0.1, 8.9) 
15-23 0% 0% 0.4 (0.1, 3.7) 0% 0% - - 2% 2% 1.5 (0.4, 5.0) 
>2 Years** 0% 0% 1.1 (0.1, 17.5) 1% 0% - - 1% 0% - - 
Missing*** 2% 1% 2.7 (0.5, 14.2) 1% 0% - - 0% 0% - - 
*Did not have symptom during the 12 months before reference date.  **Symptom started >2 years before reference date.  ***Symptom onset date missing.   
Note: „0-2‟=0-2.99 months etc. cOR 95%CI are calculated relative to the number of women at risk of symptom for each time point.  An average rate of „new‟ control 
symptom frequency was used for each symptom.  Half a control was added to each calculation for stability.  Bolded values have 95% confidence intervals above 1.0.   
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Months 
Before 
Diagnosis 
Questionnaire Interview GP Notes 
Cases 
(n=249) 
Controls 
(n=268) 
cOR 95% CI 
Cases 
(n=145) 
Controls 
(n=125) 
cOR 95% CI 
Cases 
(n=223) 
Controls 
(n=227) 
cOR 95% CI 
Loss of Appetite 
           
None* 63% 98% - - 54% 85% - - 80% 98% - - 
0-2 18% 0% 244.6 (66.5, 898.9) 17% 2% 16.4 (8.2, 32.9) 12% 1% 48.6 (19.0, 124.1) 
3-5 9% 0% 90.7 (23.9, 343.9) 15% 1% 11.1 (5.6, 22.3) 3% 0% 9.4 (2.9, 30.3) 
6-8 4% 0% 41.0 (10.2, 165.3) 6% 0% 3.4 (1.4, 8.2) 1% 0% 4.6 (1.1, 18.9) 
9-11 2% 0% 14.2 (2.9, 70.3) 6% 10% 3.7 (1.6, 8.5) 1% 0% 4.5 (1.1, 18.7) 
12-14 0% 0% 3.5 (0.3, 36) 1% 0% 0.4 (0.1, 3.0) 0% 0% - - 
15-23 0% 0% 1.2 (0.1, 12) 0% 1% - - 2% 1% 2.5 (0.7, 8.4) 
>2 Years** 2% 0% 4.4 (0.5, 39.3) 1% 2% 0.6 (0.1, 3.5) 0% 0% - - 
Missing*** 1% 1% 1.1 (0.2, 7.7) 0% 0% - - 0% 0% - - 
             
Vaginal Discharge 
           
None* - - - - - - - 
 
89% 96% - - 
0-2 - - - - - - - - 1% 0% 3.5 (0.9, 13.6) 
3-5 - - - - - - - - 4% 0% 10.4 (3.9, 28.0) 
6-8 - - - - - - - - 0% 0% 1.1 (0.1, 9.0) 
9-11 - - - - - - - - 0% 0% 1.1 (0.1, 9.0) 
12-14 - - - - - - - - 1% 0% 3.3 (0.9, 12.8) 
15-23 - - - - - - - - 3% 2% 2.2 (0.7, 6.5) 
>2 Years** - - - - - - - - 0% 0% 1.0 (0.1, 16.4) 
Missing*** - - - - - - - 0% 0% - - 
*Did not have symptom during the 12 months before reference date.  **Symptom started >2 years before reference date.  ***Symptom onset date missing.   
Note: „0-2‟=0-2.99 months etc. cOR 95%CI are calculated relative to the number of women at risk of symptom for each time point.  An average rate of „new‟ control 
symptom frequency was used for each symptom.  Half a control was added to each calculation for stability.  Bolded values have 95% confidence intervals above 1.0.  
„Loss of appetite‟ is „Loss of appetite or feeling full quickly‟ on interview   
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Months 
Before 
Diagnosis 
Questionnaire Interview GP Notes 
Cases 
(n=249) 
Controls 
(n=268) 
cOR 95% CI 
Cases 
(n=145) 
Controls 
(n=125) 
cOR 95% CI 
Cases 
(n=223) 
Controls 
(n=227) 
cOR 95% CI 
Irregular Vaginal Bleeding 
          
None* 84% 97% - - 94% 99% - - 95% 100% - - 
0-2 6% 0% 21.2 (8.7, 51.4) 0% 0% 0.0 - 0% 0% 5.7 (0.4, 71.7) 
3-5 3% 0% 9.9 (3.6, 27.1) 1% 0% 9.6 (1.1, 81.0) 0% 0% 5.7 (0.4, 71.4) 
6-8 2% 0% 7.2 (2.4, 21.2) 1% 0% 9.5 (1.1, 79.8) 1% 0% 11.3 (1.3, 94.1) 
9-11 1% 0% 3.5 (0.9, 13.5) 1% 0% 4.7 (0.4, 59.3) 1% 0% 16.7 (2.3, 119.5) 
12-14 1% 1% 2.3 (0.5, 11.1) 1% 1% 4.7 (0.4, 58.9) 0% 0% 0.0 - 
15-23 0% 0% 0.4 (0.0, 3.1) 0% 0% - - 1% 0% 5.5 (0.8, 39.3) 
>2 Years** 1% 0% - - 1% 0% - - 0% 0% - - 
Missing*** 0% 0% - - 0% 0% - - 0% 0% - - 
             
Postmenopausal Bleeding 
         
None* - - - - 89% 98% - - 88% 97% - - 
0-2 - - - - 6% 1% 19.4 (5.5, 68.3) 8% 0% 20.3 (8.4, 49.0) 
3-5 - - - - 3% 1% 8.1 (1.9, 34.5) 3% 1% 6.6 (2.2, 19.7) 
6-8 - - - - 0% 0% - - 0% 0% 1.1 (0.1, 8.7) 
9-11 - - - - 0% 1% - - 1% 1% 2.2 (0.4, 10.3) 
12-14 - - - - 1% 0% 2.0 (0.2, 18.4) 0% 0% - - 
15-23 - - - - 0% 0% - - 0% 0% - - 
>2 Years** - - - - 1% 0% - - 0% 0% - - 
Missing*** - - - - 1% 0% - - 0% 0% - - 
*Did not have symptom during the 12 months before reference date.  **Symptom started >2 years before reference date.  ***Symptom onset date missing.   
Note: „0-2‟=0-2.99 months etc. cOR 95%CI are calculated relative to the number of women at risk of symptom for each time point.  An average rate of „new‟ control 
symptom frequency was used for each symptom.  Half a control was added to each calculation for stability.  Bolded values have 95% confidence intervals above 1.0. 
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4.1.6 Symptom Sensitivity & Specificity 3-14 Months Before 
Reference Date 
One of the key objectives of this study was to assess the potential for using symptoms 
as a tool for earlier diagnosis by way of minimising the time between symptom onset to 
(appropriate) referral.  In this scenario, it was appropriate to consider symptoms in 
terms of sensitivity (proportion of cases with the symptom) and specificity (proportion of 
controls without the symptom).  In order to quantify the proportion of cases that would 
potentially be referred earlier; cumulative symptom incidence over one year was 
examined along with the time between symptom onset and referral.  For a more 
conservative (and clinically relevant) approach, symptoms that started within 3 months 
(2.99 months) of diagnosis were excluded.  As detailed in the Methods section, this 
allowed calculation of symptom incidence with at least 1 month of actual lead time.  In 
addition, Table 4-7 demonstrated that symptom incidence for cases and controls were 
similar 15 months before reference date.  Thus, symptoms that were present during 3-
14 (i.e. 3 to 14.99) months before reference date were used to examine cumulative 
symptom incidence over one year.  Again, symptoms that started more than 2 years 
prior and symptoms with missing onset dates were excluded.  Hence, in Table 4-8 to 
Table 4-10 sensitivity was calculated as the annual incidence of each symptom in 
cases, and specificity was equivalent to (1-annual incidence) of each symptom in 
controls.  It is important to note that symptom specificity will not necessarily be 
representative of women in the general population since control women were 
apparently healthy volunteers.   
Crucially, sensitivity was greatly reduced by restricting symptoms to 3-14 months.  
Symptom sensitivity was comparable for questionnaire and interview.  The most 
sensitive symptoms according to the questionnaire were abdominal bloating (30%), 
increase in abdominal size (27%) and pelvic/abdominal pain or discomfort (26%).  
Importantly, 64% of cases reported at least one relevant symptom (i.e. „possibly 
related‟ to ovarian cancer, see Appendix VI) 3-14 months before diagnosis.  For 
interview, sensitivity was highest for fatigue (41%), increased abdominal size (38%), 
and pelvic/abdominal pain or discomfort (34%).  As many as 81% of cases reported at 
least one ovarian cancer related symptom.  Again, symptom sensitivity on GP notes 
was lower with the greatest proportions observed for pelvic/abdominal pain or 
discomfort (26%), urinary other (17%) and urinary frequency or urgency (13%).  70% of 
cases had least one relevant symptom recorded in their notes over the year examined. 
136 
Specificity was relatively high on the questionnaire.  According to the questionnaire, 
specificity for at least one relevant symptom was 80%.  The corresponding specificity 
on interview was only 37%.  Lump in abdomen and loss in appetite both had a 
specificity of 100%, and the lowest specificity for any symptom was 95%.  Other 
symptoms such as vaginal discharge and change in bowel habit also had a specificity 
of 100%, however these were not specifically asked about on the questionnaire or 
interview.  Specificity was worse on interview for bloating (94%), fatigue (89%), 
pelvic/abdominal pain (91%), urinary frequency/urgency (91%) and indigestion (93%).  
Otherwise, values were similar to those in the questionnaire.  GP note symptom 
specificity was 90% for urinary other and pelvic/abdominal pain; however specificity 
was higher for the remaining symptoms. 
All of the odds ratios for each of the 14 symptoms that appeared on the questionnaire 
were significant.  Case-control differences were also significant on interview for all 
individual symptoms except for diarrhoea, PMB and vaginal discharge. Ten of the 18 
(individual) symptoms were recorded significantly more in cases than controls 
according to GP notes 
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Table 4-8 Questionnaire Symptom Incidence 3-14 Months Before Reference Date 
with Crude Odds Ratios (OR) & 95% Confidence Intervals  
Symptom 
Cases 
n=249 
Controls 
n=268 
OR (95%CI) P value 
Lump In Abdomen 15 (6%) 0 (0%) - (4.5, -) <0.0001 
Loss Of Appetite  38 (15%) 1 (0%) 48.1 (6.5, 353.0) 0.0001 
Increase in Abdominal Size 67 (27%) 6 (2%) 16.1 (6.8, 37.8) <0.0001 
Pelvic/Abdo. Pain/Discomfort 65 (26%) 8 (3%) 11.5 (5.4, 24.5) <0.0001 
Abdominal Bloating 74 (30%) 11 (4%) 9.9 (5.1, 19.2) <0.0001 
Weight Loss 37 (15%) 5 (2%) 9.2 (3.5, 23.8) <0.0001 
Nausea Or Vomiting 21 (8%) 3 (1%) 8.1 (2.4, 27.6) 0.0008 
Constipation 28 (11%) 6 (2%) 5.5 (2.2, 13.6) 0.0002 
Fatigue 57 (23%) 14 (5%) 5.4 (2.9, 10.0) <0.0001 
Diarrhoea 19 (8%) 6 (2%) 3.6 (1.4, 9.2) 0.0071 
IVB 19 (8%) 6 (2%) 3.6 (1.4, 9.2) 0.0071 
Urinary Frequency/Urgency 37 (15%) 13 (5%) 3.4 (1.8, 6.6) 0.0002 
Indigestion 33 (13%) 12 (4%) 3.3 (1.6, 6.5) 0.0007 
Back Pain 25 (10%) 11 (4%) 2.6 (1.3, 5.4) 0.0102 
Change In Bowel Habit* 1 (0%) 0 (0%) - 
 
Urinary Other* 2 (1%) 0 (0%) - 
 
PMB* 0 (0%) 0 (0%) - 
 
Vaginal Discharge* 0 (0%) 0 (0%) - 
 
Other Possibly Related 12 (5%) 3 (1%) 4.5 (1.2, 16.0) 0.0215 
None 89 (36%) 214 (80%) 0.1 (0.1, 0.2) <0.0001 
*Symptoms were not specifically listed on the questionnaire. 
Symptoms are in order of highest to lowest odds ratios for individual symptoms.  Bolded values 
are significant at p<0.05 level.   
PMB is postmenopausal bleeding.  IVB is irregular vaginal bleeding (includes all IVB except for 
PMB). 
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Table 4-9 Interview Symptom Incidence 3-14 Months Before Reference Date with 
Crude Odds Ratios (OR) & 95% Confidence Intervals 
Symptom 
Cases 
n=145 
Controls 
n=125 
OR (95%CI) P value 
Urinary Other* 14 (10%) 0 (0%) - (3.4, -) 0.0001 
Lump In Abdomen 9 (6%) 0 (0%) - (2.1, -) 0.0041 
Loss Of Appetite**  33 (23%) 1 (1%) 36.5 (4.9, 271.5) 0.0004 
Constipation 24 (17%) 1 (1%) 24.6 (3.3, 184.7) 0.0018 
Increase in Abdominal Size 55 (38%) 6 (5%) 12.1 (5.0, 29.4) <0.0001 
Weight Loss 25 (17%) 3 (2%) 8.5 (2.5, 28.8) 0.0006 
Nausea Or Vomiting 14 (10%) 2 (2%) 6.6 (1.5, 29.5) 0.014 
Change In Bowel Habit 7 (5%) 1 (1%) 6.3 (0.8, 51.8) 0.0875 
Abdominal Bloating 43 (30%) 8 (6%) 6.2 (2.8, 13.7) <0.0001 
Fatigue 60 (41%) 14 (11%) 5.6 (2.9, 10.7) <0.0001 
Pelvic/Abdo. Pain/Discomfort 50 (34%) 11 (9%) 5.5 (2.7, 11.1) <0.0001 
IVB 6 (4%) 1 (1%) 5.4 (0.6, 45.1) 0.1228 
Back Pain 16 (11%) 4 (3%) 3.8 (1.2, 11.5) 0.0211 
Urinary Frequency/Urgency 33 (23%) 11 (9%) 3.1 (1.5, 6.3) 0.0027 
Indigestion 25 (17%) 9 (7%) 2.7 (1.2, 6.0) 0.016 
Diarrhoea 9 (6%) 3 (2%) 2.7 (0.7, 10.2) 0.1444 
Vaginal Discharge* 6 (4%) 2 (2%) 2.7 (0.5, 13.4) 0.2371 
PMB 5 (3%) 2 (2%) 2.2 (0.4, 11.5) 0.3522 
Other Possibly Related 24 (17%) 7 (6%) 3.3 (1.4, 8.1) 0.0071 
None 27 (19%) 79 (63%) 0.1 (0.1-0.2) <0.0001 
*Symptoms not specifically asked about on interview 
**Loss of appetite or feeling full quickly‟ 
Symptoms are in order of highest to lowest odds ratios for individual symptoms.  Bolded values 
are significant at p<0.05 level.   
PMB is postmenopausal bleeding.  IVB is irregular vaginal bleeding (includes all IVB except for 
PMB). 
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Table 4-10 GP Notes Symptom Incidence 3-14 Months Before Reference Date 
with Crude Odds Ratios (OR) & 95% Confidence Intervals 
Symptom 
Cases 
n=223 
Controls 
n=227 
OR (95%CI) P value 
Lump In Abdomen 6 (3%) 0 (0%) - (1.6, - ) 0.0143 
Increase in Abdominal Size 14 (6%) 1 (0%) 15.1 (2.0, 116.1) 0.0089 
Loss Of Appetite  12 (5%) 1 (0%) 12.9 (1.7, 99.7) 0.0146 
IVB 6 (3%) 1 (0%) 6.2 (0.7, 52.3) 0.091 
Vaginal Discharge 14 (6%) 3 (1%) 5.0 (1.4, 17.7) 0.0124 
Pelvic/Abdo. Pain/Discomfort 58 (26%) 22 (10%) 3.3 (1.9, 5.6) <0.0001 
Weight Loss 7 (3%) 2 (1%) 3.6 (0.7, 17.7) 0.1091 
Abdominal Bloating 15 (7%) 5 (2%) 3.2 (1.1, 9.0) 0.0267 
Constipation 26 (12%) 10 (4%) 2.9 (1.3, 6.1) 0.0063 
Urinary Frequency/Urgency 28 (13%) 13 (6%) 2.4 (1.2, 4.7) 0.014 
Change In Bowel Habit 18 (8%) 8 (4%) 2.4 (1.0, 5.6) 0.0442 
Urinary Other 39 (17%) 22 (10%) 2.0 (1.1, 3.5) 0.0171 
Back Pain 28 (13%) 16 (7%) 1.9 (1.0, 3.6) 0.0521 
PMB 9 (4%) 5 (2%) 1.9 (0.6, 5.7) 0.2698 
Nausea Or Vomiting 17 (8%) 11 (5%) 1.6 (0.7, 3.5) 0.2264 
Fatigue 19 (9%) 14 (6%) 1.4 (0.7, 2.9) 0.3404 
Indigestion 23 (10%) 17 (7%) 1.4 (0.7, 2.7) 0.2943 
Diarrhoea 13 (6%) 11 (5%) 1.2 (0.5, 2.8) 0.6428 
Other Possibly Related 41 (18%) 37 (16%) 1.2 (0.7, 1.9) 0.5591 
None 68 (30%) 121 (53%) 0.4 (0.3, 0.6) <0.0001 
Symptoms are in order of highest to lowest odds ratios for individual symptoms.  Bolded values 
are significant at p<0.05 level.   
PMB is postmenopausal bleeding.  IVB is irregular vaginal bleeding (includes all IVB except for 
PMB).  
4.1.7 GP Visits 
Since GP visit data for cases were only extracted up to a „cut-off point‟, visits observed 
at 0 to 2 (i.e. 0 to 2.99) months prediagnosis exclude any visits made between „cut-off‟ 
date and diagnosis (median 1.3 months, IQR 0.7-1.9).  Examination of GP visits 
showed that cases began to consult for problems more frequently 6-8 months prior to 
diagnosis (see Figure 4-10).  This effect became even more prominent when visits 
were restricted to those in which a possibly related symptom was recorded (see Figure 
4-11).  For cases, the number of routine visits decreased as problem visits increased 
(N.B. if problems were mentioned at routine visits, a problem visit code was assigned).  
About 40% of cases and controls had a problem GP visit in any quarter, until 6-8 
months before diagnosis (at which point this proportion increased for cases). 
The median number of problem visits over the 2 year period was 7 (IQR 3-11) for 
cases and 4 (IQR 2-8) for controls (p<0.0001).  Routine visits were much more 
140 
comparable with a case median of 3 (IQR 1-7) and control median of 4 (IQR 2-6) 
(p=0.0783).   
Figure 4-10 Proportion of Women with Problem versus Routine Visits Prior to 
Reference Date Per Prediagnostic Quarter 
 
Figure 4-11 Proportion of Women with Problem GP Visits Prior to Diagnosis 
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4.1.8 Grouped Symptoms 
Symptoms possibly related to ovarian cancer were grouped into five categories 
including abdominal, GI, urinary, gynaecological and general (see 3.3.10 and Appendix 
VI for details).  These provided a more general impression of the timing and extent to 
which each of the named body systems were affected.  As with the individual 
symptoms, longstanding symptoms were excluded and graphs show cumulative 
incidence of „new‟ symptoms in the two years prior to reference date.  Grouped control 
symptom frequency was relatively constant over the two year period examined for all 
sources (see Figure 4-12, Figure 4-13, Figure 4-14).  In contrast, cases exhibited sharp 
increases in grouped symptom incidence for all sources.  This was most pronounced 
for abdominal, GI and general symptoms and least for gynaecological symptoms.  
Increases were evident earliest on questionnaire data (15 months prior to diagnosis), 
then interview (12 months before diagnosis) and closer to diagnosis on GP notes (6 
months).   
Self-reported data shared a similar pattern of symptom onset with abdominal, GI, 
general symptoms diverging first, followed by gynaecological and urinary symptoms.  
Abdominal symptoms were the most commonly reported, followed by GI and general 
symptoms.  Conversely, symptom groups in GP note data all seemed to separate 
around the same time point of 6 months prior to reference date with the exception of 
urinary symptoms.  These were recorded in slight excess for cases from 18 months 
before diagnosis, however there was a much sharper increase around 6 months.  In 
corroboration with self-reported data, abdominal and GI symptoms were amongst the 
most prevalent.  However, unlike self-reported data, sensitivity and specificity for 
general symptoms was lower in GP notes. 
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Figure 4-12 Questionnaire - Cumulative Grouped Symptoms Per Quarter Before 
Reference Date 
 
Abdominal: Pelvic/abdominal pain or discomfort, bloating, increased abdominal size 
Gastrointestinal (GI): indigestion, diarrhoea, constipation, change in bowel habit, GI other, 
nausea or vomiting 
Gynaecological: Postmenopausal bleeding, irregular vaginal bleeding, pain with intercourse, 
post-coital bleeding, vaginal discharge 
Urinary: Frequency, urgency, incontinence, dysuria, retention, change in smell or colour, 
haematuria 
General: Loss of appetite, weight loss, fatigue 
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Figure 4-13 Interview - Cumulative Grouped Symptoms Per Quarter Before 
Reference Date 
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Figure 4-14 GP Notes - Cumulative Grouped Symptoms Per Quarter Before 
Reference Date 
 
4.1.9 Symptom Severity & Frequency  
Severity and frequency for symptoms present over one year (i.e. 3-14.99 months 
before reference date) were analysed for case-control differences.  Longstanding 
symptoms and symptoms with missing onset were excluded.  The maximum severity 
and frequency was taken for each woman for each data source.  Rating of symptoms 
was intended to represent severity (mild, moderate, severe) and frequency (1-4, 5-15, 
16-31 days per month) for when the symptom first started.  A test for linear trend in 
severity was significant for questionnaire (p=0.0047) and interview (p=0.0493), showing 
that women reporting moderate or severe symptoms were more likely to be cases than 
women reporting mild symptoms (see Table 4-11).   
As shown in Table 4-11, women with more frequent symptoms were more likely to be 
cases according to both questionnaire (p=0.0152) and interview (p=0.0024) 
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Table 4-11 Crude Odds Ratios with 95% Confidence Intervals for Symptom 
Severity & Frequency for 3-14 Months Before Reference Date 
 Questionnaire Interview 
Severity OR 95%CI OR 95%CI 
 Mild 1.0 - 1.0 - 
 Moderate 1.1 0.5, 2.6 2.4 1.0, 5.8 
 Severe 3.3 1.2, 8.6 2.4 1.0, 5.8 
Frequency OR 95%CI OR 95%CI 
 1-4 days 1.0 - 1.0 - 
 5-15 days 1.3 0.3, 4.7 0.6 0.1, 3.9 
 16-31 days 2.9 0.9, 9.0 4.0 0.9, 17.5 
Bolded values have 95% confidence intervals above 1.0 
Table 4-12 and Table 4-13 show symptom severity and frequency for individual 
symptoms for symptoms reported at anytime (excluding longstanding symptoms).  In 
general, for cases symptom severity was rated in higher proportions as moderate on 
questionnaire, and mild on interview.  Frequency ratings were typically 16-31 days per 
month for most symptoms reported by cases on both sources.  Numbers of individual 
control symptoms with severity and frequency data were too small to study trends.  
However, overall the proportion of symptoms that were rated as mild was generally 
larger.  At least 80% of cases who reported bloating, increased abdominal size and 
loss of appetite had the respective symptom with a frequency of 16-31 days per month. 
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Table 4-12 Symptom Severity on Self-Reported Data* (Anytime) 
 Questionnaire Interview 
 Cases Controls Cases Controls 
Pelvic/Abdo Pain n=131 n=20 n=82 n=17 
 Mild 32/124 (26%) 2/15 (13%) 31/67 (46%) 4/16 (25%) 
 Moderate 57/124 (46%) 11/15 (73%) 22/67 (33%) 8/16 (50%) 
 Severe 35/124 (28%) 2/15 (13%) 14/67 (21%) 4/16 (25%) 
Missing 7/131 (5%) 5/20 (25%) 15/82 (18%) 1/17 (6%) 
Bloating n=171 n=35 n=81 n=22 
 Mild 26/156 (17%) 10/24 (42%) 40/71 (56%) 16/20 (80%) 
 Moderate 73/156 (47%) 11/24 (46%) 23/71 (32%) 3/20 (15%) 
 Severe 57/156 (37%) 3/24 (13%) 8/71 (11%) 2/20 (10%) 
Missing 15/171 (9%) 11/35 (31%) 10/81 (12%) 2/22 (9%) 
↑Abdo Size n=167 n=22 n=111 n=19 
 Mild 15/151 (10%) 5/11 (45%) 66/99 (67%) 10/14 (71%) 
 Moderate 54/151 (36%) 4/11 (36%) 23/99 (23%) 3/14 (21%) 
 Severe 82/151 (54%) 2/11 (18%) 10/99 (10%) 1/14 (7%) 
Missing 16/167 (10%) 11/22 (50%) 12/111 (11%) 5/19 (26%) 
Back Pain n=59 n=42 n=37 n=18 
 Mild 22/53 (42%) 5/33 (15%) 19/32 (59%) 11/17(65%) 
 Moderate 21/53 (40%) 21/33 (64%) 10/32 (31%) 2/17 (12%) 
 Severe 10/53 (19%) 7/33 (21%) 3/32 (9%) 4/17 (24%) 
Missing 6/59 (10%) 9/42 (21%) 5/37 (14%) 1/18 (6%) 
Constipation n=74 n=25 n=40 n=11 
 Mild 9/63 (14%) 2/14 (14%) 10/33 (30%) 6/8 (75%) 
 Moderate 37/63 (59%) 9/14 (64%) 8/33 (24%) 2/8 (25%) 
 Severe 17/63 (27%) 3/14 (21%) 15/33 (45%) 0/8 (0%) 
Missing 11/74 (15%) 11/25 (44%) 7/40 (18%) 3/11 (27%) 
Diarrhoea n=49 n=20 n=18 n=8 
 Mild 9/38 (24%) 5/15 (42%) 5/14 (36%) 6/7 (86%) 
 Moderate 19/38 (50%) 5/15 (42%) 4/14 (29%) 0/7 (0%) 
 Severe 10/38 (26%) 2/15 (17%) 5/14 (36%) 1/7 (14%) 
Missing 11/49(22%) 8/20 (40%) 4/18 (22%) 1/8 (13%) 
Indigestion n=77 n=43 n=52 n=27 
 Mild 21/64 (33%) 14/32 (44%) 24/48 (50%) 18/24 (75%) 
 Moderate 29/64 (45%) 14 (44%) 12 (25%) 2 (10%) 
 Severe 14/64 (22%) 4 (13%) 12 (25%) 4 (17%) 
Missing 13/77 (17%) 11/43 (26%) 4/52 (8%) 3/27 (11%) 
Loss of Appetite n=87 n=4 n=58 n=5 
 Mild 16/79 (20%) 1/3 (33%) 25/48 (52%) 2/5 (40%) 
 Moderate 38/79 (48%) 0/3 (0%) 16/48 (33%) 1/5 (20%) 
 Severe 25/79 (32%) 2/3 (67%) 7/48 (15%) 2/5 (40%) 
Missing 8/87 (9%) 1/4 (25%) 10/58 (11%) 0/5 (0%) 
*Severity rated as mild, moderate or severe 
Lump in abdomen, PMB, IVB, change in bowel habit and vaginal discharge excluded from 
calculations. 
Boxes shaded in grey show symptoms that have noticeably different severity for cases versus 
controls. 
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Table 4-12 continued 
 Questionnaire Interview 
 Cases Controls Cases Controls 
Nausea/Vomiting n=77 n=14 n=40 n=11 
 Mild 19/68 (28%) 5/12 (42%) 10/22 (45%) 4/6 (67%) 
 Moderate 31/68 (46%) 4/12 (33%) 8/22 (36%) 0/6 (0%) 
 Severe 18/68 (26%) 3/12 (25%) 4/22 (18%) 2/6 (33%) 
Missing 9/77 (12%) 2/14 (14%) 18/40 (45%) 5/11 (25%) 
Urinary Freq/Urge n=96 n=32 n=55 n=18 
 Mild 20/87 (23%) 5/30 (17%) 27/48 (56%) 10/16 (63%) 
 Moderate 31/87 (36%) 4/30 (13%) 12/48 (25%) 4/16 (25%) 
 Severe 18/87 (21%) 3/30 (10%) 9/48 (19%) 2/16 (13%) 
Missing 9/96 (10%) 2/32 (6%) 7/55 (13%) 2/18 (11%) 
Weight Loss n=83 n=9 n=38 n=4 
 Mild 12/73 (16%) 0/6 (0%) 17/29 (59%) 0/1 (0%) 
 Moderate 31/73 (42%) 6/6 (100%) 7/29 (24%) 1/1 (100%) 
 Severe 30/73 (41%) 0/6 (0%) 5/29 (17%) 0/1 (0%) 
Missing 10/83(12%) 3/9 (33%) 9/38 (24%) 3/4 (75%) 
Fatigue n=125 n=39 n=80 n=33 
 Mild 22/108 (20%) 9/26 (35%) 39/73 (53%) 23/29 (79%) 
 Moderate 64/108 (59%) 11/26 (42%) 26/73 (36%) 5/29 (17%) 
 Severe 22/108 (20%) 6/26 (23%) 8/73 (11%) 1/29 (3%) 
Missing 17/125 (14%) 13/39 (33%) 7/80 (9%) 4/33 (12%) 
*Severity rated as mild, moderate or severe 
Lump in abdomen, PMB, IVB, change in bowel habit and vaginal discharge excluded from 
calculations 
Boxes shaded in grey show symptoms that have noticeably different severity for cases versus 
controls. 
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Table 4-13 Symptom Frequency (days per month) on Self-Reported Data* 
(Anytime) 
 Questionnaire Interview 
 Cases Controls Cases Controls 
Pelvic/Abdo Pain n=131 n=21 n=82 n=17 
 1-4 17/121 (14%) 5/15 (33%) 8/60 (13%) 3/13 (23%) 
 5-15 30/121 (25%) 7/15 (47%) 7/60 (12%) 4/13 (31%) 
 16-31 74/121 (61%) 3/15 (20%) 45/60 (75%) 6/13 (46%) 
Missing 10/131 (8%) 6/21 (29%) 22/82 (27%) 4/17 (24%) 
Bloating n=171 n=35 n=81 n=22 
 1-4 4/147 (3%) 8/26 (31%) 0/65 (0%) 2/9 (22%) 
 5-15 16/147 (11%) 13/26 (50%) 7/65 (11%) 4/9 (44%) 
 16-31 127/147 (86%) 5/26 (19%) 58/65 (89%) 3/9 (33%) 
Missing 24/171 (14%) 9/35 (26%) 16/81 (20%) 13/22 (59%) 
↑Abdo Size n=167 n=22 n=111 n=19 
 1-4 0/146 (0%) 2/14 (14%) 0/98 (0%) 1/10 (10%) 
 5-15 11/146 (8%) 9/14 (64%) 3/98 (3%) 0/10 (0%) 
 16-31 135/146 (92%) 3/14 (21%) 95/98 (97%) 10/10 (90%) 
Missing 21/167 (13%) 8/22 (36%) 13/111 (12%) 9/19 (47%) 
Back Pain n=59 n=42 n=37 n=18 
 1-4 10/53 (19%) 4/30 (13%) 2/21 (10%) 0/7 (0%) 
 5-15 26/53 (49%) 10/30 (33%) 5/21 (24%) 2/7 (29%) 
 16-31 17/53 (32%) 16/30 (53%) 14/21 (67%) 5/7 (71%) 
Missing 6/59 (10%) 12/42 (29%) 16/37 (43%) 11/18 (61%) 
Constipation n=74 n=25 n=40 n=11 
 1-4 10/61 (16%) 5/15 (33%) 2/30 (7%) 0/2 (0%) 
 5-15 24/61 (39%) 5/15 (33%) 3/30 (10%) 1/2 (50%) 
 16-31 27(44%) 5/15 (33%) 25/30 (83%) 1/2 (50%) 
Missing 13/74 (18%) 10/25 (40%) 10/40 (25%) 9/11 (82%) 
Diarrhoea n=49 n=20 n=18 n=8 
 1-4 12/43 (28%) 7/14 (50%) 2/10 (20%) 1/3 (33%) 
 5-15 16/43 (37%) 4/14 (29%) 1/10 (10%) 1/3 (33%) 
 16-31 15 (35%) 3/14 (21%) 7/10 (70%) 1/3 (33%) 
Missing 6/49(12%) 6/20 (30%) 8/18 (44%) 5/8 (63%) 
Indigestion n=77 n=43 n=52 n=27 
 1-4 16/65 (25%) 13/15 (33%) 5/40 (13%) 2/11 (18%) 
 5-15 22/65 (34%) 7/15 (33%) 10/40 (25%) 5/11 (45%) 
 16-31 27/65 (42%) 8/15 (33%) 25/40 (63%) 4/11 (36%) 
Missing 12/77 (16%) 15/43 (35%) 12/52 (23%) 16/27 (59%) 
Loss of Appetite n=87 n=4 n=58 n=5 
 1-4 7/81 (9%) 1/3 (33%) 0/45 (0%) 0/4 (0%) 
 5-15 9/81 (11%) 0/3 (0%) 3/45 (7%) 0/4 (0%) 
 16-31 65/81 (80%) 2/3 (67%) 42/45 (93%) 4/4 (100%) 
Missing 6/87(9%) 1/4 (25%) 13/58 (22%) 1/5 (20%) 
*Frequency is rated as days per month 
Lump in abdomen, PMB, IVB, change in bowel habit and vaginal discharge excluded from 
calculations 
Boxes shaded in grey show symptoms that have noticeably different frequency for cases versus 
controls. 
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Table 4-13 continued 
 Questionnaire Interview 
 Cases Controls Cases Controls 
Nausea/Vomiting n=77 n=14 n=40 n=11 
 1-4 20/68 (29%) 6/11 (55%) 2/18 (11%) 0/3 (0%) 
 5-15 17/68 (25%) 2/11 (18%) 6/18 (33%) 2/3 (67%) 
 16-31 31/68 (46%) 3/11 (27%) 10/18 (56%) 1/3 (33%) 
Missing 9/77 (12%) 3/14 (21%) 22/40 (55%) 8/11 (73%) 
Urinary Freq/Urge n=96 n=32 n=55 n=18 
 1-4 5/88 (6%) 6/22 (27%) 0/50 (0%) 0/13 (0%) 
 5-15 18/88 (20%) 4/22 (18%) 5/50 (10%) 1/13 (8%) 
 16-31 65/88 (74%) 12/22 (55%) 45/50 (90%) 12/13 (92%) 
Missing 8/96 (8%) 10/32 (31%) 5/55 (9%) 5/18 (28%) 
Fatigue n=125 n=39 n=80 n=33 
 1-4 5/105 (5%) 2/26 (8%) 0/73 (0%) 3/22 (14%) 
 5-15 18/105 (17%) 9/26 (35%) 7/73 (10%) 2/22 (9%) 
 16-31 82/105 (78%) 15/26 (58%) 66/73 (90%) 17/22 (77%) 
Missing 20/125 (16%) 13/39 (33%) 7/80 (9%) 11/33 (33%) 
*Frequency is rated as days per month 
Lump in abdomen, PMB, IVB, change in bowel habit and vaginal discharge excluded from 
calculations. 
Boxes shaded in grey show symptoms that have noticeably different frequency for cases versus 
controls. 
Changes in symptom severity were recorded on interview; however there was a 
considerable amount of missing responses.  Data were available for 65% (469/723) of 
symptoms in cases and 42% (81/192) of symptoms in controls.  The options were 
„improved‟, „same‟, or „worsened‟.  Of the informative symptoms, a linear test for trend 
showed that women were significantly more likely to be a case if they reported 
worsening symptoms (p<0.0001).   
4.1.10 Early versus Advanced Stage 
Most women with early stage disease had at least one symptom that started at anytime 
before diagnosis (100% [GP], 96% [I], 95% [Q]).  Similarly, women with late stage 
disease were also highly symptomatic (100% [both GP & I], 98% [Q]).  Cumulative 
symptom frequency was calculated for cases according to stage.  Overall, the 
symptoms reported by women with early versus late stage disease were comparable.  
However, there was a tendency for women with late stage disease to report higher 
symptom incidence close to diagnosis across all data sources.  These included 
indigestion, fatigue, loss of appetite, weight loss, constipation and nausea or vomiting.  
This reached statistical significance at diagnosis for indigestion, loss of appetite, 
abdominal bloating, increased abdominal size, nausea/vomiting and weight loss (see 
Figure 4-15 to Figure 4-17).  This remained significant at 3 months prior to diagnosis 
for indigestion (GP notes; p=0.0299 and questionnaire; p=0.0067), and weight loss 
(interview; p=0.0068).  Increased abdominal size was more common in GP notes for 
cases at 3 months before (p=0.0190), but not at diagnosis („cut-off‟).   
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In contrast, urinary symptoms, lump in abdomen and gynaecological symptoms were 
more prominent in early stage disease however these differences were not statistically 
significant at any time point (see Figure 4-15, Figure 4-16, Figure 4-17).  The figures 
shown contain the symptoms which showed the most pronounced differences between 
early and late disease for each data source.   
Figure 4-15 Cumulative Symptom Frequency for Early versus Late Disease - 
Questionnaire  
 
Note: Graphs show p-values using log rank test comparing rates in the two years before 
diagnosis. 
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Figure 4-16 Cumulative Symptom Frequency for Early versus Late Disease - 
Interview 
Note: Graphs show p-values using log rank test comparing rates in the two years before 
diagnosis. 
„Loss of appetite‟ is „Loss of appetite or feeling full quickly‟ on interview 
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Figure 4-17 Cumulative Symptom Frequency for Early versus Late Disease - GP 
Notes 
 
Note: Graphs show p-values using log rank test comparing rates in the two years before 
diagnosis. 
The median number of symptoms for early versus late disease is shown in Table 4-14.  
Women with late stage disease reported more symptoms than their early stage 
counterparts for the three data sources.   
Table 4-14 Early vs. Late Disease: Median Number of Symptoms (up to 
diagnosis) per Data Source 
 Early Late P value 
Questionnaire n=100 n=132  
 Median (IQR) 5 (2-7) 6 (3-9) 0.0036 
Interview n=57 n=79  
 Median (IQR) 5 (3-7) 6 (4-9) 0.0425 
GP Notes n=93 n=117  
 Median (IQR) 3 (2-6) 5 (3-7) 0.0006 
4.1.11 Number of Symptoms 
The number of symptoms possibly related to ovarian cancer was counted for each 
source (excluding longstanding symptoms).  The median number of (new) symptoms 
reported was higher for cases in all three data sources.  Symptom reporting was 
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greatest on questionnaire with a median of 6 (IQR 3-8) and 0 (IQR 0-2) for cases and 
controls, respectively.  The next highest was for interview, then GP notes. 
Table 4-15 Number of Symptoms 
 Cases Controls P value 
Questionnaire  n=249 n=268  
 Median (IQR) 6 (3-8) 0 (0-2) <0.0001 
Telephone Interview n=145 n=125  
 Median (IQR) 5 (4-8) 2 (0-3) <0.0001 
GP Notes n=223 n=227  
 Median (IQR) 4 (2-7) 1 (0-3) <0.0001 
Excludes „other unrelated‟ symptoms 
4.1.12 Route of Diagnosis 
Route of diagnosis was examined by looking at the first GP referral made for 
symptoms.  Although accident and emergency (A&E) is not a true referral, this was 
included since these women had either: 
1) Never been given a referral by the GP (despite consulting) 
2) Never consulted the GP, or 
3) Consulted the GP but symptoms became so severe that a referral 
appointment could not be executed within the referral timeframe.   
The vast majority of women were diagnosed via symptoms (89%), the remaining 11% 
were identified by incidental findings (5.5%) or screening studies (5.9%) (see Table 
4-16).  Rapid referral to gynaecological-oncology (G/O) was the most common initial 
referral made, yet still only comprised less than half of first referrals.  Only 49% of 
cases were initially referred to a gynaecology department.  Twenty percent (44/225) of 
cases were sent to gastrointestinal clinics, 18 of the 44 (41%) were via rapid referral.  
One fifth of cases presented as emergencies before a GP referral was made or 
successfully executed.  For some women, referral to A&E or rapid referral G/O may 
have been on recommendation by the radiographer after suspicious lesion(s) found on 
ultrasound, which had been ordered by their GP.   
Interestingly, all incidentally diagnosed women reported potentially related symptoms 
on interview and GP notes in the year before diagnosis and only one woman reported 
having no symptoms on questionnaire.  In contrast, 12 of the 15 women who were 
screen-detected were asymptomatic according to GP notes.  However, all reported at 
least one symptom on interview and questionnaire, many of which were present 
months before diagnosis. 
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Table 4-16 First Referral 
Referral Type Number (%) 
Rapid Referral Gynaecological Oncology 91 (40) 
General Surgery 16 (7) 
GI Physician* 10 (4) 
General Gynaecology 20 (9) 
Urgent to Other Specialties 24 (11) 
Routine to Other Specialities** 5 (2) 
A&E GP-initiated 28 (12) 
A&E Patient-initiated 20 (9) 
Unknown 11 (5) 
Total Referrals 225 (89) 
N/A*** 29 (11) 
TOTAL 254 (100) 
*Private GI physician referrals (n=4) 
**One woman had a routine referral to clinical oncology as she was still undergoing follow up for 
colon cancer 
***Screen-detected (n=15), incidental diagnosis (n=14)  
4.1.13 Delays in Diagnosis 
Delays in diagnosis were examined using all „possibly related‟ symptoms that started 
within 15 months prior to diagnosis (symptoms that started >15 months before 
diagnosis were omitted).  Women who were screen-detected (n=15) or incidentally 
diagnosed (n=14) were excluded from the analyses.  Of the remaining women, 9% 
(19/220), 1% (1/124) and 3% (5/197) had no eligible symptoms on questionnaire, 
interview and GP notes, respectively.  These women were classified as having no 
delays in diagnosis (not zero delay).  Note that delays could not be derived for women 
who had missing dates for symptom onset or first GP visit for all eligible symptoms, 
hence these women were also classified as having no delay. 
Table 4-17 below shows that the longest median patient delay was reported on 
interview at 3.0 months (IQR 0.0-7.0).  Conversely, patient delay was almost non-
existent according to GP notes.  Provider delays were similar for self-reported data, 
however the largest interval was 4.4 months (IQR 2.0-10.0) in GP notes.  Total delay 
ranged between a median of 5.0 months (GP notes) and 8.4 months (interview).  The 
overall total delay (combined data) was 9.8 months (IQR 5.0-12.3) (based on 222 
women with available data, 3 women had no eligible symptoms in any of the 3 data 
sources). 
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Table 4-17 Delays in Diagnosis (Months) 
 Questionnaire 
n=220 
Interview 
n=124 
GP Notes 
n=197 
Women with No Delay 19 (9%) 1 (1%) 5 (3%) 
    
Patient Delay n=161 (73%) n=107 (86%) n=192 (97%) 
 Median 1.0 3.0 0.0 
 IQR 0.0-5.0 0.0-7.0 0.0-0.3 
 Mean 3.1 3.8 0.5 
 Range 0.0-13.0 0.0-12.0 0.0-9.0 
    
Provider Delay n=161 (73%) n=107 (86%) n=192 (97%) 
 Median 2.1 2.7 4.4 
 IQR  1.4-4.8 1.4-4.8 2.0-10.0 
 Mean 3.6 3.6 5.9 
 Range 0.0-13.2 0.1-12.5 0.1-14.9 
    
Total Delay n=201 (91%) n=123 (99%) n=192 (97%) 
 Median 5.6 8.4 5.0 
 IQR 2.8-11.4 4.0-10.4 2.6-10.4 
 Mean 6.6 7.3 6.5 
 Range 0.2-14.8 0.1-14.9 0.5-14.9 
Table 4-18 shows that GPs took a median of 1.7 months to make a referral to any 
department.  The median interval between first GP visit (for symptom) to appropriate 
referral was 2.7 months. 
Of the women who self-presented to A&E with GP note data available, 3 had no prior 
GP visits for (eligible) symptoms (3/18 with GP notes).  Similarly, of the women who 
were sent by their GP to A&E, only 3 had no (eligible) symptoms recorded in their 
notes (3/26 with GP notes).   
The median time from first GP referral to date of diagnosis was similar for rapid referral 
G/O versus all other referrals (1.4 months, IQR 1.1-2.0 and 1.8 months IQR 1.0-3.2, 
respectively).  When referrals to A&E were excluded, median time from first GP referral 
to diagnosis was slightly longer at 2.3 months (IQR 1.4-5.0). 
156 
Table 4-18 Time to Referral (Months) 
 
Any Referral 
n=195 
Appropriate Referral* 
n=195 
Provider Delay n=191 (98%) n=189 (97%) 
 Median 1.7 2.7 
 IQR  0.2-7.2 0.5-8.2 
*Appropriate referral was considered to be any gynaecological referral.  If this date was missing, 
„cut-off‟ date was used 
Women with unknown referral pathways were excluded from total delay except for one woman 
in whom first referral date was known but referral type was unknown 
4.1.14 Goff’s Symptom Index 
The criteria for a positive “test” according to the symptom index developed by Goff et 
al. were applied to women in our study.108  Specifically, this was reporting of any one of 
pelvic/abdominal pain, increased abdominal size/bloating, difficulty eating/feeling full 
quickly with a frequency of 16-31 days per month but for less than 1 year (see 3.3.10 
Definition of Study Variables for full details).  Symptoms that were not ongoing at time 
of questionnaire or interview completion were included since Goff‟s survey also 
included these.  The index was tested on data for women aged ≥50, then on women of 
all ages including a split by stage.   
Sensitivity and specificity (based on cumulative incidence over 1 year) for interview 
data in women aged ≥50 was very similar to Goff‟s confirmatory sample, as shown in 
Table 4-19.  Sensitivity for early stages was almost identical to the Goff data based on 
questionnaire answers.  Conversely, questionnaire sensitivity for women aged ≥50 and 
late stage disease were lower in comparison to Goff‟s Index.   
To gain an impression of how the index would perform at least 3 months before 
diagnosis, the same criteria were applied to symptoms present 3-14 months before 
diagnosis.  Based on cumulative incidence for 1 year (over 3-14 months), sensitivity for 
both sources was markedly reduced but specificity remained the same or better (Table 
4-19). 
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Table 4-19 Sensitivity & Specificity Calculated According to Goff’s Index for Questionnaire & Interview Data 
 
Goff 
Data
108
 
 Symptoms at Anytime   3-14 Months Before Reference Date 
  Questionnaire 95%CI Interview 95%CI  Questionnaire 95%CI Interview 95%CI 
Women aged ≥50           
Sensitivity 
66.7% 58.5% 
(131/224) 
51.7%, 65.0% 70.8% 
(92/130) 
62.2%, 78.4%  27.2% 
(61/224) 
21.5%, 33.6% 46.2% 
(60/130) 
37.4%, 55.1% 
Specificity  
90.0% 98.9% 
(265/268) 
96.8%, 99.8% 89.6% 
(112/125) 
82.9%, 94.3%  98.9% 
(265/268) 
96.8%, 99.8% 93.6% 
(117/125) 
87.8%, 97.2% 
Women All Ages           
Sensitivity  
- 59.0% 
(147/249) 
52.6%, 65.2% 71.7% 
(104/145) 
63.7%, 78.9%  32.9% 
(82/249) 
27.1%, 39.1% 48.9% 
(71/145) 
40.6%, 57.4% 
Specificity 
- 98.9% 
(265/268) 
96.8%, 99.8% 89.6% 
(112/125) 
82.9%, 94.3%  98.5% 
(264/268) 
96.8%, 99.8% 92.8% 
(116/125) 
86.8%, 96.7% 
Early Stage           
Sensitivity 
56.7% 57.0% 
(57/100) 
46.7%, 66.9% 68.4% 
(39/57) 
54.8%, 80.1%  28.0% 
(28/100) 
19.5%, 37.9% 49.1% 
(28/57) 
35.6%, 62.7% 
Late Stage           
Sensitivity 
79.5% 65.2% 
(86/132) 
56.4%, 73.2% 75.9%  
(60/79) 
65.0%, 84.9%  37.1% 
(49/132) 
28.9%, 50.0% 51.9% 
(41/79) 
40.4%, 63.3% 
Note: 95% confidence intervals were not provided in the Goff paper.  Feeling full quickly was only recorded on interview so in our data sensitivity may be lower, and 
specificity may be higher, than expected for questionnaire data 
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4.1.15 Development of a Potential Symptom Index 
In order to explore the potential for developing a symptoms index, two different 
approaches were employed.  The first approach used the results of the univariate 
analyses to produce an unweighted score.  The second involved using results from a 
multivariate analysis (backwards stepwise selection regression) on the questionnaire 
data to develop a weighted score.  Both techniques excluded longstanding symptoms 
from the analyses.  Neither of these approaches were ideal, however both were felt to 
be adequate for exploratory purposes.  
4.1.15.1 Unweighted Symptoms Index 
Two (crude) symptoms indices were devised using two different OR thresholds from 
the univariate analyses.  Both thresholds were derived from data on symptoms present 
over one year (3-14 months before reference date) as per Table 4-8 to Table 4-10.  
The first index was based on symptoms with ORs of ≥10 in at least two data sources 
(Index 1).  The second was limited to symptoms with ORs of ≥5 (or symptoms with 
case frequency of ≥6% for infinite ORs) in at least two data sources (Index 2).  Women 
who had at least one index symptom over the year examined were considered to be 
positive for the index (see Table 4-20).  Median time from first index symptom to 
diagnosis was calculated for women who were positive, and this served as a measure 
of diagnostic lead time.  Note that because this was based on symptoms 3-14 months 
before reference date, the minimum possible median was 3 and the maximum was 
14.99.  Index 1 included women with at least one of the following symptoms during 3-
14 months before reference date: 
 Increased abdominal size  
 Loss of appetite  
Index 2 included women with at least one of the following symptoms during 3-14 
months before reference date: 
 Increased abdominal size 
 Loss of appetite 
 Pelvic/abdominal pain or discomfort 
 Lump in abdomen 
 Constipation 
 Fatigue 
 Bloating 
 Nausea or vomiting 
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 Weight loss 
As expected, Index 2 produced the greatest sensitivity for cases and the longest 
median (diagnostic) lead times; however these were offset by a loss in specificity.  The 
highest values (for both indices) were observed for interview data, followed by 
questionnaire and GP notes.  According to interview, 74% (95%CI 67%, 81%) of cases 
were positive for Index 2, with a median of 8 months from first index symptom onset to 
diagnosis.  Corresponding figures for questionnaire data were 57% (95%CI 51%, 63%) 
of cases with a median of 7 months (diagnostic) lead time.  For GP notes, this was 
45% (95%CI 38%, 52%) of cases positive for the index.  The change in sensitivity 
between Index 1 and Index 2 was greatest for GP notes with a 34% increase from 1 to 
2.  Corresponding loss in specificity was 21%.  Questionnaire and interview data had 
similar magnitudes of sensitivity increase, however the decrease in specificity was 
double that on interview compared to questionnaire. 
In order to examine actual lead time, Table 4-21 shows the proportion of women that 
were positive for Index 2 at various intervals before diagnosis, with 2 months for 
referral to diagnosis taken into account.  In the table, the proportion of women with an 
index symptom between 5-8 (i.e. 5 to 7.99) months before diagnosis is shown as the 
proportion of women with 3-5 months (actual) lead time.  According to these 
calculations, between 9% (GP notes) and 18% (interview) of cases had an actual lead 
time of 3-5 months.  Between 26% (GP notes) and 56% (interview) of cases had at 
least 3 months actual lead time (sum of 3-5 to 9-12 months lead time).  Note that 43% 
(questionnaire), 26% (interview) and 55% (GP notes) of cases had no Index 2 
symptoms between 3-14 months of diagnosis, and therefore no actual lead time. 
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Table 4-20 Number (%) [95%CI] of Women with Positive Index Over 1 Year (3-14 Months Before Reference Date), Median Time from Earliest 
Index Symptom Onset to Reference Date (Months) & Crude Odds Ratios (95% CI) Per Source 
  Questionnaire  Interview  GP Notes 
 
 Cases 
n=249 
Controls 
n=268 
OR 
(95%CI) 
 
 
Cases 
n=145 
Controls 
n=125 
OR (95%CI) 
 
 
Cases 
n=223 
Controls 
n=227 
OR (95%CI) 
Index 1* n (%) 86 (35%) 7 (3%) 20 (9, 51)  68 (47%) 7 (6%) 15 (6, 40)  25 (11%) 2 (1%) 14 (3, 125) 
 95%CI [29%, 41%] [1%, 5%] -  [39%, 55%] [2%, 11%] -  [7%, 16%] [0%, 3%] - 
Median time 
(IQR)  
 6 (4-9) - -  6 (4-9) - -  5 (4-8) - - 
Index 2** n (%) 142 (57%) 36 (13%) 9 (5, 14)  108 (74%) 33 (26%) 8 (5, 15)  100 (45%) 49 (22%) 3 (2, 5) 
 95%CI [51%, 63%] [10%, 18%] -  [67%, 81%] [19%, 35%] -  [38%, 52%] [16%, 28%] - 
Median time 
(IQR)  
 7 (5-12) 12 (8-12) -  8 (5-10) 11 (6-12) -  6 (4-10) 10 (7-13) - 
*Symptoms present 3-14 months before diagnosis with case-control OR ≥10 in at least 2 sources (increased abdominal size & loss of appetite)  
**Symptoms present 3-14 months before diagnosis with case-control OR ≥5 (or present in ≥6% of cases if OR was infinite) in at least 2 sources (increased 
abdominal size, lump in abdomen, loss of appetite, pelvic/abdominal pain or discomfort, constipation, fatigue, bloating, nausea or vomiting, weight loss) 
Note: Median for controls with Index 1 not shown due to small numbers 
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Table 4-21 Number (%) of Cases Positive for Index 2 at Various Actual Lead times using Symptoms Over 1 Year (3-14 Months Before 
Diagnosis) 
 Questionnaire  Interview  GP Notes 
Lead Time* 
Cases 
n=249 
95%CI 
 
 
Cases 
n=145 
95%CI 
 
 
Cases 
n=223 
95%CI 
None 107 (43%) 37% to 49%  37 (26%) 19% to 33%  123 (55%) 48% to 62% 
≥1 month** 142 (57%) 51% to 63%  108 (74%) 67% to 81%  100 (45%) 38% to 52% 
1-2 months 41 (16%) 12% to 22%  27 (19%) 13% to 26%  41 (18%) 14% to 24% 
3-5 months 41 (16%) 12% to 22%  26 (18%) 12% to 25%  20 (9%) 6% to 14% 
6-8 months 21 (8%) 5% to 13%  38 (26%) 19% to 34%  23 (10%) 7% to 15% 
9-11 months 39 (16%) 11% to 21%  17 (12%) 7% to 18%  16 (7%) 4% to 11% 
*Lead time is time from first index symptom (present 3-14.99 months before diagnosis) to 2 months prior to diagnosis 
**Number (%) of women with at least 1 month of actual lead time for symptoms present over 3-14.99 months before diagnosis 
Values are calculated as women positive for Index 2 using symptoms present 3-14.99 months before diagnosis. 
Note: „1-2 months‟=1.0 to 2.99 months, „3-5 months‟=3.0 to 5.99 months, etc. 
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A 3-point scoring system was devised using the two indices:   
 Score 0 if have none of the symptoms in Index 1 or Index 2 
 Score 1 if have any of the symptoms in Index 2 that are not in Index 1 (5≥OR>10) 
 Score 2 if have any of the symptoms in Index 1 (≥OR 10) 
This was applied to data for symptoms present 3-14 months before diagnosis, the 
results are shown below in Table 4-22.  Clinical application of a 3-point score might 
involve offering „targeted screening‟ to women with a score of 1, and a more urgent test 
or referral for a score of 2.  However, the score would have „missed‟ 43%, 26% and 
55% of cases for questionnaire, interview and GP notes, respectively, within 3 months 
of diagnosis.  The score performed the best on interview data, with a sensitivity of 28% 
and specificity of 90%. 
Table 4-22 Unweighted Score in Each Data Source for Symptoms Over 1 Year (3-
14 Months Before Reference Date) 
Score Cases Controls Sensitivity 1-Specificity 
Questionnaire n=249 n=268   
0 107 232 - - 
1 56 29 22% 11% 
2 86 7 35% 3% 
Interview n=145 n=125   
0 37 92 - - 
1 40 26 28% 10% 
2 68 7 47% 3% 
GP Notes n=223 n=227   
0 123 178 - - 
1 75 47 34% 21% 
2 25 2 11% 1% 
N.B. A score of 1 in the table refers to the proportion of women with an Index 1 symptom that is 
not in Index 2 (i.e. not loss of appetite or increased abdominal size) 
4.1.15.2 Weighted Score 
A weighted scoring system based on questionnaire data for symptoms at anytime 
(excluding longstanding symptoms) was developed.  All of the symptoms that were 
presented individually in the main tables were put into the model (18 symptoms).  A 
significance level of p=0.1 was required for removal and p=0.05 for entry.  Symptoms 
that were significantly associated with cases in the model were used to derive a weight 
for each criterion.  This had the advantage of accommodating for the varying predictive 
power of each symptom and of accounting for multiple symptoms.  The resultant model 
identified 12 symptoms that were independently associated with ovarian cancer.  Table 
4-23 shows the log odds ratios and derived weights for symptoms identified in the 
regression model output.  In order to simplify the calculations for a weighted score, 
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derived weights were converted to integers by rounding.  Symptoms that were dropped 
from the model because of perfect prediction (i.e. not reported by any controls), were 
automatically given a weight of +5.  The range of possible scores was between 0 and 
24.   
Table 4-23 Log Odds Ratio and Derived Weights for Symptoms Identified in the 
Model 
Variable 
Log odds ratio 
(β Coefficient) 
Derived Weight 
Pelvic/Abdominal Pain or Discomfort 1.537135 +2 
Abdominal Bloating 1.074012 +1 
Increase in Abdominal Size 1.4292 +1 
Back Pain -0.67347 0 
Loss of Appetite 2.19223 +2 
Irregular Vaginal Bleeding 1.806627 +2 
Weight Loss 1.133038 +1 
Change in Bowel Habit* - +5 
Lump in Abdomen* - +5 
Postmenopausal Bleeding* - +5 
Vaginal Discharge* - +5 
Urinary Other* - +5 
*Symptoms that were dropped from the model due to perfect prediction of case status 
As this approach was more data-driven the model was applied only to data for 
symptoms present 3-14 months before reference date and was cross-validated (for 
questionnaire data only).  The resultant sensitivity corresponds to the proportion of 
cases that could be „identified‟ at least 3 months prior to (current) diagnosis, and 1-
specificity corresponds to the proportion of women in general population who would be 
identified over 12 months. 
Scores were derived for each source as shown in Table 4-24.  Two thresholds for the 
score were selected based on the proportion of cases versus controls correctly 
identified at various cut-off points.  For self-reported data, the same two thresholds 
were used, however for GP notes the spread of scores was different enough to justify 
devising separate thresholds. 
For self-reported data, the first threshold was set at a score of 4 and above.  The 
second threshold was a score between 1 and 3.  Again, any women meeting the first 
threshold might be sent for an „urgent‟ investigation or procedure, whereas anyone 
meeting the second threshold might be offered „targeted screening‟ according to 
routine timelines.  For scores of 0 no action would be taken.  Based on these 
assumptions, for the questionnaire data 31.7% (95%CI 26.0%, 37.9%) of cases and 
9.0% (95%CI 5.8%, 13.0%) of controls would be sent for „targeted screening‟ and 
24.1% (95%CI 18.9%, 29.9%) of cases and 0.7% (95%CI 0.1%, 2.7%) of controls 
would have an „urgent‟ test or referral.  Likewise, based on interview data 25.5% 
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(95%CI 18.6%, 33.4%) of cases and 16.0% (95%CI 10.0%, 23.6%) of controls would 
be „screened‟, and 43.4% (95%CI 35.2%, 51.9%) of cases and 4.0% (95%CI 1.3%, 
9.1%) of controls would have an „urgent‟ test or referral (Table 4-24). 
The two thresholds for GP notes were set at scores of 1-9 for „targeted screening‟ and 
≥10 for „urgent‟ testing or referral.  This translated into „screening‟ on 46.2% (95%CI 
39.5%, 53.0%) of cases and 20.7% (95%CI 15.6%, 26.6%) of controls (Threshold 1), 
and „urgent‟ investigation for 6.7% (95%CI 3.8%, 10.9%) of cases and 1.3% (95%CI 
0.3%, 3.8%) of controls (Threshold 2).   
For questionnaire data, the advantage of adding the second threshold is a 31.7% gain 
in sensitivity for only a 9.0% loss in specificity.  For interview, corresponding figures 
were 25.5% additional sensitivity, 16.0% loss in specificity, and for GP notes this was 
46.2% sensitivity, and 20.7% specificity. 
The sensitivity and specificity of the weighted index varied between the three data 
sources.  As seen in Table 4-24 and Figure 4-18 to Figure 4-20, the weighted score 
performed better on interview data.  Performance was noticeably reduced when 
applied to the GP data.   
If a single threshold were to be used with a cut-off score of 1, reasonable sensitivity 
and specificity can still be achieved (Table 4-25).  For the questionnaire, it achieves 
55.8% sensitivity (95%CI 49.4%, 62.1%) with 90.3% (95%CI 86.1%, 93.6%) specificity.  
On interview, one could achieve 69.0% (95%CI 60.8%, 76.4%) but with only 80.0% 
(95%CI 71.9%, 86.6%) specificity.  By raising the threshold of the index (for interview), 
one could increase the specificity to 96.0% (95%CI 90.9%, 98.7%) but the sensitivity 
would be reduced to 43.4% (95%CI 35.2%, 51.9%).  For GP notes, the sensitivity is 
similar to that from the questionnaire (52.9% [95%CI 46.1%, 59.6%]), but the specificity 
is comparable to that of the interview (78.0% [95%CI 16.8%, 28.0%]). 
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Table 4-24 Weighted Score for Each Data Source for Symptoms Over 1 Year (3-14 Months Before Reference Date) 
 Questionnaire Interview GP Notes 
Score 
Cases 
n=249 
Controls 
n=268 
Cases 
n=145 
Controls 
n=125 
Cases 
n=223 
Controls 
n=227 
0 44.2% 90.3% 31.0% 80.0% 47.1% 80.0% 
1 8.0% 3.7% 10.3% 6.4% 4.5% 1.8% 
2 18.5% 3.0% 12.4% 6.4% 11.2% 4.0% 
3 5.2% 2.2% 2.8% 3.2% 3.1% 0.4% 
4 9.2% 0.7% 7.6% 0.8% 1.3% 0.4% 
5 4.0% 0.0% 7.6% 2.4% 11.7% 9.3% 
6 3.6% 0.0% 6.9% 0.0% 1.8% 0.4% 
7 2.4% 0.0% 6.9% 0.0% 9.9% 3.5% 
8-9 2.4% 0.0% 5.5% 0.0% 2.7% 0.9% 
10-24 2.4% 0.0% 9.0% 0.8% 6.7% 1.3% 
TOTAL 100% 100% 100% 100% 100% 100% 
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Table 4-25 Cumulative Performance of Weighted Scoring System for Symptoms Over 1 Year (3-14 Months Before Reference Date) for Each 
Data Source 
 Questionnaire Interview GP Notes 
Score 
Sensitivity 
n=249 
1-Specificity 
n=268 
Sensitivity 
n=145 
1-Specificity 
n=125 
Sensitivity 
n=223 
1-Specificity 
n=227 
0 100% 100% 100% 100% 100% 100% 
1 55.8% 9.7% 69.0% 20.0% 52.9% 22.0% 
2 47.8% 6.0% 58.6% 13.6% 48.4% 20.3% 
3 29.3% 3.0% 46.2% 7.2% 37.2% 16.3% 
4 24.1% 0.7% 43.4% 4.0% 34.1% 15.9% 
5 14.9% 0.0% 35.9% 3.2% 32.7% 15.4% 
6 10.8% 0.0% 28.3% 0.8% 21.1% 6.2% 
7 7.2% 0.0% 21.4% 0.8% 19.3% 5.7% 
8-9 4.8% 0.0% 14.5% 0.8% 9.4% 2.2% 
10-24 2.4% 0.0% 9.0% 0.8% 6.7% 1.3% 
Bolded values meet Threshold 1, italicised values meet Threshold 2  
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Figure 4-18 Receiver Operating Curve (ROC) for Questionnaire Data using 
Weighted Score on Symptoms Over 1 Year (3-14 Months Before Reference Date) 
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Figure 4-19 Receiver Operating Curve (ROC) for Interview Data using Weighted 
Score on Symptoms Over 1 Year (3-14 Months Before Reference Date) 
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Figure 4-20 Receiver Operating Curve (ROC) for GP Note Data using Weighted 
Score on Symptoms Over 1 Year (3-14 Months Before Reference Date) 
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Figure 4-21 Receiver Operative Curves (ROC) for Symptoms Reported at Anytime 
Questionnaire Data 
 
A 10-fold cross validation was performed on the model using questionnaire data for 
symptoms at anytime (i.e. the same data used to derive the original model).  Figure 
4-21 compares the resultant receiver operator curves (ROC) for the original model, the 
cross-validated version and the weighted score.  Each ROC was similar showing that 
each of the models/score performed equally well.   
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Figure 4-22 Receiver Operative Curves (ROC) for Symptoms Reported Over 3-14 
Months Before Reference Date on Questionnaire 
 
Figure 4-22 contains the same ROCs as above applied to questionnaire data for 
symptoms present over 3-14 months before reference date (1 year).  At first glance, the 
cross-validated version performance appears to be poor in comparison to the other 
models.  However, when sensitivity is less than 0.5, there is actually very little 
difference between the 3 models.   
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5 CHAPTER 5: Case-Control Discussion & 
Conclusions 
5.1 Discussion 
The findings of this chapter will be discussed in several different segments.  This will 
include: 
 Sensitivity of Prediagnostic Symptoms 
 Specificity of Prediagnostic Symptoms 
 Salient Symptoms 
 Symptom Lead Time  
 Exploring the Potential For a Symptoms Index 
 Route of Diagnosis 
 Delays in Diagnosis 
 Early versus Late Stage Disease 
 Potential for Using Symptoms as a Tool for „Early‟ Detection 
 Potential for „Targeted Screening‟ 
 Comparison of the Data Sources 
 Severity & Frequency 
 Missing Data 
 Study Advantages  
 Study Limitations  
Sensitivity of Prediagnostic Symptoms 
In the present study, there was little interest in the full spectrum of symptoms, but 
rather only the sensitive and specific ones.  In corroboration with previous studies, 
abdominal and gastrointestinal symptoms predominated, while gynaecological 
symptoms were rare.6-9, 12, 15, 16, 20, 21, 67-69, 75, 89, 104  Ninety-seven percent (questionnaire, 
[Q]) and 100% (interview, [I]) of cases had at least one relevant symptom at diagnosis 
(including longstanding symptoms).  The most sensitive symptoms (excluding 
longstanding) in self-reported data were pelvic/abdominal pain (Q 53%, I 57%), 
increased abdominal size (Q 67%, I 77%), abdominal bloating (Q 69%, I 56%) and 
fatigue (Q 50%, I 55%).  According to the GP note data, pelvic/abdominal pain or 
discomfort (58%) and increased abdominal size (27%) were of relatively high 
sensitivity, as were urinary other (37%) and nausea/vomiting (25%).  Importantly, 
pelvic/abdominal pain or discomfort and increased abdominal size were the only 
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symptoms that were consistently amongst the top three most sensitive symptoms for all 
data sources.  While these figures are not appropriate for direct comparison to the 
existing literature (due to the exclusion of longstanding symptoms), the underlying 
theme of abdominal pain, increased abdominal size, and bloating being the most 
common symptoms reported is in strong agreement with previous studies.6-12, 15-17, 19-21, 
67-69, 75, 89, 97, 99, 101, 104   
Much emphasis has been placed upon symptoms at diagnosis, however there is little to 
be gained by detecting symptoms that only develop within 2-3 months of diagnosis.  
This is because any symptoms presenting after this point offer little opportunity for 
intervention.  In this study, the median time between first referral and diagnosis was 1.6 
months (IQR 1.1, 2.5).  Thus, it appears that according to current UK clinical practice, 
the time it takes to get from any referral to ovarian cancer diagnosis is typically around 
2 months.  Time between rapid referral G/O to diagnosis was not much shorter at 1.4 
months (IQR 1.1-2.0).  Critically, the interval we wish to have an impact on is the time 
between symptom onset and referral (as shown by the black arrows in Figure 5-1).  
Most of the current literature has failed to take this into account when evaluating their 
findings.  In the UK, the period between referral and diagnosis is already being 
tightened as part of a Department of Health strategy to reduce cancer waiting times.  
The most recent waiting time targets were set at a maximum of 2 months (62 days) 
from urgent GP referral to first definitive treatment.132 
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Figure 5-1 Schematic Diagram Showing Typical Pathway from Oncogenesis to 
Ovarian Cancer Diagnosis 
 
Unfortunately, there was a large reduction in individual symptom sensitivity 3-14 
months before diagnosis compared to symptoms at diagnosis (~20-30% for the most 
sensitive symptoms).  Crude odds ratios for individual symptoms were still large and 
significant at the p<0.05 level for many symptoms, however only in relatively small 
proportions of women.  Nonetheless, 81%, 70% and 64% of cases still had at least one 
relevant symptom on interview, GP notes and questionnaire, respectively.  A similar 
pattern of symptom sensitivity was maintained, however fatigue became comparatively 
more prominent on interview data while increased abdominal size and nausea/vomiting 
ceased to feature prominently on GP notes.  Pelvic/abdominal pain or discomfort 
remained amongst the most sensitive symptoms (interview [36%], questionnaire [26%] 
and GP notes [26%]).  Smith and colleagues also looked at symptom frequency for 
specific prediagnostic time periods using coded billing records.20  They found that 
abdominal pain was the most frequently coded symptom at 1-3 months (31%) and 4-6 
months (8.9%) prior to diagnosis.  Generally, symptom incidence was low in the Smith 
study, particularly during 6 months or longer before diagnosis.  Another study that used 
medical insurance claim forms, examined temporal symptoms patterns over the 9 
months before diagnosis.21  By 0-30 days prior to diagnosis abdominal pain had been 
recorded in 83% of cases.  At 31-60 days prior, just 23% of cases had a recording of 
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abdominal pain.  For both of these studies, symptom recording was restricted by 
coding rules, hence results probably underestimate actual symptom prevalence.  
Overall, individual symptom sensitivity in the present study was less than 50% for all 
symptoms and all sources over the 3-14 months before diagnosis.  These data indicate 
that there is clustering of symptoms close to diagnosis. 
Specificity of Prediagnostic Symptoms 
Specificity is regarded as a crucial element of any symptoms tool for ovarian cancer 
diagnosis given the potentially serious physiological, psychological and financial 
downstream consequences of false positives.  It is dictated by the background rate of 
relevant symptoms both in primary care (i.e. symptoms that elicit healthcare-seeking 
behaviour) and in the general non-consulting population (i.e. all symptoms experienced 
by women).  Specificity was highest for loss of appetite, lump in abdomen and 
increased abdominal size for all three data sources (between 98-100% over one year 
[3-14 months before diagnosis]).  Likewise, case-control differences over 3-14 months 
prior to reference date were also the greatest for these 3 symptoms, for all data 
sources (ORs all >10, see Table 4-8 to Table 4-10).  Symptoms with significant case-
control differences for GP notes also included pelvic/abdominal pain or discomfort, 
vaginal discharge, bloating, constipation, change in bowel habit, urinary 
frequency/urgency and urinary other.   
Even though this study was not the ideal setting in which to examine symptom 
specificity (due to the potential for self-selection bias and a „healthy volunteer effect‟133), 
it still provided useful data in an area for which there is a paucity of evidence.  The 
exclusion of pre-existing (longstanding) symptoms greatly improved specificity, with 
relatively low numbers of controls reporting „new‟ symptoms on any data source.  
Importantly, there was only a modest loss in sensitivity for the symptoms that seemed 
to be the most affected by over-reporting (see Figure 4-2).   
In general, controls reported more longstanding symptoms than cases.  Reasons for 
this are unclear, but perhaps this reflects excess reporting of mild symptoms in 
controls, which cases failed to mention due to overshadowing by severe symptoms.  
Also, patients are known to over-report symptoms that correspond to current illness 
and underreport those that predate the illness.116  Similarly, Vine et al.7 found that 
limiting symptoms to those that started within 2 years of diagnosis reduced control 
symptom frequency from 52% to 38%, whereas case symptom frequencies remained 
the same.  Collectively, these discrepancies imply that symptom studies which include 
longstanding existing symptoms may overestimate case-control differences, symptom 
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sensitivity, delays and symptom lead time.  This incongruence in symptom reporting by 
controls will be discussed further in „Comparison of the Data Sources‟. 
Salient Symptoms 
The most salient ovarian cancer symptoms according to the exploratory analyses for 
symptoms indices (discussed later) were: 
 Increased abdominal size (both scores) 
 Loss of appetite (both scores) 
 Pelvic/abdominal pain or discomfort (both scores) 
 Lump in abdomen (both scores) 
 Abdominal bloating (both scores) 
 Weight loss (both scores) 
 Constipation (both scores) 
 Fatigue (both scores) 
 Nausea or vomiting (unweighted score only) 
 Change in bowel habit (weighted score only) 
 Irregular vaginal bleeding (weighted score only) 
 Postmenopausal bleeding (weighted score only) 
 Vaginal discharge (weighted score only) 
 Urinary other symptoms (weighted score only) 
All of the symptoms in the Goff Index,108 also featured in our list, except for difficulty 
eating or feeling full quickly which were not listed on our survey.  Increased abdominal 
size, bloating, pelvic or abdominal pain or discomfort, weight loss, constipation, fatigue 
and loss of appetite were found to be salient in both of the approaches and are the 
most likely to be useful symptoms in any future ovarian cancer symptoms index.  Back 
pain was found to be negatively associated with ovarian cancer in the multivariate 
analysis.  Potentially, back pain could be used as a negative discriminator in a 
symptoms tool.  Some of the symptoms were highly predictive due to a very low 
number of controls reporting the symptoms which produced large ORs (i.e. lump in 
abdomen, loss of appetite, vaginal discharge, change in bowel habit, IVB, PMB, 
nausea/vomiting).  Conversely, the remaining symptoms on the list were relatively 
common in control women, but were still reported in excess by cases (i.e. fatigue, 
bloating). 
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Symptom Lead Time 
Data from all three sources indicated that symptoms associated with disease develop 
15 months prior to diagnosis.  The (diagnostic) lead time of individual symptoms was 
quantified by calculating continuation odds ratios at different periods before diagnosis, 
using only symptoms that were „new‟ in the last 2 years and assuming a constant rate 
of „new‟ symptoms for controls.  The continuation odds provided a more realistic 
estimate of (diagnostic) lead time by only including women who were still „at risk‟ of 
developing the symptom at each time point relative to diagnosis.  Also, the resultant 
confidence intervals were wider but more accurate.  Any seasonal variations in control 
symptoms were expected to have smoothed over the two years worth of data.  A priori, 
one might anticipate some increases in symptom incidence due to ageing but these 
should have been minimal given the short period examined (i.e. two years).  Also, Goff 
and colleagues found that reporting of potentially related ovarian cancer symptoms in 
clinic controls (aged 15-90 years) decreased with age.75   
The data from individual symptoms in this study suggested that there is a maximum 
diagnostic lead time of 15 (i.e. 14.99) months.  However, after allowing 2 months for 
time between referral and diagnosis (median 1.6 months in this study), the real 
potential maximum referral lead time (i.e. actual lead time) is probably more in the 
region of 12 months.  Odds ratios were substantially larger closer to diagnosis for all 
symptoms, but were close to 1 at 15-23 months before reference date.  This indicated 
that currently ovarian cancer is symptomatic for about 15 months prior to diagnosis.   
In general, odds ratios were larger for questionnaire data due to lower symptom 
reporting in controls.  Certain symptoms (bloating, indigestion, back pain, fatigue) were 
recorded less frequently in the GP notes, potentially reflecting symptoms which are too 
common or mild to prompt presentation to primary care.  On interview, controls 
reported higher rates of the same symptoms, which substantiated this theory.  
Conversely, recording bias is another possible explanation.  Bankhead et al. found that 
many symptoms women claimed to have reported to the GP were not actually recorded 
by the GP.94  Both are possible explanations for the lower sensitivity observed in GP 
notes.  Loss of appetite and pelvic/abdominal pain or discomfort appeared to provide a 
maximum of 9-11 months (diagnostic) lead time across all data sources.  The longest 
(diagnostic) lead time in GP notes was for urinary frequency/urgency, which was 
recorded in significantly more cases than controls 12-14 months before diagnosis (OR 
2.9, 95%CI 1.2, 6.8).   
Symptom lead time for individual symptoms differed between each data source.  In 
general, lead time was longer for self-reported data compared to GP note data.  GP 
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notes may be the most accurate since they are based on real dates, whereas self-
reported dates are based on rounded dates (15th day of the month).  However, as 
shown by the patient delay data, symptom onset dates in GP notes are likely to have 
been visit dates rather than true onset dates.  Problem GP visits clearly started to 
diverge around 6 months before diagnosis (see Figure 4-11) which lends support to a 
more conservative diagnostic lead time of around 6 months in GP note data.  
Cumulative incidence of pelvic/abdominal pain for cases in GP notes sharply increased 
within 6 months of diagnosis.  A study examining insurance claims also found that 
abdominal pain and GI symptoms displayed a similar pattern, albeit at the more latent 
time point of 90 days (~3 months) prior to diagnosis.21 
Exploring the Potential for a Symptoms Index 
When the potential for development of a symptoms index was considered, the idea was 
to take an exploratory approach and there was no desire to over-interpret the findings.  
A symptoms index is the most likely way in which „targeted screening‟ would be applied 
since the positive predictive value (PPV) and sensitivity of individual symptoms is liable 
to be too small.  It should be noted that none of the scores devised formally took into 
account the timing of symptoms.  However, both scores were applied to data on 
symptoms that were present 3-14 months before diagnosis.   
Specificity for Index 1 was extremely high, however sensitivity was poor and the largest 
proportion of cases that would have been detected was 47% (interview).  The 
sensitivity and specificity for Index 2 was much more promising, hence will be 
discussed in greater detail. 
Based on Index 2 for symptoms reported over 1 year, sensitivity was between 45% 
(GP notes) and 74% (interview) and specificity was between 74% (interview) and 87% 
(questionnaire).  This is equivalent to between 13% (questionnaire) and 26% 
(interview) of healthy women that would require testing over one year.  After time for 
referral to diagnosis was accounted for, the proportion of cases with an actual lead time 
of at least 3 months was between 26% (GP notes) and 56% (interview).  Thus, there is 
potential to bring forward diagnosis in a reasonable proportion of cases.  Median time 
from first Index 2 symptom to diagnosis was 6 months for GP notes and 8 months for 
interview, indicating a sizeable gain in diagnostic lead time for these women.  After 
allowing for time from referral to diagnosis, this would be reduced to 4 and 8 months of 
actual lead time, respectively.   
The performance of Index 2 (unweighted score) was very similar to that of the weighted 
score using the cut-off of 1.  However, notably the specificity of the Index 2 was slightly 
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better (except on questionnaire).  It is of interest to consider the difference in the 
performance of the weighted index using the different data sources. The sensitivity of 
52.9% in GP notes is attainable since these are essentially prospectively recorded 
data.  The fact that the specificity is only 78.0% which is considerably lower than on 
questionnaire, but similar to interview, suggests that many of these symptoms were 
transitory and/or self-limiting and therefore were not reported or recalled by controls at 
the time of recruitment.  However, on interview these may have been reported or 
recalled in response to probing.  Whether this means that there would be potential to 
improve the specificity of the index by requiring that the symptoms should be present 
for several weeks is unclear.  Potentially, the triage should take into account not only 
the blood test result, but also whether the symptoms are still present by the time the 
result are available (typically likely to be about 2 weeks after the sample is taken). The 
greatest sensitivity for the thresholds chosen was for interview data at 69%, with a 
corresponding specificity of 80%.  The greater sensitivity observed in the interview data 
suggests that it may be possible to impact on a greater proportion of ovarian cancers if 
women were to recognise symptoms and go to their GP earlier.  The challenge would 
be to do that without dramatically reducing the specificity of the index.  Another 
important finding was that in order to obtain over 90% specificity with the GP notes, the 
sensitivity falls to just 21.1%.  Corresponding sensitivity on questionnaire and interview 
was 55.8% and 46.2%, respectively.  It may be that women with high scores on the 
weighted index are already being referred by their GPs, so that the real gains for 
women with high scores are to be made by encouraging such women to consult with 
primary care sooner.  On the other hand, it may simply be due to the fact that the 
weighted index was derived using questionnaire data (which is similar to the interview 
data). 
As this process was hypothesis-generating, cross-validation was performed on the 
questionnaire data.  The ROCs in Figure 4-21 showed that when the models and score 
were applied to symptoms reported at anytime, each approach performed equally well.  
However, when these were applied to symptoms present over 3-14 months before 
reference date (1 year), each of the approaches performed much worse (Figure 4-22).  
Overall, this demonstrated that timing of symptoms is crucial when developing a 
symptoms index.  This fact is further exemplified by the results from the application of 
our data to the Goff index (discussed later).  Furthermore, any potential model used to 
develop a symptoms index is likely to require validation and needs to carefully consider 
the source of the data. 
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As expected, symptom lead time (diagnostic and actual) was generally longer on self-
reported data versus GP note data for individual and Index symptoms.  This may reflect 
the period between symptom onset and health-seeking, in which case encouraging 
women to present to primary care earlier could increase the number of women with a 
sizeable lead time in GP notes.  Another possible explanation for this apparent excess 
in lead time is that the delay in seeking healthcare is more accurately measured by 
self-reported data.  Alternatively, recall bias or recall error may have played a role.   
The longest (diagnostic) lead times for Index 1 and 2 were reported on interview, but 
again, it is unclear whether this is artificially long or represents „real‟ lead time.  
Perhaps the timing of the interview created a bias since they were conducted after 
diagnosis which may have increased recall bias and recall error.  However, anchor 
points were used on interview, which can aide recall, particularly with regard to dates.  
As such, symptom start dates on interview were expected to be more accurate than 
those on questionnaire.  At the time of interview, most cases were already aware of 
their final diagnosis.  Consequently, one might anticipate excess recall bias on 
interview versus questionnaire.  Presumably, this disparity would be relatively modest 
as at the time of questionnaire completion cases are already aware that there is a high 
probability of cancer and patient anxiety will be high.  Ultimately, it is unclear to what 
extent each of these contributed to the discrepancies in lead time.  A more complex 
combined analysis using an algorithm may elucidate this.  The possible reasons for 
discrepancies between data sources are discussed in further detail later. 
Route of Diagnosis 
First GP referral was difficult to extract for some women, and required subjective 
interpretation.  The subjectivity arose from deciding which symptoms are attributable to 
disease.  For women who were relatively symptom-free until a given point, route of 
diagnosis was easy to identify.  For women who had a high background rate of 
symptoms, previous referrals often confused matters.  For example, a woman may 
have been referred to secondary care one year before diagnosis for an acute episode 
of abdominal pain.  This may be followed by a symptom-free period until an abdominal 
lump is palpated two months before diagnosis, for which she is sent to rapid referral 
G/O.  In this situation, one might choose to assume that the referral for abdominal pain 
was unrelated and should not be counted, conversely, one might decide that this earlier 
referral for abdominal pain was the first GP referral.  For the purposes of studying route 
of diagnosis in this study, the former assumption was made.  A further issue was that 
some GP medical records were sparse.  In the most extreme situations, there would be 
documentation of a referral, but no record of any visit or symptoms.   
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Almost all cases were diagnosed via symptoms, however only 40% were initially 
referred to a rapid referral to gynaecological-oncology clinic.  This is a vast 
improvement on the 14% reported by a previous study based on data from 3 years 
after the introduction of rapid referral.134  Referral to GI specialists continued to be 
common.  One fifth were referred to gastrointestinal clinics, and 40% of these were 
urgent referrals which indicate that GPs suspected something serious, but erroneously 
assigned aetiology.  This is not surprising given that most symptoms were abdominal 
or gastrointestinal.   
Interestingly, the median time between referral and diagnosis was similar for rapid 
referral G/O versus all other referral types (1.4 months, IQR 1.1-2.0 and 1.8 months 
IQR 1.0-3.2, respectively).  Both of these medians fall within the current government 
target of 62 days from urgent cancer referral to first definitive treatment132 (date of 
diagnosis is usually date of surgery in ovarian cancer).  Even when emergencies were 
excluded, the corresponding increase in median delay was less than one month 
(median 2.3 months, IQR 1.4-5.0).   
Overall, the findings from the present study confirmed previous reports of convoluted 
diagnostic routes in ovarian cancer.8, 11, 99  However, this did not appear to translate in 
to unacceptable delay (in referral to diagnosis) since the timelines are still coming 
within government targets.  Also, convoluted diagnostic routes are not specific to 
ovarian cancer.  Of all cancers diagnosed in the UK in 2005, just 42% were diagnosed 
via urgent cancer referrals and 5% through screening programmes.135  Subsequently, 
more than 50% of cancers were diagnosed via other routes such as opportunistic 
diagnoses, A&E and non-urgent referrals.   
Delays in Diagnosis 
Delays in diagnosis are commonly divided into patient and provider delay.  The former 
refers to the interval between symptom onset and healthcare-seeking, and the latter 
refers to interval required to make the diagnosis after first presentation.   
Delay calculations are complicated by the subjectivity associated with symptom 
attribution.  If no restrictions are placed on how far back symptom history is reviewed; 
delays can be artificially large.  An extreme example of this is a Norwegian study which 
found that some women reported symptoms that started 10 years before diagnosis.13  
In our study, no differences in case-control symptom incidence were observed beyond 
15 months prior to diagnosis.  Hence, delay calculations were based on symptoms 
which started in the last 15 months before diagnosis.  Restricting the symptoms to 
those new in the last 15 months has the drawback of reducing the apparent delays for 
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women who had symptoms associated with disease before this cut-off.  However, 
judging by the data in the present study, this would be very rare.  The advantage of 
using the cut-off is that it avoids the much greater problem of including spurious (pre-
existing) symptoms which would artificially inflate delays.   
Women with no symptoms according to our definition (i.e. none that started in the last 
15 months and were „possibly related‟ to ovarian cancer) were excluded from the 
analysis of delays.  These women were considered to be ineligible for delay 
calculations, rather than being included as having a delay of 0.  The rationale for this 
was that women with symptoms who sought healthcare promptly and had no delay 
were not the same as women who had no symptoms and therefore no delay.  
Therefore, all the delay calculations were based on symptomatic women (with eligible 
symptoms, as defined above).  Women who were screen-detected or incidentally-
diagnosed were also excluded.  As these methods for calculating delays were novel, 
the delays results are not strictly comparable to those from other studies.  Also, it 
should be noted that default dates of the 15th of the month were used in self-reported 
data, whereas the dates in GP note data were exact.  This could have contributed to 
discrepancies between self-reported and GP note delays.  Finally, delay data were 
missing for women with missing symptom onset date and/or first GP visit date, which 
may have affected the results. 
Patient delay varied with each source.  According to the questionnaire, patient delay 
was a median of 1 month (IQR 0-5).  On interview, the median patient delay was 3 
months (IQR 0-7) which was comparable to previous studies that also found patient 
delays of 2-3 months.8, 18  A median of 0 months (IQR 0.0-0.3) patient delay was 
reported in GP notes, however it is unlikely that this is a true indication of patient delay.  
It is reasonable to assume that this is spurious and that either GPs did not accurately 
record symptom onset or women did not report it.  Most of the GP notes received were 
from computerised records, and there has been evidence to suggest that 
documentation of symptom duration is better in paper versus electronic records.121  A 
previous GP record study in the UK found that 78% of women with ovarian cancer 
consulted within one month of symptom onset, suggesting that patient delay in this 
country is small.11   
Other reasons for differences in patient delay between data sources are less clear.  As 
with symptom lead time data, it is possible that interview data contain more accurate 
dates due to the use of anchor points during elicitation.  Conversely, perhaps 
questionnaire dates were more accurate as there was a shorter period of recall time.  
While a delay of 1 month (found on questionnaire) is probably of little consequence, a 
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delay of 3 months (found on interview) may be of greater concern.  However, in the 
consideration of patient delay, it is important to allow a reasonable amount of time to 
get from symptom onset, to decision to consult, to making and executing the 
appointment (about 1-4 weeks depending on the symptom).  Once this is accounted 
for, the remaining delay could reflect women failing to recognise symptoms as being 
important and dismissing them as normal body changes.104, 107  Most women were 
symptomatic according to our definition for delay calculations (91% [Q], 99% [I], 97% 
[GP]).  The interquartile range for patient delay for self-reported data was 0-5 months 
(Q) and 0-7 months (I), thus a quarter of symptomatic cases had a patient delay longer 
than 5 or 7 months, respectively.  However, it should be noted that patient delays were 
only calculated on a proportion of symptomatic women due to missing data (see Table 
4-17).  Nevertheless, these data suggest that at least 25% of symptomatic women are 
not seeking health care within a reasonable time frame.  A survey in the UK conducted 
by Dr Foster Intelligence found that only 16% of women knew that ovarian cancer 
existed, and just 34% of women were able to name a single symptom associated with 
ovarian cancer (http://www.ovarian.org.uk/news/awareness_study.asp).  A lack of 
awareness of atypical symptoms has been linked to the risk of patient delay in other 
cancers.136  However, in ovarian cancer there are many unanswered questions, and 
the fact remains that there is still no evidence to prove that getting women to present 
earlier will save lives.  Hence, it would be prudent to carry out further research before 
promoting symptoms awareness in women, however, as already discussed in Part I 
symptoms awareness campaigns have been ongoing for some time. 
Provider delays were shorter in self-reported versus GP note data (median of 2.1, 2.7 
and 4.4 months for questionnaire, interview and GP notes, respectively).  Again, note 
that provider delays were only calculated on a proportion of symptomatic women.  GP 
notes are considered to be the most reliable data source for provider delay, and 4.4 
months is a significant length of time.  Moreover, these data indicate that 50% of 
symptomatic women had a provider delay of at least 4.4 months which is concerning.  
In addition, a quarter of symptomatic women had delays of at least 4.8 months (self-
reported) or 10.0 months (GP notes).  All three of the provider delays identified in this 
study were longer than the mean or median provider delays of ≤1 month reported in 
most of the literature,6, 14, 68, 89 although a median of 3 months for early stage disease 
was reported in one study.7  Delay calculations in this study were restricted to 
symptoms new in the 15 months prior to diagnosis.  Thus, one would expect provider 
delays to be shorter than those reported by studies without symptom timing restrictions.  
It is possible that this excess in delay is specific to the UK, since most provider delays 
have been based on studies performed in other countries.  However, Kirwan and 
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colleagues found that 73% of women were diagnosed within 3 months of first GP 
consultation in the UK.11   
Overall, the provider delays identified in this study are of concern.  Potentially, 
increasing ovarian cancer symptom awareness in GPs could help with this.  However, 
as with patient delay, if GP education is to be considered, it should be done so with the 
knowledge that there is no evidence to show that it will be beneficial.  Also, women 
may still be diagnosed with advanced disease, even if provider delays are eradicated.   
As already inferred, provider delays are comprised of mandatory phases in the 
diagnostic work-up (e.g. time taken for tests and appointments), in addition to genuine 
delays.  The sources of (genuine) provider delays are more obvious than those of 
patient delays.  The vast majority almost certainly stem from misdiagnosis and 
incorrect referral pathways, while the rest are due to delays in healthcare system and 
diagnostic testing errors.  These include waiting time for appointments or surgery and 
administrative errors (e.g. results not being reported, letters misplaced).  Diagnostic 
testing errors can arise if abdominal rather than pelvic ultrasound is performed or if the 
ultrasound examiner is not experienced enough, and possibly if CA125 levels are not 
elevated.  Patient characteristics such as co morbidities and frequency of GP visits 
could contribute to a prolonged diagnostic pathway.  Diagnostic overshadowing occurs 
when doctors misattribute symptoms to pre-existing co-morbidities. Symptoms of 
frequent attenders may be taken less seriously by GPs compared to symptoms of 
women who rarely consult.   
Uncertainty regarding the current diagnostic tools for ovarian cancer may play a role in 
provider delays.  A study in the UK found that some GPs did not feel confident ordering 
CA125 tests, urgent ultrasound and fast-track referral due to insufficient knowledge of 
the criteria required and the criticism received when referral is deemed inappropriate.85  
Physician confusion over the role of CA125 was exemplified by a UK audit which found 
that 48 out of 799 CA125 tests ordered were for male patients (in whom there is no 
specific use).137   
Women who presented to A&E before referral was made (or carried out) presumably 
had a sudden onset of severe symptom(s) or a sudden worsening of symptom(s).  Or 
else, perhaps there was some sort of miscommunication between the women and their 
GPs, which culminated in the severity of symptoms being downplayed or 
underestimated.  Importantly, the majority of women who presented to A&E had at 
least one prior visit to the GP for symptoms, which may indicate „missed opportunities‟.  
However, this is speculative and there were insufficient data to verify this.  Potentially, 
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these women had aggressive cancers which developed rapidly producing severe 
symptoms over a short period of time.  Notably, although emergency visits are usually 
associated with faster diagnosis, some women were not necessarily diagnosed as a 
(direct or indirect) result of the A&E visit, but instead followed a convoluted diagnostic 
route.   
In countries where GPs have a gate-keeping role, there is often mounting pressure on 
scarce resources.  Given that the average GP will see one case of ovarian cancer 
every five years,30 using a „targeted screening‟ approach could help by providing a 
quick assessment of women in whom there is low suspicion of disease.  This would 
remove some of the „guess-work‟ that is required early on in the diagnostic work-up, 
when GPs may be considering a number of possible and more plausible causes.  
Obviously, this would need to be accompanied by clear protocols to address issues 
such as intermediate CA125 results, and to ensure that women with disease are not 
further delayed by this process.  Also, the proportion of women without disease who 
meet testing thresholds would need to be sufficiently low to avoid overloading GPs. 
Total delay was the longest for interview data with a median of 8.4 months.  In contrast, 
median delay was approximately 5 months for both questionnaire and GP note data.  
Once again, it is not clear if this excess on interview is real or due to recall error or 
recall bias.  The combined total delay quantified the longest possible delay according to 
all of the data (although the maximum is 15 months due to the methods used).  This 
was a median of 9.8 months, which is shorter than the median (total) delay of 12 
months reported by another UK study.99  A US study also reported a median total delay 
of 12 months.7  However, these are all longer than the total delays reported in other 
countries (see Part I systematic review, median delay typically between 2-4 months).6, 8, 
13, 67, 78, 89, 112  
Time from first GP visit (for an eligible symptom) to referral was of particular interest.  
Data showed that the median interval was 1.7 months for any referral versus 2.7 
months for an „appropriate‟ referral (i.e. to gynaecology).  Thus, it appears that health 
care providers (GP and specialists) take an extra month to make an „appropriate‟ 
referral.   
Despite misdiagnosis being cited as a cause of delays in diagnosis.6-10, 12, 15-17, 19-21, 67-69, 
75, 89, 97, 99, 101, 104 the difference in median time between referral and diagnosis was less 
than 2 weeks for rapid referral G/O versus any referral (1.4 and 1.8 months, 
respectively).  Irritable bowel syndrome (IBS) and diverticular disease have been 
implicated in the misdiagnosis and delays in diagnosis of ovarian cancer.  Our findings 
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did not support this, and the proportion of cases and controls with each condition was 
similar (see Table 4-1).  Also, the proportion of cases with each condition was modest 
(<10%).  Yet, less than half of the cases were initially given a rapid referral to G/O.  
These data are somewhat conflicting, but on the whole it seems that most women with 
ovarian cancer are not appropriately referred initially, but this may only have a small 
influence on time to diagnosis. 
Delays in diagnosis are important as they have been shown to affect survival in other 
types of cancer.138  In ovarian cancer, any association between delays in diagnosis and 
survival are yet to be proven.  Crucially, our study demonstrated that delays in 
diagnosis do exist in a reasonable proportion of women.  Furthermore, these delays 
appear to be longer than those reported in other countries.  Most of the delay appears 
to be during the interval between first GP visit to diagnosis (provider delay) rather than 
between symptom onset and first GP visit (patient delay).  Reasons for this are still 
unclear.  So far social class has not been found to be a significant factor for overall 
delay in British women with ovarian cancer.139  Insufficient data exist in delays in 
diagnosis and further work is needed.  In particular, identifying which of the data 
sources provides the most accurate measure of diagnostic delay would be important, 
given the varying results from each data source. 
Symptoms in Early versus Late Stage Disease 
Detection of women while disease is in its early stages is the underlying goal of any 
ovarian cancer screening programme.  Nowadays, the existence of prediagnostic 
symptoms in early stage disease is much more widely accepted.  Almost all women 
with early stage disease reported symptoms in the present study (100% [GP], 96% [I], 
95% [Q]).  However, to date there has been little evidence to suggest that there is a 
chronological pattern to symptom development that would allow identification of women 
at early stages before they „progress‟ to late stages.  In fact in our study, the temporal 
pattern of symptoms for early versus late stage disease appeared to be extremely 
similar (see Figure 4-15 to Figure 4-17).  This is at odds with the findings of Olson et 
al.69 who found that symptom duration tended to be shorter for early versus late 
disease.   
This failure to establish a temporal symptom pattern and the lack of evidence for 
„progression‟ of symptoms has often been ascribed to women with early stages having 
biologically less aggressive disease than women with late stages, and vice versa.9, 12  
This hypothesis will be discussed further later on in this chapter. 
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The overall spectrum of symptoms was also comparable for the two groups with a few 
key exceptions.  Early stage disease was associated with more urinary symptoms, IVB, 
PMB and findings of an abdominal lump, however these failed to reach significance 
even at diagnosis for any data source.  These findings concur with previous symptom 
studies which also found that women with early stage disease tended to report more 
urinary symptoms, gynaecological symptoms68, 94, 101 and an abdominal mass.16, 68  This 
tendency for urinary symptoms to predominate in early disease could be due to tumour 
pressure effects since early stage tumours are known to be larger.12, 140   
Women with advanced stage disease reported more indigestion, loss of appetite, 
abdominal bloating, increased abdominal size, nausea/vomiting and weight loss.  
These differences were statistically significant for increased abdominal size, indigestion 
and weight loss 3 months prior to diagnosis.  These findings also correlate well with the 
literature.  Several studies have found that abdominal swelling, fatigue and 
gastrointestinal symptoms101 were cited more frequently by women with advanced 
stage disease.9, 12, 16, 68, 69  Another feature of our data that corroborates well with the 
literature, is that women with late stage disease reported a significantly greater number 
of symptoms (see Table 4-14).8, 12, 75, 104   
Systemic or constitutional symptoms (i.e. fatigue, weight loss, loss of appetite) are 
often assumed to be indicative of advanced stage disease.  While this may be a valid 
presumption for cancers in general, it does not seem to hold true for ovarian cancer.  
Several studies have shown that women with benign, borderline and early stage 
disease also experience the same systemic symptoms.6, 7, 9, 13, 67, 68, 75  In our study, 
systemic symptoms were also cited by women with early stage disease (see Figure 
4-15 to Figure 4-17). 
Potential for Using Symptoms as a Tool for ‘Early’ Detection in Ovarian Cancer 
Early detection of cancer in general is an area of growing interest due to the favourable 
relationship between early diagnosis and lower mortality rates.  The underlying 
hypothesis for using ovarian cancer symptoms as a tool for this is that acting on 
symptoms quickly will result in earlier stage diagnosis thereby reducing avoidable 
deaths and improving mortality.  Although this hypothesis is a long way from being 
proven, the current study has shown that ovarian cancer clearly elicits symptoms in the 
months before diagnosis, even in early stage disease.  The majority of these symptoms 
first appeared within 3 months of diagnosis, however in a small proportion of women; 
symptoms were detectable as much as 12-14 months before diagnosis.  
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Much emphasis has been placed upon the tendency for ovarian cancer symptoms to 
be persistent.69, 75, 99  This apparent persistence is irrelevant in the approach proposed 
in this thesis, as testing would be offered the first time a woman presents with a 
symptom(s).  However, one may wish to set a minimum duration for any potential 
symptoms screening tool.   
Since ovarian cancer is relatively rare, and the downstream consequences of a positive 
screening test are serious, it has been suggested that a screening test (leading to 
surgery) for ovarian cancer needs to have a specificity of at least 99.6% to be 
acceptable.51  More recently, positive screening may be managed by repeat screening 
or further non-invasive testing, so the specificity needs to be balanced against the 
consequences of a false positive at each „testing‟ stage.  The situation with ovarian 
cancer is also complicated by the possibility that the inherent biology of the disease 
may be such that some aggressive tumours develop so rapidly that „early‟ detection is 
not viable.66  Hence, slow growing tumours may have a bigger window of opportunity 
for detection.  This concept challenges the notion that temporally early detection and 
treatment of cancer is always associated with a favourable outcome.  However, this 
may only be an issue for a minority of cases and there still could be a sizeable 
proportion of women in whom diagnosis could be expedited.  As mentioned earlier, 
symptoms that started within 3 months of diagnosis are unlikely to provide any valuable 
lead time since much of this period is already needed for referral to diagnosis.   
Unfortunately, there are two critical unknowns in the oncogenesis pathway for ovarian 
cancer.  The first is the length of time between the onset of malignancy to the 
appearance of symptoms.  The second is the period of advancement required to alter 
the natural history of disease.  There are virtually no data on the growth rate of ovarian 
cancer tumours, however hysterectomy studies have shown that disease can develop 
in as little as one year.141  Optimal surgical cytoreduction (i.e. <1 cm residual disease) 
is one of the most significant prognostic factors in ovarian cancer.142-144  The probability 
of attaining optimal surgical cytoreduction can be thought of as a function of time, the 
details of which are currently unknown.  It is possible that even a short (actual) 
symptom lead time of 1-2 months could be critical.  Clearly, this is speculative and 
further research is required to prove this.  Nevertheless, these short gains in lead time 
may be worthwhile pursuing if there is potential for psychological and physiological 
benefit, providing the „harm versus help‟ issue is addressed.   
Positive predictive value (PPV) of symptoms was not calculated since accurate 
computation requires data on the prevalence of women aged ≥45 with occult ovarian 
cancer in the general population, and the proportion of such women who have 
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symptoms.  These data are currently unknown.  Estimates should be available from the 
UKCTOCS study in the future.  It is worth noting that in previous studies, PPV has 
been calculated based on the assumption that symptom sensitivity is constant before 
diagnosis.  However, prediagnostic symptom sensitivity (and therefore PPV) is likely to 
fluctuate over time, with greater sensitivity expected closer to diagnosis.  This was 
demonstrated by the change in OR of symptoms at different prediagnostic periods.  
Questionnaire sensitivity (i.e. cases) for bloating at diagnosis was 71%, but only 30% 
3-14 months before diagnosis.  Therefore, any future PPV calculations should take this 
into account.   
The concept of using symptom recognition as the first step in a multi-step screening 
programme is not new.  A UK group performed a pilot study in primary care practices in 
East London to investigate the feasibility of implementing a „targeted screening‟ 
programme.111  However, GP compliance was hugely variable, and no cases of ovarian 
cancer were identified.  Hence, strong conclusions regarding the potential effectiveness 
of „targeted screening‟ could not be drawn.  Since the initiation of this thesis, Goff et 
al.108 have taken this to the next level by developing a symptoms index.   
The symptoms index developed by the Goff group aims to discriminate between 
women with undiagnosed ovarian cancer and healthy women.108  The index was 
evaluated retrospectively on a set of cases and controls (high risk women participating 
in a screening study), working with the assumption that women with a positive index 
would be sent for CA125 testing and TVS.103  Using this approach, they hoped to be 
able to identify women at the primary care level who do not have elevated CA125 but 
might benefit from immediate TVS.  This strategy removes the disadvantage of the low 
sensitivity of CA125 which is just 50% for stage I cancers,145 but the lack of specificity 
of TVS could be a major issue.63  The authors found that half (11%) of the cases who 
did not test positive for CA125 tested positive for the index.  For the index in 
combination with CA125 as a first-line test, there were 53% of cases who were positive 
for both.  Sensitivity for early stage disease was relatively high for the index and CA125 
combined with 81% of cases testing positive for at least one of the index or CA125.  
The corresponding proportion of women with late stage disease was 95%.  While these 
figures are promising, specificity could be a problem since 17% (combined tests) and 
12% (index) of their control group also tested positive.  Importantly, timing of symptoms 
was not taken into account in these results. 
Application of the Goff index to our data produced strikingly similar results to those 
reported by the group.  Notably, our symptoms survey did not specifically ask about 
difficulty eating or feeling full quickly, which may explain some of the lower sensitivity 
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observed in comparison to Goff‟s findings.  Also, the frequency of 16-31 days per 
month was applied to our data instead of >12 times per month.  Otherwise our data 
were largely comparable.  Critically, there was a large reduction in sensitivity for 
symptoms reported at anytime versus symptoms restricted to 3-14 months (1 year) 
before diagnosis.  Sensitivity was reduced to just 27% for women aged ≥50 on 
questionnaire data.  Again, this highlights the importance of accounting for timing of 
symptoms when developing a symptoms index. 
The sensitivity and specificity of the secondary test is critical for any potential 
symptoms-based diagnostic tool.  Currently, this would be a CA125 test and/or a 
transvaginal ultrasound (TVS), however in the future there may be a better test.  
Recent data suggest that the specificity of TVS would be too low for this purpose.63  
Perhaps a better approach would be to use both symptoms and CA125 as a first line 
test.  If CA125 results are intermediate, a follow up test with TVS and/or repeat CA125 
could be done, after 12 weeks.  The risk of Ovarian Cancer (ROC) algorithm that is 
employed in UKCTOCS could also be tied in with the serial CA125 testing.  Obviously 
the acceptability and feasibility of such a proposal would need to be fully assessed.  
Results from an unpublished study indicate that much work would need to be done to 
get GPs on board with such an approach (Megan Goldsmith et al., Primary Care Group 
Oxford, unpublished data). 
Potential for ‘Targeted Screening’ 
„Targeted screening‟ would be more akin to routine referral in that the index of 
suspicion would be substantially less than that required for rapid referral (due to the low 
predictive value of symptoms).  For most symptoms, the duration would need to be 
long enough for women to consider making a GP appointment (e.g. loss of appetite for 
one day is unlikely prompt health-seeking behaviour).  Once the woman has presented 
to the GP, the decision as to whether testing would be offered immediately or whether 
it would be more sensible to „watch and wait‟ would probably be at GP discretion.  Any 
„targeted screening‟ programme would probably require 1-2 weeks to acquire the blood 
sample and process results.  After allowing for these factors, one would need to allow a 
minimum of 2-3 months from symptom onset to diagnosis for „targeted screening‟.   
In order for „targeted screening‟ to be useful, there are several important factors to 
consider.  Firstly, if population screening is unable to offer any mortality benefit, it is 
extremely unlikely (if not impossible) that symptoms will have an impact on mortality.  
The efficacy of population screening for ovarian cancer is still unknown (results are 
awaited from the UKCTOCS study due in 2015).  Currently, population ovarian 
screening in postmenopausal women is thought to provide about 1.9 years of mean 
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lead time.146  Results from the present study indicate that the longest (diagnostic) lead 
time given by symptoms is 14 months (or 12 months actual lead time), but only in a 
minority of women.  Data from Index 2 suggest that 45%-74% of women would have a 
diagnostic lead time of at least 3 months.  Secondly, even if population screening is 
shown to favourably impact survival, the amount of lead time required to achieve this 
remains unknown.  It may be that less than 1.9 years is required to see a stage shift.  If 
the requisite length of time was say, 6-9 months, there is a possibility that „targeted 
screening‟ would still have a competitive impact.  Also, some of the 1.9 years might be 
due to „overdiagnosis‟ of indolent cancers by population screening.  In addition, if the 
time to get from a first-line test to diagnosis (in population screening) takes several 
months, the estimated lead time would be shorter than 1.9 years.  Thirdly, the 
proportion of women with symptoms that would have a positive screening test is 
unknown (assuming screening test is CA125 and/or TVS).  Under the present 
circumstances, if women with symptoms do not test positively with CA125 and/or TVS, 
„targeted screening‟ would be futile.  Currently, the relationship between CA125 levels 
and symptoms is poorly defined, and marked variability was found in a small set of 
case studies.147  Finally, if the cost-benefit ratio was more favourable for „targeted 
screening‟ than population screening, „targeted screening‟ may be the more viable 
option.   
Comparison of the Data Sources 
At the study outset, the duration of telephone interviews, symptom data quality and 
response-rate to GP note request and interview were unknown.  In addition, this study 
aimed to collect a large volume of complex data from a difficult patient group.  Thus, it 
was anticipated that several aspects would change as the study evolved.  The decision 
as to what proportion of each of the 3 data sources would be obtained for each subject 
was altered as the study progressed based on feasibility, experience and response-
rates.   
Perceived benefits of using three modalities to collect the same data were as follows.  
The main advantage of the questionnaire was that it allowed for baseline symptom data 
to be obtained rapidly from all women in the study.  This was prudent given the 
difficulties in studying acutely unwell women with high mortality.  It was anticipated that 
symptom data would be complex to collect and would require clarification.  Telephone 
interviews provided an opportunity to explore symptoms in greater detail by probing for 
additional information and to detect subtleties which were likely to be excluded from a 
paper questionnaire.  This was important since a previous study had shown that 
symptom reporting can vary depending on semantic interpretation and the women‟s 
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perception of symptom aetiology.94, 99  Interviews also have the advantage of having a 
motivating effect on the respondent, by providing full, clear definitions and provide the 
opportunity for probing ambiguous responses, or querying inconsistent answers.  GP 
notes have the crucial advantage of providing objective data for symptoms and 
symptom lead time without recall bias.  Of the three data sources, GP notes were 
viewed as providing the most robust data on lead time.  As such, questionnaire and 
interview data are generally viewed as being more sensitive but less specific than GP 
note data.   
As outlined in Chapter 2, there are various types of bias and errors inherently 
associated with each data source.  For self-reported data the main types are recall bias 
and recall error.  For GP note data, these are recording bias and recording error.  
Differences between the data sources were not formally analysed, however there were 
some clear distinctions.   
Self-reported data were fairly comparable in terms of sensitivity for symptoms that were 
specified on the checklist, however spontaneously reported symptoms were 
volunteered more readily on interview.  This could be due to the questionnaire format 
which may have been inadequately designed to capture such complex data, especially 
given that it was nested within a larger questionnaire with other demanding questions 
(e.g. “what was your skirt size in your early twenties?”).  Also, asking women about 
specific symptoms is different from asking women to spontaneously report symptoms.  
This was exemplified on interview by the observation that only women who were 
specifically asked about night sweats reported them.   
Symptom reporting was higher on interview than questionnaire for both cases and 
controls.  Also, most women who reported having no symptoms on questionnaire, 
subsequently reported symptoms on interview or in GP notes.  Recall bias (on 
interview) is an unlikely explanation since symptoms were often recorded in GP notes.  
These discrepancies may reflect semantic issues or recall error.  They could be related 
to women not perceiving the symptoms as being associated with cancer, as highlighted 
by previous studies.17, 107  During the interview, women were reminded that symptoms 
should be reported regardless of any perceived causes, whereas for questionnaire it is 
unclear how frequently this was done, if at all.  Perhaps the timing of administration 
played a role.  Cases were recruited at a stressful time when there would have been a 
constant barrage of forms to sign and motivation may have been low.  Likewise, 
controls were recruited in busy clinics and may have rushed to complete their 
questionnaires.  In contrast, interviews were performed in a quieter environment with 
fewer distractions (subjects were usually at home) and there was an opportunity to 
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probe and discuss symptoms more freely.  On interview, loss of appetite was asked as 
„loss of appetite or feeling full quickly‟.  These two symptoms are distinct and should 
not have been combined, but unfortunately this error was only noticed later on in the 
study.  Nonetheless, this oversight did not appear to have any major effect on the data.  
The magnitude of difference in incidence for loss of appetite between questionnaire 
and interview was comparable to those observed for other symptoms. 
Overall, controls reported a relatively constant rate of new symptoms.  However, there 
was some tendency for increased symptom reporting closer to the reference date (see 
Figure 4-3).  As expected, this was not observed in the GP note data.  A possible 
explanation is „forward telescoping‟, a phenomenon in which subjects have no clear 
date or event to bind their recall.148  As a consequence, remote events (outside of the 
reference period) tend to be brought forward in time and are reported as occurring 
more recently.  The risk of telescoping is known to increase in proportion to the length 
of time subjects are asked to recall over116 and 12 months is a fairly long period of time.   
Another disparity between questionnaire and interview results was for severity rating.  
On interview, symptoms were generally reported as less severe.  Perhaps, asking 
details for when the symptom first started may have been too difficult or detailed to 
extract on a questionnaire format.  However, this trend was not observed for frequency 
data. 
One of the largest differences in symptom reporting was observed in control women.  
Controls reported considerably more symptoms on interview than questionnaire (see 
Figure 4-7 and Figure 4-8).  This could be due to under-reporting on the questionnaire 
or over-reporting on interview.  Alternatively, this may be explained by qualitative 
symptom properties.   
Although this is an epidemiological study focussed on quantitative endpoints, there 
were various qualitative issues that were highlighted via the interview process.  These 
issues shed light on some of the difficulties in obtaining symptom data such as the 
inability of the chosen symptom measures to accommodate for the variable nature of 
the symptoms investigated, and may in part explain some of the missing data.  
Specifically, when symptoms occur in extremely variable patterns it is confusing to try 
and assign frequency in „days per month‟.  For example, a woman may have an acute 
episode of abdominal pain that lasts for one day, followed by several pain-free months, 
and then have the pain again lasting for several weeks.  In these situations the 
symptom onset date and ongoing status also become confusing to identify.   
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Symptoms that were activity-dependent were also problematic as they vary with the 
amount or type of activity.  This often occurred with fatigue, indigestion and back pain.  
Hence, onset dates, frequency and severity are difficult to assign for activity-dependent 
symptoms.  Indigestion, bloating, fatigue, constipation, back pain and urinary 
frequency/urgency were reported in particularly higher proportions during interview, 
especially for controls.  Anecdotally, this seemed to be due to a reluctance (cases and 
controls) to report symptoms that were mild, transient, activity-dependent, longstanding 
or perceived as being „normal‟ for their age.  All of these symptoms were recorded on 
interview but may have been omitted from the questionnaire since women often did not 
think they were relevant when any of the aforementioned vague features were present.   
Some women (particularly controls) were reluctant to report symptoms on interview for 
which they had already assigned a cause.  One control attributed urinary frequency 
and fatigue to ageing and said “all my friends have the same changes”.  Another 
control reported fatigue then added “but it‟s normal for my age”.  Likewise, there 
seemed to be an unwillingness to report symptoms that were diet-related since onset 
was typically sporadic and causes were „known‟.  These findings echoed the reports of 
Bankhead et al.99 who found that mislabelling and misinterpretation of symptoms can 
affect symptom measures.   
Related to this, is the issue with symptom definition and how this can vary between 
clinical definitions, what is normal for the patient, and what is perceived by the patient.  
For example, most women on interview considered constipation to mean having less 
than daily bowel motions.  The term „increase in abdominal size‟ was chosen over 
„abdominal swelling‟ and „abdominal distension‟ since previous research has shown 
that most women have a poor understanding of the latter terms.94  However, during 
interview it became apparent that „increase in abdominal size‟ was reported if a woman 
felt that she had gained weight, particularly with controls.  Abdominal distension in 
women with ovarian cancer is often associated with weight gain due to collection of 
ascitic fluid; however this is clearly clinically distinct from weight gain due to increased 
body mass.  As a corollary, increased abdominal size may be over-reported by controls 
in self-reported data, and is unlikely to represent true abdominal distension.  Indeed, 
50% (17/34) of controls who reported increased abdominal size also reported weight 
gain on interview, compared to just 10% (11/115) of cases.  This is also reflected by 
the low incidence of increased abdominal size in GP notes.  All of these factors can 
contribute to variable responses in self-reported symptom data and should be taken 
into consideration in any further studies involving collecting symptom data directly from 
women.   
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GP note data are distinctive in several important ways.  Recording of symptoms in GP 
notes are diagnosis-driven24 and therefore may not accurately reflect the full spectrum 
of symptoms experienced by women (reflecting recording bias).  As such, symptom 
sensitivity was expected to be lower compared with self-reported data.  This was 
typically around the magnitude of 10-40%.  Despite this, GP notes are still considered 
to be the „hardest‟ and least (recall) biased data.  Another advantage of the GP notes 
collected for the study was that records were from various geographical regions.  This 
eliminated any potential recording bias arising from using any one particular surgery or 
region.  In addition to recording bias, women have been found to selectively report 
symptoms to GPs,94 which may also contribute to lower symptom sensitivity in GP 
notes.  Finally, GP note data do not contain accurate symptom duration data, therefore 
some of the symptoms included as incident symptoms in our study may have in fact 
been prevalent or longstanding.   
Overall, the symptoms recorded in the GP notes for cases were encouragingly similar 
to those recorded on self-reported data (see Table 4-8, Table 4-9, Table 4-10).  Any 
disparities observed were mainly for symptoms that were not specifically listed on the 
questionnaire/interview checklist (such as vaginal discharge, other urinary symptoms 
etc.).  One of the key expected differences between GP notes and self-reported data 
was that the latter would detect symptoms that are not reported to the GP.  The four 
most sensitive symptoms according to self-reported data were increased abdominal 
size, pelvic/abdominal pain or discomfort, abdominal bloating, and fatigue.  Conversely, 
on GP notes the latter two were replaced by „urinary other‟ and nausea/vomiting, both 
of which were reported in negligible amounts on self-reported sources.  However, 
nausea or vomiting ceased to feature in the top four most common symptoms once 
symptoms were restricted to those present over 3-14 months before diagnosis.  This 
incongruence could reflect real differences in what symptoms women report to their 
GP.   
Alternatively, some of the symptoms recorded in the GP notes may reflect signs as 
opposed to symptoms for which a woman sought medical advice.  For example, a lump 
in the abdomen that was palpated by the GP on examination but was not noticed by 
the woman.  There was no real desire to distinguish between the two in the present 
study, however this could have contributed to differences in symptom frequency 
between GP notes and self-reported data.   
Urinary symptoms featured consistently more prominently in cases and controls, on GP 
notes in comparison to self-reported data.  „Urinary other‟ comprised a group of 
symptoms that were not necessarily related (i.e. dysuria, incontinence, haematuria, 
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retention, poor stream, changes in urine colour or smell).  The comparatively lower 
reporting of „urinary other‟ symptoms on self-reported data is probably because they 
were not specifically asked for in the survey.  However, this does not explain the case-
control differences observed.  Moreover, urinary frequency or urgency were specifically 
asked for on self-reported data, and they were also recorded noticeably more often on 
GP notes.  Further research is required to elucidate the reasons for this discrepancy in 
urinary symptom reporting between data sources. 
Severity & Frequency 
Severity and frequency are not necessarily independent.  One would expect that as 
frequency increases, perceived severity also increases.  Information regarding severity 
and frequency of symptoms may only be useful if they can be used as a discriminatory 
tool in a symptoms index.  Both parameters are expected to vary with disease 
progression and possibly activity, so ratings were requested for when the symptom first 
started.  The two studies which have examined severity and frequency did not set any 
rating criteria.69, 75  In the absence of any instructions for the timing of when severity 
and frequency should be rated, a reasonable assumption would be that ratings are 
given arbitrarily or with a bias towards the most extreme.   
The trend towards lower severity ratings on interview could indicate that women did not 
follow or read this timing instruction (i.e. severity/frequency when symptoms first 
started) on questionnaire.  Women who reported severe and more frequent symptoms 
were more likely to be cases, as were women who had symptoms that worsened over 
time.  In contrast, women who reported symptoms that stayed the same over time were 
more likely to be controls.   
Further analyses are planned to address severity and frequency more formally.  Given 
the propensity for severity and frequency to change over time, there may be potential 
to incorporate increases in severity and/or frequency (i.e. worsening) into a decision 
rule.  For example, if CA125 results are subthreshold one might decide to repeat 
CA125 in 12 weeks if symptoms are worsening, conversely a „watch and wait‟ 
approach may be more appropriate if symptoms are the same or better. 
Missing Data 
Missing data were probably attributable to several factors.  Symptoms can be difficult to 
accurately recall, especially if they are acute and sporadic.  Women may have been 
simply unable to recall start dates or symptom characteristics (especially if they started 
a long time ago).  As mentioned above, when symptoms occur in variable patterns (e.g. 
once every 3-5 months for 1 week) it can be difficult to identify when the symptom 
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started and to assign frequency.  Severity is also challenging to assess if there is 
variation over time.  Control questionnaire data quality appeared to be lower than that 
of the cases and contained more missing data.  This may have been attributable to a 
lack of motivation, since one would expect cases to have more of a vested interest in 
contributing to the research and having their symptoms analysed.   
Study Advantages 
Previous studies have used either medical records or self-reported (symptom 
checklists or open-ended questions) to obtain symptom data.  This is the first study we 
are aware of that has used three different sources to collect the same data.  The 
advantage of this approach was that the low sensitivity of medical records could be 
balanced by the low specificity of self-reported data.  In order to truly maximise on this, 
a combined analysis is required.  Given that the data sources vary with regard to 
several different aspects, a complex algorithm needs to be devised, and this is 
currently planned for a future analysis. 
One of the key advantages to this study was the novel approach of using continuation 
odds ratios to examine symptom incidence over the period leading up to diagnosis.  
Most studies have collected data retrospectively, and in their interpretation of results 
they have failed to account for the way in which symptoms develop when they occur 
prospectively in real time.  As demonstrated in this study, much of what is observed at 
diagnosis (in terms of symptom severity, frequency and incidence) may dramatically 
differ in the preceding months.  
Also, the systematic accrual of newly diagnosed cases in participating hospitals meant 
that women consented to participate without regardless of symptom history.  As a 
corollary, we expect less selection bias.  Likewise, controls were consecutively 
recruited at attendance for annual screening, and were not selected based on 
symptoms. 
Study Limitations 
Possible limitations of this study include that the control group were derived from a 
screening study.  Screening studies are known to favour subjects who tend to be 
healthier and of higher sociodemographic background than the general population.  
Furthermore, UKCTOCS-enrolled women who have significant symptoms or who are 
unwell may further self-select by choosing not to attend screening.  This would not 
affect the main UKOPS study biological endpoints, however this could affect symptom 
data collection.  The potential for self-selection bias is one of the reasons why the GP 
workload study was undertaken (Part III).  The analysis of GP notes from an 
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unselected population should highlight any effects of self-selection on the symptom 
specificity observed in the present study.  There may have been some bias against 
women with particularly advanced disease since these women may have felt too unwell 
to participate.  Indeed, the study had quite a large proportion of women with early stage 
disease (40%).  Unfortunately, information on what proportion of women with ovarian 
cancer were not approached or refused to participate at each centre was not available.   
The fact that we treated symptoms with missing onset dates as if they were 
longstanding symptoms would have underestimated symptom sensitivity for cases, but 
it was felt that this conservative approach was better. 
Another potential drawback is that cases and controls came from slightly different age 
groups and have different menopausal status.  Cases were a mix of pre-, peri- and 
post- menopausal women aged 45 and above, whereas controls were all post-
menopausal, aged 50-74 at UKCTOCS entry (i.e. a maximum of 81 years in our study 
since UKCTOCS started 7 years before UKOPS).  However, 88% of cases were aged 
50 and above.  Possible implications of this are that symptom sensitivity and odds 
ratios may be inaccurate for symptoms that are common (or rare) in the peri-
menopause or due to menses.  Some of the main differences would be expected in 
vaginal bleeding symptoms, however these are not highly reported by women with 
ovarian cancer.  In addition, the proportion of women with IVB or PMB in our study was 
very similar to those reported by previous studies.  Similarly, the inclusion of cases 
aged over 74 (despite having limited controls in this age group [16%]) in the final 
analysis was justified by the fact that their symptom profiles were comparable to those 
in the original target age group of 45-74.   
The fact that all of the interviews and the data extraction from GP notes were 
performed by the same person who was not blinded to case-control status could have 
introduced some bias.  However, all symptoms were extracted using a systematic 
coding frame and a standardised interview script were used to try to minimise any such 
bias.  Equally, the questionnaire was administered by different nurses at each centre 
and each nurse may have influenced questionnaire completion differently, or offered 
varying levels of help.  At some centres, the nurse always completed the questionnaire 
with the women.  Certainly, there were less missing data from these centres.  Also, in 
retrospect, the questionnaire design was too complicated for the context of this study.  
For example, symptom duration was meant to be captured by the question „how long 
have you had this?‟  During the data cleaning process it was clear that many women 
had recorded this incorrectly since duration did not match up with the start dates 
reported and time of questionnaire completion.  In the data cleaning process, duration 
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was recalculated based on the symptom onset date.  Questions requiring the subject to 
perform arithmetic (such as duration) should have been avoided.   
In development of the symptom indices, incidentally-diagnosed women were included 
since excluding them would unduly make the indices appear more favourable.  Screen-
detected women were also included since their self-reported symptom profiles 
appeared to be similar to women who were detected via symptoms.  However, in 
retrospect it would have been more appropriate to exclude screen-detected women as 
any length of symptom duration would be censored by the screening.   
A further possible criticism is that questionnaire was not validated, which gives rise to 
uncertainty over whether the questionnaire detected what it was designed to detect.  
However, the results indicated that there was much internal validity.  The evidence for 
this included: 
 No case-control differences were observed for any symptom beyond 15 months 
prior to reference date suggesting that recall bias (if present) is limited to the first 15 
months). 
 Control symptoms over time were uniform suggesting that there is no increase in 
recall error in controls (although minor increases were observed close to date of 
consent). 
 Odds ratios close to diagnosis were extremely large (i.e. OR>20), showing that the 
questionnaire was able to identify features that are present in the weeks preceding 
diagnosis of ovarian cancer. 
 Case-control comparisons for unrelated symptoms were similar suggesting that the 
survey was distinguishing ovarian cancer symptoms from other symptoms. 
 Symptoms recorded in GP notes were similar to self-reported data also suggesting 
that the survey was detecting ovarian cancer symptoms. 
Collectively, these provide confidence to assume that the findings were real, despite 
use of an unvalidated questionnaire. 
Many assumptions had to be made when databasing and cleaning the data, hence 
databasing rules were devised to ensure consistency.  In general, these rules favoured 
a conservative approach which underestimated case-control differences.  For example, 
symptoms that had missing onset dates were treated as longstanding symptoms and 
therefore were not included in odds ratios and symptom sensitivity.  Also, the sensitivity 
of 1 year‟s worth of symptom incidence was examined with the 3 months prior to 
diagnosis excluded.  One of the potentially controversial databasing rules was to 
assume that symptoms were ongoing if ongoing status was missing.  However, our 
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approach was not dependent on symptom duration, but rather on the first time the 
symptom appeared.   
Due to poor recruitment, several women who did not meet the original eligibility criteria 
were included.  A restricted analysis excluding these women was performed, leaving 
155 cases and 244 controls (see 3.3.11 Data Analysis).  Results did not imply that the 
inclusion of the “ineligible” women had any dramatic effects on the study outcomes.  
According to the questionnaire, crude ORs (95%CI) for abdominal/pelvic pain or 
discomfort 3-14 months before diagnosis were 12.8 (5.4, 30.2) in the restricted analysis 
versus 11.5 (5.4, 24.5) in the main analysis.  On interview, abdominal/pelvic pain or 
discomfort at diagnosis was cited by 54% (95% CI: 41, 67) versus 63% (95% CI: 54, 
71) of cases for the restricted and main analysis, respectively.   
5.2 Conclusions 
Until a viable screening tool is identified, symptoms remain the most common 
diagnostic route for ovarian cancer.  The present study has shown that the diagnostic 
process could be initiated at least 3 months earlier than the current date of diagnosis, 
in 45% (GP notes) to 74% (interview) of cases.  However, it is unrealistic to assume 
that diagnosis could be bought forward by the full amount of symptom lead time since 
testing, referral and histological confirmation (i.e. final diagnosis) requires several 
weeks.  Given that between 22% (GP notes) to 26% (interview) of healthy women 
would also require testing in one year, it would not be reasonable to refer any woman 
with an Index symptom for urgent assessment.  Nevertheless, after allowing 2 months 
for referral to diagnosis, 26% (GP notes) to 56% (interview) of cases would still have 
their actual diagnosis bought forward by at least 3 months.  Since residual disease is a 
strong predictor of survival, this small window of opportunity could potentially have an 
impact.   
Problem GP visits in cases start to increase about 6 months prior to diagnosis 
providing further evidence that there is potential to bring forward diagnosis.  Symptoms 
associated with ovarian cancer appear to develop within 15 months of diagnosis.  It 
may be important to exclude symptoms which started earlier than this in any future 
study of symptoms in women with ovarian cancer. 
It is crucial to take the timing of symptoms into account when assessing any potential 
symptoms-based diagnostic tool or performing studies on symptoms.  Symptom 
incidence for cases decreases with increasing time before diagnosis.  Even from as 
little as 3 months prior to diagnosis, large reductions in symptom incidence were 
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observed.  Other symptom characteristics such as frequency and severity are also 
likely to increase over time in cases.   
Methods of symptom data elicitation are important determinants of symptom reporting.  
Further analysis to combine the data from each of the three data sources will help to 
elucidate these differences. 
Abdominal and gastrointestinal symptoms were commonly cited by cases which may 
explain the convoluted diagnostic routes observed, with less than 50% of women being 
initially referred to rapid referral gynaecological-oncology.  However, referral type did 
not seem to translate into a delay in diagnosis.   
Crucially, a worrying proportion (approximately 25%) of symptomatic women had 
patient and provider delays of longer than 4 months (Table 4-17).  There are many 
unanswered questions relating to increasing symptoms awareness and its 
repercussions (negative and positive).  Ideally, further research should be carried out 
before promoting symptoms awareness in women or GPs.   
The total and provider delays identified in this study were slightly longer than most that 
have been reported in the literature, despite using methods that would tend to favour 
shorter delays.  This could indicate that delays in the UK are longer, which would be 
consistent with what some researchers have suspected to be the cause of the poorer 
survival rates observed in comparison to other European countries.  However, given 
the variation in delays with each data source, and in the literature, further research is 
needed to confirm this. 
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PART III: PUBLIC HEALTH IMPLICATIONS 
Part III will explore the potential impact of „targeted‟ ovarian cancer screening on public 
health resources.  This includes a pilot study using electronic patient records to 
estimate the GP workload associated with offering „targeted screening‟, and a general 
discussion on the findings of this thesis, ending with suggested future directions. 
 
  
203 
6 CHAPTER 6: Primary Care Workload: Implications of 
‘Targeted’ Ovarian Cancer Screening 
6.1 Introduction 
This was a pilot study designed to provide a crude extrapolation of the general 
practitioner (GP) workload associated with offering „targeted‟ ovarian cancer screening.  
Consideration of workload impact is crucial given the pressure on primary care 
clinics.149  In particular, we wished to estimate the proportion of women who would be 
offered „targeted screening‟ over the course of 1 year.  In order to do this, the 
proportion of women aged 45-74 presenting to primary care in one week who reported 
vague symptoms possibly related to ovarian cancer was used to estimate the 
proportion who would present in one year.  This study also provided the opportunity to 
gain perspective on the case-control data from the previous section, given that the 
controls were from a screening study, and a „healthy volunteer effect‟ (i.e. women who 
volunteer for screening studies tend to be healthier on average with a better chance of 
survival) was anticipated.   
The most sensible approach for collecting the requisite data was via an „audit-type‟ 
study examining GP medical records.  Most GP practices in the UK have switched from 
handwritten to electronic patient records (EPR).  By using practices with EPR systems 
in place, it was possible to obtain large amounts of data rapidly with a simple 
download.  Anonymous individual-level records of women aged 45-74 consulting during 
a single week were extracted from two urban and two non-urban GP practices based in 
London, Newbury, Bracknell and Wokingham.   
6.2 Aims 
6.2.1 Primary Objective 
 To determine the proportion of women aged 45-74 and 55-74 years, 
presenting to primary care clinics with vague symptoms common to ovarian 
cancer in one week. 
6.2.2 Secondary Objectives 
 To identify the proportion of symptom(s) that: 
o Can be attributed a priori to any particular disease or condition. 
o Cannot be attributed a priori to any particular disease or condition  
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 To estimate the age-specific incidence of all vague ovarian cancer 
symptoms and of unattributable vague ovarian cancer symptoms 
6.3 Methods 
6.3.1 Study Population 
Inclusion Criteria  
 Women aged 45-74 years presenting to primary care during the study period (one 
week) 
 Permanently registered patients  
Exclusion Criteria 
 History of ovarian cancer 
 Women receiving active treatment for other cancers (except for hormonal treatment 
only) 
Restriction to postmenopausal women was desirable; however menopausal status is 
not routinely documented in GP notes so this was not possible.  Ascertainment of 
menopausal status requires specific information such as length of time since last 
menstrual period, luteinising hormone levels, length of hormone replacement therapy 
(HRT) treatment and previous hysterectomy.  Since the average age of menopause is 
50;150 the range of 45-74 years was applied.  The upper age limit was in put place 
because it is unlikely that „screening‟ would be offered to women older than 74.  Only 
permanently registered patients were included since testing is unlikely to be offered to 
women who are difficult to follow-up.   
Initially, history of bilateral oophorectomy was also an exclusion criterion however this 
had to be dropped due to its poor and often contradictory documentation in the notes 
(e.g. some women had a unilateral oophorectomy recorded years after the date of a 
bilateral oophorectomy). 
6.3.2 Selection of GP Practices 
GP surgeries were selected based on list size, EPR system and location.  Each GP 
surgery had to meet the following criteria: 
 List size of at least 5500 
 EMIS LV (see details below) EPR system in place for more than one year 
with no handwritten notes.   
 At least one female GP 
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 No unusual demographic composition 
The threshold for list size was based on the average of 5891 patients for England set 
by the 2004 General Medical Services contract.151  Although several EPR systems are 
available in the UK; EMIS (Egton Medical Information Systems) LV was chosen, 
primarily because of its use in the Clinical Effectiveness Group (CEG) at Queen Mary 
University (QMUL).  The CEG provided access and support which were critical for 
developing the search strategy.  In addition, EMIS is the most common EPR in primary 
care with around 55% of GPs using it daily.152  There are three different versions 
available including EMIS Primary Care System (PCS), EMIS Limited Version (LV) and 
EMIS Web.  The requirement for at least one year of EMIS-use was applied in attempt 
to gain high quality data since EPR data quality is likely to vary with the user-
friendliness of each software package and the skill of individual users.  The exclusion 
of handwritten notes was to obviate the need to decipher handwriting and manually 
anonymise data.  At least one female GP was required at each practice in case women 
are reluctant to report gynaecological symptoms to male GPs, or pelvic vaginal 
examinations are less likely to be performed by male GPs.  Surgeries with unusual 
demographic compositions (such as a disproportionate number of young women) were 
excluded in order to gain a representative sample. 
6.3.3 Study Design 
A cross-sectional analysis of GP notes was performed at the following practices: 
 Chrisp Street Practice – an urban surgery in London (week examined 29.10.07 to 
05.11.07) 
 Northcroft Surgery – an urban surgery in Newbury (week examined 15.05.08 to 
22.05.08) 
 Woosehill Surgery – a non-urban surgery in Wokingham (week examined 15.05.08 
to 22.05.08) 
 Boundary House Surgery – a non-urban surgery in Bracknell (week examined 
25.06.08 – 07.07.08) 
As mentioned above, an electronic search was performed at each practice.  The 
search strategy was developed and tested with dummy patient data using the „EMIS 
Aspects‟ search function at the CEG.  Piloting of the search strategy and the EMIS 
anonymiser (an executable program specially written at the Wolfson Institute to 
anonymise the data) was performed at Chrisp Street practice.  After the first successful 
download, the data were cleaned and extracted, and a brief analysis was performed to 
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ensure that the main study endpoints were achievable before the remaining downloads 
were performed.   
The week examined preceded the date of data download by one day in order to allow 
time for data entry for visits outside of the surgery.  This produced a more complete 
dataset.  There was no requirement for the download to occur during the same week in 
each practice.  The main steps in the data collection process involved: 
1) Defining the search population – i.e. women aged 45 to 74 who visited between the 
census dates. 
2) Using the EMIS patient summary function to create a text file containing the 
relevant (non-anonymous) information.   
3) Saving the patient summary file to the computer desktop. 
4) Running the EMIS anonymiser – this produced three comma separated (csv) files 
which contained the anonymised data linked by unique patient identification 
numbers. 
The anonymous csv data files were then taken from the surgery to be cleaned and 
analysed.   
The patient summary function produces standardised content with options to add extra 
information.  For the present study, additional data on the last 10 „consultations‟ 
(including visits in the census period), significant past and active events/diseases (i.e. 
medical history), and ethnicity were requested.  „Consultations‟ in EMIS LV includes 
events that are not actual consultations such as letters (incoming and outgoing), and 
lab results.  Therefore, each dataset required cleaning to obtain the true proportion of 
women with a consultation in the census week.  Consultation data contained details of 
visit dates, symptoms (free text and coded), tests, prescriptions, and referrals.  By 
looking at the last 10 „consultations‟ before the date of download, information on 
symptom development was gleaned.   
Consultations for this study were defined as surgery visits, home visits and telephone 
calls with a GP or nurse.  These included after hours visits.  Telephone calls were only 
included if symptoms were mentioned or medical advice was discussed.  Certain visits, 
such as visits with a phlebotomist, were excluded.  Visits for smears and inoculations 
were included (even though the reason for visit was not an active health problem) on 
the premise that women may still report symptoms.  Eligibility criteria for consultations 
are listed below in Table 6-1.  Women had to have at least one eligible consultation in 
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the study period to be included in the analysis.  If more than one consultation per day 
occurred, each was counted individually as a single consultation.  However, most data 
are presented as the number of women who consulted during the period, not the 
number of consultations. 
Table 6-1 Consultations versus Non-Consultations 
Consultation Non-Consultation 
Any surgery visit, home visit or telephone call 
with a GP or nurse (telephone calls must have 
involved medical advice or symptom reporting) 
Blood tests with phlebotomist 
Visits with a counsellor 
Smoking clinics 
The following data were extracted: 
 Consultation dates 
 Location of visits (e.g. home visit or GP surgery) 
 GP or nurse consulted 
 Symptoms recorded 
 Co-morbidities  
 Age of women (years) 
 Tests or referrals ordered (including reason for referral if data permitted) 
Other general data taken from each surgery included: 
 Details of total list size age and sex breakdown 
 Proportion of women aged 45-74 and 55-74 in the practice  
 Number of GPs  
 Full-time or part-time work status of each GP 
 Total number of women registered with the practice 
All consultations were manually examined for symptoms since the majority of 
symptoms were recorded as free text.  Extracted symptoms were binary coded as 
relevant or not relevant to ovarian cancer according to a pre-defined list of „key‟ 
symptoms (see Table 6-2).  This „key‟ symptom list was based on symptoms commonly 
reported in the literature by women with ovarian cancer.6-8, 12, 16, 17, 67, 69, 75, 89  Frequency, 
urgency and retention were the only urinary symptoms considered to be salient.  The 
terms „UTI‟, „cystitis‟ and „urinary symptoms‟ frequently appeared in the notes without 
any specific symptom details.  These were included as „key‟ symptoms since urgency 
or frequency were likely to be present.  Although back pain has frequently been cited in 
other studies it was excluded in the present study since no case-control differences 
were observed in the study in Part II.  Likewise, back pain was not found to be a 
discriminatory factor in Goff‟s case-control study.75  Irregular menstrual bleeding was 
also excluded since „targeted screening‟ would most likely be limited to 
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postmenopausal women.  As in the case-control study (Part II), „key‟ symptoms were 
open to interpretation.  The symptom definitions devised in the Part II were applied to 
the data (e.g. „feels weak‟ was considered to be fatigue).  The full list of symptoms 
included from each practice is found in Appendix X.  
Table 6-2 ‘Key’ Ovarian Cancer Symptoms 
Pelvic or abdominal pain or discomfort 
Abdominal bloating 
Increased abdominal size/abdominal distension 
Abdominal lump 
Indigestion or heartburn 
Constipation 
Diarrhoea 
Nausea or vomiting 
Other GI symptoms (e.g. wind, change in bowel habit) 
Loss of appetite 
Difficulty eating 
Weight loss 
Fatigue 
Urinary frequency/urgency/retention (including terms „UTI‟,‟ cystitis‟) 
Postmenopausal bleeding 
Post-coital bleeding  
Pain during intercourse 
Vaginal discharge 
In attempt to refine the estimation of true potential workload; „key‟ symptoms were 
examined in more detail.  Information from previous visits and medical history was 
used to binary code each „key‟ symptom according to the following: 
1) „New‟ – in the last 3 months 
2) „Worsened‟ (based on information in free text) 
3) „Attributable‟ 
These categories allowed for formulation of different workload estimates for different 
clinical scenarios.  All ‟key‟ symptoms were included regardless of whether they were 
mentioned at a nurse or GP consultation. 
The 3 month threshold for the definition of a „new‟ symptom was based on the median 
time between census week visit and earliest real consultation obtained by downloading 
the last 10 before download date (as per search strategy).  The lowest median from 
each of the four practices was 3.5 months (IQR 1.4-7.8).  Thus, 3 months was felt to be 
a reasonable time period over which to assume consultation details would be available 
for most women.  Any symptom that was not recorded in the 3 months prior to 
reference date was considered to be „new‟.  The labelling of „new‟ took in to account 
symptom groupings as defined in Part II (e.g. loose bowels and diarrhoea were both 
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considered to be diarrhoea).  It was not possible to know about symptoms that were 
present but not reported or recorded, so this classification served only as a rough 
approximation.  Notably, if a woman presented for the first time with a symptom that 
started 6 months ago, this would still be classified as „new‟.  Also, if a woman consulted 
for the same symptom twice within 7 days, but the first visit was before the census 
week and the second visit was in the census week, the latter would be classified as 
„old‟ even though in clinical practice it would still be considered „new‟.  This because 
our interest was in reports of symptoms that might have led to a „screening test‟ if 
„targeted‟ screening is introduced.  Clearly, if testing was performed the first time the 
symptom was reported, it would not be repeated 3 days later.   
An attempt was made to separate symptoms that were attributable a priori to pre-
existing or new disease (e.g. acute lower back pain after injury) from symptoms that 
could not be attributed to any particular disease or condition.  This was done because 
testing is unlikely to be offered to women with longstanding symptoms from pre-existing 
conditions (assuming no worsening or change).  Equally, GPs may not wish to offer 
testing when other causes are more likely (e.g. fatigue associated with cold or flu 
symptoms).  The decision over which symptoms were attributable was arbitrary as 
there are many possible causes for any given symptom and many possible symptoms 
for any given disease.  For example, chronic gastritis alone could elicit dyspepsia, 
epigastric pain, bloating, nausea, flatulence and loss of appetite, although one may not 
wish to consider the entire list of potentially related symptoms to be attributable.  
Medical history and consultation data (from previous and census week visits) were 
used in the classification process.  In general, the designation of „attributable‟ status 
was conservative and in reality a GP may decide not to offer testing in many more 
scenarios than those selected for this study.  Mainly sensible and straightforward 
causes were permitted such as fatigue after major surgery, nausea after whiplash 
injury, vomiting with alcohol withdrawal.  The most common reasons for „attributable‟ 
labelling included: 
 GI symptoms and history of IBS or diverticulitis/diverticular disease 
 Indigestion/acid reflux/epigastric pain and history of these, or, gastritis or recently 
documented Helicobacter pylori infection 
 Fatigue and symptoms typical of viral infections, common cold or chest infections 
 Diarrhoea/nausea/vomiting and viral symptoms (e.g. muscle ache, runny nose etc.) 
Since this was a pilot study these relatively loose definitions of „attributable‟ were felt to 
be acceptable.   
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„Key‟ symptoms were coded into major symptom groups for each practice including 
abdominal, gastrointestinal (GI), gynaecological, urinary and general (details listed in 
Appendix X).  This provided an overall impression of what types of symptoms women 
in the target age group visit primary care with.  Coding was kept closely in line with the 
case-control study rules from Part II in this thesis.  Symptoms listed in the US ovarian 
cancer consensus statement153 were flagged, however the criterion of daily symptoms 
for more than a few weeks was not possible to apply with the limited information 
available.   
6.3.4 Sample Size  
In the UK, women aged 45-74 have an average of 1600 consultations per GP per 
year.154  This is equivalent to approximately 32 visits per GP per week.  With four 
average sized GP practices a total of 15-20 GPs would be included in the study, 
therefore we expected to get around 550 visits made by women aged 45-74 in one 
week. 
Based on the assumption that 550 visits were expected during the study, Table 6-3 
shows the various 95% confidence intervals associated with different proportions of 
these visits being eligible for testing during one week (i.e. estimate of workload).  
Table 6-3 Table of 95%CI associated with different proportions of visits that 
trigger ‘targeted screening’ for women aged 45-74 (based on 550 visits) 
Proportion 95% CI 
20% 16.7-23.6 
10% 7.6-12.8 
6% 4.2-8.3 
2% 1.0-3.5 
6.3.5 Analysis 
Analysis of study data was performed using two age bands: 
1) Women aged 45-54 years (mixture of pre-, peri- and post-menopausal) 
2) Women aged 55-74 years (predominantly postmenopausal) 
The smaller age band of 55-74 was intended to provide data that would be more 
representative of postmenopausal women.  The two groups were compared in terms of 
symptom prevalence. 
Symptoms were analysed on an individual and collective basis.  The proportion of 
women aged 45-74 and 55-74 who presented during the census week with symptoms 
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was calculated with 95% confidence intervals for proportions.  This was done according 
to different symptom categories including: 
 Any „key‟ symptom 
 Any „new‟ „key‟ symptom 
 Any „key‟ symptom unattributable to other diseases 
 Any „key‟ symptoms for which testing would realistically be offered (as described 
above) 
 ≥3 key symptoms 
 ≥3 key symptoms with at least one „new‟ or „worsened‟ 
 Any one of each grouped symptom (i.e. abdominal, GI, gynaecological, urinary, 
general) 
 Any consensus symptom 
If the same „key‟ symptom was reported more than once in the census week by the 
same woman, it was counted as one „key‟ symptom. 
In reality, „targeted screening‟ would not be performed in all women presenting with 
„key‟ symptoms, such as women who are already awaiting ultrasound or who have 
recently been tested.  Hence, the consultation data for each woman with a „key‟ 
symptom were closely examined and women who would realistically be offered testing 
were identified.  The following women were excluded: 
 Women who already met the criteria for testing in a visit in the 3 months prior to 
census week – one would not offer testing twice within this period. 
 Women who had a pelvic ultrasound scan in the past 6 months (since second level 
screening is likely to include pelvic ultrasound). 
 Women who already had a rapid referral to gynaecological oncology in the past 6 
months. 
 Women in palliative care (testing would not be offered to women with a short life 
expectancy). 
 Women referred, or undergoing investigations for, a possible malignancy (including 
ultrasound). 
 Women who only mentioned „key‟ symptoms that had already resolved. 
 Women who only had „key‟ symptoms that were classified as „attributable‟. 
In the consideration of ≥3 key symptoms, calculations were performed separately for 
≥3 reported in the census week (i.e. calculated over the entire week‟s worth of visits) 
and ≥3 reported in one census day.  However, these were identical so results are 
reported as ≥3 key symptoms in one week. 
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In order to make the data more comparable with the case-control study, the symptom 
index (Index 2) developed in Part II, was applied to the data.  Index symptoms 
included: 
 Increased abdominal size 
 Lump in abdomen 
 Loss of appetite 
 Pelvic/abdominal pain or discomfort 
 Constipation 
 Fatigue 
 Bloating 
 Nausea or vomiting  
 Weight loss.   
Any women with at least one index symptom during the reference week were identified.  
A second definition of „new‟ versus „old‟ was devised.  Symptoms were considered to 
be „new‟ if no other index symptoms appeared in the previous 10 „consultations‟.  
Symptoms recorded more than one year before the reference week were excluded 
from this criterion.   
A crude extrapolation to estimate the proportion of women in each age group and each 
symptom category that would be offered testing over one year was performed using the 
equation: 
 
if p is the proportion of women to be offered testing in a single week. 
6.4 Results 
A total of seven practices were approached and five agreed to participate.  One urban 
London practice was excluded as the list size was too small.  The original plan was to 
collect data from one urban and one non-urban practice from London and Oxfordshire 
each.  Unfortunately, only one suitable practice from London agreed to participate in 
time to take part (Chrisp Street Practice).  Thus, an extra surgery was obtained from 
Oxfordshire.  Only anonymised data were used in the current study, however because 
the data collection process was novel, initially there was some confusion over which 
approvals were required.  Advice regarding this was sought from the Patient 
Information Advisory Group (PIAG), Barts and the London Research & Development 
Office and the East London and the City Ethics Committee.  PIAG approval was 
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deemed unnecessary so long as the researcher did not see any identifiable data and 
the download was performed by a member of the surgery staff.  Research Ethics 
Committee approval was also not obligatory.  The requirement for Primary Care Trust 
(PCT) approval was less clear and the two PCTs that were approached responded 
differently.  The North East London Consortium for Research and Development 
(NELCRAD) could not decide whether the proposed work constituted a formal research 
study or an audit.  Ultimately, NELCRAD suggested that the study could be taken on as 
a GP-run study in which case PCT approval would not be required.  This is how the 
study was run at Chrisp Street Practice.  For the three remaining GP practices 
examined, PCT approval was provided by the Oxford Primary Care Trust. 
Table 6-5 contains GP surgery details and the number of women consulting during the 
census week for each individual practice and overall.  The combined list size was 
38,921, including 5737 women aged 45-74 and 3031 women aged 55-74.  A total of 
479 women aged 45-74 and 287 women aged 55-74, consulted during one week.  Of 
the women aged 45-74 who consulted during the week, two had a previous history of 
ovarian cancer and two were receiving treatment for an active cancer (see Table 6-6).  
As mentioned in 6.3.1 Study Population, these women were excluded from the analysis 
since testing would not be offered to such women in clinical practice.  This left a total of 
475 women aged 45-74 and 285 women aged 55-74 for analysis. 
Females comprised approximately 50% of the practice population for all surgeries.  The 
proportion of registered females that were aged 45-74 and 55-74 at each practice was 
also comparable (combined results 15% and 8%, respectively).  In contrast, the 
proportion of women in each age group who consulted during the week varied between 
practices.  At Chrisp Street (14%) and Northcroft (11%) practices, the proportion of 
women consulting was more than twice that of Boundary House (5%) and Woosehill 
surgery (5%).  However, of the women consulting in each age group, the proportion 
that reported symptoms was similar for all four practices.  Likewise, the proportion of 
consulting women who reported „key‟ symptoms was also comparable.  Interestingly, 
symptom reporting did not differ between the smaller predominantly postmenopausal 
group and the larger mixed peri- and post- menopausal group. 
Overall, 8% of all women aged 45-74 consulted during the census week.  Of the 
consulters, 62% (293/475) reported at least one symptom and 17% (80/475) had at 
least one „key‟ symptom.  Corresponding figures for women aged 55-74 were similar 
with 9% presenting in the census week, 57% with any symptom and 15% with any „key‟ 
symptom.   
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Approximately 60% of consultations made by women in the broader target age group 
(45-74) were with the GP.  Most of the consultations took place in person at the surgery 
(see Table 6-4).  A similar rate of telephone consultations took place at each surgery 
except for Northcroft surgery, which had noticeably fewer.  Some women consulted 
more than once in the week and although 475 women consulted, there were 566 
consultations. 
Symptom reporting was higher at GP versus nurse consultations.  Of the women aged 
45-74 who reported „key‟ symptoms, 86% (69/80) were during a GP visit and 14% 
(11/80) were during a nurse visit. 
Table 6-4 Consultation Location 
Number of Visits (%) 
 Chrisp St Boundary Northcroft Woosehill Total 
Women aged 45-74      
Surgery 160 (77%) 60 (83%) 170 (93%) 86 (83%) 476 
Telephone 43 (21%) 12 (17%) 6 (3%) 17 (16%) 78 
Home 4 (2%) - 7 (4%) 1 (1%) 12 
    TOTAL 566 
Women aged 55-74  
Surgery 92 (77%) 37 (84%) 108 (93%) 49 (80%) 286 
Telephone 24 (20%) 7 (16%) 4 (3%) 11 (18%) 46 
Home 3 (3%) - 4 (3%) 1 (2%) 8 
    TOTAL 340 
Note that women may have more than one consultation during the census week 
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Table 6-5 Details of GP Surgery & Women Aged 45-74 (55-74) Consulting During Census Week 
 Chrisp St Woosehill Northcroft Boundary TOTAL 
List size 11504 10652 8928 7837 38921 
Total number females 5645 (49%) 5388 (51%) 4503 (50%) 4022 (51%) 19558 (50%) 
Total number females aged 45-74 1210 (11%) 1809 (17%) 1457 (16%) 1261 (16%) 5737 (15%) 
Total number females aged 55-74 658 (6%) 861 (8%) 877 (10%) 635 (8%) 3031 (8%) 
GPs at practice 
 Full-time 
 Part-time 
 Total 
 
1 
11 
12 
 
3 
2 
5 
 
3 
2 
5 
 
3 
1 
4 
 
10 
16 
26 
Women aged 45-74 consulting during week      
 with GP 133 56 124 38 351 
 with Nurse 50 36 45 24 155 
 Total (GP or nurse) 168* 85 163** 59 475 
Proportion consulting of all women aged 45-74  14% 5% 11% 5% 8% 
Women with ≥1 symptom recorded 112/168 (67%) 50/85 (59%) 93/163 (57%) 38/59 (68%) 293/475 (62%) 
Women with ≥1 „key‟ symptom 27/168 (16%) 14/85 (16%) 28/163 (17%) 11/59 (19%) 80/475 (17%) 
Proportion of women in age group with ≥1 „key‟ 
symptom 
27/1210 (2.2%) 14/1809 (0.8%) 28/1457 (1.9%) 11/1261 (0.9%) 80/5737 (1.4%) 
Women aged 55-74 consulting during week      
 with GP 73 36 77 22 208 
 with Nurse 31 17 30 16 94 
 Total (GP or nurse) 96 51 104* 35 286 
Proportion consulting of all women aged 55-74 15% 6% 12% 6% 9% 
Women with ≥1 symptom recorded 56/96 (58%) 31/51 (61%) 54/104 (52%) 21/35 (60%) 162/286 (57%) 
Women with ≥1 „key‟ symptom 12/96 (13%) 8/61 (13%) 18/104 (17%) 5/35 (14%) 43/286 (15%) 
Proportion of women in age group with≥1 „key‟ symptom 12/658 (1.8%) 8/861 (0.9%) 18/877 (2.1%) 5/635 (0.8%) 43/3031 (1.4%) 
*
Excludes one woman with ovarian cancer 
**
Excludes one woman with ovarian cancer and two women with active cancer  
Note that combined total numbers of women consulting during census week exclude women with ovarian or other active cancers.  Women aged 45-74 (n=4), women 
aged 55-74 (n=1) 
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Table 6-6 contains demographic details of women who consulted in each age group.  
Ethnicity data were poorly documented at the most of the surgeries examined, however 
the majority of women are likely to be British or mixed British according to the surgery 
catchment areas.  The proportion of consulting women with IBS or diverticular 
problems recorded was similar across all practices. 
Table 6-6 Demographic Details of Women with a Consultation in the Census 
Week 
 Chrisp St Woosehill Boundary Northcroft TOTAL 
Women aged 45-74 n=168 n=85 n=59 n=163 475 
 Median Age (IQR) 58 (49-67) 56 (51-63) 56 (49-67) 60 (51-65) 58 (50-66) 
Ethnicity      
 British/Mixed British  110 (65%) 24 (28%) - 1 (1%) 133 (28%) 
 Black* 9 (5%) - - - 10 (2%) 
 Unknown 50 (30%) 61 (72%) 59 (100%) 162 (99%) 332 (70%) 
Relevant Diseases      
 IBS  9 (5%) 11 (13%) 4 (7%) 15 (9%) 39 (8%) 
 Diverticular problem** 8 (5%) 5 (6%) 4 (7%) 11 (7%) 28 (6%) 
Women aged 55-74 n=96 n=51 n=35 n=104 286 
 Median Age (IQR) 66 (59-72) 62 (58-67) 64 (59-71) 63 (60-68) 63 (60-69) 
Ethnicity      
 British/Mixed British 64 (67%) 14 (27%) - 1 (1%) 79 (28%) 
 Black* 9 (10%) - - - 9 (3%) 
 Unknown 23 (24%) 37 (73%) 35 (100%) 103 (99%) 198 (69%) 
Relevant Diseases      
 IBS  6 (6%) 5 (10%) 3 (9%) 12 (12%) 26 (9%) 
 Diverticular problem** - 2 (4%) 3 (9%) 10 (9%) 15 (5%) 
*Includes Caribbean, Black British 
**Includes diverticular disease, diverticulosis, diverticulitis 
Grouped symptom proportions were more variable between practices due to smaller 
numbers (Table 6-7).  GI symptoms were the most commonly reported and 
gynaecological symptoms were the least common.  A greater proportion of women 
reported GI symptoms at Northcroft and Boundary surgeries, however this could be 
due to random variation.  Overall, symptom reporting was comparable for all grouped 
symptom categories.  
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Table 6-7 Proportion of Women in each Age Group Presenting During the Week 
with Grouped Symptoms (95%CI) at each Surgery 
Percentage of Women with Symptom (95%CI) 
 
Chrisp Street Woosehill Northcroft Boundary 
Women aged 45-
74   
n=168 n=85 n=59 n=163 
Abdominal 
 
4.2 (1.7, 8.4) 3.5 (0.7, 10.0) 3.1 (1.0, 7.0) 5.1 (1.1, 14.1) 
GI 
 
7.1 (3.7, 12.1) 4.7 (1.3, 11.6) 11.0 (6.7, 16.9) 11.9 (4.9, 22.9) 
Urinary 
 
1.8 (0.4, 5.1) 4.7 (1.3, 11.6) 1.8 (0.4, 5.3) - 
Gynaecological 
 
0.6 (0.0, 3.3) - 0.6 (0.0, 3.4) - 
General* 6.5 (3.3, 11.4) 4.7 (1.3, 11.6) 6.1 (3.0, 11.0) 6.8 (1.9, 16.5) 
Women aged 55-
74 
n=96 n=51 n=35 n=104 
Abdominal 3.1 (0.6, 8.9) 3.9 (0.5, 13.4) 1.9 (0.2, 6.8) 2.9 (0.1, 14.9) 
GI 7.3 (3.0, 14.4) 5.9 (1.2, 16.2) 11.5 (6.1, 19.3) 8.6 (1.8, 23.1) 
Urinary 2.1 (0.3, 7.3) 2.0 (0.0, 10.4) 2.9 (0.6, 8.2) - 
Gynaecological - - 1.0 (0.0, 5.2) - 
General* 4.2 (1.1, 10.3) 5.9 (1.2, 16.2) 2.9 (0.6, 8.2) 5.7 (0.7, 19.2) 
*Includes weight loss, loss of appetite, fatigue 
Table 6-8 shows the estimated proportion of women who presented at each practice in 
each age range that would be offered testing in one week based on different criteria.  
According to the basic testing threshold of any „key‟ symptom, 80 women (i.e. 16.8% of 
consulting women) aged 45-74 would be eligible, which is equivalent to 1.4% (95%CI 
0.2%, 1.7%) of all women aged 45-74 (combined list size).  The proportion of „key‟ 
symptoms that were considered to be „unattributable‟ to other diseases varied between 
surgeries.   
Of women aged 45-74 who had a „key‟ symptom, 57 out of 80 (71%) reported a „new‟ 
symptom.  For women aged 55-74, this was 28 out of 43 (65%).  Hence, about two 
thirds of women with „key‟ symptoms would require testing if the threshold was based 
on „new‟ symptoms only. 
In order to get a more clinically relevant estimate, women who would not realistically be 
offered testing were excluded (e.g. women with „attributable‟ symptoms only, women in 
palliative care or already referred for a malignancy etc.).  The proportion of women who 
required testing was markedly reduced across all practices.  The overall figures were 
29 women aged 45-74 (i.e. 6.1% of consulting women) and 12 women aged 55-74 (i.e. 
4.2% of consulting women).   
All women who had ≥3 „key‟ symptoms also had at least one „new‟ or worsening 
symptom, thus only data for women with ≥3 „key‟ symptoms are presented in Table 6-8.  
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Very few of the consulting women met this testing threshold; just 3.0% at Chrisp Street, 
1.8% at Northcroft surgery and none at Woosehill and Boundary surgeries.   
Reporting of consensus symptoms varied slightly at each practice but overall was low 
(5.9% of women aged 45-74).  The proportion of women that met each testing 
threshold was comparable for each age group. 
The symptom index (Index 2) that was developed in Part II, was applied to the data 
(see Table 6-9).  Again, results were similar for each age group, as few as 0.8% of all 
eligible women reported at least one new index symptom over the week. 
Table 6-10 shows the estimated proportion of women in each age group that would 
require testing in one year.  An estimated 51.8% (95%CI 44.0%, 59.7% for 45-74 
group) of women would present with a „key‟ symptom in each age group.  For any new 
index symptom, 35.4% (95%CI 27.5%, 44.0%) and 32.7% (95%CI 22.2%, 44.8%) of 
women aged 45-74 and 55-74, respectively would be tested in one year.  The 
proportion of women who were estimated to report 3 or more „key‟ symptoms was very 
low, just 7.0% (95%CI 3.1%, 13.3%) of women aged 45-74. 
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Table 6-8 Estimated Proportion of Women to Offer Testing to in One Week According to Different Testing Thresholds (GP or Nurse)  
Number (percentage) with 95% Confidence Intervals 
 Chrisp Street Woosehill Northcroft Boundary TOTAL 
 n (%) 95%CI n (%) 95%CI n (%) 95%CI n (%) 95%CI n (%) 
Women Aged 45-74 n=168  n=85  n=163  n=59  n=475 
Key Symptoms          
 Any 27 (16.1) 10.9, 22.5 14 (16.5) 9.3, 26.1 28 (17.2) 11.7, 23.9 11 (18.6) 9.7, 30.9 80 (16.8) 
 „New‟ 20 (11.9) 7.4, 17.8 10 (11.8) 5.8, 20.6 20 (12.3) 7.7, 18.3 7 (11.9) 4.9, 22.9 57 (12.0) 
 „Unattributable‟* 18 (10.7) 6.5, 16.4 7 (8.2) 3.4, 16.2 15 (9.2) 5.2, 14.7 8 (13.6) 6.0, 25.0 48 (10.1) 
 Actually Eligible for Test** 13 (7.7) 4.2, 12.9 2 (2.4) 0.3, 8.2 10 (6.1) 3.0, 11.0 4 (6.8) 1.9, 16.5 29 (6.1) 
 ≥3 Key Symptoms 5 (3.0) 1.0, 6.8 - - 3 (1.8) 0.4, 5.3 - - 8 (1.7) 
Any Consensus Symptom 10 (6.0) 2.9, 10.7 7 (8.2) 3.4, 16.2 8 (4.9) 2.1, 9.4 3 (5.1) 1.1, 14.1 28 (5.9) 
Women Aged 55-74 n=96  n=51  n=104  n=35  n=286 
Key Symptom          
 Any 12 (12.5) 6.6, 20.8 8 (15.7) 7.0, 28.6 18 (17.3) 10.6, 26.0 5 (14.3) 4.8, 30.3 43 (15.0) 
 „New‟ 7 (7.3) 3.0, 14.4 6 (11.8) 4.4, 23.9 13 (12.5) 6.8, 20.4 2 (5.7) 0.7, 19.2 28 (9.8) 
 „Unattributable‟* 7 (7.3) 3.0, 14.4 2 (3.9) 0.5, 13.5 9 (8.7) 4.0, 15.8 4 (11.4) 3.2, 26.7 22 (7.7) 
 Actually Eligible for Test** 5 (5.2) 1.7, 11.7 - - 6 (5.8) 2.1, 12.1 1 (2.9) 0.1, 14.9 12 (4.2) 
 ≥3 Key Symptoms 3 (3.1) 0.6, 8.9 - - 2 (1.9) 0.2, 6.8 - - 5 (1.7) 
Any Consensus Symptom 5 (5.2) 1.7, 11.7 3 (5.9) 1.2, 16.2 5 (4.8) 1.6, 10.9 1 (2.9) 0.1, 14.9 14 (4.9) 
*Symptoms unattributable to other diseases 
**Excludes women who would not be offered testing because symptoms attributable to other diseases, pre-existing symptom, referred to ultrasound or other 
specialists, in palliative care, already would have been tested at previous visits etc. 
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Table 6-9 Number (%) of Women with an Index 2 Symptom – All Consulting and All in Age Group 
 Chrisp Woosehill Northcroft Boundary TOTAL 
Women aged 45-74*      
Consulting Women n=168 95%CI n=85 95%CI n=163 95%CI n=59 95%CI n=475 
 18 (10.7%) 6.5%, 16.4% 9 (10.6%) 5.0%, 19.2% 18 (11.0%) 6.7%, 16.9% 3 (5.1%) 1.1%, 14.1% 48 (10.1%) 
          
All Women in Age Gp. n=1210 95%CI n=1809 95%CI n=1457 95%CI n=1261 95%CI n=5737 
 18 (1.5%) 0.9%, 2.3% 9 (0.5%) 0.2%, 0.9% 18 (1.2%) 0.7%, 1.9% 3 (0.2%) 0.0%, 2.2% 48 (0.8%) 
Women aged 55-74**          
Consulting Women n=96 95%CI n=51 95%CI n=104 95%CI n=35 95%CI n=286 
 7 (7.3%) 3.0%, 14.4% 6 (11.8%) 4.4%, 23.9% 10 (9.6%) 4.7%, 17.0% 0 - 23 (8.0%) 
          
All Women in Age Gp. n=658 95%CI n=861 95%CI n=877 95%CI n=635 95%CI n=3031 
 7 (1.1%) 0.4%, 2.2% 6 (0.7%) 0.3%, 1.5% 10 (1.1%) 0.5%, 2.1% 0 - 23 (0.8%) 
*Excludes one woman with recent colectomy for suspected colon cancer and one woman in palliative care 
**Excludes one woman with recent colectomy for suspected colon cancer 
Note: Index 2 symptoms include increased abdominal size, lump in abdomen, loss of appetite, pelvic/abdominal pain or discomfort, constipation, fatigue, bloating, 
nausea or vomiting and weight loss. 
Abbreviations: Gp. Is “Group” 
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Table 6-10 Proportion of Women to be Screened Extrapolated Estimate Over 1 
Year with 95% Confidence Intervals 
 Percentage 95% CI 
Women Aged 45-74   
Key Symptom   
 Any 51.8% 44.0%, 59.7% 
 „New‟ 40.5% 32.5%, 49.0% 
 „Unattributable‟* 35.4% 27.5%, 44.0% 
 Actually Eligible for Test** 23.2% 16.2%, 31.5% 
 ≥3 Key Symptoms 7.0% 3.1%, 13.3% 
Any Consensus Symptom 22.5% 15.6%, 30.8% 
Any New Index 2 Symptom 35.4% 27.5%, 44.0% 
Women Aged 55-74   
Key Symptom   
 Any 52.4% 41.6%, 63.2% 
 „New‟ 38.3% 27.4%, 50.2% 
 „Unattributable‟* 31.5% 21.1%, 43.6% 
 Actually Eligible for Test** 18.6% 10.1%, 30.3% 
 ≥3 Key Symptoms 8.2% 2.7%, 18.2% 
Any Consensus Symptom 21.4% 12.3%, 33.2% 
Any New Index 2 Symptom 32.7% 22.2%, 44.8% 
 Actually Eligible for Test** 14.3% 8.6%, 21.9% 
*Symptoms unattributable to other diseases 
**Excludes women who would not be offered testing because symptoms attributable to other 
diseases, pre-existing symptom, referred to ultrasound or other specialists, in palliative care, 
already would have been tested at previous visits etc. 
A total of 15 blood tests and 3 ultrasounds were ordered during the week for women 
aged 45-74 presenting with a „key‟ symptom.  However, only 10 of the blood tests were 
ordered for investigation of symptoms and the rest were routine.  This is equivalent to 
19% (15/80) of women in the age group consulting during the week with „key‟ 
symptoms receiving a blood test.  Six women were referred for further care. 
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6.5 Discussion 
GP workload is an important consideration in the feasibility assessment for „targeted‟ 
ovarian cancer screening.  Consultation rates are known to be high in the very young 
and very old, and appear to be on the increase for older age groups in the UK (over 
65s).155  The total number of women visiting in one week was 479, slightly less than the 
550 visits expected based on the estimates from the Office of Health Economics. 154  
However, some women visited more than once in the week and the total number of 
consultations was actually 560, which is very close to our projection. Unfortunately, 
multiple visits were not accounted for in our calculations, thus our sample size was 
slightly smaller than desired.   
„Targeted screening‟ might only be offered to women with more than one relevant 
symptom.  Many of the individual symptoms that might prompt testing alone are 
already likely to prompt a referral to secondary care, for example PMB, lump in 
abdomen, change in bowel habit or abdominal distension (with suspected ascites).  
Under these circumstances, the index of suspicion for malignancy would be too high for 
„targeted screening‟.  Conversely, testing for urinary frequency or fatigue alone could 
result in a surplus of unnecessary testing in women with simple urinary tract or viral 
infections.  In order to address these issues, theoretical testing was assessed on 
several different levels in this study. 
One of the main arguments against the promotion of using symptoms as a tool for early 
detection of ovarian cancer is the lack of specificity of symptoms which would result in 
many women requiring unnecessary investigation.  More than 50% of postmenopausal 
women suffer from at least one of vaginal discomfort, dysuria, dyspareunia, recurrent 
lower UTI and urinary incontinence.156  This pilot study has indicated that only a small 
proportion of women aged 45-74 present to primary care with symptoms potentially 
related to ovarian cancer per week.  However, extrapolation over one year estimated 
that „targeted screening‟ would potentially be offered to about half of all women aged 
45-74 (51.8%) if no restrictions were set.  Although this is a large proportion of women, 
the extrapolations over one year in this study are likely to be slightly overestimated.  
This was exemplified by the substantial reduction in testing when only „new‟ and 
„unattributable‟ symptoms were included.  The proportion of women estimated to 
require testing over one year for a „new‟ symptom was 40.5% (95%CI 32.5%, 49.0%), 
and for an „unattributable‟ symptom this was 35.4% (95%CI 27.5%, 44.0%).  The 
criteria for defining „new‟ were limited to the data available.  In the present study, „new‟ 
index symptoms were supposed to be new in the last year.  However, it is likely that we 
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had insufficient consultation data to cover this period and some of the symptoms 
categorised as „new‟ were in fact „old‟.  Furthermore, menopausal status was unknown 
in this study, and „targeted‟ screening is likely to be restricted to postmenopausal 
women.  Therefore, in reality the number of women to be offered testing would be 
slightly lower. 
Symptom reporting in the 45-74 year age group was relatively high (approximately 2/3 
of women consulting), however „key‟ symptom reporting was not.  Any testing threshold 
for „targeted screening‟ is likely to include some sort of symptom duration restriction 
which was unaccounted for in this analysis.  For example, it would not be sensible to 
test after one day of loss of appetite.  The symptom index produced by Goff et al. 
requires symptoms to have been present for less than one year but more than 12 times 
per month.108  The application of similar criteria should further reduce the number of 
women who require testing, as would the restriction to only certain „key‟ symptoms as 
in Goff‟s index (increased abdominal size or bloating, pelvic or abdominal pain, 
difficulty eating or feeling full quickly).  Furthermore, testing would not be offered to 
women who have already been recently tested (say the last 6-12 months) which would 
also decrease testing numbers.  According to Index 2 (developed in Part II), only an 
estimated 35.4% (95%CI 27.5%, 44.0%) of women aged 45-74 would require testing in 
one year. 
The proportion of women who were actually eligible for „testing‟ was intended to 
provide a more clinically realistic estimate.  Although the approach used was crude, 
this almost halved the proportion of women who would require „testing‟ for any ‟key‟ 
symptom (51.8% [95%CI 44.0%, 59.7%] was reduced to 23.2% [95% CI 16.2%, 
31.5%]) and any „new‟ Index 2 symptom. 
Despite having diverse locations, the four GP practices studied showed comparable 
proportions of women in each age group reporting at least one „key‟ symptom.  In 
contrast, the proportion of „key‟ symptoms that were „attributable‟ to other diseases 
varied and one GP practice had no women with „attributable‟ symptoms, however this 
assessment was vague.  Due to the clinical judgement required on a case-by-case 
basis for this category, it should not be over-interpreted for this study.  Moreover, 
clinical diagnosis can be delayed due to misattribution of symptom aetiology.  It is 
unclear why the proportion of women that consulted relative to list size in each age 
group differed across surgeries.  This was unexpected and possibly due to the short 
period examined.  Although the women were analysed in two different age bands, very 
few differences were observed between the smaller more postmenopausal age group 
that and the larger mixed menopausal status age group. 
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No other published studies have investigated the incidence of typical ovarian cancer 
symptoms in primary care in women aged 45-74 using medical record data.  Goff et al. 
collected survey symptom data on women presenting to primary care, however they 
included women as young as 15 who probably have a different spectrum of 
symptoms.75  The only other published study that has investigated „targeted ovarian 
cancer screening‟ was a prospective pilot study which randomised GP practices to 
being able to refer (or not refer) women aged ≥45 with symptoms potentially related to 
ovarian cancer for immediate CA125 testing and transvaginal ultrasound.111  Study 
compliance was poor and only 39 out of 79 practices made referrals during the study 
period.  Referral patterns were also extremely variable between GPs.  Over the 
recruitment period that spanned almost 2½ years, only 317 women were referred.  
Clearly, this is much lower than the present study‟s estimated numbers.  Since no 
cases of ovarian cancer were identified in the study population, no indication of 
whether or not symptoms may facilitate earlier detection could be inferred.  
Current referral criteria for rapid access gynaecological-oncology clinics (relevant to 
ovarian cancer) only include two symptoms: suspicious pelvic mass and PMB (if not on 
HRT).  Thus, there are many ovarian cancer symptoms that do not meet rapid referral 
guidelines.  „Targeted screening‟ may provide a useful tool to utilise when these 
symptoms are present but suspicion of ovarian cancer is not sufficient to prompt 
referral or more expensive investigations. 
Potential limitations of this study include that GP practices were limited to those with 
EMIS LV and therefore may not be representative of all practices across the UK.  Also, 
there may be bias from GP surgeries that were willing to participate, as they may have 
been more organised practices with better quality notes.  Another drawback is that the 
study was small and only one week‟s worth of consultations was examined.  This 
period is too short to take into account seasonal variations in consultations (for 
example, all patients over 65 are offered free flu vaccinations in the winter months).  In 
addition, the prevalence of „key‟ symptoms in the population of women aged 45-74 that 
did not consult in the census week remains unknown.  Consultation rates have been 
shown to be higher in rural than in inner-city and urban areas155 and no rural practices 
were included in the current study.  Another issue to consider, is that recording in GP 
notes tends to be diagnosis driven,24 and actual reporting of symptoms in primary care 
may in fact be underestimated by this study.  Also, the prevalence of „key‟ symptoms in 
the non-consulting population could be high.  If women were to be encouraged to seek 
health-care for these symptoms, the associated GP workload could become much 
greater. 
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However, importantly this study has provided much needed data on ovarian cancer 
symptom prevalence in primary care, albeit limited.  The results will help to design 
future studies and provides „ballpark‟ figures. 
Further work is planned to gain longitudinal data to confirm these pilot findings, and to 
refine the potential testing thresholds.   
6.6 Conclusions 
According to these pilot data, 40.5% (95%CI 44.0%, 59.7%) of women aged 45-74 
present to primary care in one year with a „new‟ ovarian cancer symptom.  An even 
smaller proportion were estimated to have an Index 2 symptom over one year (35.4% 
[95%CI 27.5%, 44.0%]).  Crucially, restricting women to those who were actually 
eligible for testing reduced the numbers considerably.  This is clearly something that 
should be built in to any future studies assessing GP workload and ovarian cancer 
symptoms.   
Although there are other issues to consider, these data are encouraging since the 
numbers are considerably less than those required for population screening and in 
reality, stricter criteria would be applied which should further reduce these figures.  
However, these data do not take into account any potential increases in symptom 
reporting at primary care from increased ovarian cancer symptom awareness of 
women in the general population.  Further work needs to be done to find out if „targeted 
screening‟ would have an acceptable NNI (number needed to investigate). 
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7 CHAPTER 7: Summary & General Discussion 
The following discussion will summarise the key findings of this thesis, and it will 
highlight what has been added to the knowledge-base of symptoms and the events 
prior to ovarian cancer diagnosis.  It will also cover the potential implications and 
identify the areas that require future work. 
The key findings of this thesis include: 
Any Symptom (possibly related to ovarian cancer) 
 Most women with ovarian cancer have symptoms at diagnosis.  
 Women with ovarian cancer start to have more problem visits to the GP 
approximately 6 months before diagnosis. 
 No case-control differences were observed beyond 15 months prior to diagnosis.  
Symptoms provide a maximum (diagnostic) lead time of about 15 (i.e. 14.99) 
months (12.99 months (actual) lead time if 2 months are allowed for from referral to 
diagnosis).   
 Delays in diagnosis were identified, 50% of symptomatic women (according to our 
definition) had at least 9.8 months (IQR 5.0-12.3) between symptom onset and 
diagnosis (combined data).  Furthermore, total and provider delays may be longer 
in the UK, however this needs to be confirmed. 
 64%-81% (depending on data source) of women with ovarian cancer reported at 
least one symptom possibly related to ovarian cancer over 1 year (3 to 14.99 
months before diagnosis).   
 However, 20%-47% of women in the general population would also have these 
symptoms over 1 year (depending on source of data, study design and precise list 
of symptoms) and therefore would be offered „targeted screening‟. 
 Based on estimates using pilot data, limiting women in the general population to 
those who would actually be eligible for „targeted screening‟ over 1 year, 
approximately halved the numbers. 
Symptom Index 
 Using a crude symptom index (to improve specificity), 45%-74% of women with 
ovarian cancer had symptoms at least 3 months prior to diagnosis.   
 13%-35% (depending on source of data and study design) of women in the general 
population had an index symptom over the course of 1 year. 
 After allowing for time from referral to diagnosis, 26%-56% of women with ovarian 
cancer had an actual symptom lead time of at least 3 months. 
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Methodological Issues 
 Timing of symptoms is an important consideration in study design given that 
symptom reporting is markedly reduced >3 months prior to diagnosis. 
 Complexities of symptoms research and related terminology have not been fully 
appreciated, and need to be addressed in future studies.   
Symptoms that were found to be highly associated with ovarian cancer included: 
 Increased abdominal size 
 Loss of appetite 
 Pelvic/abdominal pain or discomfort 
 Lump in abdomen 
 Constipation 
 Fatigue 
 Abdominal bloating 
 Weight loss 
Other symptoms that were associated with ovarian malignancy included: 
 Change in bowel habit 
 Irregular vaginal bleeding 
 Postmenopausal bleeding 
 Vaginal discharge 
 Nausea or vomiting 
 Urinary other symptoms 
Back pain was found to be inversely associated with ovarian cancer, hence should 
probably only be used in future studies as a negative discriminatory factor for cases, if 
at all. 
Importantly, this thesis has shown that consideration of the timing of symptoms is 
critical.  Symptom data that are collected retrospectively need to be carefully evaluated 
in the light of symptoms as a process over time.  Recently, the Department of Health 
(UK) released ovarian cancer key messages for health professionals,157 in which much 
emphasis was placed upon the severity, frequency and persistence of ovarian cancer 
symptoms.  However, these are attributes of symptoms that were described in 
hindsight (i.e. at diagnosis), and there are no prospective data to confirm these claims.  
Ovarian cancer symptoms may have very different severity and frequency when they 
first appear compared with at diagnosis.  Also, some symptoms do not need to be 
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sustained temporally to be salient (e.g. postmenopausal bleeding, acute episodes of 
severe pain).   
The Goff index108 was developed using data on symptoms at diagnosis.  When the 
same index was applied to our data, performance for symptoms at diagnosis was 
similar, but performance for symptoms that started between 3-14 months before 
diagnosis was markedly worse.  Therefore, the provocative series of studies published 
by the Goff group may have sparked premature optimism for a symptoms-based 
diagnostic tool for ovarian cancer.8, 75, 103, 108  Nevertheless, it is encouraging that the 
same or similar symptoms in the Goff index were found to be salient in the crude 
indices explored for this thesis.  Furthermore, it should be pointed out that the 
possibility of developing a symptoms tool to facilitate earlier diagnosis remains viable.  
However, it is paramount that retrospectively collected symptom data are viewed from 
a real life perspective (i.e. as events that may change as a function of time).   
Prospective data would greatly advance our knowledge of what would truly be feasible.  
As such, Goff‟s prospective validation work on the symptoms index is keenly awaited.  
However, there is an important distinction between Goff‟s ongoing work and the 
approach suggested in this thesis.  Goff‟s index is being assessed as a questionnaire 
which is administered to women attending primary care.  This could produce very 
different results from offering „testing‟ based on symptoms spontaneously reported by 
women at primary care.  Also, the Goff index includes symptoms that are present for up 
to 12 months, which could be prone to recall error and potentially could greatly 
increase the proportion of women that would require „testing‟ by including „older‟ 
symptoms. 
At University College London (UCL), another ongoing prospective study in ovarian 
cancer symptoms is taking place.  The study aims to prospectively evaluate symptoms 
in apparently healthy women participating in the UKCTOCS ovarian cancer screening 
trial.  The study is using an ovarian cancer symptoms questionnaire that was recently 
validated using the EORTC guidelines (Penny Allen, Institute for Women‟s Health, 
UCL, personal communication).  The results from this study should provide extremely 
useful prospective data on symptoms in ovarian cancer and data on the relationship 
between CA125 and symptoms. 
Interpretation of symptom data and the development of any symptoms-based tool will 
need to be considered carefully.  One of the main issues is how the symptom data 
were elicited as this would have an impact on what setting the tool could be sensibly 
used.  In general, there are several different ways in which symptoms could be used to 
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bring forward diagnosis.  Each would produce dramatically different sensitivity and 
specificity.  The 3 main approaches include: 
1) Offer „testing‟ based on a list of symptoms spontaneously reported by women at the 
GP 
2) Offer „testing‟ based on a list of symptoms specifically asked about by the GP when 
women present to primary care (for any reason) 
3) Encourage women to visit their GP for symptoms on a list  
The balance will be between sensitivity, lead time and specificity (or GP workload).  
Using the first approach, one would expect lower sensitivity but better specificity.  The 
second would have higher sensitivity but lower specificity.  The third would have higher 
sensitivity but substantially lower specificity.   
The use of continuation odds ratios in this thesis was a novel approach which has not 
been applied before in ovarian cancer symptoms.  They provided a measure that 
combined the advantages of a hazard ratio and an odds ratio.  The major advantage of 
the continuation odds was that it allowed us to quantify symptom lead time by 
examining the proportion of incident symptoms in cases and controls over time.  This 
allowed the retrospectively collected data to be considered in a prospective manner.   
Another aspect of timing that emerged from this thesis was that ovarian cancer 
symptoms develop within 15 months of diagnosis.  It seems increasingly unlikely that 
symptoms which manifest more than two years before diagnosis are associated with 
ovarian cancer, except perhaps in rare cases.  Exacerbation of symptoms from pre-
existing co-morbidities is entirely conceivable and any symptoms-based strategy may 
need to accommodate for this (in order to avoid diagnostic overshadowing).  However, 
for the most part it would seem that the critical period for symptoms data collection is 
within 15 months prior to diagnosis.   
Prompt diagnosis after presentation for symptoms is an ideal outcome and has the 
additional benefit of providing reassurance to patients.  Any delays in diagnosis are 
likely to cause anxiety and frustration, yet with ovarian cancer the advancement of 
diagnosis by one month is unlikely to influence morbidity or survival.  Equally, an 
expedition of two months may not produce any clinically relevant benefit.  Results from 
the case-control study showed that it is crucial to omit symptoms reported in the 3 
months before diagnosis as there could be a clustering of symptoms experienced 
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during this time.  Certainly, in one other study, the period 1-3 months before diagnosis 
showed much higher symptom prevalence than any of the earlier periods examined.20    
It remains controversial as to whether or not ovarian cancer behaves in a progressive 
manner (i.e. develops stepwise from stage I to IV).  To date, researchers have been 
unable to distinguish between early and late stage disease via the presence or 
absence of any particular symptoms.  It is entirely plausible that some early versus late 
tumours may arise out of completely different biological pathways.  Moreover, there is 
no concrete evidence to suggest that women detected with advanced disease actually 
experienced symptoms when disease was in its „early‟ stages.  This assumption is at 
the crux of any symptoms-based diagnostic tool.  Currently, the detection of advanced 
ovarian malignancies at an earlier time point would not translate into gains in survival 
or mortality.  However, a proportion of women may benefit from improved quality of life 
as a result of smaller disease volume and optimal surgical clearance, in addition to the 
psychological benefits of being detected „earlier‟.  Ultimately, as the time taken to get 
from localised tumour to disseminated disease is unknown, the impact of any period of 
diagnostic advancement is also unknown.   
Symptoms (and data relating to symptoms) are highly subjective, and therefore rather 
more complicated to study than is often appreciated.  Much of the research performed 
to date has failed to recognise the weaknesses stemming from this subjectivity.  For 
example, data on symptom duration and delays are hugely dependent on which 
symptoms are deemed to be attributable to ovarian cancer.  If constipation that started 
5 years before diagnosis is considered to be relevant, delay in diagnosis and symptom 
duration will be correspondingly long.  The systematic review in Chapter 2 outlined 
some of the methodological issues associated with carrying out and evaluating 
symptom studies in ovarian cancer.  Methods of symptom elicitation and collection 
have a significant bearing on outcome measures.  Simply asking if patients had 
symptoms before diagnosis may yield inadequate data due to preconceptions about 
which symptoms are attributable to ovarian cancer.  Moreover, mislabelling and 
misinterpretation of symptoms seem to be a significant problem.   
Patient and provider delays varied markedly with each data source in our study.  As 
demonstrated in the systematic review, delays data in ovarian cancer overall have 
been extremely variable.  Again, this is attributable to the subjectivity in identifying 
symptoms that are associated with ovarian cancer, and whether or not calculations are 
based on all women or symptomatic women only.  The methods used for calculation of 
delays needs to be standardised and details should be explicitly described in study 
methods.  Given the evidence (or lack of it), education of women and GP‟s seems to be 
231 
premature at this stage.  While the ovarian cancer key messages released by the 
Department of Health157 may be useful in that GPs may be more likely to consider 
ovarian cancer in women who present with the symptoms listed, there is still no 
evidence to show that this would bring diagnosis forward or have any positive impact at 
all.  There are many unanswered questions and more robust research which takes into 
account the various methodological issues is desperately needed.   
Crucially, this thesis has provided data on symptoms in the general population (primary 
care consulting and non-consulting).  Table 7-1 compares the proportion of women in 
the general population who would require „testing‟ over the course of 1 year according 
to each of the studies in this thesis.  The proportion of women aged 45-74 in the 
general population that would also require „testing‟ over one year appears to be around 
35%-41% in the GP workload data (see Table 7-1).  Llimiting women to those who 
would actually be tested in a clinical setting approximately halved the numbers.  Only 
about 23% (95%CI 16%, 32%) of women with a „new‟ „key‟ symptom were estimated to 
be actually eligible for „testing‟.  In the case-control study, the proportion varied greatly 
with each data source, despite being based on the same women.  This highlights again 
the need for careful consideration of data source and methodology when estimating 
symptom specificity.  GP note and interview data were the most similar to the GP 
workload data.  Theoretically, self-reported data represent a mix of symptoms for which 
women have sought health care and those for which they have not.  Thus, the 
specificity of self-reported data is expected to be lower than that of GP note data, 
however this was not observed.  This may be due to overestimation in the extrapolation 
(GP workload) or perhaps could reflect difficulties in recalling transient symptoms in the 
self-reported data.  After the application of a symptoms index, the proportion of women 
to be „tested‟ reduced across all women (both studies).  Examination of GP workload 
using longitudinal data is expected to produce even smaller estimates.  In addition, 
„targeted screening‟ would most sensibly be offered based on incident (not prevalent) 
symptoms, with a minimum screening interval.  Both of these factors should further 
reduce the proportion of women in the general population who would require „testing‟. 
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Table 7-1 Comparison of Estimates for the Proportion of Women in the General Population who would be Offered ‘Targeted Screening’ 
Over 1 Year (95%CI) - Controls (Case-Control Study) versus Women in GP Workload Study 
 Controls from Case-Control Study  GP Workload Study 
 Questionnaire 
% (95%CI) 
Interview 
% (95%CI) 
GP Notes 
% (95%CI) 
 
New 
% (95%CI) 
Actually Eligible** 
% (95%CI) 
Any Symptom* 20.1% (15.5%, 25.5%) 36.8% (28.4%, 45.9%) 46.7% (40.1%, 53.4%)  40.5% (32.5%, 49.0%) 23.2% (16.2%, 31.5%) 
       
Index 2 Symptom*** 13.4% (9.6%, 18.1%) 26.4% (18.9%, 35.0%) 21.6% (16.4%, 27.5%)  35.4% (27.5%, 44.0%) 14.3% (8.6%, 21.9%) 
*Any symptom possibly related to ovarian cancer (as per Appendix VI) incident over 3-14.99 months before consent for case-control study.  Any new (last 3 months) 
„key‟ symptom (as per Appendix X) estimated over 1 year for GP workload study. 
**Women who would actually be eligible for testing based on a new „key‟ symptom.  Excludes women who would not be offered testing because symptoms 
attributable to other diseases, pre-existing symptom, referred to ultrasound or other specialists, in palliative care, already would have been tested at previous visits 
etc. 
***Any one of increased abdominal size, lump in abdomen, loss of appetite, pelvic/abdominal pain or discomfort, constipation, fatigue, bloating, nausea or vomiting, 
weight loss 
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The concept of identifying a symptom index using multiple symptoms is attractive given 
that the positive predictive value (PPV) of individual symptoms is likely to be extremely 
low (less than 1%).  A symptom index could provide a useful differential upon which the 
threshold for suspicion could be lowered, such that women who are at theoretically 
higher risk of disease will undergo a simple „screening‟ procedure.  Symptoms of 
ovarian cancer are predominantly abdominal and gastrointestinal.  The normal 
investigations for abdominal symptoms include barium meal or enema, colonoscopy 
and sigmoidoscopy.  Such tests are expensive and can be painful, therefore the 
inclusion of a CA125 blood test as part of a standard differential diagnosis for GI 
symptoms may be easy to justify.   
Importantly, „targeted screening‟ as proposed in this thesis, is not totally dependent on 
the success of CA125 testing.  The principle of using vague symptoms to prompt a 
blood test for ovarian cancer can be supported by any blood-borne marker testing that 
may become clinically available in the future.  However, there will need to be clear 
protocols developed if CA125 is to be used. 
Regrettably, symptoms-based strategies remain unproven and it is prudent that 
decision-making and dissemination of information is founded on empirical evidence.  
Currently, there is insufficient evidence to advocate that women should be made aware 
of the symptoms and encouraged to consult primary care givers for symptoms.  
Ultimately, the goal of cancer screening is to reduce mortality.  In cancer screening, it is 
critical to consider what is being detected.  If screening (symptoms-based or 
conventional) is only able to detect disease that would have had a good prognosis 
without screen-detection and/or disease that has a poor prognosis despite being 
screen-detected, the likelihood of a mortality benefit is low.  In the absence of 
evidence, it is misleading to propagate the idea that acting on symptoms will save lives.  
Ovarian cancer symptoms research should be continued with scientific rigour in a 
logical manner which ensures that all of the lessons learnt so far are incorporated, and 
that hasty conclusions are not drawn.   
The future of any paradigm based on symptoms is contingent on the elucidation of 
several key unanswered questions: 
 Is symptom lead time sufficiently long to translate into benefits in survival, mortality, 
quality of life or psychological well-being? 
 What proportion of women in the general population (consulting and non-
consulting) will also require testing? (i.e. NNI [number needed to investigate]) 
 Will increasing symptoms awareness increase GP workload? 
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 What is the relationship between the potential second line tests and symptoms? 
(i.e. will ovarian cancer be detected) 
Assuming that these questions are answered and „targeted screening‟ remains feasible 
in light of these answers, there are still many more general (but significant) hurdles that 
would need to be overcome.  These include: 
 The heterogeneity of ovarian cancer – will all (or at least a reasonable proportion 
of) tumours benefit from symptoms-based efforts? 
 Increasing symptoms awareness is not the same as changing behaviour.  How 
feasible is it to get women and GPs to act on symptoms to produce these benefits? 
 What would be done about negative investigations but persistent symptoms? 
In the pilot study that examined the feasibility of „targeted screening‟, GP compliance 
was poor.111  The reasons for this will need to be carefully examined.  Early detection 
may be hindered by women who delay presenting to healthcare even armed with 
knowledge of symptoms, and by patients who do not attend referral visits.158  Also, 
unravelling the relationship between symptoms and CA125 levels, and between 
symptoms and ovarian cancer survival, is integral to the goals listed above.  Finally, a 
crucial unanswered question for the UK is why do British women have lower survival 
rates than the rest of the world?   
Future Work 
For future research (or any symptoms tool that relies on women‟s ability to interpret 
symptoms), it is imperative that the language and terminology used is clear and 
consistent.  Also, the tools used to elicit symptom data should be carefully considered.  
The recently validated ovarian cancer symptoms questionnaire should prove invaluable 
for addressing some of these measurement issues.   
As mentioned previously, there are two ongoing prospective studies in ovarian cancer 
symptoms (validated symptoms questionnaire in healthy volunteers [UK] and the Goff 
index in primary care [US]).  In tandem with this work, more research should be 
dedicated to confirming the pilot data in this study regarding the proportion of women in 
the general population that would need „targeted screening‟.   
Recently, a study investigated the GP acceptability of blood testing based on 
symptoms in ovarian cancer (Megan Goldsmith et al., Primary Care Group Oxford, 
unpublished data).  The main findings were that the concept of „targeted screening‟ 
was foreign to GPs and many felt that such a scheme would delay diagnosis.  Clearly, 
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there are many more steps that need to be taken before „targeted screening‟ could be 
implemented.   
More work is also needed to better define delays in diagnosis, and to identify barriers in 
the diagnostic process.  Any studies investigating delays should allow for the 
mandatory phases in the diagnostic pathway.  Specifically, efforts should be directed at 
standardising the definition and quantification of „delays‟ in diagnosis.  Moreover, the 
identification of more appropriate terms to describe the interval between symptom 
onset and first GP visit, first GP visit and diagnosis, and symptom onset and diagnosis, 
is long overdue. 
Given the current evidence, efforts to increase symptoms awareness in women and 
GPs are probably premature.  It would be prudent to wait for stronger evidence (in the 
form of the ongoing prospective studies), before any strong recommendations for 
increasing awareness are made.   
In the future, perhaps electronic patient record systems could play a valuable role by 
generating automatic flags to prompt GPs to offer testing based on symptoms and act 
as reminders for repeat testing.   
Lastly, in Part II, the case-control data were extremely complex, and many more 
avenues remain unexplored that were beyond the scope of this thesis.  Planned 
analyses include a combined analysis, examination of the relationship between 
symptoms and survival (all of the women have been flagged with the Office of National 
Statistics [ONS]).   
Although the development of a screening test via proteomics or other genetically-based 
tools is more likely to produce a much needed survival shift in ovarian cancer, this 
could be years away from clinical practice.  Also, the efficacy of population screening in 
ovarian cancer will not be clear until 2015.  Therefore, symptoms research continues to 
play a major role in the potential for early detection of ovarian cancer.  Even if 
symptoms are ultimately proven to be an ineffective tool for expediting diagnosis in 
ovarian cancer, this would also constitute an important finding, as scarce resources 
could be directed to other areas.   
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8 Appendices 
8.1 Appendix I Health Changes/Symptoms Questionnaires 
Order inserted: 
Amendment 2 Questionnaire Version 2 dated January 2006 (first version in use for 
current thesis project, telephone interview consent added, version and date was not 
changed in error) 
Amendment 3 Questionnaire Version 3 dated June 2006 (version used in most of the 
women in this thesis, designed to improve data quality and completion) 
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8.2 Appendix II UKOPS Health Changes Guidelines 
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8.3 Appendix III Telephone Interview Script for Cases 
Hello, may I speak with [patient name] please…   
If patient comes to the phone: 
My name is [interviewer name], I‟m calling with regard to the ovarian cancer study you 
are taking part in, is this a convenient time to speak?  If not I can call back at a time 
that would suit you better… 
If no to timing: [interviewer to arrange a time that best suits the subject] 
If no to further interview:  That‟s fine.  Thank you for your time, take care. 
If yes: You agreed to do an optional telephone interview as part of the study; it usually 
takes between 10-30 minutes.  Are you still happy to do the interview?  It‟s completely 
up to you…. 
If no: That‟s fine.  Thank you for your time, take care. 
If yes: Thank you, we really appreciate it.  I‟d like to arrange a suitable time to call you 
back to perform the interview.  When would be best?  
After time arranged: 
Thank you again, I will speak to you then.  Take care. 
Interview: 
Hello it‟s [interviewer name] speaking, may I speak to [patient name] please. 
Once patient comes to the phone: 
Hello, it‟s [interviewer name] calling to do the interview for the ovarian cancer study.  Is 
it still okay for you do to the interview today? 
If no to further interview:  That‟s not a problem at all.  Thank you for your time, take 
care. 
If no to timing: [interviewer to arrange another a time that best suits the subject] 
If yes:   
Thank you.  If you feel tired or wish to stop at any time, please let me know. 
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The research we‟re doing is to try to find out if there‟s any way we can diagnose 
ovarian cancer earlier by examining the events that occur before diagnosis.  If you feel 
tired or wish to stop at any time, please let me know.  The interview is about any 
symptoms or health problems you may have noticed in the 12 months before you had 
your operation/started chemotherapy (mention specific month).  You answered similar 
questions in the clinic, but we‟re hoping to get a bit more information using this 
interview.  Do you know if you will have any further treatment?  [If yes ask for start date 
of further treatment] 
It‟s important that you let me know if you have experienced any of these regardless of 
whether or not you think they have anything to do with your diagnosis. 
Go through symptom questions on telephone interview form. 
Did you experience any other changes or is there anything else you would like to 
mention?  
Patients will be asked to give details about the path of diagnosis. 
Changes in severity over time 
Thank you very much for your time, I really appreciate it and it‟s really helped us. Is 
there anything you‟d like to ask me? 
Maintaining focus of interview 
I‟m sorry to hear that, from what you‟ve told me it sounds like you have had a difficult 
time.  Do you feel ready/able to continue with the interview? 
There is a lot of uncertainty, symptoms are non-specific and the vast majority of women 
with these symptoms will not have ovarian cancer 
I can tell you‟ve been thinking about this. Do you feel ready/able to continue with the 
interview? 
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8.4 Appendix IV Telephone Interview Script for Controls 
Hello, may I speak with [volunteer name] please…   
If volunteer comes to the phone: 
My name is [interviewer name], I‟m calling with regard to the ovarian cancer study you 
volunteered for, is this a convenient time to speak?  If not I can call back at a time that 
would suit you better… 
If no to timing: [interviewer to arrange a time that best suits the subject] 
If no to further interview:  That‟s fine.  Thank you for your time, take care. 
If yes: You agreed to do an optional telephone interview as part of the study; it should 
take about 10 minutes.  Are you still happy to do the interview?  It‟s completely up to 
you… 
If no: That‟s fine.  Thank you for your time, take care. 
If yes: Thank you, we really appreciate it.  I‟d like to arrange a suitable time to call you 
back to perform the interview.  When would be best?  
After time arranged: 
Thank you again, I will speak to you then.  Take care. 
Interview: 
Hello it‟s [interviewer name] speaking, may I speak to [volunteer name] please. 
Once volunteer comes to the phone: 
Hello, it‟s [interviewer name] calling to do the interview for the ovarian cancer study.  Is 
it still okay for you do to the interview today? 
If no to further interview:  That‟s not a problem at all.  Thank you for your time, take 
care. 
If no to timing: [interviewer to arrange another a time that best suits the subject] 
If yes: 
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The research we‟re doing is to try to find out if there‟s any way we can diagnose 
ovarian cancer earlier by examining events that occur before diagnosis and comparing 
them to that of women without cancer.  The interview is about any symptoms or health 
problems you may have noticed in the 12 months before you were recruited to the 
study.  The symptoms that I‟m going to ask you about are quite common in post-
menopausal women.  You answered similar questions at the clinic, but we‟re hoping to 
get a bit more information using this interview.   
Go through symptom questions on telephone interview form. 
Thank you very much for your time, I really appreciate it and it‟s really helped us.   
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8.5 Appendix V Telephone Interview Form 
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8.6 Appendix VI UKOPS Database Rules 
GP Visit Coding 
GP Visits: 
 Surgery visits 
 Home visits 
 A&E visits 
 Out-of-hours visits 
 Telephone consultations  
 NHS triage calls 
Visit Exclusions: 
 Visits for blood only 
 Telephone calls where test results are reported ONLY (i.e. no recording of 
symptoms or referrals) 
Each visit was categorised as either problem or routine.  If more than one consultation 
or visit occurred on the same day, it was recorded as one visit (e.g. nurse and GP visit 
on same day, or telephone consultation and surgery visit on same day). 
Problem Visits included: 
 Visits/consultations where the main reason seemed to be for a symptom or 
problem, including follow-up/review of undiagnosed problems.  Once problems 
were diagnosed, these became routine review visits. 
Routine Visits included: 
 Nurse visits 
 Medication reviews 
 Immunizations/vaccine/injections 
 Asthma/hypertension/diabetes reviews 
 Well women clinics (pelvic vaginal examination [PV], smear, breast examination) 
If a routine and problem visit took place on the same day, problem code overrode 
routine.  If a problem that would normally constitute a separate visit was mentioned at a 
routine visit, the visit was classified as a problem. 
Visit data were extracted up until date of consent for controls and „cut-off‟ date for 
cases.  „Cut-off date‟ was date that pelvic or ovarian aetiology was first suspected. 
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Symptom Coding 
Any sign or symptom recorded in interview, questionnaire or in GP notes, was 
considered to be a symptom regardless of perceived or documented aetiology.  For GP 
notes, symptoms were extracted from both read codes and free text.  If a diagnosis 
was recorded without symptoms, the diagnosis was entered into the database as a 
„symptom‟ if the condition is typically associated with key ovarian cancer symptoms 
(e.g. women with cystitis usually experience urinary frequency). 
Relevance to ovarian cancer was determined in line with findings from previous studies 
and discussion with the clinical investigators.  Key symptoms were those in the 
questionnaire list, symptoms „other possibly related‟ were any symptoms not in the key 
symptom list that may be related to ovarian cancer.  One exception to this was change 
in bowel habit which was included as a key symptom since this overlaps with 
constipation and diarrhoea.  Many symptoms recorded were obviously not related to 
ovarian cancer (such as itchy eyes, ear ache etc.).  The decision was made not to 
database these individually, instead they were recorded as „other unrelated‟ with no 
details of onset date, duration, severity etcetera.  If more than one unrelated symptom 
was mentioned on any given source (questionnaire or interview) or visit date (GP 
notes) they were databased as a single symptom „other unrelated‟.   
The purpose of the following list was to create guidelines for databasing symptoms 
from the free text in GP notes and the additional symptoms on the interview and 
questionnaire.  It was not intended to be an exhaustive list that includes every possible 
description of each symptom. 
Symptom Definitions 
Main Symptoms (Possibly Related to Ovarian Cancer) 
Abdominal swelling/Increased abdominal size/abdominal distension 
 Abdominal swelling due to weight gain (weight gain coded also) 
 Dragging sensation in abdomen 
 Hard abdomen 
 Hard tummy 
 Heavy solid feeling in abdomen 
Abdominal bloating (includes bloating associated with eating) 
 Abdominal fullness  
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 „Blown up‟ 
 Feeling full 
Abdominal/pelvic pain or discomfort 
 Abdominal pain worse when eats 
 Colicky abdominal pain 
 Felt something moving inside tummy (possible ascites) 
 Felt something moving inside (possible ascites) 
 Suprapubic pain/discomfort  
 Wind pains 
 Upper abdominal pain 
 Discomfort in hypochondrium 
 Upper left quadrant pain 
 Lower abdominal pain 
 Iliac fossa pain  
 Salpingitis 
Back pain 
 Flank pain  
 Sciatica (many women self-report this as back pain) 
 Sub-scapular/rib pain 
Change in bowel habit 
 Change in stool size/consistency 
 Mucous in stool 
 Stringy stool 
 Urgency to pass motion 
Constipation 
 Could not pass stool 
 Difficulty passing stool/difficulty passing motion 
 Not emptying bowels regularly, coded as „constipation‟ unless indication 
that this was a change in bowel habit 
 Painful defecation 
 Sensation of not emptying bowel 
 Tenesmus 
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Diarrhoea 
 Explosive watery stool 
 Explosive bowel motions 
 Faecal urgency 
 Loose stool 
 Viral gastroenteritis 
Fatigue  
 Lack of energy 
 Lethargy/lethargic 
 Malaise 
 Feeling unwell 
 Generally unwell 
 Feels sluggish 
 Feels sick 
 Feels weak 
 Tiredness 
Indigestion 
 Dyspepsia 
 Heartburn 
 Acid reflux/reflux 
 Epigastric discomfort 
 Epigastric pain (if alone) & not part of abdominal/pelvic pain 
 Borborygmi 
 Belching/burping 
 Hiccups 
 Regurgitation/regurgitation of bile 
 Reflux of bile into mouth  
 Oesophagitis 
Loss of appetite 
 Anorexia 
Irregular vaginal bleeding (see also PV bleed) 
 Post-coital bleeding 
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 Post-menopausal bleeding (on questionnaire only) 
Urinary frequency or urgency 
 Frequency (including nocturia) 
 Urgency 
Vomiting/Nausea 
 Retching 
Leg swelling 
 Peripheral oedema 
 Thigh swelling/upper thigh swelling 
Other Possibly Related to Ovarian Cancer 
GI Other 
 Faecal incontinence 
 Dampness from back passage 
 IBS-like symptoms 
 Flatulence 
 Flatus 
 Passing wind/increased wind/wind 
 Variable bowel habit  
Mood 
 Low mood 
 Anxiety 
 Agitated 
 Distressed 
 Stress 
 Depressed/seems depressed/depression 
 Irritable 
 Restlessness 
 Panic attack 
PR bleed 
 Black stool 
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 Blood in stool 
 Bleeding on defecation 
 Dark blood stain in stool 
PV/PR Bleeding unspecified 
 Blood in toilet 
 Blood on wiping 
 Occasional bleeding 
Difficulty breathing 
 Breathlessness 
 Dyspnoea 
 SOB 
 SOB on activity or exertion 
 NOT wheezing 
DVT-related 
 Calf pain 
 DVT 
 Leg cramps 
 Leg pain/tender calves/thigh pain 
 Leg spasms 
Urinary other 
 Dysuria 
 Incontinence (all types)/leakage/stress/latch key/urge 
 UTI/Coliform UTI/possible infection/Cystitis 
 Retention/Could not pass urine/difficulty passing urine/poor stream/reduced 
urine output/retention with full bowel Outflow obstruction Nocturnal difficult 
passing urine 
 Bladder pressure symptoms 
 Dark urine/concentrated urine/darker colour & smell change 
 Smelly urine 
 Haematuria/blood in urine 
 Urinary symptoms 
 Nocturnal enuresis 
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N.B. Although all women with urge incontinence have urgency, if they have this 
diagnosis they would have had investigations to demonstrate that they had detrusor 
instability, so this symptom was not included as urinary urgency. 
Pain Radiation 
 Buttock to leg pain 
 Hip to leg pain 
Utero-Vaginal Prolapse 
 Bulge in vagina 
 Cystocoele 
 Felt as if pelvis was going to fall out 
 Sensation of lump between legs/vaginal lump/vulval lump 
 Sinking feeling in pelvis 
 Vaginal fullness 
Sleep disorders 
 Insomnia 
 Poor sleep 
 Sleep disturbance 
Groin/Loin Pain 
 Groin pain 
 Loin pain/ache 
Other miscellaneous 
 Painful intercourse 
 Vaginal discharge 
 Ankle swelling 
 Dysmenorrhoea 
 Hip pain 
 Lump in neck (could be lymph node related in advanced cases) 
 Menorrhagia 
 Painful lower ribs 
 PE 
 Pleurisy 
 Weight gain (including from ascites as women may think weight gain) 
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Other Unrelated to Ovarian Cancer 
Vasovagal 
 Black out 
 Black out 
 Collapse  
 Cold & clammy 
 Dizziness/dizzy 
 Faint 
 Feels faint 
 Giddy/giddiness 
 Vertigo 
 Wobbly 
 Acne/spotty skin 
 Asymmetry of breasts 
 Bad taste in mouth 
 Bleeding under skin on leg 
 Boil of vulva 
 Breast lump 
 Breast pain 
 Breast swelling  
 Change in taste 
 Chest pain/ache lower R chest/lower chest pain 
 Cough 
 Dysphagia/oesophageal dysmotility/solid food stuck in oesophagus 
 Eczematous rash on leg 
 Elbow pain 
 Fever 
 Genitourinary system diseases (too unspecified to include) 
 Hair falling out more 
 Headache 
 Hot flushes 
 Itchy nipples 
 Knee swelling (if knee ONLY) - leg swelling if includes leg/right knee 
swelling 
 Leg rash 
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 Lump over upper left quadrant 
 Lump right groin  
 Memory loss 
 Migraine 
 Neck pain 
 Nerve pain in leg 
 Night sweats/sweats 
 Phlebitis 
 Pins & needles fingers/arms/legs 
 PR lump 
 Rectal pain 
 Rectal mass 
 Recurrent nose bleeds 
 Retrosternal pain 
 Rib pain 
 Shivers 
 Shoulder pain/pain between shoulder blades 
 Spotty skin 
 Submandibular mass 
 Surface fatty lump on abdomen 
 Thick coating on tongue  
 Vaginal cyst 
 Vaginal irritation 
 Vaginal itch 
 Vaginal pain when bowels open 
 Vulval irritation 
 Vulval itch 
 Vulval pain 
 Vulval rash 
 Weight loss (intentional) 
Major Symptom Groups  
Abdominal Symptoms 
 Pelvic/Abdominal pain or discomfort 
 Abdominal bloating 
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 Increased abdominal size/abdominal swelling 
GI Symptoms 
 Change in bowel habit 
 Constipation 
 Diarrhoea 
 GI other (flatulence, variable bowel habit, IBS symptoms) 
 Indigestion 
 Nausea/vomiting 
Gynaecological Symptoms 
 Irregular vaginal bleeding 
 Postmenopausal bleeding 
 Pain with intercourse 
 Vaginal discharge 
Urinary Symptoms 
 Urinary frequency or urgency 
 Dysuria 
 Incontinence (all types)/leakage/stress/latch key/urge 
 UTI/Coliform UTI/possible infection/Cystitis 
 Retention/Could not pass urine/difficulty passing urine/poor stream/reduced 
urine output/retention with full bowel Outflow obstruction Nocturnal difficult 
passing urine 
 Bladder pressure symptoms 
 Dark urine/concentrated urine/darker colour & smell change 
 Smelly urine 
 Haematuria/blood in urine 
 Urinary symptoms 
 Nocturnal enuresis 
General Symptoms 
 Fatigue 
 Loss of appetite 
 Weight loss 
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Goff Index Symptoms 
Increased Abdominal size/Bloating 
 Abdominal bloating 
 Increased abdominal size/abdominal swelling 
Pelvic or abdominal pain 
 Pelvic or abdominal pain as defined in list above 
Difficulty eating or feeling full quickly 
 Loss of appetite (interview data only since feeling full quickly was only 
specifically asked about on interview) 
Dates 
 Dates with only month and year but no day, were entered as the 15th of the 
month.  E.g. Oct 05 was entered as 15 Oct 05. 
 Symptom onset dates in GP notes were derived based on visit date and 
symptom duration if duration information was available.  E.g. „started 5/7‟ 
would have an onset date of 5 days before the visit date entered.  
 Date ranges where two months were given were entered as the 1st day of 
the 2nd month e.g. Oct 05 – Nov 05 was entered as 01 Nov 05. 
 Date ranges where >2 months were given were entered as the midpoint 
e.g. Jul 05 to Sep 05 midpoint would be 15th Aug 05; Jul 05 to Oct 05 
would be 1st Sep 05. 
 If duration was >2 years coded as „25‟ months  
 Source date of clinic letters taken as date of clinic visit not date of letter 
typing 
 Date of diagnosis for other significant co morbidities was taken as first date 
of diagnosis that appeared in notes 
 Cut-off-date is date when ovarian or pelvic aetiology first suspected 
(includes „?pelvic mass‟) 
 If additional text implied that dates were definitely not midpoint of the month 
then entry of a more sensible default date was permitted.  E.g. „Early 
March‟ was coded as 01 Mar 06 
 Nonsensical symptom onset dates and „dates GP told‟ on self-reported 
data were amended if sensible.  Otherwise „date GP told‟ was changed to 
missing.  E.g. one of the case questionnaires was completed in October 
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2006, with a symptom whose onset was June 2006, duration 4 months, and 
„date GP told‟ May 2006.  In this situation, the onset date was kept since it 
matched the duration, and the „date GP told‟ was discarded. 
 Some questionnaires answers contained text where numbers were 
expected.  These were dealt with in the following manner: 
o Frequency: 
 „Most days‟ = 16-31 days 
 „All‟ = 16-31 days 
 „Sometimes‟ = missing 
 „Variable‟ = missing  
 „Couple of weeks without‟ = 5-15 days 
o Duration 
 „>1 year‟ = 13 months 
 For unknown CA125 and US test dates – Date of earliest letter mentioning 
results was entered 
General Rules 
 Symptom ongoing status was assumed to be „yes‟ if ongoing was missing.  
 If a start date and duration were nonsensical, the start date would be 
trusted and a new duration was derived provided the symptom was 
ongoing.  Derived start dates were based on date of diagnosis (for cases) 
and consent (for controls).   
 If only a start year was provided, the midpoint between January of the start 
year and the date of diagnosis (or consent) was taken.   
 Used midpoint for ranges where a single entry was required  
 Record of blood samples taken at GP were linked to visits even if not 
actually taken on day of visit/request if within 5 days of visit. 
 If GP was asked to order CA125 this was not recorded as GP ordered 
CA125 
 Only databased women as „postmenopausal‟ if there was documentation in 
the notes to reflect this (e.g. >1 year amenorrhea) 
 Nurse visits for changing dressing for a problem code as routine unless a 
problem occurs with wound 
 If no pre-treatment CA125 results were available a default value of „9999‟ 
was entered if levels were known to be abnormal or raised  
 If women provided reasons for weight loss such as stress or anxiety, these 
were also recorded as symptoms. 
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8.7 Appendix VII Data Cleaning Flowcharts 
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8.8 Appendix VIII Example Questionnaire 
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8.9 Appendix IX Worked Example of Continuation Odds Ratio 
The following is an example of how the continuation odds ratio for abdominal bloating 
3-5 months before diagnosis was calculated for the questionnaire data (in Table 4-7).  
A total of 34 cases, reported the onset of (new) abdominal bloating between 3-5 
months prior to diagnosis.     
Table 8-1 Number Cases and Controls with Abdominal Bloating on Questionnaire 
at Different Periods Before Reference Date 
Months Before Reference Date Cases Controls 
None 66 214 
0-2 82 1 
3-5 34 2 
6-8 16 2 
9-11 9 4 
12-14 15 3 
15-23 3 3 
>2 years 11 18 
Missing start date 13 21 
TOTAL 249 268 
Normally, an odds ratio for case-control symptom differences would be calculated as: 
 
This is equivalent to: 
 
Below are the calculations for obtaining the average number of controls „at risk‟ of still 
getting the symptom at 3-5 months prior to diagnosis.  Women who had abdominal 
bloating for >2 years are excluded (n=18), as are women with missing onset dates 
since they are treated as if their symptom started >2 years ago (n=21).  Hence, the 
sum of these women is subtracted from total number of controls (n=268), which leaves 
the total number of controls who are „at risk‟ of developing bloating for the first time 
over the 2 years prior to reference date.  The total number of months that have passed 
from 2 years prior to reference date to 3-5 months (n=21) is multiplied by the average 
(control) rate of bloating per month.  This is subtracted from the total number of 
controls who are „at risk‟ of developing bloating for the first time in the 2 years prior to 
reference date. 
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The number of cases „at risk‟ is simply the number of cases who have not yet had bloating by 3-5 months prior to diagnosis. 
 
 
Therefore, the continuation odds ratio (cOR) is calculated as: 
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8.10 Appendix X GP Workload Symptom Lists 
Table 8-2 GP Workload Symptoms  
Chrisp Street Woosehill Northcroft Boundary 
Abdominal Bloating 
Abdominal Cramp 
Abdominal Discomfort 
Abdominal Distension 
Abdominal Pain 
Acute Cystitis 
Bowel Symptoms 
Constipation 
Cystitis Symptoms 
Diarrhoea 
Difficulty Eating 
Dyspepsia 
Epigastric Discomfort 
Epigastric Pain 
Fatigue 
Feeling Full 
Feeling Unwell 
Feels Strange 
Feels Unwell 
Feels Weak 
Gastric Problems 
Gastric Symptoms 
GI Symptoms 
Heartburn 
Indigestion 
Loose Stool 
Loose Stools 
Loss Of Appetite 
Low Energy 
Lower Abdominal Pain 
Malaise 
Nausea 
Pain When Eating 
Postmenopausal 
bleeding 
Reflux 
Reflux Symptom 
Suprapubic Discomfort 
Tired 
Urinary Frequency 
Urinary Symptoms 
Urinary Urgency 
Vaginal Discharge 
Vomiting 
Weight Loss 
Abdominal Discomfort 
Abdominal Distension 
Abdominal Pain 
Acid Reflux 
Bloated 
Bloating 
Borborygmi 
Change In Stool 
Constipation 
Diarrhoea 
Difficulty Emptying 
Bowel 
Difficulty Passing 
Urine 
Fatigue 
Feels Unwell 
Fullness In 
Epigastrium 
Heartburn 
Incomplete Evacuation 
Bowel 
Indigestion 
Lethargic 
Loss Of Appetite 
Low Energy 
Lower Abdominal Pain 
Nausea 
Painful Intercourse 
Postmenopausal 
bleeding 
Post-Coital Bleeding 
Reflux 
Soft Stools 
Tired 
Urinary Frequency 
Urinary Retention 
Urinary Symptoms 
Urinary Urgency 
UTI Symptoms 
Vaginal Discharge 
Variable Bowel Habit 
Vomiting 
Watery Stools 
Weight Loss 
Wind 
Abdominal Bloating 
Abdominal Distension 
Abdominal Pain 
Acid Reflux 
Anorexia 
Belching 
Bowel Frequency 
Bowel Irregular 
Bowel Urgency 
Change Bowel Habit 
Constipation 
Diarrhoea 
Dyspepsia 
Epigastric Discomfort 
Epigastric Pain 
Fatigue 
Feels Unwell 
Flatulence 
Food Regurgitation 
Heartburn 
Increased Bowel 
Frequency 
Indigestion 
Loose Bowel 
Loose Stool 
Loss Of Appetite 
Low Energy 
Lower Abdominal Pain 
Nausea 
Pain On Eating 
Postmenopausal 
bleeding 
Recurrent UTI 
Sticky Stool 
Tenesmus 
Tired 
Upper Abdominal Pain 
Urinary Frequency 
Urinary Urgency 
Vaginal Discharge 
Variable Bowel Habit 
Vomiting 
Weight Loss 
Wind 
Abdominal 
Bloating 
Abdominal Mass 
Abdominal Pain 
Abdominal 
Swelling 
Acid Reflux 
Belching 
Cystitis 
Diarrhoea 
Epigastric Pain 
Fatigue 
Feels Unwell 
Felt Unwell 
GI Problems 
Indigestion 
Loss Of Appetite 
Nausea 
Urinary Frequency 
Urinary Symptoms 
Urinary Urgency 
UTI 
Vomiting 
Weight Loss 
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Table 8-3 GP Workload Symptom Groups 
Chrisp Street Woosehill Northcroft Boundary 
Abdominal  
Abdominal bloating 
Abdominal cramp 
Abdominal discomfort 
Abdominal distension 
Abdominal pain 
Lower abdominal pain 
Feeling full 
Suprapubic discomfort 
Abdominal discomfort 
Abdominal distension 
Abdominal pain 
Abdominal bloating/bloated 
Fullness in epigastrium 
Lower abdominal pain 
Abdominal bloating 
Abdominal pain 
Abdominal distension 
Lower abdominal pain 
Upper abdominal pain 
Abdominal bloating 
Abdominal mass 
Abdominal swelling 
Abdominal pain 
GI 
Bowel symptoms 
Constipation 
Diarrhoea 
Difficulty eating 
Dyspepsia 
Epigastric pain/discomfort 
GI symptoms 
Gastric problems 
Gastric symptoms 
Heartburn 
Indigestion 
Loose stool/loose stools 
Nausea 
Pain when eating 
Reflux/reflux symptoms 
Vomiting 
Acid reflux/reflux 
Borborygmi 
Constipation 
Diarrhoea 
Difficulty emptying bowel 
Heartburn 
Incomplete evacuation of bowel 
Indigestion 
Nausea 
Soft stools 
Variable bowel habit 
Vomiting 
Watery stools 
Wind 
Change in stool 
Acid reflux 
Anorexia 
Belching 
Bowel Frequency 
Bowel irregular 
Bowel urgency 
Change in bowel habit 
Constipation 
Diarrhoea 
Flatulence 
Food regurgitation 
Heartburn 
Increased bowel frequency 
Indigestion 
Loose bowel 
Loose stool 
Loss of appetite 
Nausea 
Pain on eating 
Acid reflux 
Belching 
Diarrhoea 
GI problems 
Indigestion 
Loss of appetite 
Nausea 
Vomiting 
Epigastric pain 
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Chrisp Street Woosehill Northcroft Boundary 
GI Continued 
  Sticky stool 
Variable bowel habit 
Weight loss 
Vomiting 
Wind 
Epigastric pain/discomfort 
 
Urinary 
Urinary urgency 
Urinary frequency 
Acute cystitis/cystitis 
Urinary symptoms 
Urinary retention 
Difficulty passing urine 
Urinary frequency 
Urinary urgency 
Urinary symptoms 
UTI symptoms 
Urinary frequency 
Urinary urgency 
Recurrent UTI 
Urinary frequency 
Urinary urgency 
Urinary symptoms 
UTI 
Cystitis 
Gynaecological 
Postmenopausal bleeding 
Vaginal discharge 
Painful intercourse 
Post-coital bleeding 
Postmenopausal bleeding 
Vaginal discharge 
Vaginal discharge 
Postmenopausal bleeding 
 
- 
General 
Fatigue 
Feels strange 
Feeling feels/ unwell 
Feels weak 
Low energy 
Malaise 
Tired 
Loss of appetite 
Weight loss 
Fatigue 
Feels unwell 
Lethargic 
Low energy 
Tired 
Loss of appetite 
Weight loss 
Fatigue 
Feels unwell 
Low energy 
Tired 
Anorexia 
Loss of appetite 
Weight Loss 
Feels unwell/felt unwell 
Loss of appetite 
Weight loss 
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Table 8-4 Consensus Symptoms 
Chrisp Street Woosehill Northcroft Boundary 
Bloating 
Abdominal bloating 
Feeling full 
Abdominal distension 
Bloating 
Fullness in epigastrium 
Abdominal distension 
Bloating 
Abdominal distension 
Abdominal bloating 
Abdominal swelling 
Pelvic or Abdominal Pain 
Abdominal discomfort 
Abdominal cramp 
Abdominal pain 
Suprapubic discomfort 
Lower abdominal pain 
Abdominal pain 
Lower abdominal pain 
Abdominal pain 
Lower abdominal pain 
Upper abdominal pain 
Abdominal pain 
Difficulty Eating or Feeling Full Quickly 
Difficulty eating - - - 
Urinary Frequency/Urgency  
Urinary frequency 
Urinary urgency 
Urinary frequency 
Urinary urgency 
Urinary frequency 
Urinary urgency 
Urinary frequency 
Urinary urgency 
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8.11 Appendix XI Innovations & Progress in Healthcare for 
Women Conference Abstract (7-8th April 2008) 
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